MXPA99003392A - Compounds and methods for immunotherapy and diagnosis of tuberculosis - Google Patents

Abstract

Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.

Description

COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND TUBERCULOSIS DIAGNOSIS TECHNICAL FIELD The present invention relates generally to detect, treat and prevent infections of Mycobacterium tuberculosis. The invention is more particularly related to polypeptides comprising a Mycobacterium tuberculosis antigen, or a portion or other variant thereof, and the use of these polypeptides for diagnosis and vaccination against Mycobacterium tuberculosis infection. BACKGROUND OF THE INVENTION Tuberculosis is a chronic infectious disease, this is usually caused by infection with Mycobacterium tuberculosis. It is a major disease in developing countries, as well as a growing problem in the developed areas of the world, with approximately 8 million new cases and 3 million deaths each year. Although the infection may be asymptomatic for a considerable period of time, the disease most commonly manifests as an acute inflammation of the lungs, resulting in fever and a nonproductive cough. If left untreated, complications and death typically result. Although tuberculosis in general can be controlled using prolonged antibiotic therapy, such treatment is not sufficient to prevent the spread of the disease. Infected individuals may be asymptomatic, but contagious for some time. In addition, although compliance with the treatment regimen is critical, the patient's behavior is difficult to verify. Some patients do not complete the course of treatment which can lead to ineffective treatment and the development of resistance to the drug. Inhibiting the spread of tuberculosis requires effective vaccination and early diagnosis of the disease. Currently, vaccination with live bacteria is the most efficient method to induce protective immunity. The most common Mycobacterium used for this purpose is Bacillus Calmette-Guerin (GCG), a avirulent strain of Mycobacterium bovis. However, the BCG's safety and efficacy is a source of controversy and some countries, such as the U.S., do not vaccinate the general public. Diagnosis is commonly achieved using a skin test, which involves intradermal exposure to tuberculin PPD (purified protein derivative). Responses of antigen-specific T cells result in measurable hardening at the injection site for 48-72 hours after injection, indicating exposure to mycobacterial antigens. Sensitivity and specificity, however, have been a problem with this test and individuals vaccinated with BCG can not be distinguished from infected individuals. While macrophages have been shown to act as the main immunity effectors of M. tuberculosis, T cells are the predominant inducers of such immunity. The essential role of T cells in protection against M. tuberculosis infection is illustrated by the frequent occurrence of M. tuberculosis in AIDS patients, due to the depletion of CD4 T cells associated with infection of human immunodeficiency virus (HIV = Human Immunodeficiency Virus). CD4 T cells reactive to Mycobacterium have been shown to be potent producers of gamma-interferon (IFN-gamma), which in turn has been shown to activate the anti-mycobacterial macrophage effective in mice. While the role of IFN-gamma in humans is less clear, studies have shown that 1,25-dihydroxy-vitamin D3 either alone or in combination with IFN-gamma or tumor necrosis factor-alpha, activates human macrophages to inhibit M. infection. tuberculosis In addition, it is known that IFN-gamma stimulates human macrophages to produce 1,25-dihydroxy-vitamin D3. Similarly, IL-12 has been shown to play a role in stimulating resistance to M. tuberculosis infection.

For a review of the immunology of M. tuberculosis infection see Chan and Kaufmman in Tuberculosis: Pathogen.es s, Protection and Control (Tuberculosis: Pathogenesis, Protection and Control), Bloom (ed.), ASM Press, Washington, DC, 1994. Accordingly, there is a need in the art for vaccines and improved methods to prevent, treat and detect tuberculosis. The present invention meets these needs and also provides other relative advantages. SUMMARY OF THE INVENTION Briefly stated, this invention provides compounds and methods for preventing and diagnosing tuberculosis. In one aspect, polypeptides are provided which comprise an immunogenic portion of a soluble M. tuberculosis antigen, or a variant of said antigen that differs only in substitutions and / or conservative modifications. In one embodiment of this aspect, the soluble antigen has one of the following N-terminal sequences: (a) Asp-Pro-Val-Asp-Ala-Val-lle-Asn-Thr-Thr-Cys-Asn-Tyr-Gly -Gln-Val-Val-Ala-Ala-Leu; (SEQ ID No. 120) (b) Ala-Val-Glu-Ser-Glu-Met-Leu-Ala-Leu-Gly-Thr-Pro-Ala-Pro-Ser; (SEQ ID No. 121) (c) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg; (SEC ID No. 122) (d) Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala-Trp-Gly-Pro; (SEQ ID No. 123) (e) Asp-Ile-Gly-Ser-Glu-Ser-Thr-Glu-Asp-Gln-Gln-Xaa-Ala-Val; (SEQ ID No. 124) (f) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val-Pro; (SEQ ID No. 125) (g) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Thr-Ala-Ala-Ser-Pro-Pro-Ser; (SEQ ID No. 126) (h) Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly; (SEC ID No. 127) (i) Asp-Pro-Ala-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Leu- Thr-Ser-Leu-Leu-Asn-Ser -Leu-Ala-Asp-Pro- Asn-Val-Ser-Phe-Ala-Asn; (SEQ ID No. 128) (j) Xaa-Asp-Ser-Glu-Lys-Ser-Ala-Thr-Ile-Lys-Val-Thr-Asp-Ala-Ser; (SEQ ID No. 134) (k) Ala-Gly-Asp-Thr-Xaa-Ile-Tyr-Ile-Val-Gly-Asn-Leu- Thr-Ala-Asp; (SEQ ID No. 135) or (1) Ala-Pro-Glu-Ser-Gly-Ala-Gly-Leu-Gly-Gly-Thr-Val-Gln-Ala-Gly; (SEQ ID No. 136) wherein Xaa can be any amino acid. In a related aspect, polypeptides are provided which comprise an immunogenic portion of an M. tuberculosis antigen, or a variant of said antigen that differs only in substitutions and / or conservative modifications, the antigen has one of the following N-terminal sequences: (m) Xaa-Tyr-Ala-Ala-Tyr-Xaa-Thr-Thr-Ala-Gly-Ile-Val-Pro-Gly-Lys-lle-Asn-Val-His-Leu-Val; (SEQ ID No. 137) or (n) Asp-Pro-Pro-Asp-Pro-His-Gln-Xaa-Asp-Met-Thr-Lys-Gly-Tyr-Tyr-Pro-Gly-Gly-Arg- Arg-Xaa-Phe; (SEQ ID No. 129) wherein Xaa can be any amino acid. In another embodiment, the soluble M. tuberculosis antigen comprises an amino acid sequence encoded by a DNA sequence selected from the group consisting of the sequence described in SEQ ID Nos. 1, 2, 4-10, 13-25 , 52, 99 and 101, the complements of said sequences and DNA sequences that hybridize to a sequence described in SEQ ID Nos. 1, 2, 4-10, 13-25, 52, 99 and 101 or a complement of the same, under moderately strict conditions.

In a related aspect, the polypeptides comprise an immunogenic portion of a M. tuberculosis antigen, or a variant of said antigen that differs only in substitutions and / or conservative modifications, wherein the antigen comprises an amino acid sequence encoded by a sequence. of DNA selected from the group consisting of the sequences described in SEQ ID Nos.: 26-51- 138, 139, 163-183 and 201, the complements of the sequences and DNA sequences that hybridize to a sequence described in SEQ ID Nos .: 26-51-138, 139, 163-183 and 201 or a supplement under moderately strict conditions. In related aspects, DNA sequences encoding the above polypeptides, expression vectors comprising these DNA sequences and host cells transformed or transfected with said expression vectors, are also provided. In another aspect, the present invention provides fusion proteins comprising a first and a second polypeptides of the invention or alternatively a polypeptide of the invention and a known M. tuberculosis antigen. Within other aspects, the present invention provides pharmaceutical compositions comprising one or more of the above polypeptides, or a DNA molecule encoding said polypeptides and a physiologically acceptable carrier. The invention also provides vaccines comprising one or more of the polypeptides as described above and a non-specific immune response enhancer, together with vaccines comprising one or more of the DNA sequences encoding said polypeptides and a non-immune response enhancer. specific . In yet another aspect, methods are provided for inducing protective immunity in a patient, comprising administering to a patient an effective amount of one or more of the above polypeptides. In additional aspects of this invention, diagnostic methods and equipment for detecting tuberculosis in a patient are provided. The methods comprise contacting dermal cells of a patient with one or more of the above polypeptides and detecting an immune response in the patient's skin. The diagnostic kits comprise one or more of the above polypeptides in combination with an apparatus sufficient to contact the polypeptide with skin cells of a patient. In yet another aspect, methods are provided for detecting tuberculosis in a patient, said methods comprising contacting dermal cells of a patient with one or more polypeptides encoded by a DNA sequence selected from the group consisting of SEQ ID. Nos .: 3, 11, 12, 140, 141, 156-160, 189-193, 199, 200 and 203, the complements of the sequences and DNA sequences that hybridize to a sequence described in SEQ ID NOS: 3 , 11, 12, 140, 141, 156-160, 189-193, 200 and 203; and detect an immune response in the patient's skin. Diagnostic equipment to use in such methods are also provided. These and other aspects of the present invention will be apparent upon reference to the following detailed description and accompanying drawings. All references herein described are incorporated by reference in their entirety as if each were incorporated individually. BRIEF DESCRIPTION OF THE DRAWINGS AND IDENTIFIERS OF SEQUENCE Figures IA and B illustrate the stimulation of proliferation and gamma interferon production in T cells derived from a first and second immune donor. tuberculosis respectively by 14 Kd antigens, 20 Kd and 26 Kd, described in Example 1. Figure 2 illustrates the stimulation of proliferation and production of gamma-interferon in T cells derived from an individual immune to M. tuberculosis by two representative polypeptides TbRa3 and TbRa9. Figures 3A-D illustrate the reactivity of antisera raised against secretory M. tuberculosis proteins, the known M. tuberculosis antigen 85b and the antigens of the invention Tb38-1 and TbH-9, respectively with M. tuberculosis lysate (hint) 2), secretory proteins of M. tuberculosis (lane 3), recombinant Tb38-1 (lane 4), recombinant TbH-9 (lane 5) and recombinant 85b (lane 5). Figure 4A illustrates the proliferation stimulus in a specific T cell clone of TbH-9 by secretory M. tuberculosis proteins, recombinant TbH-9 and a TbRall control antigen. Figure 4B illustrates the stimulation of gamma interferon production in a TbH-9 specific T cell clone by secretory M. tuberculosis proteins, PPD and recombinant TbH-9. Figures 5A and B illustrate the stimulation of gamma interferon proliferation and production in TbH9-specific T cells by the fusion protein TbH9-Tb38-1. Figures 6A and B illustrate the stimulation of gamma interferon proliferation and production in TB38-1-specific T cells by the fusion protein TbH9-Tb38-1. Figures 7A and B illustrate the stimulation of gamma interferon proliferation and production in T cells that previously show to respond to both TbH-9 and Tb38-1 by the fusion protein TbH9-Tb38-l. Figures 8A and B illustrate the stimulation of gamma interferon proliferation and production in T cells derived from a first individual immune to M. tuberculosis by the representative polypeptides XP-1, RDIF6, RDIF8, RDIF10 and RDIF11. Figures 9A and B illustrate the stimulation of gamma interferon proliferation and production in T cells derived from a second individual immune to M. tuberculosis by the representative XP-1 polypeptides, RDIF6, RDIF8, RDIF10 and RDIF11. SEC ID. No. 1 is the DNA sequence of TbRal. SEC ID. No. 2 is the DNA sequence of TbRalO. SEC ID. No. 3 is the DNA sequence of TbRall. SEC ID. No. 4 is the DNA sequence of TbRal2. SEC ID. No. 5 is the DNA sequence of TbRal3. SEC ID. No. 6 is the DNA sequence of TbRal6. SEC ID. No. 7 is the DNA sequence of TbRal7. SEC ID. No. 8 is the DNA sequence of TbRal8. SEC ID. No. 9 is the DNA sequence of TbRal9.

SEC ID. No. 10 is the DNA sequence of TbRa24.

SEC ID. No. 11 is the DNA sequence of TbRa26.

SEC ID. No. 12 is the DNA sequence of TbRa28.

SEC ID. No. 13 is the DNA sequence of TbRa29.

SEC ID. No. 14 is the DNA sequence of TbRa2A.

SEC ID. No. 15 is the DNA sequence of TbRa3.

SEC ID. No. 16 is the DNA sequence of TbRa32.

SEC ID. No. 17 is the DNA sequence of TbRa35.

SEC ID. No. 18 is the DNA sequence of TbRa36.

SEC ID. No. 19 is the DNA sequence of TbRa4.

SEC ID. No. 20 is the DNA sequence of TbRa9.

SEC ID. No. 21 is the DNA sequence of TbRaB.

SEC ID. No. 22 is the DNA sequence of TbRaC.

SEC ID. No. 23 is the DNA sequence of TbRaD.

SEC ID. No. 24 is the DNA sequence of YYWCPG.

SEC ID. No. 25 is the DNA sequence of AAMK.

SEC ID. No. 26 is the DNA sequence of TbL-23.

SEC ID. No. 27 is the DNA sequence of TbL-24.

SEC ID. No. 28 is the DNA sequence of TbL-25.

SEC ID. No. 29 is the DNA sequence of TbL-28.

SEC ID. No. 30 is the DNA sequence of TbL-29.

SEC ID. No. 31 is the DNA sequence of TbH-5.

SEC ID. No. 32 is the DNA sequence of TbH-8.

SEC ID. No. 33 is the DNA sequence of TbH-9.

SEC ID. No. 34 is the DNA sequence of TBM-1.

SEC ID. No 35 is the DNA sequence of TbM-3. SEC ID. No 36 is the DNA sequence of TbM-6. SEC ID. No 37 is the DNA sequence of TbM-7. SEC ID. No 38 is the DNA sequence of TbM-9. SEC ID. No 39 is the DNA sequence of TbM-12. SEC ID. No 40 is the DNA sequence of TbM-13. SEC ID. No 41 is the DNA sequence of TbM-14. SEC ID. No 42 is the DNA sequence of TbM-15. SEC ID. No 43 is the DNA sequence of TbH-4. SEC ID. No 44 is the DNA sequence of TbH-4-FWD. SEC ID. No 45 is the DNA sequence of TbH-12. SEC ID. No 46 is the DNA sequence of Tb38-1. SEC ID. No 47 is the DNA sequence of Tb38-4. SEC ID. No 48 is the DNA sequence of TbL-17. SEC ID. No. 49 is the DNA sequence of TbL-20. SEC ID. No. 50 is the DNA sequence of TbL-21. SEC ID. No 51 is the DNA sequence of TbH-16. SEC ID. No. 52 is the DNA sequence of DPEP. SEC ID NO. 53 is the deduced amino acid sequence of DPEP. SEC ID NO. 54 is the protein sequence of N-terminal DPV antigen. SEC ID NO. 55 is the sequence of the N-terminal antigen protein AVGS ID of SEC NO. 56 is the N-terminal AAMK antigen protein sequence. SEC ID NO. 57 is the N-terminal antigen protein sequence YYWC. SEC ID NO. 58 is the N-terminal DIGS antigen protein sequence. SEC ID NO. 59 is the protein sequence of N-terminal antigen AEES. SEC ID NO. 60 is the protein sequence of N-terminal antigen DPEP. SEC ID NO. 61 is the N-terminal antigen protein sequence APKT. SEC ID NO. 62 is the N-terminal DPAS antigen protein sequence. SEC ID NO. 63 is the amino acid sequence deduced from TbRal. SEC ID NO. 64 is the amino acid sequence deduced from TbRalO. SEC ID NO. 65 is the deduced amino acid sequence of TbRal1. SEC ID NO. 66 is the amino acid sequence deduced from TbRal2. SEC ID NO. 67 is the amino acid sequence deduced from TbRal3.

SEC ID NO. 68 is the amino acid sequence deduced from TbRal6. SEC ID NO. 69 is the amino acid sequence deduced from TbRal7. SEC ID NO. 70 is the amino acid sequence deduced from TbRal8. SEC ID NO. 71 is the amino acid sequence deduced from TbRal9. SEC ID NO. 72 is the deduced amino acid sequence of TbRa24. SEC ID NO. 73 is the amino acid sequence deduced from TbRa26. SEC ID NO. 74 is the amino acid sequence deduced from TbRa28. SEC ID NO. 75 is the amino acid sequence deduced from TbRa29. SEC ID NO. 76 is the amino acid sequence deduced from TbRa2A. SEC ID NO. 77 is the deduced amino acid sequence of TbRa3. SEC ID NO. 78 is the amino acid sequence deduced from TbRa32. SEC ID NO. 79 is the amino acid sequence deduced from TbRa35.

SEC ID NO. 80 is the amino acid sequence deduced from TbRa36. SEC ID NO. 81 is the amino acid sequence deduced from TbRa4. SEC ID NO. 82 is the amino acid sequence deduced from TbRa9. SEC ID NO. 83 is the amino acid sequence deduced from TbRaB. SEC ID NO. 84 is the deduced amino acid sequence of TbRaC. SEC ID NO. 85 is the amino acid sequence deduced from TbRaD. SEC ID NO. 86 is the amino acid sequence deduced from YYWCPG SEC ID NO. 87 is the amino acid sequence deduced from TBAAMK SEC ID NO. 88 is the amino acid sequence deduced from Tb38-1. SEC ID NO. 89 is the deduced amino acid sequence of TbH-4. SEC ID NO. 90 is the amino acid sequence deduced from TbH-8. SEC ID NO. 91 is the amino acid sequence deduced from TbH-9.

SEC ID NO. 92 is the amino acid sequence deduced from TbH-12. SEC ID NO. 93 is the amino acid sequence of Peptide 1 Tb38-1. SEC ID NO. 94 is the amino acid sequence of Peptide 2 Tb38-1. SEC ID NO. 95 is the amino acid sequence of Peptide 3 Tb38-1. SEC ID NO. 96 is the amino acid sequence of Peptide 4 Tb38-1. SEC ID NO. 97 is the amino acid sequence of Peptide Tb38-1. SEC ID NO. 98 is the amino acid sequence of Peptide 6 Tb38-1. SEC ID NO. 99 is the DNA sequence of DPAS. SEC ID NO. 100 is the deduced amino acid sequence of DPAS. SEC ID NO. 101 is the DNA sequence of DPV. SEC ID NO. 102 is the deduced amino acid sequence of DPV. SEC ID NO. 103 is the DNA sequence of ESAT-6. SEC ID NO. 104 is the deduced amino acid sequence of ESAT-6. SEC ID NO. 105 is the DNA sequence of TbH-8-2 ID of SEC NO. 106 is the DNA sequence of TbH-9FL. SEC ID NO. 107 is the deduced amino acid sequence of TbH-9FL. SEC ID NO. 108 is the DNA sequence of TbH-9-1. SEC ID NO. 109 is the deduced amino acid sequence of TbH-9-1. SEC ID NO. 110 is the DNA sequence of TbH-9-4. SEC ID NO. 111 is the deduced amino acid sequence of TbH-9-4. SEC ID NO. 112 is the DNA sequence of Tb38-IF2 IN.

SEC ID NO. 113 is the DNA sequence of Tb38-2F2 RP.

SEC ID NO. 114 is the deduced amino acid sequence of Tb37-FL. SEC ID NO. 115 is the deduced amino acid sequence of Tb38-IN. SEC ID NO. 116 is the DNA sequence of Tb38-IF3. SEC ID NO. 117 is the deduced amino acid sequence of Tb38-IF3. SEC ID NO. 118 is the DNA sequence of Tb38-IF5. SEC ID NO. 119 is the DNA sequence of Tb38-IF6. SEC ID NO. 120 is the N-terminal amino acid sequence deduced from DPV. SEC ID NO. 121 is the N-terminal amino acid sequence deduced from AVGS.

SEC ID NO. 122 is the N-terminal amino acid sequence deduced from AAMK. SEC ID NO. 123 is the N-terminal amino acid sequence deduced from YYWC. SEC ID NO. 124 is the N-terminal amino acid sequence deduced from DIGS. SEC ID NO. 125 is the N-terminal amino acid sequence deduced from AEES. SEC ID NO. 126 is the N-terminal amino acid sequence deduced from DPEP. SEC ID NO. 127 is the N-terminal amino acid sequence deduced from APKT. SEC ID NO. 128 is the deduced amino acid sequence of DPAS. SEC ID No. 129 is the antigen protein sequence N-terminal DPPD. SEC ID NO. 130-133 are the protein sequences of four fragments of cyanogen bromide of DPPD. SEC ID NO. 134 is the N-terminal protein sequence of XDS antigen. SEC ID NO. 135 is the N-terminal protein sequence of AGD antigen. SEC ID NO. 136 is the N-terminal protein sequence of APE antigen.

SEC ID NO. 137 is the N-terminal protein sequence of XYI antigen. SEC ID NO. 138 is the DNA sequence of TbH-29. SEC ID NO. 139 is the DNA sequence of TbH-30. SEC ID NO. 140 is the DNA sequence of TbH-32. SEC ID NO. 141 is the DNA sequence of TbH-33. SEC ID NO. 142 is the predicted amino acid sequence of TbH-29. SEC ID NO. 143 is the predicted amino acid sequence of TbH-30. SEC ID NO. 1444 is the predicted amino acid sequence TbH-32. SEC ID NO. 145 is the predicted amino acid sequence TbHTbH-33. SEC ID NO: 146-151 are PCR primers used in the preparation of a fusion protein containing TbRa3, 38 kD and Tb38-1. SEC ID NO: 152 is the DNA sequence of the fusion protein containing TbRa3, 38 kD and Tb38-1. SEC ID NO: 153 is the amino acid sequence of the fusion protein containing TbRa3, 38 kD and Tb38-1.

SEC ID NO: 154 is the DNA sequence of M. tuberculosis antigen of 38 kD.

SEC ID NO: 155 is the DNA sequence of M. tuberculosis antigen of 38 kD. SEC ID NO: 156 is the DNA sequence of the M. tuberculosis antigen of XP14. SEC ID NO: 157 is the DNA sequence of the M. tuberculosis antigen of XP24. SEC ID NO: 158 is the DNA sequence of the M. tuberculosis antigen of XP31. SEC ID NO: 159 is the DNA sequence of the antigen of. tuberculosis of XP32. SEC ID NO: 160 is the DNA sequence of the M. tuberculosis antigen of XP32.

SEC ID NO: 161 is the predicted amino acid sequence of XP14. SEC ID NO: 162 is the predicted amino acid sequence encoded by the reverse complement of XP14. SEC ID NO: 163 is the DNA sequence of XP27. SEC ID NO: 164 is the DNA sequence of XP36. SEC ID NO: 165 is the 5 'DNA sequence of XP4. SEC ID NO: 166 is the 5 'DNA sequence of XP5. SEC ID NO: 167 is the 5 'DNA sequence of XP17. SEC ID NO: 168 is the DNA sequence 5 'of XP30. SEC ID NO: 169 is the 5 'DNA sequence of XP2.

SEC ID NO: 170 is the 3 'DNA sequence of XP2. SEC ID NO: 171 is the DNA sequence 5 'of XP3. SEC ID NO: 172 is the 3 'DNA sequence of XP3. SEC ID NO: 173 is the DNA sequence 5 'of XP6. SEC ID NO: 174 is the 3 'DNA sequence of XP6. SEC ID NO: 175 is the DNA sequence 5 'of XP18. SEC ID NO: 176 is the 3 'DNA sequence of XP18. SEC ID NO: 177 is DNA sequence 51 of XP 19. SEC ID NO: 178 is the 3 'DNA sequence of XP 19. SEC ID NO: 179 is the 5' DNA sequence of XP22. SEC ID NO: 180 is the 3 'DNA sequence of XP22. SEC ID NO: 181 is the 5 'DNA sequence of XP25. SEC ID NO: 182 is the 3 'DNA sequence of XP25. SEC ID NO: 183 is the full-length DNA sequence of TbH4-XPl. SEC ID NO: 184 is the predicted amino acid sequence of TbH4-XPl. SEC ID NO: 185 is the predicted amino acid sequence encoded by the reverse complement of TbH4-XP1. SEC ID NO: 186 is a first predicted amino acid sequence encoded by XP36. SEC ID NO: 187 is a second predicted amino acid sequence encoded by XP36.

SEC ID NO: 188 is the predicted amino acid sequence encoded by the reverse complement of XP36. SEC ID NO: 189 is the DNA sequence of RDIF2. SEC ID NO: 190 is the DNA sequence of RDIF5. SEC ID NO: 191 is the DNA sequence of RD1F8. SEC ID NO: 192 is the DNA sequence of RDIF10. SEC ID NO: 193 is the DNA sequence of RDIF11. SEC ID NO: 194 is the predicted amino acid sequence of RDIF2. SEC ID NO: 195 is the predicted amino acid sequence of RDIF5. SEC ID NO: 196 is the predicted amino acid sequence of RDIF8. SEC ID NO: 197 is the predicted amino acid sequence of RDIF10. SEC ID NO: 198 is the predicted amino acid sequence of RDIF11. SEC ID NO: 199 is the 5 'DNA sequence of RDIF12. SEC ID NO: 200 is the 3 'DNA sequence of RDIF12. SEC ID NO: 201 is the DNA sequence of RDIF7. SEC ID NO: 202 is the predicted amino acid sequence of RDIF7. SEC ID NO: 203 is the DNA sequence of DIF2-1. SEC ID NO: 204 is the predicted amino acid sequence of DIF2-1.

SEQ ID NO: 205-212 are PCR primers in the preparation of a fusion protein containing TbRa3, 38 kD, Tb38-1 and DPEP (hereinafter referred to as TbF-2). SEC ID NO: 213 is the DNA sequence of the TbF-2 fusion protein. SEC ID NO: 214 is the amino acid sequence of the TbF-2 fusion protein. DETAILED DESCRIPTION OF THE INVENTION As noted above, the present invention is generally directed to compositions and methods for preventing, treating and diagnosing tuberculosis. Compositions of the subject matter of the invention include polypeptides comprising at least an immunogenic portion of a M. tuberculosis antigen or a variant of said antigen that differs only in substitutions and / or conservative modifications. Polypeptides within the scope of the present invention include but are not limited to, M. antigens. soluble immunogenic tuberculosis. An "M. antigen" soluble tuberculosis "is a protein of M. tuberculosis origin that is present in a culture filtrate of M. tuberculosis. As used here, the term "polypeptide" encompasses amino acid chains of any length, including full-length proteins (ie, antigens), where the amino acid residues are bound by covalent peptide bonds. In this manner, a polypeptide comprising an immunogenic portion of one of the above antigens may consist entirely of the immunogenic portion or may contain additional sequences. Additional sequences may be derived from the native M. tuberculosis antigen or may be heterologous and said sequences may (but do not require) be immunogenic. "Immunogenic" as used herein, refers to the ability to produce an immune response. { by cellular example) in a patient, such as a human, and / or in a biological sample. In particular, antigens that are immunogenic (and immunogenic portions or other variants of said antigens) are capable of stimulating cell proliferation, interleukin-12 production and / or gamma-interferon production in biological samples comprising one or more cells selected from the group of T cells, NK cells, B cells and macrophages, wherein the cells are derived from an individual immune to M. tuberculosis. Polypeptides comprising at least an immunogenic portion of one or more M. tuberculosis antigens can generally be used to detect tuberculosis or induce protective immunity against tuberculosis in a patient.

The compositions and methods of this invention also encompass variants of the above polypeptides.

A "variant" as used herein, is a polypeptide that differs from the native antigen only in substitutions and / or conservative modifications, such that the ability of the polypeptide to induce an immune response is retained. Said variants can generally be identified by modifying one of the above polypeptide sequences and evaluating the immunogenic properties of the modified polypeptide using for example the representative methods described herein. A "conservative substitution" is one in which an amino acid is replaced with another amino acid having similar properties, such that a person skilled in the peptide chemistry art will expect the second structure and hydropathic nature of the polypeptide to be substantially free of charge. change. In general, the following amino acid groups represent conservative changes: (1) wing, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. Variants can also be modified (or alternatively) for example by the removal or addition of amino acids that have minimal influence on the immunogenic properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide can be conjugated to a signal sequence (or leader) at the N-terminus of the protein that co-translationally or post-translationally directs the transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide. { for example poly-His) or to improve the binding of the polypeptide with a solid structure. For example, a polypeptide may be conjugated to an immunoglobulin Fc region. In a related aspect, combination polypeptides are described. A "combination polypeptide" is a polypeptide comprising at least one of the above immunogenic portions and one or more additional immunogenic M. tuberculosis sequences, which are joined by a polypeptide linkage on a single amino acid chain. The sequences can be linked directly (ie, without intercalated amino acids) or can be linked by a linker sequence. { by Gly-Cys-Gly example) that does not significantly decrease the immunogenic properties of the component polypeptides.

In general, M. tuberculosis antigens and DNA sequences encoding said antigens can be prepared using any of a variety of methods. For example, soluble antigens can be isolated from culture filtrate of M. tuberculosis by procedures known to those of ordinary skill in the art, including reverse phase chromatography and anion exchange. Purified antigens are then evaluated for their ability to produce an appropriate immune response. { for example cellular) using for example the representative methods described herein. Immunogenic antigens can then be partially sequenced using techniques such as traditional Edman chemistry. See Edman and Berg, Eur. J. Biochem. 80: 116-132, 1967. Immunogenic antigens can also be produced recombinantly using a DNA sequence encoding the antigen, which has been inserted into an expression vector and expre in appropriate host DNA molecules encoding soluble antigens can be isolated at classify or sift from an appropriate M. tuberculosis expression library with anti-sera. { for example rabbit) developed specifically against soluble M. tuberculosis antigens. DNA sequences encoding antigens that may or may not be soluble can be identified by sorting or screening a cDNA or genomic M. tuberculosis expression library with sera obtained from patients infected with M. tuberculosis. These sieves can in general be performed using well known techniques, for those of ordinary skill in the art, such as those described by Sambrook et al., Molecular Cloning: A Laboratory Manual (Molecular Cloning: A Laboratory Manual), Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989. DNA sequences encoding soluble antigens can also be obtained by screening from a genomic DNA library or M. tuberculosis cDNA appropriate for DNA sequences that hybridize to degenerate oligonucleotides derived from partial amino acid sequences of soluble antigens. isolated Degenerate oligonucleotide sequences for use in said screen can be designed and synthesized and the screen can be performed as described (for example) Sambrook et al., Molecular Cloning: A Laboratory Manual (Molecular Cloning: A Laboratory Manual), Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989 (and references cited therein). Polymerase chain reaction (PCR = Polymerase Chain Reaction) can also be employed using the above oligonucleotides in methods well known in the art to isolate a nucleic acid probe from a genomic library or cDNA. The library screen can then be made using the isolated probe. Alternatively, genomic or cDNA libraries derived from M. tuberculosis can be directly sifted using peripheral blood mononuclear cells (PBMCs) or T cell lines or clones derived from one or more individuals immune to M. tuberculosis. In general, PBMCs and / or T cells for use in such screens can be prepared as described below. Direct library screens can generally be made by assaying recombinant protein collections expressed by the ability to induce proliferation and / or production of gamma interferon in T cells derived from an individual immune to M. tuberculosis. Alternatively, potential T cell antigens can first be selected based on antibody reactivity as described above. Regardless of the method of preparation, the antigens (and their immunogenic portions) described here (which may or may not be soluble) have the ability to induce an immunogenic response. More specifically, the antigens have the ability to induce proliferation and / or cytokine production (ie, gamma-interferon and / or interleukin-12 production) in T cells, NK cells, B cells and / or macrophages derived from an immune individual. to M. tuberculosis. The selection of cell type to be used in evaluating an immunogenic response to an antigen will of course depend on the desired response. For example, the production of interleukin-12 is more easily evaluated using preparations containing B cells and / or macrophages. An individual immune to M. tuberculosis is one that is considered resistant to the development of tuberculosis by virtue of having mounted an effective T cell response in M. tuberculosis (ie substantially free of disease symptoms). Said individuals can be identified based on a strongly positive intradermal skin test response (i.e., greater than approximately induration with diameter of mm) to tuberculosis proteins (PPD) and an absence of any signs of or symptoms of tuberculosis disease. T cells, NK cells, B cells and macrophages derived from individuals immune to M. tuberculosis can be prepared using methods known to those of ordinary skill in the art. For example, a preparation of PBMCs (ie peripheral blood mononuclear cells) can be used without further separation of the component cells. PBMCs in general can be prepared for example using density centrifugation through Ficoll ™ (Winthrop Laboratories, NY). T cells for use in the assays described herein can also be purified directly from PBMCs. Alternatively, an enriched T cell line reactive against microbacterial proteins or T cell clones reactive to individual mycobacterial proteins, it can be used. Such T cell clones can be generated for example by culturing PBMCs from individuals immune to M. tuberculosis with mycobacterial proteins for a period of 2-4 weeks. This allows expansion of only the T cells specific for mycobacterial protein, resulting in a line composed only of said cells. These cells can then be cloned and tested with individual proteins using methods known to those of ordinary skill in the art to more precisely define the specificity of individual T cells. In general, antigens that prove to be positive in assays for proliferation and / or cytokine production (ie production of gamma interferon and / or interleukin-12) performed using T cells, NK cells, B cells and / or macrophages derived from an individual immune to M. tuberculosis, are considered immunogenic.

Such assays may be performed for example using the representative procedures described below. Immunogenic portions of said antigens can be identified using similar assays, and may be present within the polypeptides described herein. The capacity of a polypeptide (for example, a immunogenic antigen, or a portion or another variant thereof) to induce cell proliferation, is evaluated by contacting cells (e.g., T cells and / or cells) NK) with the polypeptide and measure the proliferation of the cells. In general, the amount of polypeptide that is sufficient for evaluation of about 10 5 cells is in the range of about 10 ng / mL to about 100 μg / mL and is preferably about 10 μg / mL. Incubation of polypeptide with cells is typically done at 37 ° C for about six days. After incubation with polypeptide, the cells are assayed for a proliferative response that can be evaluated by methods known to those of ordinary skill in the art, such as exposing cells to a radiolabeled thymidine pulse and measuring incorporation of the label into cellular DNA. In general, a polypeptide that results at least in a threefold increase in proliferation on the background (i.e. the proliferation observed for cells grown without polypeptide) is considered capable of inducing proliferation. The ability of a polypeptide to stimulate the production of gamma interferon and / or interleukin-12 in cells can be assessed by contacting the cells with the polypeptide and measuring the level of gamma interferon or interleukin-12 produced by the cells. In general, the amount of polypeptide that is sufficient for the evaluation of about 10 5 cells is in the range of about 10 ng / mL to about 100 μg / mL and is preferably about 10 μg / mL. The polypeptide can, but does not require, being immobilized on a solid support, such as a biodegradable bed or microsphere, such as those described in US Pat. Nos. 4,897,268 and 5,075,109. Incubation of polypeptide with the cells is typically done at 37 ° C for about six days. Following incubation with polypeptide, the cells are assayed for gamma interferon and / or interleukin-12 (or one or more subunits thereof), which can be evaluated by methods known to those of ordinary skill in the art, such as an assay enzyme-linked immunosorbent (Enzyme-Linked Immunosorbent Assay) or in the case of the P70 IL-12 subunit, a bioassay such as an assay that measures T cell proliferation. In general, a polypeptide that results in production of at least 50 pg of gamma interferon per mL of cultivated supernatant (containing 104-105 T cells per mL), it is considered capable of stimulating the production of gamma interferon. A polypeptide that stimulates the production of at least 10 pg / mL of subunit IL-12 P70, and / or at least 100 pg / mL of subunit IL-12 P40, by 105 macrophages or B cells (or by 3 x 105 PBMC), it is considered capable of stimulating the production of IL-12. In general, immunogenic antigens are those antigens that stimulate proliferation and / or cytokine production (ie production of gamma interferon and / or interleukin-12) in T cells, NK cells, B cells and / or macrophages derived from at least about 25. % of individuals immune to M. tuberculosis. Among these immunogenic antigens, polypeptides having superior therapeutic properties can be distinguished based on the magnitude of the responses in the above assays and based on the percentage of individuals for whom a response is observed. In addition, antigens that have superior therapeutic properties will not stimulate the proliferation and / or production of in vitro cytokine. cells derived from more than about 25% of individuals that are not immune to M. tuberculosis, thereby eliminating responses that are not specifically due to cells that respond to M. tuberculosis.

Those antigens that induce a response in a high percentage of preparations of T cells, NK cells, B cells and / or macrophages from immune individuals of M. tuberculosis (with low incidence of responses in cellular preparations of other individuals) have superior properties therapeutic Antigens with superior therapeutic properties can also be identified based on their ability to decrease the severity of M. tuberculosis infection in experimental animals, when administered as a vaccine. Suitable vaccine preparations for use in experimental animals are described in detail below. The efficacy can be determined based on the ability of the antigen to provide at least about a 50% reduction in the number of bacteria and / or at least about a 40% decrease in mortality after experimental infection. Suitable experimental animals include mice, guinea pigs and primates. Antigens that have superior diagnostic properties can generally be identified based on the ability to produce a response in an intradermal skin test in an individual with active tuberculosis, but not in a test performed on an individual who is not infected with M. tuberculosis. Skin tests can generally be performed as described below with a response of at least one 5 mm induration considered positive. Immunogenic portions of the antigens described herein can be prepared and identified using well-known techniques, such as those summarized by Paul, Fundamental Immunology (Fundamental Immunology), 3a Edition, Raven Press, 1993, p. 243-247 and references cited therein. Such techniques include classifying polypeptide portions of the native antigen for immunogenic properties. The representative assays of proliferation and cytokine production described herein can generally be employed in these classifications. An immunogenic portion of a polypeptide is a portion that, with such representative assays, generates an immuno-response (e.g., proliferation, gamma interferon production and / or interleukin-12 production) that is substantially similar to that generated by the antigen. of full length. In other words, an immunogenic portion of an antigen can generate at least about 20% and preferably about 100% of the proliferation induced by the full-length antigen in the model proliferation assay described herein. An immunogenic portion can also or alternatively stimulate the production of at least about 20% and preferably about 100% of gamma interferon and / or interleukin-12 induced by the full-length antigen in the model assay described herein. Portions and other variants of M. antigens. tuberculosis can be generated by synthetic or recombinant means. Synthetic polypeptides having less than about 100 amino acids and generally less than about 50 amino acids, can be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides can be synthesized using any of the commercially available solid phase techniques, such as the Merrifield solid phase synthesis method, wherein amino acids are added sequentially to an increasing amino acid chain. See Merrifield, J. Am. Chem. Soc. 85: 2149-2146, 1963. Equipment for automated synthesis of the polypeptides is commercially available from suppliers such as Applied BioSystems, Inc., Foster City, CA, and may be operated in accordance with the manufacturer's instructions. Variants of a native antigen can generally be prepared using standard mutagenesis techniques such as oligonucleotide-directed site-specific mutagenesis. Sequences of the DNA sequence can also be removed using standard techniques to allow preparation of truncated polypeptides. Recombinant polypeptides containing portions and / or variants of a native antigen, can be easily prepared from a DNA sequence encoding the polypeptide using a variety of techniques well known to those of ordinary skill in the art. For example, supernatants of convenient vector / host systems that secrete recombinant protein into culture media can first be concentrated using a commercially available filter. Following the concentration, the concentrate can be applied to a convenient purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps may be employed, to further purify a recombinant protein. Any of a variety of expression vectors known to those of ordinary skill in the art may be used to express recombinant polypeptides of this invention. Expressions can be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule encoding a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli, yeast or a mammalian cell line such as COS or CHO. The DNA sequences expressed in this manner can encode antigens of natural origin, portions of antigens of natural origin or other variants thereof. In general, regardless of the method of preparation, the polypeptides described herein are prepared in substantially pure form. Preferably, the polypeptides are at least about 80% pure, more preferably at least about 90% pure, and especially at least about 99% pure. In certain preferred embodiments, which are described in detail below, the substantially pure polypeptides are incorporated into vaccines or pharmaceutical compositions for use in one or more of the methods described herein. In certain specific embodiments, the present invention describes polypeptides comprising at least an immunogenic portion of a M. tuberculosis soluble antigen having one of the following N-terminal sequences or its variant, which differs only in substitutions and / or conservative modifications: (a) Asp-Pro-Val-Asp-Ala-Val-Ile-Asn-Thr-Thr-Cys-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala-Leu; (SEQ ID No. 120) (b) Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro-Ala-Pro-Ser; (SEQ ID No. 121) (c) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg; (SEQ ID No. 122) (d) Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala-Trp-Gly-Pro; (SEQ ID No. 123) (e) As -Ile-Gly-Ser-Glu-Ser-Thr-Glu-sp-Gln-Gln-Xaa-Ala-Val; (SEQ ID No. 124) (f) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val-Pro; (SEQ ID No. 125) (g) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Ala-Ala-Ala-Ser-Pro-Pro-Ser; (SEQ ID No. 126) (h) Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly; (SEC ID No. 127) (i) Asp-Pro-Ala-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Al-Gln-Leu-Thr-Ser-Leu-Leu-Asn-Ser -Leu-Ala-Asp-Pro-Asn-Val-Ser-Phe-Ala-Asn; (SEQ ID No. 128) (j) Xaa-Asp-Ser-Glu-Lys-Ser-Ala-Thr-Ile-Lys-Val-Thr-Asp-Ala-Ser; (SEQ ID No. 134) (k) Ala-Gly-Asp-Thr-Xaa-Ile-Tyr-lle-Val-Gly-Asn-Leu-Thr-Ala-Asp; (SEQ ID No. 135) or (1) Ala-Pro-Glu-Ser-Gly-Ala-Gly-Leu-Gly-Gly-Thr-Val-Gln-Ala-Gly; (SEQ ID No. 136) wherein Xaa can be any amino acid, preferably a cysteine residue. A DNA sequence encoding the antigen identified as (g) above, is provided in SEQ ID NO. 52, and the polypeptide encoded by SE ID NO. 52 is provided in SEC ID NO. 53. A DNA sequence encoding the antigen defined as (a) above, is provided in SEQ ID NO. 101; its deduced amino acid sequence is provided in SEQ ID NO. 102. A DNA sequence corresponding to the antigen (d) above is provided in SEQ ID NO. 24, a DNA sequence corresponding to the antigen (c) is provided in SEC NO. 25 and a DNA sequence corresponding to antigen (i) is provided in SEQ ID NO. 99; its deduced amino acid sequence is provided in SEQ ID NO. 100. In a further specific embodiment, the present invention describes polypeptides comprising at least an immunogenic portion of an M. antigen. tuberculosis that has one of the following N-terminal sequences or its variant that differs only in substitutions and / or conservative modifications. (m) Xaa-Tyr-Ile-Ala-Tyr-Xaa-Thr-Thr-Ala-Gly-lle-Val-Pro-Gly-Lys-Ile-Asn-Val-His-Leu-Val; (SEQ ID No. 137) or (n) Asp-Pro-Pro-Asp-Pro-His-Gln-Xaa-Asp-Met-Thr-Lys-Gly-Tyr-Tyr-Pro-Gly-Gly-Arg- Arg-Xaa-Phe; (SEC ID No. 129) wherein Xaa can be any amino acid, preferably a cysteine residue. In other specific embodiments, the present invention describes polypeptides comprising at least an immunogenic portion of a soluble M. tuberculosis antigen (or a variant of said antigen) comprising one or more of the amino acid sequences encoded by (a) the DNA sequences of SEC ID NOS: 1, 2, 4-10, 13-25 and 52; (b) the complements of said DNA sequences, or (c) DNA sequences substantially homologous to a sequence in (a) or (b). In further specific embodiments, the present invention describes polypeptides comprising at least an immunogenic portion of a M. tuberculosis antigen (or a variant of said antigen) that may or may not be soluble, comprising one or more of the amino acid sequences encoded by (a) the DNA sequences of SEQ ID Nos: 26-51, 138, 139, 163-183 and 201, (b) the complements of these DNA sequences or (c) DNA sequences substantially homologous to sequence in (a) or (b). In the specific embodiments discussed above, M. tuberculosis antigens include variants that are encoded by DNA sequences that are substantially homologous to one or more of the DNA sequences specifically disclosed herein. "Substantial homology" as used herein, refers to DNA sequences that are capable of hybridizing under moderately stringent conditions. Convenient moderately stringent conditions include a pre-wash in a solution of 5X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridize at 50 ° C-65 ° C, 5X SCC, overnight or in the case of cross-species homology at 45 ° C, 0.5X SCC; -following washing twice at 65 ° C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS). These hybridizing DNA sequences are also within the scope of this invention, as are nucleotide sequences which, due to code degeneracy, encode an immunogenic polypeptide that is encoded by a hybridizing DNA sequence. In a related aspect, the present invention provides fusion proteins comprising a first and a second polypeptide of the invention or alternatively a polypeptide of the present invention and an antigen of M.known tuberculosis such as the 38 kD antigen described by Andersen and Hansen, Infect. Immun. 57: 2481-2488, 1989, (Genbank Accession No. M30046) or ESAT-6 (SEQ ID Nos. 103 and 104), together with variants of these fusion proteins. The fusion proteins of the present invention may also include a linker peptide between the first and second polypeptides. A DNA sequence encoding a fusion protein of the present invention is constructed using known recombinant DNA techniques to assemble separate DNA sequences encoding the first and second polypeptides into an appropriate expression vector. The 3 'end of the DNA sequence encoding the first polypeptide is ligated with and without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide, such that the reading frames of the sequences are in phase to allow mRNA translation of the two DNA sequences into a single fusion protein that retains the biological activity of both the first and second polypeptides. A peptide linker sequence can be used to separate the first and second polypeptides by a sufficient distance to ensure that each polypeptide is doubled in its secondary and tertiary structures. This peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences can be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) its inability to adopt a secondary structure that can interact with functional epitopes in the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that can react with functional polypeptide epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other almost neutral amino acids, such as Thr and Ala can also be employed in the linker sequence. Sequences of amino acids that can be used in a useful manner or linkers include those described in Maratea et al., Gene 40: 39-46, 1985; Murphy and collaborators, Proc. Na tl. Acad. Sci. USA 83: 8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Pat. No. 4,751,180. The linker sequence can be from 1 to about 50 amino acids in length. Peptide sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid Tregions that can be used to separate functional domains and prevent spherical interference. The ligated DNA sequences are operably linked for convenient transcriptional or transcriptional regulatory elements. The regulatory elements responsible for DNA expression are located only 5 'with respect to the DNA sequence encoding the first polypeptides. Similarly, stop codons required for end transcription and translational termination signals are only present 3 'to the DNA sequence encoding the second polypeptide. In another aspect, the present invention provides methods for using one or more of the above polypeptides or fusion proteins (or DNA molecules encoding said polypeptides) to induce protection immunity against tuberculosis in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may be affected with a disease or may be free of disease and / or detectable infection. In other words, protective immunity can be induced to prevent or treat tuberculosis. In that aspect, the polypeptide, fusion protein or DNA molecule, is generally present within a pharmaceutical composition and / or a vaccine. Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof) and a physiologically acceptable carrier. Vaccines may comprise one or more of the above polypeptides and a non-specific immune response enhancer such as an adjuvant or a liposome (in which the polypeptide is incorporated). These vaccines and pharmaceutical compositions may also contain other M. tuberculosis antigens, either incorporated in a combination of polypeptides or present within a separate polypeptide. Alternatively, a vaccine may contain DNA encoding one or more polypeptides as described above, such that the polypeptides are generated in itself. In these vaccines, the DNA can be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacterial and viral expression systems. Suitable nucleic acid expression systems contain the DNA sequences necessary for expression in the patient (such as convenient termination signal and promoter). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmete-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA can be introduced using a viral expression system. { for example vaccines or other viruses of rash, retrovirus or adenovirus) that may involve the use of a competent virus of non-pathogenic replication (defective). Techniques for incorporating DNA into these expression systems are well known to those of ordinary skill in the art. DNA can also be "naked", as described for example by Ulmer et al., Science 259: 1745-1749, 1993 and revised by Cohen, Science 259: 1691- 1692, 1993. The absorption of naked DNA can be increased by coating the DNA on biodegradable beads, which are transported efficiently in the cells. In a related asp a DNA vaccine as described above can be administered simultaneously or sequentially to any of a polypeptide of the present invention or a known antigen of M. tuberculosis, such as a 38 kD antigen described previously. For example, administration of DNA encoding a polypeptide of the present invention, either "naked" or in a delivery system as described above, can be followed by administration of an antigen in order to improve the immuno protve effof the vaccine . Routes and frequencies of administration as well as doses, will vary from individual to individual and may be parallel to those currently used in immunization using BCG. In general, the pharmaceutical compositions and vaccines can be administered by injon (for example intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (for example by aspiration) or orally. Between 1 and 3 doses can be administered for a period of 1-36 weeks. Preferably, 3 doses are administered at 3-4 month intervals and booster vaccines can be delivered periodically. Alternate protocols may be appropriate for individual patients. A convenient dose is an amount of polypeptide or DNA that when administered as described above, is capable of raising an immune response in an immunized patient, sufficient to protthe patient against M. tuberculosis infon for at least 1 to 2 years. In general, the amount of polypeptide present in a dose (or produced in itself by the DNA in a dose) is in the range of about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg , and preferably about 100 pg to about 1 μg. Suitable dose sizes will vary with the patient size, but typically are in the range of about 0.1 mL to about 5 mL. While any convenient carrier known to those of ordinary skill in the art can be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injon, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose and magnesium carbonate, may be employed. Biodegradable microspheres (for example galactide polylactic) can also be used as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are described, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,109. Any of a variety of adjuvants can be employed in the vaccines of this invention to nonspecifically improve the immune response. Most adjuvants contain a substance designed to protthe antigen against rapid catabolism such as aluminum hydroxide or mineral oil, and a non-specific stimulator of immune response such as lipid A, Bortadella pertusis or Mycobacterium tuberculosis. Adjuvants Convenient are commercially available for example as Incomplete Freund's Adjuvant and Freund's Complete Adjuvant (Difco Laboratories) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ). Other suitable adjuvants include alum, biodegradable microspheres, monophosphoryl lipid A, and quil A. In another asp this invention provides methods for using one or more of the polypeptides described above to diagnose tuberculosis, using a skin test. As used herein, a "skin test" is any test performed directly on a patient in which a delayed-type hypersensitivity (DTH) reaction (such as swelling, redness, or dermatitis) is measured. ) after intradermal injection of one or more polypeptides as described above. This injection can be accomplished using any convenient device sufficient to contact the polypeptide or polypeptides with skin cells of the patient, such as a tuberculin syringe or 1 mL syringe. Preferably, the reaction is measured at least 48 hours after injection, more preferably after 48-72 hours. The DTH reaction is a cell-mediated immune response, which is higher in patients who have previously been exposed to the test antigen (i.e. the immunogenic portion of the polypeptide employed or its variant). The answer can be measured visually, using a rule. In general, the response that is greater than about 0.5 cm in diameter, preferably greater than about 1.0 cm in diameter, is a positive response indicative of tuberculosis infection, which may or may not be manifested as an active disease. The polypeptides of this invention are preferably formulated for use in a skin test as a pharmaceutical composition containing a polypeptide and a physiologically acceptable carrier as described above. These compositions typically contain one or more of the above polypeptides in an amount in the range of about 1 μg to about 100 μg, preferably about 10 μg to about 50 μg in a volume of 0.1 mL. Preferably, the carrier employed in said pharmaceutical compositions is a saline solution with appropriate preservatives such as phenol and / or Tween 80MR. In a preferred embodiment, a polypeptide employed in a skin test is of sufficient size to remain at the site of injection for the duration of the reaction period. In general, a polypeptide that is at least 9 amino acids in length is sufficient. The polypeptide is also preferably decomposed by macrophages at injection times to allow presentation to T cells. These polypeptides may contain repeats of one or more of the above sequences and / or other immunogenic or non-immunogenic sequences. The following Examples are offered by way of illustration and not by way of limitation. EXAMPLES EXAMPLE 1 PURIFICATION AND CHARACTERIZATION OF POLYPEPTIDES OF FILTRATION OF CULTIVATION OF M. TUBERCULOSIS This example illustrates the preparation of soluble M. tuberculosis polypeptides by culture filtrate. Unless otherwise noted, all percentages in the following example are given by weight by volume. M. tuberculosis (any of H37Ra, ATCC No. 25177 or H37Rv, ATCC No. 25618) is grown in sterile GAS medium at 37 ° C for fourteen days. The medium is then vacuum filtered (leaving the volume of the cells) through a 0.45 μ filter to a sterile 2.5 L bottle. The medium is then passed through a 0.2 μ filter into a sterile 4 ml bottle. L, and NaN3 is added to the culture filtrate at a concentration of 0.04%. The bottles are then placed in a cold room at 4 ° C.

The culture filtrate is concentrated by placing the filtrate in a 12 L tank which has been autoclaved and supplying the filtrate in a 400 ml Amicon agitation cell that has been rinsed with ethanol and contains a MWCO membrane of 10,000 kDa. The pressure is maintained at 4.22 kg / cm2 (60 psi) using nitrogen gas. This procedure reduces the volume from 12 L to approximately 50 ml. The culture filtrate is dialyzed in 0.1% ammonium bicarbonate using a cellulose ester membrane MWCO of 8,000 kDa, with two changes of ammonium bicarbonate solution. The protein concentration is then determined by a commercially available BCA assay (Pierce, Rockford, IL). The dialyzed culture filtrate is then lyophilized, and the polypeptides are resuspended in distilled water. The polypeptides were dialyzed against 0.01 mM 1,3-bis [tris (hydroxymethyl) -methylamino] propane, pH 7.5 (Bis-Tri propane buffer), the initial conditions for anion exchange chromatography. Fractionation was performed using gel perfusion chromatography on a POROS 146 II Q / M 4.6 mm × 100 mm anion exchange column (Perseptive BioSystems, Framingham, MA) equilibrated in 0.01 mM Bis-Tris propane buffer with pH 7.5. Polypeptides were eluted with a linear 0-0.5 M NaCl gradient in the above buffer system. The column eluent is verified at a wavelength of 220 nm. Those collected from polypeptides eluting from the anion exchange column were dialyzed against distilled water and lyophilized. The resulting material is dissolved in 0.1% trifluoroacetic acid (TFA) pH 1.9 in water, and the polypeptides were purified on a Delta-Pak C18 column (Waters, Milford, MA) pore size of 300 Angstroms, particle size 5 microns ( 3.9 x 150 mm). The polypeptides were eluted from the column with a linear gradient of 0-60% dilution buffer (0.1% TFA in acetonitrile). The flow rate was 0.75 ml / minute and the HPLC eluent was verified at 214 nm. Fractions containing the eluted polypeptides are harvested to maximize the purity of the individual samples.

Approximately 200 purified polypeptides were obtained. The purified polypeptides were then screened or sorted for the ability to induce T cell proliferation in PBMC preparations. The PBMCs from donors known as positive skin test PPDs and whose T cells were shown to proliferate in response to PPD and soluble proteins in MTB crude were cultured in medium comprising RPMI 1640 supplemented with 10% human serum and 50%. μg / ml gentamicin. Purified polypeptides were added in duplicate at concentrations of 0.5 to 10 μg / mL. After six days of culture in 96-well round bottom plates in a volume of 200 μl, 50 μl of medium is removed from each well for determination of IFN-gamma levels as described below. The plates were then pulsed with 1 μCi / well of tritiated thymidine for an additional 18 hours, harvested and the tritium uptake was determined using a gas flash counter. Fractions that resulted in proliferation in both replicates three times greater than the proliferation observed in cells cultured in medium alone, were considered positive. IFN-gamma was measured using an enzyme-linked immunosorbent assay (ELISA = Enzyme-Linked Immunosorbent Assay). ELISA plates were coated with a mouse monoclonal antibody directed to human IFN-gamma (PharMingen, San Diego, CA) in PBS for four hours at room temperature. Then wells were blocked with PBS containing 5% (P / V) dehydrated milk without fat, for 1 hour at room temperature. The plates were then washed six times in PBS / 0.2% TWEEN-20 and samples diluted 1: 2 in culture medium in the ELISA plates were incubated overnight at room temperature. The fresh plates were washed and a polyclonal rabbit anti-human IFN-gamma serum diluted 1: 3000 in PBS / 10% normal goat serum was added to each well. The plates were then incubated for two hours at room temperature, washed and anti-rabbit IgG coupled with horseradish peroxidase (Sigma Chemical So., St. Louis, MO) was added at a dilution of 1: 2000 in PBS / dehydrated milk without 5% fat. After two additional hours of incubation at room temperature, the plates were washed and TMB substrate was added. The reaction was stopped after 20 minutes with 1 N sulfuric acid. Optical density was determined at 450 nm using 570 nm as the reference wavelength. Fractions that resulted in both replicates giving a double OD greater than the average OD of cells cultured in medium alone, plus 3 standard deviations, were considered positive. For sequencing, the polypeptides were individually dried on glass fiber filters treated with Biobrene ™ (Perkin Elmer / Applied BioSystems Division, Foster City, CA). Filters with polypeptides were loaded on a Perkin Elmer / Applied BioSystems Procise 492 Protein Sequencer. The polypeptides were sequenced from the mino terminal and using traditional Edman chemistry. The amino acid sequence is determined for each polypeptide by comparing the retention time of the PTH amino acid derivative to the appropriate PTH derivative standards.

Using the procedure described above, antigens having the following N-terminal sequences were isolated: (a) Asp-Pro-Val-Asp-Ala-Val-Ile-Asn-Thr-Thr-Xaa-Asn-Tyr-Gly-Gln -Val-Val-Ala-Ala-Leu; (SEQ ID No. 54) (b) Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro-Ala-Pro-Ser; (SEQ ID No. 55) (c) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg; (SEQ ID No. 56) (d) Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala-Trp-Gly-Pro; (SEQ ID No. 57) (e) Asp-Ile-Gly-Ser-Glu-Ser-Thr-Glu-Asp-Gln-Gln-Xaa-Ala-Val; (SEQ ID No. 58) (f) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val-Pro; (SEQ ID No. 59) (g) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Ala-Ala-Ala-Ala-Pro-Pro-Ala; (SEQ ID No. 60) and (h) Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly; (SEQ ID No. 61) wherein Xaa can be any amino acid. An additional antigen is isolated using a HPLC microperforation purification step in addition to the procedure described above. Specifically, 20 μl of a fraction comprising a mixture of antigens from the previously described chromatographic purification step is purified on an Aquapore C18 column (Perkin Elmer / Applied Biosystems Division, Foster City, CA) with a pore size of 7 microns , column size 1 mm x 100 mm, in HPLC Perkin Elmer / Applied Biosystems Division Model 172. Fractions in the column were eluted with a linear gradient of 1% / minute acetonitrile (containing 0.05% TFA) in water (0.05 % TFA) at a flow rate of 80 μl / minute. The eluent was verified at 250 nm. The original fraction is separated into four major peaks plus other smaller components and a polypeptide is obtained which is illustrated to have a molecular weight of 12,054 Kd (by mass spectrometry) and the following N-terminal sequence: (i) Asp-Pro- Ala-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Gln-Thr-Ser-Leu-Leu-Asn-Asn-Leu-Ala-Asp-Pro-Asp-Val-Ser- Phe-Ala-Asp (SEC ID No. 62). This polypeptide is shown to induce proliferation and IFN-gamma production in PBMC preparations, using the assays described above. Additional soluble antigens were isolated from M. tuberculosis culture filtrate as follows.

Culture filtrate of M. tuberculosis is prepared as described above. After dialysis against Bis-Tris propane buffer, at pH 5.5, fractionation is performed using anion exchange chromatography on a Poros QE 4.6 x 100 mm column (Perseptivé Biosystems) equilibrated in Bis-Tris propane buffer pH 5.5. Polypeptides were eluted with a linear gradient of 0-1.5 M NaCl in the above buffer system at a flow rate of 10 ml / min. The column eluent is verified at a wavelength of 214 nm. Fractions eluting from the ion exchange column were pooled and subjected to reverse phase chromatography using a Poros R2 4.6 x 100 mm column (Perseptive Biosystems). The polypeptides were eluted from the column with a linear gradient of 0-100% acetonitrile (0.1% TFA) at a flow rate of 5 ml / min. The eluent was verified at 214 nm. Fractions containing the eluted polypeptides were lyophilized and resuspended in 80 μl of 0.1% aqueous TFA and further subjected to reverse phase chromatography on a Vydac C4 4.6 × 150 mm column (Western Analytical, Temecula, CA) with a linear gradient of 0- 100% acetonitrile (0.1% TFA) at a flow rate of 2 ml / min. The eluent is verified at 214 nm. The fraction with biological activity is separated into a main peak plus other smaller components. Western blotting of this peak on PVDF membrane revealed three major bands of molecular weights 14 Kd, 20 Kd and 26 Kd. These polypeptides were determined to have the following N-terminal sequences, respectively: (j) Xaa-Asp-Ser-Glu-Lys-Ser-Ala-Thr-Ile-Lys-Val-Thr-Asp-Ala-Ser; (SEC ID No. 134) (k) Ala-Gly-Asp-Thr-Xaa-Ile-Tyr-Ile-Val-Gly-Asn-Leu-Thr-Ala-Asp; (SEQ ID No. 135) and (1) Ala-Pro-Glu-Ser-Gly-Ala-Gly-Leu-Gly-Gly-Thr-Val-Gln-Ala-Gly; (SEQ ID No. 136) wherein Xaa can be any amino acid. Using the assays described above, it was shown that these polypeptides induce proliferation and IFN-gamma production in PBMC preparations. Figures IA and IB show the results of these assays using PBMC preparations of a first and second donor, respectively. DNA sequences encoding the antigens designated (a), (c), (d) and (g) above are obtained by screening a genomic M. tuberculosis library using degenerate oligonucleotides labeled at the end 32P corresponding to the N-terminal sequence and containing codon derivation M. tuberculosis. The Classification performed using an area corresponding to antigen (a) above identifies a clone having the sequence provided in SEQ ID No. 101. The polypeptide encoded by SEQ ID No. 101 is provided in SEQ ID No. 102. Classification performed using a probe corresponding to antigen (g) above identifies a clone having the sequence provided in SEQ ID No. 52. The polypeptide encoded by SEQ ID No. 52 is provided in SEQ ID No. 53. classification performed using a probe corresponding to the antigen (d) above, identifies a clone having the sequence provided in SEQ ID No. 24, and the classification made with a probe corresponding to the antigen (c) identifies a clone that has the sequence provided in SEQ ID No. 25. The above amino acid sequences were compared to known amino acid sequences in the gene bank using the STAR DNA system. The searched database contains approximately 173,000 proteins and is a combination of Swiss, PIR databases, along with translated protein sequences (Version 87). No significant homologies were detected to the amino acid sequences for the antigens (a) - (h) and (1). The amino acid sequences for the antigen (i) it is found to be homologous with a sequence of M. leprae The entire length sequence of M. leprae is amplified from the genomic DNA using the sequence obtained from GENBANK. This sequence is then used to classify the M. tuberculosis library described below in Example 2, and a full length copy of the M. tuberculosis homologue is obtained (ID of SEC No. 99). The amino acid sequence for the antigen (j) is found to be homologous to a protein of M. known tuberculosis that results in a sequence of DNA To the best of the knowledge of the inventors, it has not previously been shown that this protein possesses T cell stimulatory activity. The amino acid sequence for the antigen (k) is related to a sequence of M. leprae. In the IFN-gamma and proliferation assays described above, using three PPD positive donors, the results for representative antigens given above are presented in Table 1: TABLE 1 TEST RESULTS OF IFN-GAMMA AND PROLIFERATION PBMC Sequence Proliferation IFN-amma (a) + (c) +++ +++ (d) ++ ++ (g) +++ +++ (h) +++ +++ In Table 1, the responses that gave an index of stimulation (SI) of between 2 and 4 (compared to cells cultured in medium alone) were classified as +, an SI of 4-8 or 2-4 at a concentration of 1 μg or less were classified as ++ and an SI greater than 8 were classified as +++. The antigen of sequence (i) is found to have a high SI (+++) for one donor and lower IS (++ and +) for the other two donors in both proliferation assays and IFN-gamma. These results indicate that these antigens are capable of inducing proliferation and / or gamma interferon production. EXAMPLE 2 USE OF PATIENT SERUM TO INSULATE M. TUBERCULOSIS ANTIGEN This example illustrates the isolation of antigens from M. tuberculosis lysate when sorting with serum from individuals infected with M. tuberculosis. M. tuberculosis dried H37Ra (Difco Laboratories) is added to a 2% NP40 solution and alternatively homogenized and sonicated three times. The resulting suspension is centrifuged at 13,000 rpm in microfuge tubes and the non-donor is placed through a 0.2 ml syringe filter. The filtrate is ligated to Macro Prep DEAE beads (BioRad, Hercules, CA). The beads were extensively washed with 20 mM Tris pH 7.5 and ligated proteins are eluted with 1 M NaCl. The 1 M NaCl eluate is dialyzed overnight against 10 mM Tris, pH 7.5.

Dialysed solution is treated with DNase and RNase at 0.05 mg / ml for 30 minutes, at room temperature and then with alpha-D-mannosidase, 0.5 U / mg at pH 4.5 for 3-4 hours at room temperature. After returning to pH 7.5, the material is fractionated by FPLC on a Bio Scale-Q-20 column.

(BioRad). The fractions were combined in nine harvested, concentrated in a Centriprep 10 (Amicon, Beverly, MA) and then classified by Western blotting for serological activity using a serum pool from patients infected with M. tuberculosis who were not immuno reactive with other antigens of the present invention. The most reactive fraction is run on SDS-PAGE and transferred to PVDF. A band of approximately 85 Kd is cut giving the sequence: (m) Xaa-Tyr-Ile-Ala-Tyr-Xaa-Thr-Thr-Ala-Gly-Ile-Val-Pro-Gly-Lys-Ile-Asn-Val -His-Leu-Val; (SEQ ID No. 137), wherein Xaa can be any amino acid. Comparison of this sequence with those in the gene bank as described above, did not reveal significant homologies with known sequences.

A DNA sequence encoding the antigen designated as (m) above is obtained by classifying a genomic Erdman M. tuberculosis strain library using labeled degenerate oligonucleotides corresponding to the N-terminal sequence of SEQ ID No. 137. A clone having the DNA sequence that is provided in SEQ ID No. 203. This sequence found to encode the amino acid sequence is provided in SEQ ID No. 204. Comparison of these sequences with those in the gene bank reveals some similarity to sequences previously identified in M. tuberculosis. EXAMPLE 3 PREPARATIONS OF DNA SEQUENCES CODING M. TUBERCULOSIS ANTIGENS This example illustrates the preparation of DNA sequences encoding M. tuberculosis antigens by classifying an M. tuberculosis expression library with sera obtained from patients infected with M. tuberculosis or with antisera developed against M. tuberculosis soluble antigens.

A. PREPARATION OF SOLUBLE ANTIGENS IN M. TUBERCULOSIS USING RABBIT ANTIBODIES AGAINST M. SUPPLIER TUBERCULOSIS Genomic DNA is isolated from M. tuberculosis strain H37Ra. The DNA is randomly sheared and used to construct an expression library using the Lambda ZAP expression system (Stratagene, La Jolla, CA). Anti-rabbit serum was generated against secretory proteins of the M. tuberculosis strains H37Ra, H37Rv and Erdman when immunising a rabbit with concentrated supernatant of cultures of M. tuberculosis. Specifically, the rabbit is first immunized subcutaneously with 200 μg of protein antigen in a total volume of 2 ml containing 10 μg of muramyl dipeptide (Calbiochem, La Jolla, CA) and 1 ml of incomplete Freund's adjuvant. Four weeks later the rabbit was boosted subcutaneously with 100 μg of antigen in incomplete Freund's adjuvant. Finally, the rabbit is immunized intravenously four weeks later with 50 μg of antigen protein. The anti-sera were used to classify the expression library as described by Sambrook et al., Molecular Cloning: A Laboratory Manual (Molecular Cloning: A Laboratory Manual), Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989. Bioteriophage plates expressing immunoreactive antigens were purified. Phagemids are rescued from the plates and the nucleotide sequences of the M. tuberculosis clones are deduced. Thirty-two clones were purified. Of these 25 represent sequences that have not been previously identified in human M. tuberculosis. Recombinant antigen was expressed and purified antigens used in the immunological analysis described in Example 1. Proteins were induced by IPTG and purified by gel elution, as described by Skeiky et al., "Exp. Med. 181: 1527-1537, nineteen ninety five.

Representative sequences of DNA molecules identified in this classification are provided in SEQ ID Nos. 1-25. The corresponding predicted amino acid sequences are illustrated in SEQ ID Nos. 63-87. Upon comparison of these sequences with known sequences in the gene bank using the databases described above, it was found that the clones referred to below as TbRA2A, TbRA16, TbRA18 and TbRA29 (SEQ ID Nos. 76, 68, 70, 75) some show homology to sequences previously identified in Mycobacterium leprae but not in M. tuberculosis. TbRAll, TbRA26, TbRA28 and TbDPEP (SEQ ID Nos .: 65, 73, 74, 53) have previously been identified in M. tuberculosis. No significant homologies were found for TbRAl, TbRA3, TbRA4, TbRA9, TbRAl0, TbRAl3, TbRAl7, TbRal9, TbRA29, TbRA32, TbRA36 and the translatory clones TbRA35 and TbRA12 (SEQ ID Nos. 63, 77, 81, 82, 64, 67, 69, 71, 75, 78, 80, 79. 66). The TbRa24 clone is overlaid with the TbRa29 clone. The results of PBMC and gamma interferon proliferation assays performed on representative recombinant antigens and using T cell preparations from various different M. tuberculosis immune patients are presented in Tables 2 and 3, respectively. TABLE 2 RESULTS OF PROLIFERATION OF PBMC TO REPRESENTATIVE SOLUBLE ANTIGENS Patient Antigen 1 2 3 4 5 6 7 8 9 10 11 12 13 TbRal - - + ++ + + - '- + ± - TbRa3 - +. ++ -T TbbRRaa99 - - nntt nntt ++ ++ nt nt nt nt nt nt nt TbRalO - - + + ± + nt. + - + ± ± - TbRall ± +. + ++ ++ + nt - ++ ++ ++ +, nt TbRal2 - - + + ± ++ + ± ± - + - - TbRal6 nt nt nt nt + nt nt nt nt nt nt nt T TbbRRaa2244 nntt nntt nntt nntt - - nt nt nt nt nt nt nt TABLE 2 (Cont.) RESULTS OF PROLIFERATION OF PBMC TO REPRESENTATIVE SOLUBLE ANTIGENS Patient Antigen 1 3 4 5 6 7 8 9 10 11 12 13 TbRa26 - + nt nt nt nt nt nt nt nt nt nt TbRa29 nt nt nt nt nt nt nt nt nt nt nt TbRa35 ++ nt ++ ++ ++ ++ nt ++ ++ ++ ++ nt TbRaB nt nt nt nt - - nt nt nt nt nt nt nt nt TbRaC nt nt nt nt nt nt nt nt nt nt nt TbRaD nt nt nt nt nt nt nt nt nt nt nt AAMK - - + - nt - nt ji nt YY - nt - nt + nt DPEP - + - ++ nt ++ _ + + _ + + nt Control - - - _ _ _ _ _ _ _ nt = not tested TABLE 3 GAMMA PRODUCTION RESULTS INTERFERONE PBMC TO REPRESENTATIVE SOLUBLE ANTIGENS Patient Antigen 1 2 3 4 5 6 7 8 9 10 11 12 13 TbRal + ++ +++ + TbRa3 - + ++ - ± - - ++ ± - TbRa9 ++ + nt nt ++ - nt nt nt nt nt nt nt TbRal0 + + + + + + nt + - + + + TABLE 3 (Cont.) RESULTS OF GAMMA PRODUCTION INTERFERONE PBMC TO REPRESENTATIVE SOLUBLE ANTIGENS Patient Antigen 1 2 3 4 5 6 7 8 9 10 11 12 13 TbRall ± + ++ ------ + nt - ++ ++ ------ ± nt TbRal2 - - + + +. --------- + ± +. - + - - TbRal6 nt nt nt nt + + nt nt nt nt nt nt nt TbRa24 nt nt nt nt + - nt nt nt nt nt nt nt nt TbRa26 ++ ++ nt nt + + nt nt nt nt nt nt nt TbRa29 nt nt nt nt + - nt nt nt nt nt nt nt nt TbRa35 ++ nt ++ ++ +++ --------- nt ++ ++ +++ --------- ++ nt TbRaB nt nt nt nt ++ + nt nt nt nt nt nt nt TbRaC nt nt nt nt nt + + nt nt nt nt nt nt nt nt TbRaD nt nt nt nt nt + + nt nt nt nt nt nt nt AAMK - - + - - - nt - - - nt ± nt YY - - - - - - nt - - - nt + nt DPEP + + + +++ + - nt +++ + + ± +. nt fr-nf-rn'1 In Tables 2 and 3, responses that gave a stimulus index (SI) of between 1.2 and 2 (compared to cells grown in medium alone), were classified as +, an SI of 2-4 is classified as +, a IF 'of 4-8 or 2-4 at a concentration of 1 μg or less, it is classified as ++ and an SI greater than 8 is classified as +++. In addition, the concentration effect on proliferation and gamma interferon production is shown for two of the above antigens in the attached Figure. Both for proliferation and gamma interferon production, TbRa3 is classified as ++ and TbRa9 as +. These results indicate that these soluble antigens can induce proliferation and / or production of gamma interferon in T cells derived from an immune individual of M. tuberculosis. B. USE OF PATIENT SERIES THAT HAVE PLEURAL OR PULMONARY TUBERCULOSIS TO IDENTIFY DNA SEQUENCES OR CODE ANTIGENS FROM M. TUBERCULOSIS The genomic DNA library described above, and an additional H37Rv library are classified using collected sera obtained from patients. with active tuberculosis. To prepare the H37Rv library, H37Rv genomic DNA strain M. tuberculosis is isolated, subjected to partial Sau3A digestion and used to construct an expression library using the Lambda Zap expression system (Stratagene, La Jolla, CA). Three different sera collected, each containing sera obtained from three individuals with active pleural or pulmonary disease, are used in the expression classification. The collected ones are designated TbL, TbM and TbH, with reference to relative reactivity with H37Ra lysate (ie TbL = low reactivity, TbM = mean reactivity and TbH) = high reactivity) both in ELISA format and immunoblotting. A fourth collection of sera from seven patients with active pulmonary tuberculosis is also used. All sera lack increased reactivity with the recombinant 38 kD M. tuberculosis phosphate-binding protein H37Ra. All the collections were pre-adsorbed with E. coli lysate and used to classify the H37Ra and H37Rv expression libraries, as described by Sambrook et al., Molecular Cloning: A Labora tory Manual (Molecular Cloning: A Manual of Laboratory), Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989. Bacteriophage plates expressing immunoreactive antigens were purified. Phagemid of the plates was rescued and the nucleotide sequences of the M. tuberculosis clones were deduced.

Thirty-two clones were purified. Of these, 31 represent sequences that have not previously been identified in human M. tuberculosis. Representative sequences of the identified DNA molecules are provided in SEQ ID Nos .: 26-51 and 105. Of these TbH8-2 (SEQ ID No. 105) is a partial clone of TbH-8 and TbH-4 (ID of SEQ. No. 43) and TbH-4-FWD (SEQ ID No. 44) are non-contiguous sequences of the same clone. Amino acid sequences for the antigens previously identified as Tb38-1, TbH4, TbH-8, TbH9 and TbH-12 are illustrated in SEQ ID Nos .: 88-92. Comparison of these sequences with known sequences in the gene bank using the databases identified above, does not reveal significant homologies to TbH-4, TbH-8, TbH9 and TbM-3, although weak homologies were found in TbH-9. TbH-12 is found to be homologous to a 34 kD antigenic protein previously identified in M. paratuberculosis (Acc.

No. S28515). Tb38-1 is found to be located 34 base pairs upstream of the open reading frame for the ESAT-6 antigen previously identified in M. bovis (Acc No. U34848) and in M. tuberculosis (Sorensen et al., Infec. Immun 63: 1710-1717, 1995). Probes derived from Tb38-1 and TbH-9, both isolated from a H37Ra library, were used to identify clones in an H37Rv library. Tb38-1 hybridized on Tb38-1F2, Tb38-1F3, Tb38-1F5 and Tb38-1F6 (SEQ ID Nos .: 112, 113, 116, 118 and 119). (SEQ ID Nos .: 112 and 113 are non-contiguous sequences of clone Tb38-1F2). Two open reading frames are deduced in Tb38-1F2; one corresponds to Tb37FL (SEQ ID No. 114), the second, a partial sequence can be homologous to Tb38-1 and is termed Tb38-IN (SEQ ID No. 115). The deduced amino acid sequence of Tb38-1F3 is presented in SEQ ID No. 117. A TbH-9 probe identifies three clones of the H37Rv: TbH-9-FL library (SEQ ID No. 106), which may be the homologue of TbH-9 (R37Ra), TbH-9-1 (SEQ ID No. 108) and TbH-9-4 (SEQ ID No. 110), all of which are sequences highly related to TbH-9. The deduced amino acid sequences for these three clones are presented in SEQ ID Nos. 107, 109 and 111. Further classification of the genomic DNA library of M. tuberculosis as described above results in the recovery of ten additional reactive clones representing seven different genes. One of these genes is identified as the 38 Kd antigen discussed above, one is determined to be identical to the 14 Kd crystalline alpha heat shock protein previously shown to be present in M. tuberculosis, and a third is determined identical to the TbH-8 antigen described above. The DNA sequences determined for the five remaining clones (hereinafter referred to as TbH-29, TbH-30, TbH-32 and TbH-33) are provided in SEQ ID NO: 138-141 respectively with predicted amino acid sequences corresponding ones that are provided in SEQ ID NO: 142-145, respectively. The amino acid and DNA sequences for these antigens were compared with those in the gene bank as described above. No homologies were found at the 5 'end of TbH-29 (containing the reactive open reading frame) although the 3' end of TbH-29 is found to be identical to the cosmid Y227 of M. tuberculosis. TbH-32 and TbH-33 are identical with the insertion element of M. tuberculosis IS6110 and the cosmid Y50 of M. tuberculosis, respectively. No significant homologies were found for TbH-30. Positive phagemids from this additional classification are used to infect E. coli XL-1 Blue MRF ', as described in Sambrook et al., above. Induction of recombinant protein is achieved by the addition of IPTG. Induced and non-induced lysates are run in duplicate between SDS-PAGE and transferred to nitrocellulose filters. Filters were reacted with serum of human M. tuberculosis (dilution 1: 200) reactive with TbH and a rabbit serum (dilution 1: 200 or 1: 250) reactive with portion 4 Kd N-terminal of lacZ. Incubations of serum were performed for 2 hours at room temperature. Ligated antibody is detected by addition of labeled 125I-Protein A and subsequent exposure to film for varying times in the range of 16 hours to 11 days. The results of the immunoblots are summarized in Table 4. TABLE 4 Human serum Antiaenous serum M. tb Anti-lacZ TbH-29 45 Kd 45 Kd TbH-30 Without reactivity 29 Kd TbH-32 12 Kd 12 Kd TbH-33 16 Kd 16 Kd Positive reaction of M. antigens. recombinant human tuberculosis with both human serum M. tuberculosis and anti-lacZ serum indicates the reactivity of human M. tuberculosis sera to the fusion protein.

Antigens reactive with anti-lacZ sera but not with human M. tuberculosis sera may be the result that the human serum M. tuberculosis recognizes conformational epitopes or the antigen-antibody binding kinetics may be such that serum exposure of 2 hours in the immunoblot is not sufficient.

The results of the T cell assays performed on Tb38-1, ESAT-6 and other representative recombinant antigens are presented in Tables 5A, B and 6 respectively below: TABLE 5A RESULTS OF PROLIFERATION OF PBMC TO REPRESENTATIVE ANTIGENS Donor Antigen 1 2 3 4 5 6 Tb38.1 +++ + - - - ++ ESAT-6 +++ + + + - + TbH-9 --- + ++ - + + ± ± TABLE 5A CONTINUATION Donor Antigen 10 11 Tb38.1 ++ +++ ESAT-6 ++ --------- TbH-9 ++ ------ ++ ++ ++ TABLE 5B RESULTS OF PRODUCTION OF GAMMA INTERFERONE PBMC TO REPRESENTATIVE ANTIGENS Antiane Donor 8 10 11 Tb38.1 +++ +++ +++ ++++ --------- ESAT-6 +++ +++ +++ +++ TABLE 5B (Cont.) PRODUCTION RESULTS OF GAMMA INTERFERONE PBMC TO REPRESENTATIVE ANTIGENS Antiane Donor 10 11 TbH- 9 ------ ++ --------- ---- ----- +++ ++ --------- ++ TABLE 6 SUMMARY OF REPLIES OF CELL-T TO REPRESENTATIVE ANTIGENS Gamma-interferon Anti-pacient Proliferation. pacien pacien pacien pacien pacien Total Gen 4 5 6 4 5 6 TbH9 ------ ++ ++ --------- ++ ++ 1.3 TbM7 - + - ++ + 4 TbH5 - + + ++ ------ ++ 8 TbL23 - + + ++ ------ + 7.5 TbH4 - ------ + ++ ++ + 7 control _ _ _ _ _ 0 These results indicate that both the antigens of M. tuberculosis of the invention and ESAT-6 can induce proliferation and / or production of gamma interferon in T cells derived from an individual immune to M. tuberculosis. To the best of the knowledge of the inventors, it has not been previously shown that ESAT-6 stimulates human immune responses. A set of six overlapping peptides covering the amino acid sequence of the Tb38-1 antigen is constructed using the method described in Example 6. The sequences of these peptides, hereinafter referred to as pepl-6, are given in SEQ ID. No. 93-98, respectively. The results of T-cell assays using these peptides are shown in Tables 7 and 8. These results confirm the existence and help localize T-cell epitopes within Tb38-1 capable of inducing proliferation and gamma-interferon production in T-cells derived from an individual immune to M. tuberculosis. TABLE 7 RESULTS OF PROLIFERATION OF PBMC TO PEPTIDES TB38-1 Peptide Patient 6 8 10 11 12 13 pepl + + pep2 + + + pep3 pep4 ++ + + pep5 ------ + + + pep6 - ----- - + + control- TABLE 8 RESULTS OF GAMMA-INTERFERONE PRODUCTION PBMC TO PEPTIDES TB38-1 Peptide Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 pepl + pep2 + - - - + +. + pep3 +. - + TABLE 8 (Cont.) GAMMA- INTERFERONE PRODUCTION RESULTS PBMC TO PEPTIDES TB38-1 Peptide Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 pep4 ++ - - - - - + - +. + - - + pep5 ++ ± - - - - + - +, - - - + pep6 + ++ - - - - ± - ± + - - + control- - - - _ _ _ _ _ _ _ _ _ Studies were carried out to determine whether the TbH-9 and Tb38- antigens 1 represent cellular proteins or are secreted in M. tuberculosis culture media. In the first study, serum from rabbits develops against A) secretory proteins of M. tuberculosis, B) antigen 85b of known recombinant M. tuberculosis secretory, C) recombinant Tb38-1 and D) recombinant TbH-9, using substantially protocols same as those described in Example 3A. Lysate from total M. tuberculosis, concentrated culture supernatant of M. tuberculosis and the recombinant antigens 85b, TbH-9 and Tb38-1 were resolved on denaturing gels, immobilized on nitrocellulose membranes and duplicated stains were probed using rabbit sera described above. The results of these analyzes using control sera (panel I) and antisera (panel II) against secretory proteins, recombinant 85b, recombinant Tb38-1 and recombinant TbH-9, are illustrated in Figures 3A-D respectively, wherein the designations of clues are as follows: 1) molecular weight protein standards; 2) 5 μg of M. tuberculosis lysate; 3) 5 μg of secretory proteins; 4) 50 ng of recombinant Tb38-1; 5) 50 ng of recombinant TbH-9; and 6) 50 ng of recombinant 85b. The recombinant antigens were engineered with six terminal histidine residues and therefore would be expected to migrate with a mobility of approximately 1 kD larger than the native protein. In Figure 3D, recombinant TbH-9 lacks approximately 10 kD of the full-length 42 kD antigen, hence the significant difference in the size of the native immunoreactive TbH-9 antigen and the lysate track (indicated by the arrow). These results demonstrate that Tb38-1 and TbH-9 are intracellular antigens and are not actively secreted by M. tuberculosis. The finding that TbH-9 is an intracellular antigen is confirmed by determining the reactivity of human T cell clones specific for TbH-9 to recombinant TbH-9, secretory M. tuberculosis proteins and PPD. A T-cell clone specific for TbH-9 (designated 131TbH-9) is generated from PBMC from a healthy PPD positive donor. The proliferative response of 131TbH-9 to secretory proteins, recombinant TbH-9 and M. tuberculosis control antigen, TbRall, is determined by measuring tritiated thymidine uptake, as described in Example 1. As illustrated in Figure 4A , the clone 131TbH-9 responds specifically to TbH-9, showing that TbH-9 is not a significant component of the secretory proteins of M. tuberculosis. Figure 4B shows the production of IFN-gamma by a specific clone of T TbH-9 second (designated PPD 800-10) which is prepared from PBMC of a healthy PPD-positive donor, after stimulation of the clone of the T cell with secretory proteins, PPD or recombinant TbH-9. These results also confirm that TbH-9 is not secreted by M. tuberculosis.

C. USE OF PATIENT BLOCKS WHICH HAVE EXTRA-PULMONARY TUBERCULOSIS TO IDENTIFY DNA SEQUENCES OR CODE ANTIGENS FROM M. TUBERCULOSIS Genomic DNA is isolated from the M. tuberculosis Erdman strain, randomly sheared and used to construct an expression library that employs the Lambda ZAP expression system (Stratagene, La Jolla, CA). The resulting library is screened using collections of sera obtained from individuals with extra-pulmonary tuberculosis, as described above in the literature.

Example 3B, with the secondary antibody which is IgG + A + M (H + L) antihuman goat conjugated with alkaline phosphatase. Eight clones are purified. Of these, it is found that 4 clones (referred to below as XP14, XP24, XP31 and XP32) have some similarity with known sequences. The DNA sequences determined for XP14, XP24 and XP31 are provided in SEQ IDs. Nos .: 156-158, respectively, with the 5 'and 3' sequences of DNA for X32 that is provided in Sec ID Nos.: 159 and 160, respectively. The amino acid sequence predicted for XP14 is provided in Seq ID No. 161. The inverse complement of XP14 is found to encode the amino acid sequence that is provided in Seq ID No. 162.

Comparison of the sequences for the remaining 14 clones (hereinafter referred to as XP1-XP6, XP17-XP19, XP22, XP25, XP27, XP30 and XP36) with those in the gene bank as described above, revealed no homologies except for the extremes 5 'of XP2 and XP6 found to have some homology with cosmids of M. known tuberculosis. The DNA sequences for XP27 and XP36 are shown in Sec ID Nos .: 163 and 164, respectively with the 5 'sequences for XP4, XP5, XP17 and XP30 shown in Sec ID Nos .: 165-168, respectively and sequences 51 and 31 for XP2, XP3, XP6, XP18, XP19, XP22 and XP25 shown in Sec ID Nos: 169 and 170; 171 and 172; 173 and 174; 175 and 176; 177 and 178; 179 and 180; and 181 and 182, respectively. XP1 is found to overlap with the DNA sequences for TbH4, described above. The full-length DNA sequence for TbH4-XPl is provided in Seq ID No .: 183. This DNA sequence is found to contain an open reading frame encoding the amino acid sequence shown in Sec ID. No : 184. The reverse complement of TbH4-XPl is found to contain an open reading frame that encodes the amino acid sequence shown in Sec ID. No .: 185. The DNA sequence for XP36 is found to contain two frames of open reading encoding the amino acid sequence shown in Seq ID Nos. Nos .: 186 and 187, with the reverse complement containing an open reading frame encoding the amino acid sequence shown in Seq ID No.: 188 Recombinant XP1 protein is prepared as described above in Example 3B, with a metal ion affinity chromatography column that is used for purification. As illustrated in Figures 8A-B and 9A-B using the assays described herein, recombinant XP1 is found to stimulate cell proliferation and IFN-gamma production in T cells isolated from immune donors immune to M. tuberculosis. D. PREPARATION OF SOLUBLE ANTIGENS IN M. TUBERCULOSIS USING DEVELOPED RABBIT ANTI-YEAR AGAINST FRACTIONATED PROTEINS WITH M. TUBERCULOSIS M. tuberculosis lysate is prepared as described above in Example 2. The resulting material is fractionated by HPLC and the fractions are classified by Western blotting by serological activity with a serum collection of patients infected with M. tuberculosis showing little or no no immunoreactivity with other antigens of the present invention. Rabbit antisera are generated against the most reactive fraction using the method described in Example 3A. The antisera are used to classify the genomic DNA expression library of Erdman strain of M. tuberculosis prepared as described above. Bacteriophage plates expressing immunoreactive antigens were purified. Phagemid of the plates is rescued and the nucleotide sequences of the M. tuberculosis clones are determined. Ten different clones were purified. Of these, one is found to be TbRa35, described above, and one was found to be the previously identified M. tuberculosis antigen HSP60. Of the eight remaining clones, seven (hereinafter referred to as RDIF2, RDIF5, RDIF8, RDIF10, RDIF11 and RDIF12) are found to contain some similarity to previously identified M. tuberculosis sequences. The DNA sequences determined for RDIF2, RDIF5, RDIF8, RDIF10 and RDIF11 are provided in Sec. ID Nos. 189-193, respectively with the corresponding predicted amino acid sequences provided in Sec. ID Nos. 194- 198 respectively. DNA sequences 51 and 3 'for RDIF12 are provided in Seq ID Nos. 199 and 200 respectively. No significant homologies were found for the RDIF-7 antigen. The determined DNA and predicted amino acid sequences for RDIF7 are provided in Seq. ID Nos. 201 and 202 respectively. An additional clone, referred to as RDIF6 is isolated however, this was found to be identical to RDIF5. RDIF6, RDIF8, RDIF10 and RDIF11 recombinants are prepared as described above. As illustrated in Figures 8A-B and 9A-B, these antigens were found to stimulate cell proliferation and IFN-gamma production in T cells isolated from donors immune to M. tuberculosis. EXAMPLE 4 PURIFICATION AND CHARACTERIZATION OF A TUBERCULINE PURIED PROTEIN DERIVATIVE POLYPEPTIDE A M. tuberculosis polypeptide is isolated from purified tuberculin protein derivative (PPD) as follows. PPD is prepared as published with some modification (Seibert, F. et al, derived from tuberculin-purified protein, preparation and analysis of a large quantity for norm, The American Review of Tuberculosis 44: 9-25, 1941). Strain Rv M. tuberculosis develops for six weeks in synthetic medium in revolving bottles at 37 ° C. The bottles containing the bacterial growth are then heated to 100 ° C in steam for 3 hours. The cultures were sterile filtered using a 0.22 μ filter and the liquid phase is concentrated 20 times using a 3 kD shear membrane. Proteins were precipitated once with 50% ammonium sulfate solution and eight times with 25% ammonium sulfate solution. The resulting proteins (PPD) were fractionated by reverse phase liquid chromatography (RP-HPLC) using a C18 column (7.8 x 300 mM; Waters, Milford, MA) in a Biocad HPLC system (Perseptive Biosystems, Framingham, MA). Fragments of the column were eluted with a linear gradient of 0-100% buffer (0.1% TFA in acetonitrile). The flow rate was 10 ml / minute and the eluent was verified at 214 nm and 280 nm. Six fractions were collected, dried, suspended in PBS and individually tested in guinea pigs infected with M. tuberculosis for induction of delayed type hypersensitivity reaction (DTH = Delayed Type Hypersensitivity). A fraction was found to induce a strong DTH reaction and subsequently was further fractionated by RP-HPLC on a Vydac C18 microperforation column (Cat. No. 218TP5115) on a Perkin Elmer HPLC / Applied Biosystems Model 172 Division. The fractions were eluted with a linear gradient from 5-1000% buffer (0.05% TFA in acetonitrile) with a flow rate of 80 μl / minute. The eluent was verified at 215 nm. Eight fractions were collected and tested by induction of DTH in guinea pigs infected with M. tuberculosis. HE found a fraction that induces strong DTH of approximate induration of 16 mm. The other fractions do not induce detectable DTH. The positive fraction is subjected to SDS-PAGE gel electrophoresis and found to contain a single protein band of approximately 12 kD molecular weight. This polypeptide, hereinafter referred to as DPPD is sequenced from the amino terminus using a Perkin Elmer / Applied Biosystems Protein Sequencer Procise Division 492 as described above and found to have an N-terminal sequence shown in Sec ID. No .: 129. Comparison of this sequence with known sequences in the gene bank as described above did not reveal known homologies. Four fragments of cyanogen bromide from DPPD were isolated and found to have the sequences shown in Sec. ID Nos. 130-133. The ability of the DPPD antigen to stimulate human PBMC to proliferate and produce IFN-gamma is assayed as described in Example 1. As shown in Table 9, DPPD is found to stimulate proliferation and produce large amounts of IFN-gamma, more than those produced by commercial PPD. TABLE 9 RESULTS OF PROLIFERATION TESTS AND INTERFERONE-GAMMA TO DPPD Stimulator Donor Proliferation (CPM) IFN-gamma (OD450) PBMC Medium 1,089 0. .17 PPD (commercial) 8,394 1. .29 DPPD 13,451 2. .21 B Medium 450 0. .09 PPD (commercial) 3, 929 1. .26 TABLE 9 (Cont.) RESULTS OF PROLIFERATION TESTS AND INTERFERONE-GAMMA TO DPPD Proliferation Stimulator Donor (CPM) IFN-gamma (OD450) PBMC DPPD 6.184 1.49 C Medium 541 0.11 PPD (commercial) 8.907 0.76 DPPD 23.024 > 2.70 EXAMPLE 5 USE OF REPRESENTATIVE ANTIGENS FOR TUBERCULOSIS DIAGNOSIS This example illustrates the effectiveness of several representative polypeptides of skin tests for the diagnosis of M. tuberculosis infection. Individuals were injected intradermally with 100 μl of either PBS or PBS plus Tween 20MR containing either 0.1 μg of protein (for TbH-9 and TbRa35) or 1.0 μg of protein (for TbRa38-l). Induration was measured between 5-7 days after injection, with a response of 5 mm or greater, which is considered positive. Of the 20 individuals tested, 2 were PPD negative and 18 were PPD positive. Of the positive PPD individuals, 3 had active tuberculosis, 3 were previously infected with tuberculosis and 9 were healthy. In a second study, 13 positive PPD individuals were tested with 0.1 μg TbRall in either PBS or PBS plus Tween 20MR as described above. The results of both studies are illustrated in Table 10. TABLE 10 RESULTS OF DTH TEST WITH REPRESENTATIVE ANTIGENS TbH- 9 Tb38-1 TbRa35 Cumulative TbRall Pos / Total Pos / Total Pos / Total Pos / Total Pos / Total PPD negative 0/2 0/2 0/2 0/2 PPD positive healthy 5/9 4/9 4/9 6/9 1/4 previous TB 3/5 2/5 2/5 4/5 3/5 TABLE 10 (Cont.) DTH TEST RESULTS WITH REPRESENTATIVE ANTIGENS TbH-9 Tb38-1 TbRa35 Cumulative TbRall Pos / Total Pos / Total Pos / Total Pos / Total Pos / Total active 3/4 3/4 0/4 4/4 1/4 TOTAL 11/18 9/18 6/18 14/18 15/13 EXAMPLE 6 SYNTHESIS OF SYNTHETIC POLYPEPTIDES Polypeptides can be synthesized on a Millipore 9050 peptide synthesizer using FMOC chemistry with HPTU activation (O-Benzotriazole-N, N, N ', N' -tetramethyluronium hexafluorophosphate). A Gly-Cys-Gly sequence can be connected to the amino terminus of the peptide to provide a method of conjugating or labeling the peptide. Rupture of the peptides from the solid support can be carried out using the following cleavage mixture: trifluoroacetic acid: ethanedithiol: thioanisole: water: phenol (40: 1: 2: 2: 3). After breaking for 2 hours, the peptides can be precipitated in cold methyl-t-butyl ether. The peptide nodules can then be dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized before purification by C18 reverse phase HPLC. A gradient of 0% -60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) can be used to elute the peptides. Following the lyophilization of the pure fractions, the peptides can be characterized using electro-mass mass spectroscopy and amino acid analysis. EXAMPLE 7 PREPARATION AND CHARACTERIZATION OF PROTEINS FUSION OF M. TUBERCULOSIS A fusion protein containing TbRa3, the 38 kD antigen and Tb38-1 is prepared as follows: Each of the DNA constructs TbRa3, 38 kD and Tb38-1 is modified by PCR in order to facilitate its fusion and the subsequent expression of the fusion protein TbRa3-38 kD-Tb38-l. TbRa3, 38 kD and Tb38-1 DNA are used to perform PCR using the primers PDM-64 and PDM-65 (Seq ID No: 146 and 147), PDM-57 and PDM-58 (Seq ID No: 148 and 149) and PDM-69 and PDM-60 (Seq ID No: 150 and 151), respectively. In each case, the DNA amplification is performed using 10 μl of 10X Pfu buffer, 2 μl 10 mM dNTPs, 2 μl each of the PCR primers at 10 μM concentration, 81.5 μl of water, 1.5 μl Pfu of DNA polymerase (Stratagene, La Jolla, CA) and 1 μl of DNA in either 70 ng / μl (for TbRa3) or 50 ng / μl (for 38 kD and Tb38-1). For TbRa3, denaturation at 94 ° C is performed for 2 minutes, followed by 40 cycles of 96 ° C for 15 seconds and 72 ° C for 1 minute, and finally for 72 ° C for 4 minutes. For 38 kD, the denaturation at 96 ° C is carried out for 2 minutes, followed by 40 cycles of 96 ° C for 30 seconds, 68 ° C for 15 seconds and 72 ° C for 3 minutes, and finally for 72 ° C for 4 minutes. minutes For denaturation of Tb38-1 at 94 ° C for 2 minutes, dry for 10 cycles of 96 ° C for 15 seconds, 68 ° C for 15 seconds and 72 ° C for 1.5 minutes, 30 cycles of 96 ° C for 15 seconds, 64 ° C for 15 seconds and 72 ° C for 1.5 and finally 72 ° C for 4 minutes. The TbRa3 PCR fragment is digested with Ndel and EcoRI and cloned directly into vector pT7 ~ L2 IL 1 using the Ndel and EcoRI sites. The 38 kD PCR fragment is digested with Sse8387I, treated with T4 polymerase DNA to make blunt ends? and then digested with EcoRI for direct cloning in the vector pT7 ~ L2Ra3-l which is digested with Stul and EcoRI. The 38-1 PCR fragment is digested with Eco47III and EcoRI and directly subcloned into pT7? L2Ra3 / 38kD-17 digested with the same enzymes. All fusion is then transferred to pET28b - using the Ndel and EcoRI sites. The fusion construct is confirmed by DNA sequencing. The expression construct is then transformed into BLR pLys S E. coli (Novagen, Madison, Wl) and develops overnight in LB broth with kanamycin (30 μg / ml) and chloramphenicol (34 μg / ml). This culture (12 ml) is used to inoculate 500 ml of 2XYT with the same antibiotics and the culture is induced with IPTG at an OD560 of 0.44 at a final concentration of 1.2 mM. Four hours post-induction, the bacteria were harvested and sonicated in 20 mM Tris (8.0), 100 mM NaCl, 0.1% DOC, 20 μg / ml Leupeptin, 20 mM PMSF followed by centrifugation at 26,000 X g. The resulting nodule is resuspended in 8 M urea, 20 mM Tris (8.0), 100 mM NaCl and ligated with Pro-bond nickel resin (Invitrogen, Carlsbad, CA). The column is washed several times with the above buffer and eluted with an imidazole gradient (50 mM, 100 mM, 500 mM imidazole is added to 8 M urea, 20 mM Tris (8.0), 1 00 mM NaCl). The eluates containing the protein of interest are then dialysed against 10 mM Tris (8.0). The amino acid and DNA sequences for the resulting fusion protein (hereinafter referred to as TbRa3-38 kD-Tb38-l) are given in Seq ID Nos: 152 and 153, respectively. A fusion protein containing the two TbH-9 and Tb38-1 antigens (hereinafter referred to as TbH9-Tb38-T) without a hinge sequence is prepared using a procedure similar to that described above. The DNA sequence for the fusion protein TbH9-Tb38-l is given in SEQ ID No: 156. The ability of the TbH9-Tb38-l fusion protein to induce T cell proliferation and IFN-gamma production in PBMC preparations are examined using the protocol described above in Example 1. PBMC from three donors employed: one that was previously shown to respond to TbH9 but not to Tb38-1 (donor 131); one showed to respond to Tb38-1 but not to TbH9 (donor 184); and one that has been shown to respond to both antigens (donor 201). The result of these studies (Figures 5-7 respectively) demonstrates the functional activity of both antigens in the fusion protein. A fusion protein containing TbRa3, the 38kD antigen, Tb38-1 and DPEP, is prepared as follows. Each of the constructs TbRa3, 38 kD and Tb38-1 is modified by PCR and cloned into vectors essentially as described above, with the primers PDM-69 (Seq ID NO: 150) and PDM-83 (Seq ID NO: 205) used for amplification of the Tb38-1A fragment. Tb38-1 A differs from Tb38-1 by a Dral site at the 3 'end of the coding region that keeps the final amino acid intact while creating a blunt restriction site that is in frame. The TbRa3 / 3 8kD / Tb3 8-1A fusion is then transferred to pET28b using the Ndel and EcoR 1 sites. DPEP DNA is used to perform PCR using primers PDM-84 and PDM85 (Seq ID NO: 206 and 207 respectively ) and 1 μl DNA at 50 ng / μl. Denaturation at 94 ° C is performed for 2 minutes, followed by 10 cycles of 96 ° C for 15 seconds, 68 ° C for 15 seconds and 72 ° C for 1.5 minutes; 30 cycles of 96 ° C for 15 seconds, 64 ° C for 15 seconds and 72 ° C for 1.5 minutes; and finally by 72 ° C for 4 minutes. The DPEP PCR fragment is digested with EcoRI and Eco72I and cloned directly into the construction pET28Ra3 / 38kD / 38-IA which is digested with Dral and EcoRI. The fusion construct is confirmed correctly by DNA sequencing. Recombinant protein is prepared as described above. The amino acid and DNA sequences for the resulting fusion protein (hereinafter referred to as TbF-2) are given in SEQ ID NO: 208 and 209, respectively. The reactivity of the TbF-2 fusion protein with sera from patients infected with M. tuberculosis is examined by ELISA using the protocol described above. The results of these studies (Table 11) show that all four antigens work independently in the fusion protein.

TABLE 11 REACTIVITY OF FUSING RECOMBINANT TBF-2 WITH TB AND NORMAL SERUM State ID TbF State TbF-2 State Serum 0D45 0D450 B931-40 TB 0.57 + 0.321 + B931-41 TB 0.601 + 0.396 + B931-109 TB 0.494 + 0.404 + B931-132 TB 1.502 + 1.292 + 5004 TB 1.806 + 1.666 + 15004 TB 2.862 + 2.468 + 39004 TB 2.443 + 1.722 + 68004 TB 2.871 + 2.575 + 99004 TB 0.691 + 0.971 + 107004 TB 0.875 + 0.732 + 92004 TB 1,632 + 1,394 + 97004 TB 1.491 + 1.979 + 118004 TB 3.182 + 3.045 + 173004 TB 3,644 + 3,578 + 175004 TB 3.332 + 2.916 + 274004 TB 3,696 + 3,716 + 276004 TB 3.243 + 2.56 + 282004 TB 1.249 + 1.234 + 289004 TB 1.373 + 1.17 + 308004 TB 3.708 + 3.355 + TABLE 11 (Cont.) REACTIVITY OF TBF-2 FUSING RECOMBINANT WITH TB AND SERUM NORMAL State ID TbF State TbF-2 State Serum 0D45 0D450 314004 TB 1.663 + 1.399 + 317004 TB 1.163 + 0.92 + 312004 TB 1.709 + 1.453 + 380004 TB 0.238 - 0.461 + 451004 TB 0.18 - 0.2 - 478004 TB 0.188 - 0.469 + 410004 TB 0.384 + 2.392 + 411004 TB 0.306 + 0.874 + 421004 TB 0.357 + 1.456 + 528004 TB 0.047 - 0.196 - A6-87 Normal 0.094 - 0.063 - A6-88 Normal 0.214 - 0.19 - A6-89 Normal 0.248 - 0.125 - A6-90 Normal 0.179 - 0.206 - A6-91 Normal 0.135 - 0.151 - A6-92 Normal 0.064 - 0.097 - A6-93 Normal 0.072 - 0.098 - A6-94 Normal 0.072 _ 0.064 _ TABLE 11 (Cont.) REACTIVITY OF FUSING RECOMBINANT TBF-2 WITH TB AND SERUM NORMAL State ID TbF State TbF-2 State Serum 0D45 0D450 A6-95 Normal 0.125 0.159 - A6-96 Normal 0.121 0.12 - Cut 0.284 0.266 TABLE 11 (CONTINUED) REACTIVITY OF FUSING RECOMBINANT TBF-2 WITH TB AND NORMAL SERUM Reactivity of ELISA Serum ID 38kD TbRa3 Tb38-1 DPEP B931-40 + B931-41 + B931-109 + B931-132 + 5004 ± 15004 + 39004 + + + 68004 + + + 99004 + 107004 + TABLE 11 (CONTINUED) REACTIVITY OF FUSING RECOMBINANT TBF-2 WITH TB AND NORMAL SERUM Reactivity of ELISA Serum ID 38kD TbRa3 Tb38-1 DPEP 92004 97004 118004 + 17300 + 175004 274004 276004 282004 289004 308004 314004 317004 312004 + 380004 ± 451004 478004 410004 411004 + + 421004 + + 528004 + TABLE 11 (CONTINUED) REACTIVITY OF FUSING RECOMBINANT TBF-2 WITH TB AND SERUM NORMAL Reactivity of ELISA Serum ID 38kD TbRa3 Tb38-1 DPEP A6-87 - A6-88 - A6-89 A6-90 A6-91 - A6-92 A6-93 A6-94 A6-95 -A6-96 - Cut A A person skilled in the art will appreciate that the order of the individual antigens within the fusion protein can be changed and that he will expect comparable activity, as long as each of the epitopes is still functionally available. In addition, truncated forms of the proteins containing active epitopes can be employed in the construction of fusion proteins. From the foregoing, it will be appreciated that while specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without departing from the spirit and scope of the invention. SEQUENCE LIST (1) GENERAL INFORMATION: (i) APPLICANT: Reed, Steven G. Skeiky, Yasir A.W. Dillon, Davin C. Campos-Neto, Antonio 'Houghton, Raymond Vedvick, Thomas S. Twardzik, Daniel R. Lodes, Michael J. (ii) TITLE OF THE INVENTION: COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS (iii) NUMBER SEQUENCE: 214 (iv) ADDRESS FOR CORRESPONDENCE: (A) RECIPIENT: SEED and BERRY LLP (B) STREET: 6300 Columbia Center, 701 Fifth Avenue (C) CITY: Seattle (D) STATE: Washington (E) COUNTRY: USA (F) CP: 98104-7092 (v) LEGIBLE FORMAT BY COMPUTER: (A) TYPE OF MEDIUM: Flexible disk (B) COMPUTER: PC COMPATIBLE WITH IBM (C) OPERATING SYSTEM: PC-DOS / MS-DOS (D) PROGRAM (SOFTWARE): Patent In Relay # 1.0, Version # 1.30 (vi) CURRENT REQUEST DATA: (A) APPLICATION NUMBER: (B) SUBMISSION DATE: 01-OCT-1997 (C) CLASSIFICATION: (viii) INFORMATION AGENT / LAWYER: (A) NAME: Maki, David J. (B) REGISTRATION NUMBER: 31,392 (C) REFERENCE NUMBER / FILE: 210121.411C7 (ix) TELECOMMUNICATIONS INFORMATION: (A) PHONE: (206) 622 -4900 (B) TELEFAX: (206) 682-6031 (2) INFORMATION FOR SEC ID. DO NOT. : 1 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 766 base pairs (B) TYPE: Nucleic Acid (C) HEBRA: Single (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 1 CGAGGCACCG GTAGTTTGAA CCAAACGCAC AATCGACGGG CAAACGAACG GAAGAACACA 60 ACCATGAAGA TGGTGAAATC GATCGCCGCA GGTCTGACCG CCGCGGCTGC AATCGGCGCC 120 GCTGCGGCCG GTGTGACTTC GATCATGGCT GGCGGCCCGG TCGTATACCA GATGCAGCCG 180 GTCGTCTTCG GCGCGCCACT GCCGTTGGAC CCGGCATCCG CCCCTGACGT CCCGACCGCC 240 GCCCAGTTGA CCAGCCTGCT CAACAGCCTC GCCGATCCCA ACGTGTCGTT TGCGAACAAG 300 GGCAGTCTGG TCGAGGGCGG CATCGGGGGC ACCGAGGCGC GCATCGCCGA CCACAAGCTG 360 AAGAAGGCCG CCGAGCACGG GGATCTGCCG CTGTCGTTCA GCGTGACGAA CATCCAGCCG 420 GCGGCCGCCG GTTCGGCCAC CGCCGACGTT TCCGTCTCGG GTCCGAAGCT CTCGTCGCCG 480 GTCACGCAGA ACGTCACGTT CGTGAATCAA GGCGGCTGGA TGCTGTCACG CGCATCGGCG 540 ATGGAGTTGC TGCAGGCCGC AGGGNAACTG ATTGGCGGGC CGGNTTCAGC CCGCTGTTCA 600 GCTACGCCGC CCGCCTGGTG ACGCGTCCAT GTCGAACACT CGCGCGTGTA GCACGGTGCG 660 GTNTGCGCAG GGNCGCACGC ACCGCCCGGT GCAAGCCGTC CTCGAGATAG GTGGTGNCTC 720 GNCACCAGNG ANCACCCCCN NTCGNC NT TCTCGNTGNT GNATGA 766 (2) INFORMATION FOR SEC ID. DO NOT . : 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 752 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 2: ATGCATCACC ATCACCATCA CGATGAAGTC ACGGTAGAGA CGACCTCCGT CTTCCGCGCA 60 GACTTCCTCA GCGAGCTGGA CGCTCCTGCG CAAGCGGGTA CGGAGAGCGC GGTCTCCGGG 120 GTGGAAGGGC TCCCGCCGGG CTCGGCGTTG CTGGTAGTCA AACGAGGCCC CAACGCCGGG 180 TCCCGGTTCC TACTCGACCA AGCCATCACG TCGGCTGGTC GGCATCCCGA CAGCGACATA 240 TTTCTCGACG ACGTGACCGT GAGCCGTCGC CATGCTGAAT TCCGGTTGGA AAACAACGAA 300 TTCAATGTCG TCGATGTCGG GAGTCTCAAC GGCACCTACG TCAACCGCGA GCCCGTGGAT 360 TCGGCGGTGC TGGCGAACGG CGACGAGGTC CAGATCGGCA AGCTCCGGTT GGTGTTCTTG 420 ACCGGACCCA AGCAAGGCGA GGATGACGGG AGTACCGGGG GCCCGTGAGC GCACCCGATA 480 GCCCCGCGCT GGCCGGGATG TCGATCGGGG CGGTCCTCCG ACCTGCTACG ACCGGATTTT 540 CCCTGATGTC CACCATCTCC AAGATTCGAT TCTTGGGAGG CTTGAGGGTC NGGGTGACCC 600 CCCCGCGGGC CTCATTCNGG GGTNTCGGCN GGTTTCACCC CNTACCNACT GCCNCCCGGN 660 TTGCNAATTC NTTCTTCNCT GCCCN AAAG GGACCNTTAN CTTGCCGCTN GAAANGGTNA 720 TCCNGGGCCC NTCCTNGAAN CCCCNTCCCC CT 752 (2) INFORMATION FOR ID SEC. NO.:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 813 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:3: CATATGCATC ACCATCACCA TCACACTTCT AACCGCCCAG CGCGTCGGGG GCGTCGAGCA 60 CCACGCGACA CCGGGCCCGA TCGATCTGCT AGCTTGAGTC TGGTCAGGCA TCGTCGTCAG 120 CAGCGCGATG CCCTATGTTT GTCGTCGACT CAGATATCGC GGCAATCCAA TCTCCCGCCT 180 GCGGCCGGCG GTGCTGCAAA CTACTCCCGG AGGAATTTCG ACGTGCGCAT CAAGATCTTC 240 ATGCTGGTCA CGGCTGTCGT TTTGCTCTGT TGTTCGGGTG TGGCCACGGC CGCGCCCAAG 300 ACCTACTGCG AGGAGTTGAA AGGCACCGAT ACCGGCCAGG CGTGCCAGAT TCAAATGTCC 360 GACCCGGCCT ACAACATCAA CATCAGCCTG CCCAGTTACT ACCCCGACCA GAAGTCGCTG 420 GAAAATTACA TCGCCCAGAC GCGCGACAAG TTCCTCAGCG CGGCCACATC GTCCACTCCA 480 CGCGAAGCCC CCTACGAATT GAATATCACC TCGGCCACAT ACCAGTCCGC GATACCGCCG 540 CGTGGTACGC AGGCCGTGGT GCTCAMGGTC TACCACAACG CCGGCGGCAC GCACCCAACG 600 ACCACGTACA AGGCCTTCGA TTGGGACCAG GCCTATCGCA AGCCAATCAC CTATGACACG 660 CTGTGGCAGG CTGACACCGA TCCGCTGCCA GTCGTCTTCC CCATTGTTGC AAGGTGAACT 720 GAGCAACGCA GACCGGGACA ACWGGTATCG ATAGCCGCCN AATGCCGGCT TGGAACCCNG 780 TGAAATTATC ACAACTTCGC AGTCACNAAA NAA 813 (2) INFORMATION FOR SEC ID. NO .: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 447 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 4: CGGTATGAAC ACGGCCGCGT CCGATAACTT CCAGCTGTCC CAGGGTGGGC AGGGATTCGC 60 CATTCCGATC GGGCAGGCGA TGGCGATCGC GGGCCAGATC CGATCGGGTG GGGGGTCACC 120 CACCGTTCAT ATCGGGCCTA CCGCCTTCCT CGGCTTGGGT GTTGTCGACA ACAACGGCAA 180 CGGCGCACGA GTCCAACGCG TGGTCGGGAG CGCTCCGGCG GCAAGTCTCG GCATCTCCAC 240 CGGCGACGTG ATCACCGCGG TCGACGGCGC TCCGATCAAC TCGGCCACCG CGATGGCGGA 300 CGCGCTTAAC GGGCATCATC CCGGTGACGT CATCTCGGTG AACTGGCAAA CCAAGTCGGG 360 CGGCACGCGT ACAGGGAACG TGACATTGGC CGAGGGACCC CCGGCCTGAT TTCGTCGYGG 420 ATACCACCCG CCGGCCGGCC AATTGGA 447 (2) INFORMATION FOR SEC ID. NO.:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 604 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : GTCCCACTGC GGTCGCCGAG TATGTCGCCC AGCAAATGTC TGGCAGCCGC CCAACGGAAT 60 CCGGTGATCC GACGTCGCAG GTTGTCGAAC CCGCCGCCGC GGAAGTATCG GTCCATGCCT 120 AGCCCGGCGA CGGCGAGCGC CGGAATGGCG CGAGTGAGGA GGCGGGCAAT TTGGCGGGGC 180 CCGGCGACGG NGAGCGCCGG AATGGCGCGA GTGAGGAGGT GGNCAGTCAT GCCCAGNGTG 240 ATCCAATCAA CCTGNATTCG GNCTGNGGGN CCATTTGACA ATCGAGGTAG TGAGCGCAAA 300 TGAATGATGG AAAACGGGNG GNGACGTCCG NTGTTCTGGT GGTGNTAGGT GNCTGNCTGG 360 NGTNGNGGNT ATCAGGATGT TCTTCGNCGA AANCTGATGN CGAGGAACAG GGTGTNCCCG 420 NNANNCCNAN GGNGTCCNAN CCCNNNNTCC TCGNCGANAT CANANAGNCG NTTGATGNGA 480 NAAAAGGGTG GANCAGNNNN AANTNGNGGN CCNAANAANC NNNANNGNNG NNAGNTNGNT 540 NNNTNTTNNC ANNNNNNNTG NNGNNGNNCN NNNCAANCNN NTNNNNGNAA NNGGNTTNTT NAATs 600 604 (2) INFORMATION FOR SEQ ID. DO NOT . : 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 633 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 6: TTGCANGTCG AACCACCTCA CTAAAGGGAA CAAAAGCTNG AGCTCCACCG CGGTGGCGGC 60 CGCTCTAGAA CTAGTGKATM YYYCKGGCTG CAGSAATYCG GYACGAGCAT TAGGACAGTC 120 TAACGGTCCT GTTACGGTGA TCGAATGACC GACGACATCC TGCTGATCGA CACCGACGAA 180 CGGGTGCGAA CCCTCACCCT CAACCGGCCG CAGTCCCGYA ACGCGCTCTC GGCGGCGCTA 240 CGGGATCGGT TTTTCGCGGY GTTGGYCGAC GCCGAGGYCG ACGACGACAT CGACGTCGTC 300 ATCCTCACCG GYGCCGATCC GGTGTTCTGC GCCGGACTGG ACCTCAAGGT AGCTGGCCGG 360 GCAGACCGCG CTGCCGGACA TCTCACCGCG GTGGGCGGCC ATGACCAAGC CGGTGATCGG 420 CGCGATCAAC GGCGCCGCGG TCACCGGCGG GCTCGAACTG GCGCTGTACT GCGACATCCT 480 GATCGCCTCC GAGCACGCCC GCTTCGNCGA CACCCACGCC CGGGTGGGGC TGCTGCCCAC 540 CTGGGGACTC AGTGTGTGCT TGCCGCAAAA GGTCGGCATC GGNCTGGGCC GGTGGATGAG 600 633 CGC CCTGACCGGC GACTACCTGT CCGTGACCGA (2) INFORMATION FOR SEC ID. NO.:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1362 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 7: CGACGACGAC GGCGCCGGAG AGCGGGCGCG AACGGCGATC GACGCGGCCC TGGCCAGAGT 60 CGGCACCACC CAGGAGGGAG TCGAATCATG AAATTTGTCA ACCATATTGA GCCCGTCGCG 120 CCCCGCCGAG CCGGCGGCGC GGTCGCCGAG GTCTATGCCG AGGCCCGCCG CGAGTTCGGC 180 CGGCTGCCCG AGCCGCTCGC CATGCTGTCC CCGGACGAGG GACTGCTCAC CGCCGGCTGG 240 GCGACGTTGC GCGAGACACT GCTGGTGGGC CAGGTGCCGC GTGGCCGCAA GGAAGCCGTC 300 GCCGCCGCCG TCGCGGCCAG CCTGCGCTGC CCCTGGTGCG TCGACGCACA CACCACCATG 360 CTGTACGCGG CAGGCCAAAC CGACACCGCC GCGGCGATCT TGGCCGGCAC AGCACCTGCC 420 GCCGGTGACC CGAACGCGCC GTATGTGGCG TGGGCGGCAG GAACCGGGAC ACCGGCGGGA 480 CCGCCGGCAC CGTTCGGCCC GGATGTCGCC GCCGAATACC TGGGCACCGC GGTGCAATTC 540 CACTTCATCG CACGCCTGGT CCTGGTGCTG CTGGACGAAA CCTTCCTGCC GGGGGGGCCCG 600 CGCGCCCAAC AGCTCATGCG CCGCGCCGGT GGACTGGTGT TCGCCCGCAA GGTGCGCGCG 660 GAGCATCGGC CGGGCCGCTC CACCCGCCGG CTCGAGCCGC GAACGCTGCC CGACGATCTG 720 GCATGGGCAA CACCGTCCGA GCCCATAGCA ACCGCGTTCG CCGCGCTCAG CCACCACCTG 780 GACACCGCGC CGCACCTGCC GCCACCGACT CGTCAGGTGG TCAGGCGGGT CGTGGGGTCG 840 TGGCACGGCG AGCCAATGCC GATGAGCAGT CGCTGGACGA ACGAGCACAC CGCCGAGCTG 900 CCCGCCGACC TGCACGCGCC CACCCGTCTT GCCCTGCTGA CCGGCCTGGC CCCGCATCAG 960 GTGACCGACG ACGACGTCGC CGCGGCCCGA TCCCTGCTCG ACACCGATGC GGCGCTGGTT 1020 GGCGCCCTGG CCTGGGCCGC CTTCACCGCC GCGCGGCGCA TCGGCACCTG GATCGGCGCC 1080 GCCGCCGAGG GCCAGGTGTC GCGGCAAAAC CCGACTGGGT GAGTGTGCGC GCCCTGTCGG 1140 TAGGGTGTCA TCGCTGGCCC GAGGGATCTC GCGGCGGCGA ACGGAGGTGG CGACACAGGT 1200 GGAAGCTGCG CCCACTGGCT TGCGCCCCAA CGCCGTCGTG GGCGTTCGGT TGGCCGCACT 1260 GGCCGATCAG GTCGGCGCCG GCCCTTGGCC GAAGGTCCAG CTCAACGTGC CGTCACCGAA 1320 GGACCGGACG GTCACCGGGG GTCACCCTGC GCGCCCAAGG AA 1362 (2) INFORMATION FOR SEC ID. NO.:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1458 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 8: GCGACGACCC CGATATGCCG GGCACCGTAG CGAAAGCCGT CGCCGACGCA CTCGGGCGCG 60 GTATCGCTCC CGTTGAGGAC ATTCAGGACT GCGTGGAGGC CCGGCTGGGG GAAGCCGGTC 120 TGGATGACGT GGCCCGTGTT TACATCATCT ACCGGCAGCG GCGCGCCGAG CTGCGGACGG 180 CTAAGGCCTT GCTCGGCGTG CGGGACGAGT TAAAGCTGAG CTTGGCGGCC GTGACGGTAC 240 TGCGCGAGCG CTATCTGCTG CACGACGAGC AGGGCCGGCC GGCCGAGTCG ACCGGCGAGC 300 TGATGGACCG ATCGGCGCGC TGTGTCGCGG CGGCCGAGGA CCAGTATGAG CCGGGCTCGT 360 CGAGGCGGTG GGCCGAGCGG TTCGCCACGC TATTACGCAA CCTGGAATTC CTGCCGAATT 420 CGCCCACGTT GATGAACTCT GGCACCGACC TGGGACTGCT CGCCGGCTGT TTTGTTCTGC 480 CGATTGAGGA TTCGCTGCAA TCGATCTTTG CGACGCTGGG ACAGGCCGCC GAGCTGCAGC 540 GGGCTGGAGG CGGCACCGGA TATGCGTTCA GCCACCTGCG ACCCGCCGGG GATCGGGTGG 600 CCTCCACGGG CGGCACGGCC AGCGGACCGG TGTCGTTTCT ACGGCTGTAT GACAGTGCCG 660 CGGGTGTGGT CTCCATGGGC GGTCGCCGGC GTGGCGCCTG TATGGCTGTG CTTGATGTGT 720 CGCACCCGGA TATCTGTGAT TTCGTCACCG CCAAGGCCGA ATCCCCCAGC GAGCTCCCGC 780 ATTTCAACCT ATCGGTTGGT GTGACCGACG CGTTCCTGCG GGCCGTCGAA CGCAACGGCC 840 TACACCGGCT GGTCAATCCG CGAACCGGCA AGATCGTCGC GCGGATGCCC GCCGCCGAGC 900 TGTTCGACGC CATCTGCAAA GCCGCGCACG CCGGTGGCGA TCCCGGGCTG GTGTTTCTCG 960 ACACGATCAA TAGGGCAAAC CCGGTGCCGG GGAGAGGCCG CATCGAGGCG ACCAACCCGT 1020 GCGGGGAGGT CCCACTGCTG CCTTACGAGT CATGTAATCT CGGCTCGATC AACCTCGCCC 1080 GGATGCTCGC CGACGGTCGC GTCGACTGGG ACCGGCTCGA GGAGGTCGCC GGTGTGGCGG 1140 TGCGGTTCCT TGATGACGTC ATCGATGTCA GCCGCTACCC CTTCCCCGAA CTGGGTGAGG 1200 CGGCCCGCGC CACCCGCAAG ATCGGGCTGG GAGTCATGGG TTTGGCGGAA CTGCTTGCCG 1260 CACTGGGTAT TCCGTACGAC AGTGAAGAAG CCGTGCGGTT AGCCACCCGG CTCATGCGTC 1320 GCATACAGCA GGCGGCGCAC ACGGCATCGC GGAGGCTGGC CGAAGAGCGG GGCGCATTCC 1380 CGGCGTTCAC CGATAGCCGG TTCGCGCGGT CGGGCCCGAG GCGCAACGCA CAGGTCACCT 1440 CCGTCGCTCC GACGGGCA 1458 (2) INFORMATION FOR SEC ID. DO NOT . : 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 862 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 9: ACGGTGTAAT CGTGCTGGAT CTGGAACCGC GTGGCCCGCT ACCTACCGAG ATCTACTGGC 60 GGCGCAGGGG GCTGGCCCTG GGCATCGCGG TCGTCGTAGT CGGGATCGCG GTGGCCATCG 120 TCATCGCCTT CGTCGACAGC AGCGCCGGTG CCAAACCGGT CAGCGCCGAC AAGCCGGCCT 180 CCGCCCAGAG CCATCCGGGC TCGCCGGCAC CCCAAGCACC CCAGCCGGCC GGGCAAACCG 240 AAGGTAACGC CGCCGCGGCC CCGCCGCAGG GCCAAAACCC CGAGACACCC ACGCCCACCG 300 CCGCGGTGCA GCCGCCGCCG GTGCTCAAGG AAGGGGACGA TTGCCCCGAT TCGACGCTGG 360 CCGTCAAAGG TTTGACCAAC GCGCCGCAGT ACTACGTCGG CGACCAGCCG AAGTTCACCA 420 TGGTGGTCAC CAACATCGGC CTGGTGTCCT GTAAACGCGA CGTTGGGGCC GCGGTGTTGG 480 CCGCCTACGT TTACTCGCTG GACAACAAGC GGTTGTGGTC CAACCTGGAC TGCGCGCCCT 540 CGAATGAGAC GCTGGTCAAG ACGTTTTCCC CCGGTGAGCA GGTAACGACC GCGGTGACCT 600 GGACCGGGAT GGGATCGGCG CCGCGCTGCC CATTGCCGCG GCCGGCGATC GGGCCGGGCA 660 CCTACAATCT CGTGGTACAA CTGGGCAATC TGCGCTCGCT GCCGGTTCCG TTCATCCTGA 720 ATCAGCCGCC GCCGCCGCCC GGGCCGGTAC CCGCTCCGGG TCCAGCGCAG GCGCCTCCGC 780 CGGAGTCTCC CGCGCAAGGC GGATAATTAT TGATCGCTGA TGGTCGATTC CGCCAGCTGT 840 GACAACCCCT CGCCTCGTGC CG 862 (2) INFORMATION FOR SEC ID. NO .: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 622 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:10: TTGATCAGCA CCGGCAAGGC GTCACATGCC TCCCTGGGTG TGCAGGTGAC CAATGACAAA 60 GACACCCCGG GCGCCAAGAT CGTCGAAGTA GTGGCCGGTG GTGCTGCCGC GAACGCTGGA 120 GTGCCGAAGG GCGTCGTTGT CACCAAGGTC GACGACCGCC CGATCAACAG CGCGGACGCG 180 TTGGTTGCCG CCGTGCGGTC CAAAGCGCCG GGCGCCACGG TGGCGCTAAC CTTTCAGGAT 240 CCCTCGGGCG GTAGCCGCAC AGTGCAAGTC ACCCTCGGCA AGGCGGAGCA GTGATGAAGG 300 TCGCCGCGCA GTGTTCAAAG CTCGGATATA CGGTGGCACC CATGGAACAG CGTGCGGAGT 360 TGGTGGTTGG CCGGGCACTT GTCGTCGTCG TTGACGATCG CACGGCGCAC GGCGATGAAG 420 ACCACAGCGG GCCGCTTGTC ACCGAGCTGC TCACCGAGGC CGGGTTTGTT GTCGACGGCG 480 TGGTGGCGGT GTCGGCCGAC GAGGTCGAGA TCCGAAATGC GCTGAACACA GCGGTGATCG 540 GCGGGGTGGA CCTGGTGGTG TCGGTCGGCG GGACCGGNGT GACGNCTCGC GATGTCACCC 600 CGGAAGCCAC CCGNGACATT CT 622 (2) INFORMATION FOR SEC ID. NO .: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1200 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:ll: GGCGCAGCGG TAAGCCTGTT GGCCGCCGGC ACACTGGTGT TGACAGCATG CGGCGGTGGC 60 ACCAACAGCT CGTCGTCAGG CGCAGGCGGA ACGTCTGGGT CGGTGCACTG CGGCGGCAAG 120 AAGGAGCTCC ACTCCAGCGG CTCGACCGCA CAAGAAAATG CCATGGAGCA GTTCGTCTAT 180 GCCTACGTGC GATCGTGCCC GGGCTACACG TTGGACTACA ACGCCAACGG CCGGTGCC 240 GGGGTGACCC AGTTTCTCAA CAACGAAACC GATTTCGCCG GCTCGGATGT CCCGTTGAAT 300 CCGTCGACCG GTCAACCTGA CCGGTCGGCG GAGCGGTGCG GTTCCCCGGC ATGGGACCTG 360 CCGACGGTGT TCGGCCCGAT CGCGATCACC TACAATATCA AGGGCGTGAG CACGCTGAAT 420 CTTGACGGAC CCACTACCGC CAAGATTTTC AACGGCACCA TCACCGTGTG GAATGATCCA 480 CAGATCCAAG CCCTCAACTC CGGCACCGAC CTGCCGCCAA CACCGATTAG CGTTATCTTC 540 CGCAGCGACA AGTCCGGTAC GTCGGACAAC TTCCAGAAAT ACCTCGACGG TGTATCCAAC 600 GGGGCGTGGG GCAAAGGCGC CAGCGAAACG TTCAGCGGGG GCGTCGGCGT CGGCGCCAGC 660 GGGAACAACG GAACGTCGGC CCTACTGCAG ACGACCGACG GGTCGATCAC CTACAACGAG 720 TGGTCGTTTG CGGTGGGTAA GCAGTTGAAC ATGGCCCAGA TCATCACGTC GGCGGGTCCG 780 GATCCAGTGG CGATCACCAC CGAGTCGGTC GGTAAGACAA TCGCCGGGGC CAAGATCATG 840 GGACAAGGCA ACG ACCTGGT ATTGGACACG TCGTCGTTCT ACAGACCCAC CCAGCCTGGC 900 TCTTACCCGA TCGTGCTGGC GACCTATGAG ATCGTCTGCT CGAAATACCC GGATGCGACG 960 ACCGGTACTG CGGTAAGGGC GTTTATGCAA GCCGCGATTG GTCCAGGCCA AGAAGGCCTG 1020 GACCAATACG GCTCCATTCC GTTGCCCAAA TCGTTCCAAG CAAAATTGGC GGCCGCGGTG 1080 AATGCTATTT CTTGACCTAG TGAAGGGAAT TCGACGGTGA GCGATGCCGT TCCGCAGGTA 1140 GGGTCGCAAT TTGGGCCGTA TCAGCTATTG CGGCTGCTGG GCCGAGGCGG GATGGGCGAG 1200 (2) INFORMATION FOR SEC ID. NO .: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1155 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 12: GCAAGCAGCT GCAGGTCGTG CTGTTCGACG AACTGGGCAT GCCGAAGACC AAACGCACCA 60 AGACCGGCTA CACCACGGAT GCCGACGCGC TGCAGTCGTT GTTCGACAAG ACCGGGCATC 120 CGTTTCTGCA ACATCTGCTC GCCCACCGCG ACGTCACCCG GCTCAAGGTC ACCGTCGACG 180 GGTTGCTCCA AGCGGTGGCC GCCGACGGCC GCATCCACAC CACGTTCAAC CAGACGATCG 240 CCGCGACCGG CCGGCTCTCC TCGACCGAAC CCAACCTGCA GAACATCCCG ATCCGCACCG 300 ACGCGGGCCG GCGGATCCGG GACGCGTTCG TGGTCGGGGA CGGTTACGCC GAGTTGATGA 360 CGGCCGACTA CAGCCAGATC GAGATGCGGA TCATGGGGCA CCTGTCCGGG GACGAGGGCC 420 TCATCGAGGC GTTCAACACC GGGGAGGACC TGTATTCGTT CGTCGCGTCC CGGGTGTTCG 480 GTGTGCCCAT CGACGAGGTC ACCGGCGAGT TGCGGCGCCG GGTCAAGGCG ATGTCCTACG 540 GGCTGGTTTA CGGGTTGAGC GCCTACGGCC TGTCGCAGCA GTTGAAAATC TCCACCGAGG 600 AAGCCAACGA GCAGATGGAC GCGTATTTCG CCCGATTCGG CGGGGTGCGC GACTACCTGC 660 GCGCCGTAGT CGAGCGGGCC CGCAAGGACG GCTACACCTC GACGGTGCTG GGCCGTCGCC 720 GCTACCTGCC CGAGCTGGAC AGCAGCAACC GTCAAGTGCG GGAGGCCGCC GAGCGGGCGG 780 CGCTGAACGC GCCGATCCAG GGCAGCGCGG CCGACATCAT CAAGGTGGCC ATGATCCAGG 840 TCGACAAGGC G CTCAACGAG GCACAGCTGG CGTCGCGCAT GCTGCTGCAG GTCCACGACG 900 AGCTGCTGTT CGAAATCGCC CCCGGTGAAC GCGAGCGGGT CGAGGCCCTG GTGCGCGACA 960 AGATGGGCGG CGCTTACCCG CTCGACGTCC CGCTGGAGGT GTCGGTGGGC TACGGCCGCA 1020 GCTGGGACGC GGCGGCGCAC TGAGTGCCGA GCGTGCATCT GGGGCGGGAA TTCGGCGATT 1080 TTTCCGCCCT GAGTTCACGC TCGGCGCAAT CGGGACCGAG TTTGTCCAGC GTGTACCCGT CGAGTAGCCT CGTCA 1140 1155 (2) INFORMATION FOR SEC ID. NO.:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1771 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 13: GAGCGCCGTC TGGTGTTTGA ACGGTTTTAC CGGTCGGCAT CGGCACGGGC GTTGCCGGGT 60 TCGGGCCTCG GGTTGGCGAT CGTCAAACAG GTGGTGCTCA ACCACGGCGG ATTGCTGCGC 120 ATCGAAGACA CCGACCCAGG CGGCCAGCCC CCTGGAACGT CGATTTACGT GCTGCTCCCC 180 GGCCGTCGGA TGCCGATTCC GCAGCTTCCC GGTGCGACGG CTGGCGCTCG GAGCACGGAC 240 ATCGAGAACT CTCGGGGTTC GGCGAACGTT ATCTCAGTGG AATCTCAGTC CACGCGCGCA 300 ACCTAGTTGT GCAGTTACTG TTGAAAGCCA CACCCATGCC AGTCCACGCA TGGCCAAGTT 360 GGCCCGAGTA GTGGGCCTAG TACAGGAAGA GCAACCTAGC GACATGACGA ATCACCCACG 420 GTATTCGCCA CCGCCGCAGC AGCCGGGAAC CCCAGGTTAT GCTCAGGGGC AGCAGCAAAC 480 GTACAGCCAG CAGTTCGACT GGCGTTACCC ACCGTCCCCG CCCCCGCAGC CAACCCAGTA 540 CCGTCAACCC TACGAGGCGT TGGGTGGTAC CCGGCCGGGT CTGATACCTG GCGTGATTCC 600 GACCATGACG CCCCCTCCTG GGATGGTTCG CCAACGCCCT CGTGCAGGCA TGTTGGCCAT 660 CGGCGCGGTG ACGATAGCGG TGGTGTCCGC CGGCATCGGC GGCGCGGCCG CATCCCTGGT 720 CGGGTTCAAC CGGGCACCCG CCGGCCCCAG CGGCGGCCCA GTGGCTGCCA GCGCGGCGCC 780 AAGCATCCCC GCAGCAAACA TGCCGCCGGG GTCGGTCGAA CAGGTGGCGG CCAAGGTGGT 840 GCCCAGTGTC GTCAT GTTGG AAACCGATCT GGGCCGCCAG TCGGAGGAGG GCTCCGGCAT 900 CATTCTGTCT GCCGAGGGGC TGATCTTGAC CAACAACCAC GTGATCGCGG CGGCCGCCAA 960 GCCTCCCCTG GGCAGTCCGC CGCCGAAAAC GACGGTAACC TTCTCTGACG GGCGGACCGC 1020 ACCCTTCACG GTGGTGGGGG CTGACCCCAC CAGTGATATC GCCGTCGTCC GTGTTCAGGG 1080 CGTCTCCGGG CTCACCCCGA TCTCCCTGGG TTCCTCCTCG GACCTGAGGG TCGGTCAGCC 1140 GGTGCTGGCG ATCGGGTCGC CGCTCGGTTT GGAGGGCACC GTGACCACGG GGATCGTCAG 1200 CGCTCTCAAC CGTCCAGTGT CGACGACCGG CGAGGCCGGC AACCAGAACA CCGTGCTGGA 1260 CGCCATTCAG ACCGACGCCG CGATCAACCC CGGTAACTCC GGGGGCGCGC TGGTGAACAT 1320 GAACGCTCAA CTCGTCGGAG TCAACTCGGC CATTGCCACG CTGGGCGCGG ACTCAGCCGA 1380 TGCGCAGAGC GGCTCGATCG GTCTCGGTTT TGCGATTCCA GTCGACCAGG CCAAGCGCAT 1440 CGCCGACGAG TTGATCAGCA CCGGCAAGGC GTCACATGCC TCCCTGGGTG TGCAGGTGAC 1500 CAATGACAAA GACACCCCGG GCGCCAAGAT CGTCGAAGTA GTGGCCGGTG GTGCTGCCGC 1560 GAACGCTGGA GTGCCGAAGG GCGTCGTTGT CACCAAGGTC GACGACCGCC CGATCAACAG 1620 CGCGGACGCG TTGGTTGCCG CCGTGCGGTC CAAAGCGCCG GGCGCCACGG TGGCGCTAAC 1680 CTTTCAGGAT CCCTCGGGCG GT AGCCGCAC AGTGCAAGTC ACCCTCGGCA AGGCGGAGCA 1740 GTGATGAAGG TCGCCGCGCA GTGTTCAAAG C 1771 (2) INFORMATION FOR SEC ID. DO NOT . : 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1058 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 14: CTCCACCGCG GTGGCGGCCG CTCTAGAACT AGTGGATCCC CCGGGCTGCA GGAATTCGGC 60 ACGAGGATCC GACGTCGCAG GTTGTCGAAC CCGCCGCCGC GGAAGTATCG GTCCATGCCT 120 AGCCCGGCGA CGGCGAGCGC CGGAATGGCG CGAGTGAGGA GGCGGGCAAT TTGGCGGGGC 180 CCGGCGACGG CGAGCGCCGG AATGGCGCGA GTGAGGAGGC GGGCAGTCAT GCCCAGCGTG 240 ATCCAATCAA CCTGCATTCG GCCTGCGGGC CCATTTGACA ATCGAGGTAG TGAGCGCAAA 300 TGAATGATGG AAAACGGGCG GTGACGTCCG CTGTTCTGGT GGTGCTAGGT GCCTGCCTGG 360 CGTTGTGGCT ATCAGGATGT TCTTCGCCGA AACCTGATGC CGAGGAACAG GGTGTTCCCG 420 TGAGCCCGAC GGCGTCCGAC CCCGCGCTCC TCGCCGAGAT CAGGCAGTCG CTTGATGCGA 480 CAAAAGGGTT GACCAGCGTG CACGTAGCGG TCCGAACAAC CGGGAAAGTC GACAGCTTGC 540 TGGGTATTAC CAGTGCCGAT GTCGACGTCC GGGCCAATCC GCTCGCGGCA AAGGGCGTAT 600 GCACCTACAA CGACGAGCAG GGTGTCCCGT TTCGGGTACA AGGCGACAAC ATCTCGGTGA 660 AACTGTTCGA CGACTGGAGC AATCTCGGCT CGATTTCTGA ACTGTCAACT TCACGCGTGC 720 TCGATCCTGC CGCTGGGGTG ACGCAGCTGC TGTCCGGTGT CACGAACCTC CAAGCGCAAG 780 GTACCGAAGT GATAGACGGA ATTTCGACCA CCAAAATCAC CGGGACCATC CCCGCGAGCT 840 CTGTCAAGAT G CTTGATCCT GGCGCCAAGA GTGCAAGGCC GGCGACCGTG TGGATTGCCC 900 AGGACGGCTC GCACCACCTC GTCCGAGCGA GCATCGACCT CGGATCCGGG TCGATTCAGC 960 TCACGCAGTC GAAATGGAAC GAACCCGTCA ACGTCGACTA GGCCGAAGTT GCGTCGACGC 1020 GTTGNTCGAA ACGCCCTTGT GAACGGTGTC AACGGNAC 1058 (2) INFORMATION FOR SEQ. NO.:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 542 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 15: GAATTCGGCA CGAGAGGTGA TCGACATCAT CGGGACCAGC CCCACATCCT GGGAACAGGC 60 GGCGGCGGAG GCGGTCCAGC GGGCGCGGGA TAGCGTCGAT GACATCCGCG TCGCTCGGGT 120 CATTGAGCAG GACATGGCCG TGGACAGCGC CGGCAAGATC ACCTACCGCA TCAAGCTCGA 180 AGTGTCGTTC AAGATGAGGC CGGCGCAACC GCGCTAGCAC GGGCCGGCGA GCAAGACGCA 240 AAATCGCACG GTTTGCGGTT GATTCGTGCG ATTTTGTGTC TGCTCGCCGA GGCCTACCAG 300 GCGCGGCCCA GGTCCGCGTG CTGCCGTATC CAGGCGTGCA TCGCGATTCC GGCGGCCACG 360 CCGGAGTTAA TGCTTCGCGT CGACCCGAAC TGGGCGATCC GCCGGNGAGC TGATCGATGA 420 CCGTGGCCAG CCCGTCGATG CCCGAGTTGC CCGAGGAAAC GTGCTGCCAG GCCGGTAGGA 480 AGCGTCCGTA GGCGGCGGTG CTGACCGGCT CTGCCTGCGC CCTCAGTGCG GCCAGCGAGC 540 GG 542 (2) INFORMATION FOR SEC ID. NO .: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 913 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 16: CGGTGCCGCC CGCGCCTCCG TTGCCCCCAT TGCCGCCGTC GCCGATCAGC TGCGCATCGC 60 CACCATCACC GCCTTTGCCG CCGGCACCGC CGGTGGCGCC GGGGCCGCCG ATGCCACCGC 120 TTGACCCTGG CCGCCGGCGC CGCCATTGCC ATACAGCACC CCGCCGGGGG CACCGTTACC 180 GCCGTCGCCA CCGTCGCCGC CGCTGCCGTT TCAGGCCGGG GAGGCCGAAT GAACCGCCGC 240 CAAGCCCGCC GCCGGCACCG TTGCCGCCTT TTCCGCCCGC CCCGCCGGCG CCGCCAATTG 300 CCGAACAGCC AMGCACCGTT GCCGCCAGCC CCGCCGCCGT TAACGGCGCT GCCGGGCGCC 360 GCCGCCGGAC CCGCCATTAC CGCCGTTCCC GTTCGGTGCC CCGCCGTTAC CGGCGCCGCC 420 GTTTGCCGCC AATATTCGGC GGGCACCGCC AGACCCGCCG GGGCCACCAT TGCCGCCGGG 480 CACCGAAACA ACAGCCCAAC GGTGCCGCCG GCCCCGCCGT TTGCCGCCAT CACCGGCCAT 540 TCACCGCCAG CACCGCCGTT AATGTTTATG AACCCGGTAC CGCCAGCGCG GCCCCTATTG 600 CCGGGCGCCG GAGNGCGTGC CCGCCGGCGC CGCCAACGCC CAAAAGCCCG GGGTTGCCAC 660 CGGCCCCGCC GGACCCACCG GTCCCGCCGA TCCCCCCGTT GCCGCCGGTG CCGCCGCCAT 720 TGGTGCTGCT GAAGCCGTTA GCGCCGGTTC CGCSGGTTCC GGCGGTGGCG CCNTGGCCGC 780 CGGCCCCGCC GTTGCCGTAC AGCCACCCCC CGGTGGCGCC GTTGCCGCCA TTGCCGCCAT 840 TGCCGCCGTT GCC GCCATTG CCGCCGTTCC CGCCGCCACC GCCGGNTTGG CCGCCGGCGC 900 CGCCGGCGGC CGC 913 (2) INFORMATION FOR SEC ID. NO .: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1872 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 17: GACTACGTTG GTGTAGAAAA ATCCTGCCGC CCGGACCCTT AAGGCTGGGA CAATTTCTGA 60 TAGCTACCCC GACACAGGAG GTTACGGGAT GAGCAATTCG CGCCGCCGCT CACTCAGGTG 120 GTCATGGTTG CTGAGCGTGC TGGCTGCCGT CGGGCTGGGC CTGGCCACGG CGCCGGCCCA 180 GGCGGCCCCG CCGGCCTTGT CGCAGGACCG GTTCGCCGAC TTCCCCGCGC TGCCCCTCGA 240 CCCGTCCGCG ATGGTCGCCC AAGTGGCGCC ACAGGTGGTC AACATCAACA CCAAACTGGG 300 CTACAACAAC GCCGTGGGCG CCGGGACCGG CATCGTCATC GATCCCAACG GTGTCGTGCT 360 GACCAACAAC CACGTGATCG CGGGCGCCAC CGACATCAAT GCGTTCAGCG TCGGCTCCGG 420 CCAAACCTAC GGCGTCGATG TGGTCGGGTA TGACCGCACC CAGGATGTCG CGGTGCTGCA 480 GCTGCGCGGT GCCGGTGGCC TGCCGTCGGC GGCGATCGGT GGCGGCGTCG CGGTTGGTGA 540 GCCCGTCGTC GCGATGGGCA ACAGCGGTGG GCAGGGCGGA ACGCCCCGTG CGGTGCCTGG 600 CAGGGTGGTC GCGCTCGGCC AAACCGTGCA GGCGTCGGAT TCGCTGACCG GTGCCGAAGA 660 GACATTGAAC GGGTTGATCC AGTTCGATGC CGCAATCCAG CCCGGTGATT CGGGCGGGCC 720 CGTCGTCAAC GGCCTAGGAC AGGTGGTCGG TATGAACACG GCCGCGTCCG ATAACTTCCA 780 GCTGTCCCAG GGTGGGCAGG GATTCGCCAT TCCGATCGGG CAGGCGATGG CGATCGCGGG 840 CCAAATCCGA TCGGGT GGGG GGTCACCCAC CGTTCATATC GGGCCTACCG CCTTCCTCGG 900 CTTGGGTGTT GTCGACAACA ACGGCAACGG CGCACGAGTC CAACGCGTGG TCGGAAGCGC 960 TCCGGCGGCA AGTCTCGGCA TCTCCACCGG CGACGTGATC ACCGCGGTCG ACGGCGCTCC 1020 GATCAACTCG GCCACCGCGA TGGCGGACGC GCTTAACGGG CATCATCCCG GTGACGTCAT 1080 CTCGGTGAAC TGGCAAACCA AGTCGGGCGG CACGCGTACA GGGAACGTGA CATTGGCCGA 1140 GGGACCCCCG GCCTGATTTG TCGCGGATAC CACCCGCCGG CCGGCCAATT GGATTGGCGC 1200 CAGCCGTGAT TGCCGCGTGA GCCCCCGAGT TCCGTCTCCC GTGCGCGTGG CATTGTGGAA 1260 GCAATGAACG AGGCAGAACA CAGCGTTGAG CACCCTCCCG TGCAGGGCAG TTACGTCGAA 13 0 GGCGGTGTGG TCGAGCATCC GGATGCCAAG GACTTCGGCA GCGCCGCCGC CCTGCCCGCC 1380 GATCCGACCT GGTTTAAGCA CGCCGTCTTC TACGAGGTGC TGGTCCGGGC GTTCTTCGAC 1440 GCCAGCGCGG ACGGTTCCGN CGATCTGCGT GGACTCATCG ATCGCCTCGA CTACCTGCAG 1500 TGGCTTGGCA TCGACTGCAT CTGTTGCCGC CGTTCCTACG ACTCACCGCT GCGCGACGGC 1560 GGTTACGACA TTCGCGACTT CTACAAGGTG CTGCCCGAAT TCGGCACCGT CGACGATTTC 1620 GTCGCCCTGG TCGACACCGC TCACCGGCGA GGTATCCGCA TCATCACCGA CCTGGTGATG 1680 AATCACACCT CGGAGTCGCA CCC CTGGTTT CAGGAGTCCC GCCGCGACCC AGACGGACCG 1740 TACGGTGACT ATTACGTGTG GAGCGACACC AGCGAGCGCT ACACCGACGC CCGGATCATC 1800 TTCGTCGACA CCGAAGAGTC GAACTGGTCA TTCGATCCTG TCCGCCGACA GTTNCTACTG 1860 GCACCGATTC TT 1872 (2) INFORMATION FOR SEC ID. NO.:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1482 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:18: CTTCGCCGAA ACCTGATGCC GAGGAACAGG GTGTTCCCGT GAGCCCGACG GCGTCCGACC 60 CCGCGCTCCT CGCCGAGATC AGGCAGTCGC TTGATGCGAC AAAAGGGTTG ACCAGCGTGC 120 ACGTAGCGGT CCGAACAACC GGGAAAGTCG ACAGCTTGCT GGGTATTACC AGTGCCGATG 180 TCGACGTCCG GGCCAATCCG CTCGCGGCAA AGGGCGTATG CACCTACAAC GACGAGCAGG 240 GTGTCCCGTT TCGGGTACAA GGCGACAACA TCTCGGTGAA ACTGTTCGAC GACTGGAGCA 300 ATCTCGGCTC GATTTCTGAA CTGTCAACTT CACGCGTGCT CGATCCTGCC CTGGGGTGA 360 CGCAGCTGCT GTCCGGTGTC ACGAACCTCC AAGCGCAAGG TACCGAAGTG ATAGACGGAA 420 TTTCGACCAC CAAAATCACC GGGACCATCC CCGCGAGCTC TGTCAAGATG CTTGATCCTG 480 GCGCCAAGAG TGCAAGGCCG GCGACCGTGT GGATTGCCCA GGACGGCTCG CACCACCTCG 540 TCCGAGCGAG CATCGACCTC GGATCCGGGT CGATTCAGCT CACGCAGTCG AAATGGAACG 600 AACCCGTCAA CGTCGACTAG GCCGAAGTTG CGTCGACGCG TTGCTCGAAA CGCCCTTGTG 660 AACGGTGTCA ACGGCACCCG AAAACTGACC CCCTGACGGC ATCTGAAAAT TGACCCCCTA 720 GACCGGGCGG TTGGTGGTTA TTCTTCGGTG GTTCCGGCTG GTGGGACGCG GCCGAGGTCG 780 CGGTCTTTGA GCCGGTAGCT GTCGCCTTTG AGGGCGACGA CTTCAGCATG GTGGACGAGG 840 CGGTCGATCA TGGCGGCAGC AACGACGTCG TCGCCGCCGA AAACCTCGCC CCACCGGCCG 900 AAGGCCTTAT TGGACGTGAC GATCAAGCTG GCCCGCTCAT ACCGGGAGGA CACCAGCTGG 960 AAGAAGAGGT TGGCGGCCTC GGGCTCAAAC GGAATGTAAC CGACTTCGTC AACCACCAGG 1020 AGCGGATAGC GGCCAAACCG GGTGAGTTCG GCGTAGATGC GCCCGGCGTG GTGAGCCTCG 1080 GCGAACCGTG CTACCCATTC GGCGGCGGTG GCGAACAGCA CCCGATGACC GGCCTGACAC 1140 GCGCGTATCG CCAGGCCGAC CGCAAGATGA GTCTTCCCGG TGCCAGGCGG GGCCCAAAAA 1200 CACGACGTTA TCGCGGGCGG TGATGAAATC CAGGGTGCCC AGATGTGCGA TGGTGTCGCG 1260 TTTGAGGCCA CGAGCATGCT CAAAGTCGAA CTCTTCCAAC GACTTCCGAA CCGGGAAGCG 1320 GGCGGCGCGG ATGCGGCCCT CACCACCATG GGACTCCCGG GCTGACACTT CCCGCTGCAG 1380 GCAGGCGGCC AGGTATTCTT CGTGGCTCCA GTTCTCGGCG CGGGCGCGAT CGGCCAGCCG 1440 GGACACTGAC TCACGCAGGG TGGGAGCTTT CAATGCTCTT GT 1482TION FOR SEC ID. NO .: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 876 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:19: GAATTCGGCA CGAGCCGGCG ATAGCTTCTG GGCCGCGGCC GACCAGATGG CTCGAGGGTT 60 CGTGCTCGGG GCCACCGCCG GGCGCACCAC CCTGACCGGT GAGGGCCTGC AACACGCCGA 120 CGGTCACTCG TTGCTGCTGG ACGCCACCAA CCCGGCGGTG GTTGCCTACG ACCCGGCCTT 180 CGCCTACGAA ATCGGCTACA TCGNGGAAAG CGGACTGGCC AGGATGTGCG GGGAGAACCC 240 GGAGAACATC TTCTTCTACA TCACCGTCTA CAACGAGCCG TACGTGCAGC CGCCGGAGCC 300 GGAGAACTTC GATCCCGAGG GCGTGCTGGG GGGTATCTAC CGNTATCACG CGGCCACCGA 360 GCAACGCACC AACAAGGNGC AGATCCTGGC CTCCGGGGTA GCGATGCCCG CGGCGCTGCG 420 GGCAGCACAG ATGCTGGCCG CCGAGTGGGA TGTCGCCGCC GACGTGTGGT CGGTGACCAG 480 TTGGGGCGAG CTAAACCGCG ACGGGGTGGT CATCGAGACC GAGAAGCTCC GCCACCCCGA 540 TCGGCCGGCG GGCGTGCCCT ACGTGACGAG AGCGCTGGAG AATGCTCGGG GCCCGGTGAT 600 CGCGGTGTCG GACTGGATGC GCGCGGTCCC CGAGCAGATC CGACCGTGGG TGCCGGGCAC 660 ATACCTCACG TTGGGCACCG ACGGGTTCGG TTTTTCCGAC ACTCGGCCCG CCGGTCGTCG 720 TTACTTCAAC ACCGACGCCG AATCCCAGGT TGGTCGCGGT TTTGGGAGGG GTTGGCCGGG 780 TCGACGGGTG AATATCGACC CATTCGGTGC CGGTCGTGGG CCGCCCGCCC AGTTACCCGG 840 ATTCGACGAA G GTGGGGGGT TGCGCCCGAN TAAGTT 876 (2) INFORMATION FOR SEC ID. NO .: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1021 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 20: ATCCCCCCGG GCTGCAGGAA TTCGGCACGA GAGACAAAAT TCCACGCGTT AATGCAGGAA 60 CAGATTCATA ACGAATTCAC AGCGGCACAA CAATATGTCG CGATCGCGGT TTATTTCGAC 120 AGCGAAGACC TGCCGCAGTT GGCGAAGCAT TTTTACAGCC AAGCGGTCGA GGAACGAAAC 180 CATGCAATGA TGCTCGTGCA ACACCTGCTC 240 GACCGCGACC TTCGTGTCGA AATTCCCGGC GTAGACACGG TGCGAAACCA GTTCGACAGA CCCCGCGAGG CACTGGCGCT GGCGCTCGAT 300 CAGGAACGCA CAGTCACCGA CCAGGTCGGT CGGCTGACAG CGGTGGCCCG CGACGAGGGC 360 GATTTCCTCG GCGAGCAGTT CATGCAGTGG TTCTTGCAGG AACAGATCGA AGAGGTGGCC 420 TTGATGGCAA CCCTGGTGCG GGTTGCCGAT CGGGCCGGGG CCAACCTGTT CGAGCTAGAG 480 AACTTCGTCG CACGTGAAGT GGATGTGGCG CCGGCCGCAT CAGGCGCCCC GCACGCTGCC 540 GGGGGCCGCC TCTAGATCCC TGGGGGGGAT CAGCGAGTGG TCCCGTTCGC CCGCCCGTCT 600 TCCAGCCAGG CCTTGGTGCG GCCGGGGTGG TGAGTACCAA TCCAGGCCAC CCCGACCTCC 660 CGGNAAAAGT CGATGTCCTC GTACTCATCG ACGTTCCAGG AGTACACCGC CCGGCCCTGA 720 GCTGCCGAGC GGTCAACGAG TTGCGGATAT TCCTTTAACG CAGGCAGTGA GGGTCCCACG 780 GCGGTTGGCC CGACCGCCGT GGCCGCACTG CTGGTCAGGT ATCGGGGGGT CTTGGCGAGC 840 AACAACGTCG G CAGGAGGGG TGGAGCCCGC CGGATCCGCA GACCGGGGGG GCGAAAACGA 900 CATCAACACC GCACGGGATC GATCTGCGGA GGGGGGTGCG GGAATACCGA ACCGGTGTAG_960_GAGCGCCAGC AGTTGTTTTT CCACCAGCGA AGCGTTTTCG GGTCATCGGN GGCNNTTAAG 1020T 1021 (2) INFORMATION FOR SEC ID. NO.:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 321 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 21: CGTGCCGACG AACGGAAGAA CACAACCATG AAGATGGTGA AATCGATCGC CGCAGGTCTG 60 ACCGCCGCGG CTGCAATCGG CGCCGCTGCG GCCGGTGTGA CTTCGATCAT GGCTGGCGGN 120 CCGGTCGTAT ACCAGATGCA GCCGGTCGTC TTCGGCGCGC CACTGCCGTT GGACCCGGNA 180 TCCGCCCCTG ANGTCCCGAC CGCCGCCCAG TGGACCAGNC TGCTCAACAG NCTCGNCGAT 240 CCCAACGTGT CGTTTGNGAA CAAGGGNAGT CTGGTCGAGG GNGGNATCGG NGGNANCGAG 300 GGNGNGNATC GNCGANCACA A 321 (2) INFORMATION FOR SEC ID. NO .: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 373 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 22: TCTTATCGGT TCCGGTTGGC GACGGGTTTT GGGNGCGGGT GGTTAACCCG CTCGGCCAGC 60 CGATCGACGG GCGCGGAGAC GTCGACTCCG ATACTCGGCG CGCGCTGGAG CTCCAGGCGC 120 CCTCGGTGGT GNACCGGCAA GGCGTGAAGG AGCCGTTGNA GACCGGGATC AAGGCGATTG 180 ACGCGATGAC CCCGATCGGC CGCGGGCAGC GCCAGCTGAT CATCGGGGAC CGCAAGACCG 240 GCAAAAACCG CCGTCTGTGT CGGACACCAT CCTCAAACCA GCGGGAAGAA CTGGGAGTCC 300 GGTGGATCCC AAGAAGCAGG TGCGCTTGTG TATACGTTGG CCATCGGGCA AGAAGGGGAA 360 373 CCG CTTACCATCG (2) INFORMATION FOR SEC ID. NO .: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 352 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:23: GTGACGCCGT GATGGGATTC CTGGGCGGGG CCGGTCCGCT GGCGGTGGTG GATCAGCAAC 60 TGGTTACCCG GGTGCCGCAA GGCTGGTCGT TTGCTCAGGC AGCCGCTGTG CCGGTGGTGT 120 TCTTGACGGC CTGGTACGGG TTGGCCGATT TAGCCGAGAT CAAGGCGGGC GAATCGGTGC 180 TGATCCATGC CGGTACCGGC GGTGTGGGCA TGGCGGCTGT GCAGCTGGCT CGCCAGTGGG 240 GCGTGGAGGT TTTCGTCACC GCCAGCCGTG GNAAGTGGGA CACGCTGCGC GCCATNGNGT 300 TTGACGACGA NCCATATCGG NGATTCCCNC ACATNCGAAG TTCCGANGGA GA 352 (2) INFORMATION FOR SEC ID. DO NOT . : 24 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 726 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 24: GAAATCCGCG TTCATTCCGT TCGACCAGCG GCTGGCGATA ATCGACGAAG TGATCAAGCC 60 GCGGTTCGCG GCGCTCATGG GTCACAGCGA GTAATCAGCA AGTTCTCTGG TATATCGCAC 120 CTAGCGTCCA GTTGCTTGCC AGATCGCTTT CGTACCGTCA TCGCATGTAC CGGTTCGCGT 180 GCCGCACGCT CATGCTGGCG GCGTGCATCC TGGCCACGGG TGTGGCGGGT CTCGGGGTCG 240 GCGCGCAGTC CGCAGCCCAA ACCGCGCCGG TGCCCGACTA CTACTGGTGC CCGGGGCAGC 300 CTTTCGACCC CGCATGGGGG CCCAACTGGG ATCCCTACAC CTGCCATGAC GACTTCCACC 360 GCGACAGCGA CGGCCCCGAC CACAGCCGCG ACTACCCCGG ACCCATCCTC GAAGGTCCCG 420 TGCTTGACGA TCCCGGTGCT GCGCCGCCGC CCCCGGCTGC CGGTGGCGGC GCATAGCGCT 480 CGTTGACCGG GCCGCATCAG CGAATACGCG TATAAACCCG GGCGTGCCCC CGGCAAGCTA 540 CGACCCCCGG CGGGGCAGAT TTACGCTCCC GTGCCGATGG ATCGCGCCGT CCGATGACAG 600 AAAATAGGCG ACGGTTTTGG CAACCGCTTG GAGGACGCTT GAAGGGAACC TGTCATGAAC 660 GGCGACAGCG CCTCCACCAT CGACATCGAC AAGGTTGTTA CCCGCACACC CGTTCGCCGG ATCGTG 720 726 (2) INFORMATION FOR SEC ID. NO .: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 580 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:25: CGCGACGACG ACGAACGTCG GGCCCACCAC CGCCTATGCG TTGATGCAGG CGACCGGGAT 60 GGTCGCCGAC CATATCCAAG CATGCTGGGT GCCCACTGAG CGACCTTTTG ACCAGCCGGG 120 CTGCCCGATG GCGGCCCGGT GAAGTCATTG CGCCGGGGCT TGTGCACCTG ATGAACCCGA 180 ATAGGGAACA ATAGGGGGGT GATTTGGCAG TTCAATGTCG GGTATGGCTG GAAATCCAAT 240 GGCGGGGCAT GCTCGGCGCC GACCAGGCTC GCGCAGGCGG GCCAGCCCGA ATCTGGAGGG 300 AGCACTCAAT GGCGGCGATG AAGCCCCGGA CCGGCGACGG TCCTTTGGAA GCAACTAAGG 360 AGGGGCGCGG CATTGTGATG CGAGTACCAC TTGAGGGTGG CGGTCGCCTG GTCGTCGAGC 4 0 TGACACCCGA CGAAGCCGCC GCACTGGGTG ACGAACTCAA AGGCGTTACT AGCTAAGACC 480 AGCCCAACGG CGAATGGTCG GCGTTACGCG CACACCTTCC GGTAGATGTC CAGTGTCTGC 540 TCGGCGATGT ATGCCCAGGA GAACTCTTGG ATACAGCGCT 580 (2) INFORMATION FOR SEC ID. NO .: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 160 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 26: AACGGAGGCG CCGGGGGGTTT TGGCGGGGCC GGGGCGGTCG GCGGCAACGG CGGGGCCGGC 60 GGTACCGCCG GGTTGTTCGG TGTCGGCGGG GCCGGTGGGG CCGGAGGCAA CGGCATCGCC 120 GGTGTCACGG GTACGTCGGC CAGCACACCG GGTGGATCCG 160 (2) INFORMATION FOR SEC ID. NO.:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 272 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. N0.:27: GACACCGATA CGATGGTGAT GTACGCCAAC GTTGTCGACA CGCTCGAGGC GTTCACGATC 60 CAGCGCACAC CCGACGGCGT GACCATCGGC GATGCGGCCC CGTTCGCGGA GGCGGCTGCC 120 AAGGCGATGG GAATCGACAA GCTGCGGGTA ATTCATACCG GAATGGACCC CGTCGTCGCT 180 GAACGCGAAC AGTGGGACGA CGGCAACAAC ACGTTGGCGT TGGCGCCCGG TGTCGTTGTC 240 GCCTACGAGC GCAACGTACA GACCAACGCC CG 272 (2) INFORMATION FOR SEC ID. NO .: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 28: GCAGCCGGTG GTTCTCGGAC TATCTGCGCA CGGTGACGCA GCGCGACGTG CGCGAGCTGA 60 AGCGGATCGA GCAGACGGAT CGCCTGCCGC GGTTCATGCG CTACCTGGCC GCTATCACCG 120 CGCAGGAGCT GAACGTGGCC GAAGCGGCGC GGGTCATCGG GGTCGACGCG GGGACGATCC 180 GTTCGGATCT GGCGTGGTTC GAGACGGTCT ATCTGGTACA TCGCCTGCCC GCCTGGTCGC 240 GGAATCTGAC CGCGAAGATC AAGAAGCGGT CAAAGATCCA CGTCGTCGAC AGTGGCTTCG 300 CGGCCTGGTT GCGCGGG 317 (2) INFORMATION FOR SEC ID. NO .: 29 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 182 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 29: GATCGTGGAG CTGTCGATGA ACAGCGTTGC CGGACGCGCG GCGGCCAGCA CGTCGGTGTA 60 GCAGCGCCGG ACCACCTCGC CGGTGGGCAG CATGGTGATG ACCACGTCGG CCTCGGCCAC 120 CGCTTCGGGC GCGCTACGAA ACACCGCGAC ACCGTGCGCG GCGGCGCCGG ACGCCGCCGT 180 GG 182 (2) INFORMATION FOR SEC ID. NO .: 30 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 308 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:30: GATCGCGAAG TTTGGTGAGC AGGTGGTCGA CGCGAAAGTC TGGGCGCCTG CGAAGCGGGT 60 CGGCGTTCAC GAGGCGAAGA CACGCCTGTC CGAGCTGCTG CGGCTCGTCT ACGGCGGGCA 120 GAGGTTGAGA TTGCCCGCCG CGGCGAGCCG GTAGCAAAGC TTGTGCCGCT GCATCCTCAT 180 GAGACTCGGC GGTTAGGCAT TGACCATGGC GTGTACCGCG TGCCCGACGA TTTGGACGCT 240 CCGTTGTCAG ACGACGTGCT CGAACGCTTT CACCGGTGAA GCGCTACCTC ATCGACACCC 300 ACGTTTGG 308 (2) INFORMATION FOR SEC ID. NO.:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 267 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO ..- 31: CCGACGACGA GCAACTCACG TGGATGATGG TCGGCAGCGG CATTGAGGAC GGAGAGAATC 60 CGGCCGAAGC TGCCGCGCGG CAAGTGCTCA TAGTGACCGG CCGTAGAGGG CTCCCCCGAT 120 GGCACCGGAC TATTCTGGTG TGCCGCTGGC CGGTAAGAGC GGGTAAAAGA ATGTGAGGGG 180 ACACGATGAG CAATCACACC TACCGAGTGA TCGAGATCGT CGGGACCTCG CCCGACGGCG 240 TCGACGCGGC AATCCAGGGC GGTCTGG 267 (2) INFORMATION FOR SEC ID. NO .: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1539 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:32: CTCGTGCCGA AAGAATGTGA GGGGACACGA TGAGCAATCA CACCTACCGA GTGATCGAGA 60 TCGTCGGGAC CTCGCCCGAC GGCGTCGACG CGGCAATCCA GGGCGGTCTG GCCCGAGCTG 120 CGCAGACCAT GCGCGCGCTG GACTGGTTCG AAGTACAGTC AATTCGAGGC CACCTGGTCG 180 ACGGAGCGGT CGCGCACTTC CAGGTGACTA TGAAAGTCGG CTTCCGCTGG AGGATTCCTG 240 AACCTTCAAG CGCGGCCGAT AACTGAGGTG CATCATTAAG CGACTTTTCC AGAACATCCT 300 GACGCGCTCG AAACGCGGTT CAGCCGACGG TGGCTCCGCC GAGGCGCTGC CTCCAAAATC 360 CCTGCGACAA TTCGTCGGCG GCGCCTACAA GGAAGTCGGT GCTGAATTCG TCGGGTATCT 420 GGTCGACCTG TGTGGGCTGC AGCCGGACGA AGCGGTGCTC GACGTCGGCT GCGGCTCGGG 480 GCGGATGGCG TTGCCGCTCA CCGGCTATCT GAACAGCGAG GGACGCTACG CCGGCTTCGA 540 TATCTCGCAG AAAGCCATCG CGTGGTGCCA GGAGCACATC ACCTCGGCGC ACCCCAACTT 600 CCAGTTCGAG GTCTCCGACA TCTACAACTC GCTGTACAAC CCGAAAGGGA AATACCAGTC 660 ACTAGACTTT CGCTTTCCAT ATCCGGATGC GTCGTTCGAT GTGGTGTTTC TTACCTCGGT 720 GTTCACCCAC ATGTTTCCGC CGGACGTGGA GCACTATCTG GACGAGATCT CCCGCGTGCT 780 GAAGCCCGGC GGACGATGCC TGTGCACGTA CTTCTTGCTC AATGACGAGT CGTTAGCCCA 840 CATCGCGGAA GG AAAGAGTG CGCACAACTT CCAGCATGAG GGACCGGGTT ATCGGACAAT 900 CCACAAGAAG CGGCCCGAAG AAGCAATCGG CTTGCCGGAG ACCTTCGTCA GGGATGTCTA 960 TGGCAAGTTC GGCCTCGCCG TGCACGAACC ATTGCACTAC GGCTCATGGA GTGGCCGGGA 1020 ACCACGCCTA AGCTTCCAGG ACATCGTCAT CGCGACCAAA ACCGCGAGCT AGGTCGGCAT 1080 CCGGGAAGCA TCGCGACACC GTGGCGCCGA GCGCCGCTGC CGGCAGGCCG ATTAGGCGGG 1140 CAGATTAGCC CGCCGCGGCT CCCGGCTCCG AGTACGGCGC CCCGAATGGC GTCACCGGCT 1200 GGTAACCACG CTTGCGCGCC TGGGCGGCGG CCTGCCGGAT CAGGTGGTAG ATGCCGACAA 1260 AGCCTGCGTG ATCGGTCATC ACCAACGGTG ACAGCAGCCG GTTGTGCACC AGCGCGAACG 1320 CCACCCCGGT CTCCGGGTCT GTCCAGCCGA TCGAGCCGCC CAAGCCCACA TGACCAAACC 1380 CCGGCATCAC GTTGCCGATC GGCATACCGT GATAGCCAAG ATGAAAATTT AAGGGCACCA 1440 ATAGATTTCG ATCCGGCAGA ACTTGCCGTC GGTTGCGGGT CAGGCCCGTG ACCAGCTCCC 1500 GCGACAAGAA CCGTATGCCG TCGATCTCGC CTCGTGCCG 1539 (2) INFORMATION FOR SEC ID. NO .: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 851 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 33: CTGCAGGGTG GCGTGGATGA GCGTCACCGC GGGGCAGGCC GAGCTGACCG CCGCCCAGGT 60 CCGGGTTGCT GCGGCGGCCT ACGAGACGGC GTATGGGCTG ACGGTGCCCC CGCCGGTGAT 120 CGCCGAGAAC CGTGCTGAAC TGATGATTCT GATAGCGACC AACCTCTTGG GGCAAAACAC 180 CCCGGCGATC GCGGTCAACG AGGCCGAATA CGGCGAGATG TGGGCCCAAG ACGCCGCCGC 240 GATGTTTGGC TACGCCGCGG CGACGGCGAC GGCGACGGCG ACGTTGCTGC CGTTCGAGGA 300 GGCGCCGGAG ATGACCAGCG CGGGTGGGCT CCTCGAGCAG GCCGCCGCGG TCGAGGAGGC 360 CTCCCACACC GCCGCGGCGA ACCAGTTGAT GAACAATGTG CCCCAGGCGC TGAAACAGTT 420 GGCCCAGCCC ACGCAGGGCA CCACGCCTTC TTCCAAGCTG GGTGGCCTGT GGAAGACGGT 480 CTCGCCGCAT CGGTCGCCGA TCAGCAACAT GGTGTCGATG GCCAACAACC ACATGTCGAT 540 GACCAACTCG GGTGTGTCGA TGACCAACAC CTTGAGCTCG ATGTTGAAGG GCTTTGCTCC 600 GGCGGCGGCC GCCCAGGCCG TGCAAACCGC GGCGCAAAAC GGGGTCCGGG CGATGAGCTC 660 GCTGGGCAGC TCGCTGGGTT CTTCGGGTCT GGGCGGTGGG 720 GTGGCCGCCA ACTTGGGTCG GGCGGCCTCG GTACGGTATG GTCACCGGGA TGGCGGAAAA TATGCANAGT CTGGTCGGCG 780 GAACGGTGGT CCGGCGTAAG GTTTACCCCC GTTTTCTGGA TGCGGTGAAC TTCGTCAACG GAAACAGTTA C 840 851 (2) INFORMATION FOR SEC ID. NO.:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 254 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:34: GATCGATCGG GCGGAAATTT GGACCAGATT CGCCTCCGGC GATAACCCAA TCAATCGAAC 60 CTAGATTTAT TCCGTCCAGG GGCCCGAGTA ATGGCTCGCA GGAGAGGAAC CTTACTGCTG 120 CGGGCACCTG TCGTAGGTCC TCGATACGGC GGAAGGCGTC GACATTTTCC ACCGACACCC 180 CCATCCAAAC GTTCGAGGGC CACTCCAGCT TGTGAGCGAG GCGACGCAGT CGCAGGCTGC GCTTGGTCAA 240 GATC 254 (2) INFORMATION FOR SEC ID. NO .: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1227 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:35: GATCCTGACC GAAGCGGCCG CCGCCAAGGC GAAGTCGCTG TTGGACCAGG AGGGACGGGA 60 CGATCTGGCG CTGCGGATCG CGGTTCAGCC GGGGGGGTGC GCTGGATTGC GCTATAACCT 120 TTTCTTCGAC GACCGGACGC TGGATGGTGA CCAAACCGCG GAGTTCGGTG GTGTCAGGTT 180 GATCGTGGAC CGGATGAGCG CGCCGTATGT GGAAGGCGCG TCGATCGATT TCGTCGACAC 240 TATTGAGAAG CAAGGTTCAC CATCGACAAT CCCAACGCCA CCGGCTCCTG CGCGTGCGGG 300 GATTCGTTCA ACTGATAAAA CGCTAGTACG ACCCCGCGGT GCGCAACACG TACGAGCACA 360 CCAAGACCTG ACCGCGCTGG AAAAGCAACT GAGCGATGCC TTGCACCTGA CCGCGTGGCG 420 'GGCCGCCGGC GGCAGGTGTC ACCTGCATGG TGAACAGCAC CTGGGCCTGA TATTGCGACC 480 AGTACACGAT TTTGTCGATC GAGGTCACTT CGACCTGGGA GAACTGCTTG CGGAACGCGT 540 CGCTGCTCAG CTTGGCCAAG GCCTGATCGG AGCGCTTGTC GCGCACGCCG TCGTGGATAC 600 CGCACAGCGC ATTGCGAACG ATGGTGTCCA CATCGCGGTT CTCCAGCGCG TTGAGGTATC 660 CCTGAATCGC GGTTTTGGCC GGTCCCTCCG AGAATGTGCC TGCCGTGTTG GCTCCGTTGG 720 TGCGGACCCC GTATATGATC GCCGCCGTCA TAGCCGACAC CAGCGCGAGG GCTACCACAA 780 TGCCGATCAG CAGCCGCTTG TGCCGTCGCT TCGGGTAGGA CACCTGCGGC GGCACGCCGG 840 GATATGCGGC GGGCGGCAGC GCCGCGTCGT CTGCCGGTCC CGGGGCGAAG GCCGGTTCGG 900 CGGCGCCGAG GTCGTGGGGG TAGTCCAGGG CTTGGGGTTC GTGGGATGAG GGCTCGGGGT 960 ACGGCGCCGG TCCGTTGGTG CCGACACCGG GGTTCGGCGA GTGGGGACCG GGCATTGTGG 1020 TTCTCCTAGG GTGGTGGACG GGACCAGCTG CTAGGGCGAC AACCGCCCGT CGCGTCAGCC 1080 GGCAGCATCG GCAATCAGGT GAGCTCCCTA GGCAGGCTAG CGCAACAGCT GCCGTCAGCT 1140 CTCAACGCGA CGGGGCGGGC CGCGGCGCCG ATAATGTTGA AAGACTAGGC AACCTTAGGA 1200 ACGAAGGACG GAGATTTTGT GACGATC 1227 (2) INFORMATION FOR SEC ID. NO .: 36 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 181 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:36: GCGGTGTCGG CGGATCCGGC GGGTGGTTGA ACGGCAACGG CGGGGCCGGC GGGGCCGGCG 60 GGACCGGCGC TAACGGTGGT GCCGGCGGCA ACGCCTGGTT GTTCGGGGCC GGCGGGTCCG 120 GCGGNGCCGG CACCAATGGT GGNGTCGGCG GGTCCGGCGG ATTTGTCTAC GGCAACGGCG 180 G 181 (2) INFORMATION FOR SEC ID. DO NOT. : 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 290 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 37: GCGGTGTCGG CGGATCCGGC GGGTGGTTGA ACGGCAACGG CGGTGTCGGC GGCCGGGGCG 60 GCGACGGCGT CTTTGCCGGT GCCGGCGGCC AGGGCGGCCT CGGTGGGCAG GGCGGCAATG 120 GCGGCGGCTC CACCGGCGGC AACGGCGGTC TTGGCGGCGC GGGCGGTGGC GGAGGCAACG 180 GGCAACGGCG CCCCGGACGG CGGCTTCGGT GTAAGGGTGG CCAGGGCGGN ATTGGCGGCG 240 GCACTCAGAG CGCGACCGGC CTCGGNGGTG ACGGCGGTGA CGGCGGTGAC 290 (2) INFORMATION FOR SEC ID. NO .: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 38 GATCCAGTGG CATGGNGGGT GTCAGTGGAA GCAT 34 (2) INFORMATION FOR SEC ID. NO .: 39 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 155 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:39 GATCGCTGCT CGTCCCCCCC TTGCCGCCGA CGCCACCGGT CCCACCGTTA CCGAACAAGC 60 TGGCGTGGTC GCCAGCACCC CCGGCACCGC CGACGCCGGA GTCGAACAAT GGCACCGTCG 120 TATCCCCACC ATTGCCGCCG GNCCCACCGG CACCG 155 (2) INFORMATION FOR SEC ID. NO .: 40 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 53 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:40: ATGGCGTTCA CGGGGCGCCG GGGACCGGGC AGCCCGGNGG GGCCGGGGGG TGG 53 (2) INFORMATION FOR SEC ID. NO .: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 132 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 41: GATCCACCGC GGGTGCAGAC GGTGCCCGCG GCGCCACCCC GACCAGCGGC GGCAACGGCG 60 GCACCGGCGG CAACGGCGCG AACGCCACCG TCGTCGGNGG GGCCGGCGGG GCCGGCGGCA 120 AGGGCGGCAA CG 132 (2) INFORMATION FOR SEC ID. NO.:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 132 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEC ID. DO NOT . : 42: GATCGGCGGC CGGNACGGNC GGGGACGGCG GCAAGGGCGG NAACGGGGGC GCCGNAGCCA 60 CCNGCCAAGA ATCCTCCGNG TCCNCCAATG GCGCGAATGG CGGACAGGGC GGCAACGGCG 120 GCANCGGCGG CA 132 (2) INFORMATION FOR SEC ID. NO .: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 702 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 43: CGGCACGAGG ATCGGTACCC CGCGGCATCG GCAGCTGCCG ATTCGCCGGG TTTCCCCACC 60 CGAGGAAAGC CGCTACCAGA TGGCGCTGCC GAAGTAGGGC GATCCGTTCG CGATGCCGGC 120 ATGAACGGGC GGCATCAAAT TAGTGCAGGA ACCTTTCAGT TTAGCGACGA TAATGGCTAT 180 AGCACTAAGG AGGATGATCC GATATGACGC AGTCGCAGAC CGTGACGGTG GATCAGCAAG 240 AGATTTTGAA CAGGGCCAAC GAGGTGGAGG CCCCGATGGC GGACCCACCG ACTGATGTCC 300 CCATCACACC GTGCGAACTC ACGGNGGNTA AAAACGCCGC CCAACAGNTG GTNTTGTCCG 360 CCGACAACAT GCGGGAATAC CTGGCGGCCG GTGCCAAAGA GCGGCAGCGT CTGGCGACCT 420 CGCTGCGCAA CGCGGCCAAG GNGTATGGCG AGGTTGATGA GGAGGCTGCG ACCGCGCTGG 480 ACAACGACGG CGAAGGAACT GTGCAGGCAG AATCGGCCGG GGCCGTCGGA GGGGACAGTT 540 CGGCCGAACT AACCGATACG CCGAGGGTGG CCACGGCCGG TGAACCCAAC TTCATGGATC 600 TCAAAGAAGC GGCAAGGAAG CTCGAAACGG GCGACCAAGG CGCATCGCTC GCGCACTGNG 660 GGGATGGGTG GAACACTTNC ACCCTGACGC TGCAAGGCGA CG 702 (2) INFORMATION FOR SEQ ID. NO .: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 298 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:44: GAAGCCGCAG CGCTGTCGGG CGACGTGGCG GTCAAAGCGG CATCGCTCGG TGGCGGTGGA 60 GGCGGCGGGG TGCCGTCGGC GCCGTTGGGA TCCGCGATCG GGGGCGCCGA ATCGGTGCGG 120 CCCGCTGGCG CTGGTGACAT TGCCGGCTTA GGCCAGGGAA GGGCCGGCGG CGGCGCCGCG 180 CTGGGCGGCG GTGGCATGGG AATGCCGATG GGTGCCGCGC ATCAGGGACA AGGGGGCGCC 240 AAGTCCAAGG GTTCTCAGCA GGAAGACGAG GCGCTCTACA CCGAGGATCC TCGTGCCG 298 (2) INFORMATION FOR SEC ID. NO.:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1058 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: ID PE SEC. DO NOT. 45: CGGCACGAGG ATCGAATCGC GTCGCCGGGA GCACAGCGTC GCACTGCACC AGTGGAGGAG 60. CCATGACCTA CTCGCCGGGT AACCCCGGAT ACCCGCAAGC GCAGCCCGCA GGCTCCTACG 120 GAGGCGTCAC ACCCTCGTTC GCCCACGCCG ATGAGGGTGC GAGCAAGCTA CCGATGTACC 180 TGAACATCGC GGTGGCAGTG CTCGGTCTGG CTGCGTACTT CGCCAGCTTC GGCCCAATGT 240 TCACCCTCAG TACCGAACTC GGGGGGGGTG ATGGCGCAGT GTCCGGTGAC ACTGGGCTGC 300 CGGTCGGGGT GGCTCTGCTG GCTGCGCTGC TTGCCGGGGT GGTTCTGGTG CCTAAGGCCA 360 AGAGCCATGT GACGGTAGTT GCGGTGCTCG GGGTACTCGG CGTATTTCTG ATGGTCTCGG 420 CGACGTTTAA CAAGCCCAGC GCCTATTCGA CCGGTTGGGC ATTGTGGGTT GTGTTGGCTT 480 TCATCGTGTT CCAGGCGGTT GCGGCAGTCC TGGCGCTCTT GGTGGAGACC GGCGCTATCA 540 CCGCGCCGGC GCCGCGGCCC AAGTTCGACC CGTATGGACA GTACGGGCGG TACGGGCAGT 600 ACGGGCAGTA CGGGGTGCAG CCGGGTGGGT ACTACGGTCA GCAGGGTGCT CAGCAGGCCG 660 CGGGACTGCA GTCGCCCGGC CCGCAGCAGT CTCCGCAGCC TCCCGGATAT GGGTCGCAGT 720 ACGDCGGCTA TTCGTCCAGT CCGAGCCAAT CGGGCAGTGG ATACACTGCT CAGCCCCCGG 780 CCCAGCCGCC GGCGCAGTCC GGGTCGCAAC AATCGCACCA GGGCCCATCC ACGCCACCTA 840 CCGGCTTTCC GAGCT TCAGC CCACCACCAC CGGTCAGTGC CGGGACGGGG TCGCAGGCTG 900 GTTCGGCTCC AGTCAACTAT TCAAACCCCA GCGGGGGCGA GCAGTCGTCG TCCCCCGGGG 960 GGGCGCCGGT CTAACCGGGC GTTCCCGCGT CCGGTCGCGC GTGTGCGCGA AGAGTGAACA 1020 GGGTGTCAGC AAGCGCGGAC GATCCTCGTG CCGAATTC 1058 (2) INFORMATION FOR SEC ID. NO .: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 327 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:46: CGGCACGAGA GACCGATGCC GCTACCCTCG CGCAGGAGGC AGGTAATTTC GAGCGGATCT 60 CCGGCGACCT GAAAACCCAG ATCGACCAGG TGGAGTCGAC GGCAGGTTCG TTGCAGGGCC 120 AGTGGCGCGG CGCGGCGGGG ACGGCCGCCC AGGCCGCGGT GGTGCGCTTC CAAGAAGCAG 180 CCAATAAGCA GAAGCAGGAA CTCGACGAGA TCTCGACGAA TATTCGTCAG GCCGGCGTCC 240 AATACTCGAG GGCCGACGAG GAGCAGCAGC AGGCGCTGTC CTCGCAAATG GGCTTCTGAC 300 CCGCTAATAC GAAAAGAAAC GGAGCAA 327 (2) INFORMATION FOR SEC ID. NO .: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 170 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 47: CGGTCGCGAT GATGGCGTTG TCGAACGTGA CCGATTCTGT ACCGCCGTCG TTGAGATCAA 60 CCAACAACGT GTTGGCGTCG GCAAATGTGC CGNACCCGTG GATCTCGGTG ATCTTGTTCT 120 TCTTCATCAG GAAGTGCACA CCGGCCACCC TGCCCTCGGN TACCTTTCGG 170 (2) INFORMATION FOR SEC ID. NO .: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 127 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:48: GATCCGGCGG CACGGGGGGT GCCGGCGGCA GCACCGCTGG CGCTGGCGGC AACGGCGGGG 60 CCGGGGGGTGG CGGCGGAACC GGTGGGTTGC TCTTCGGCAA CGGCGGTGCC GGCGGGCACG 120 GGGCCGT 127 -2) INFORMATION FOR SEC ID. NO .: 49 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 81 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 49: CGGCGGCAAG GGCGGCACCG CCGGCAACGG GAGCGGCGCG GCCGGCGGCA ACGGCGGCAA 60 CGGCGGCTCC GGCCTCAACG G 81 (2) INFORMATION FOR SEC ID. NO .: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 149 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:50: GATCAGGGCT GGCCGGCTCC GGCCAGAAGG GCGGTAACGG AGGAGCTGCC GGATTGTTTG 60 GCAACGGCGG GGCCGGNGGT GCCGGCGCGT CCAACCAAGC CGGTAACGGC GGNGCCGGCG 120 GAAACGGTGG TGCCGGTGGG CTGATCTGG 149 (2) INFORMATION FOR SEC ID. NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 355 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO: 51: CGGCACGAGA TCACACCTAC CGAGTGATCG AGATCGTCGG GACCTCGCCC GACGGTGTCG 60 ACGCGGNAAT CCAGGGCGGT CTGGCCCGAG CTGCGCAGAC CATGCGCGCG CTGGACTGGT 120 TCGAAGTACA GTCAATTCGA GGCCACCTGG TCGACGGAGC GGTCGCGCAC TTCCAGGTGA 180 CTATGAAAGT CGGCTTCCGC CTGGAGGATT CCTGAACCTT CAAGCGCGGC CGATAACTGA 240 GGTGCATCAT TAAGCGACTT TTCCAGAACA TCCTGACGCG CTCGAAACGC GGTTCAGCCG 300 ACGGTGGCTC CGCCGAGGCG CTGCCTCCAA AATCCCTGCG ACAATTCGTC GGCGG 355 (2) INFORMATION FOR SEC ID. No.:52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 999 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. N:. 52: ATGCATCACC ATCACCATCA CATGCATCAG GTGGACCCCA ACTTGACACG TCGCAAGGGA 60 CGATTGGCGG CACTGGCTAT CGCGGCGATG GCCAGCGCCA GCCTGGTGAC CGTTGCGGTG 120 CCCGCGACCG CCAACGCCGA TCCGGAGCCA GCGCCCCCGG TACCCACAAC GGCCGCCTCG 180 CCGCCGTCGA CCGCTGCAGC GCCACCCGCA CCGGCGACAC CTGTTGCCCC CCCACCACCG 240 GCCGCCGCCA ACACGCCGAA TGCCCAGCCG GGCGATCCCA ACGCAGCACC TCCGCCGGCC 300 GACCCGAACG CACCGCCGCC ACCTGTCATT GCCCCAAACG CACCCCAACC TGTCCGGATC 360 GACAACCCGG TTGGAGGATT CAGCTTCGCG CTGCCTGCTG GCTGGGTGGA GTCTGACGCC 420 GCCCACTTCG ACTACGGTTC AGCACTCCTC AGCAAAACCA CCGGGGACCC GCCATTTCCC 480 GGACAGCCGC CGCCGGTGGC CAATGACACC CGTATCGTGC TCGGCCGGCT AGACCAAAAG 540 CTTTACGCCA GCGCCGAAGC CACCGACTCC AAGGCCGCGG CCCGGTTGGG CTCGGACATG 600 GGTGAGTTCT ATATGCCCTA CCCGGGCACC CGGATCAACC AGGAAACCGT CTCGCTCGAC 660 GCCAACGGGG TGTCTGGAAG CGCGTCGTAT TACGAAGTCA AGTTCAGCGA TCCGAGTAAG 720 CCGAACGGCC AGATCTGGAC GGGCGTAATC GGCTCGCCCG CGGCGAACGC ACCGGACGCC 780 GGGCCCCCTC AGCGCTGGTT TGTGGTATGG CTCGGGACCG CCAACAACCC GGTGGACAAG 840 GGCGCGGCCA AG GCGCTGGC CGAATCGATC CGGCCTTTGG TCGCCCCGCC GCCGGCGCCG 900 GCACCGGCTC CTGCAGAGCC CGCTCCGGCG CCGGCGCCGG CCGGGGAAGT CGCTCCTACC 960 999 CCGACGACAC CGACACCGCA GCGGACCTTA CCGGCCTGA (2) INFORMATION FOR SEC ID. NO.:53 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 332 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 53: Met His His His His His His His His Met His Gln Val Asp Pro Asn Leu Thr 1 5 10 15 Arg Arg Lys Gly Arg Leu Wing Wing Leu Wing Wing Wing Wing Wing Wing 25 30 Wing Ser Leu Val Thr Val Wing Val Pro Wing Thr Wing Asn Wing Asp Pro 35 40 45 Glu Pro Wing Pro Pro Val Thr Thr Wing Wing Pro Pro Pro Ser Thr 50 55 60 Wing Wing Pro Pro Wing Pro Wing Thr Pro Val Ala Pro Pro Pro Pro 65 70 75 80 Wing Wing Wing Asn Thr Pro Asn Wing Gln Pro Gly Asp Pro Asn Wing Wing 85 90 95 Pro Pro Pro Wing Asp Pro Asn Wing Pro Pro Pro Pro Val lie Pro Wing 100 105 110 Asn Wing Pro Gln Pro Val Arg lie Asp Asn Pro Val Gly Gly Phe Ser 115 120 125 Phe Ala Leu Pro Wing Gly Trp Val Glu Ser Asp Ala Wing His Phe Asp 130 135 140 Tyr Gly Ser Ala Leu Leu Ser Lys Thr Thr Gly Asp Pro Pro Phe Pro 145 150 155 160 Gly Gln Pro Pro Pro Val Wing Asn Asp Thr Arg lie Val Leu Gly Arg 165 170 175 Leu Asp Gln Lys Leu Tyr Wing Ser Wing Glu Wing Thr Asp Ser Lys Wing 180 185 190 Wing Wing Arg Leu Gly Ser Asp Met Gly Glu Phe Tyr Met Pro Tyr Pro 195 200 205 Gly Thr Arg lie Asn Gln Glu Thr Val Ser Leu Asp Wing Asn Gly Val 210 215 220 Ser Gly Ser Ala Ser Tyr Tyr Glu Val Lys Phe Ser Asp Pro Ser Lys 225 230 235 240 Pro Asn Gly Gln lie Trp Thr Gly Val lie Gly Ser Pro Ala Wing Asn 245 250 255 Wing Pro Asp Wing Gly Pro Pro Gln Arg Trp Phe Val Val Trp Leu Gly 260 265 270 Thr Ala Asn Asn Pro Val Asp Lys Gly Ala Ala Lys Ala Leu Ala Glu 275 280 285 Ser lie Arg Pro Leu Val Pro Wing Pro Pro Wing Pro Pro Wing Pro Pro 290 295 300 Wing Glu Pro Wing Pro Wing Pro Wing Pro Wing Gly Glu Val Wing Pro Thr 305 310 315 320 Pro Thr Thr Pro Thr Pro Gln Arg Thr Leu Pro Wing 325 330 (2) INFORMATION FOR SEC ID. NO .: 54 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 54: Asp Pro Val Asp Ala Val lie Asn Thr Thr Xaa Asn Tyr Gly Gln Val 1 5 10 15 Val Ala Ala Leu 20 (2) INFORMATION FOR SEC ID. DO NOT. : 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 55: Val Glu Wing Being Gly Met Leu Wing Leu Gly Thr Pro Wing Pro Being 1 5 10 15 (2) INFORMATION FOR SEC ID. DO NOT. : 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 56: Ala Ala Met Lys Pro Arg Thr Gly Asp Gly Pro Leu Glu Ala Ala Lys 1 5 10 15 Glu Gly Arg (2) INFORMATION FOR SEC ID. DO NOT. : 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 57: Tyr Tyr Trp Cys Pro Gly Gln Pro Phe Asp Pro Wing Trp Gly Pro 1 5 10 15 (2) INFORMATION FOR SEC ID. DO NOT. : 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 58 Asp lie Gly Ser Glu Ser Thr Glu Asp Gln Gln Xaa Ala Val 1 5 10 (2) INFORMATION FOR SEC ID. NO .: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amine acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 59 Glu Glu Wing Ser lie Thr Xaa Glu Xaa lie Val Pro 1 5 10 (2) INFORMATION FOR SEC ID. NO .: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 60 Asp Pro Glu Pro Wing Pro Pro Val Pro Thr Wing Wing Wing Pro Pro 1 5 10 15 To (2) INFORMATION FOR SEC ID. DO NOT. : 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 61: Ala Pro Lys Thr Tyr Xaa Glu Glu Leu Lys Gly Thr Asp Thr Gly 1 5 10 15 (2) INFORMATION FOR SEC ID. DO NOT. : 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:62 Asp Pro Wing Being Wing Pro Asp Val Pro Thr Wing Wing Gln Gln Thr Ser 1 5 10 15 Leu Leu Asn Asn Leu Asp Pro Asp Val Wing Ser Phe Asp Wing 20 25 30 (2) INFORMATION FOR SEC ID. DO NOT. : 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 187 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 63: Thr Gly Ser Leu Asn Gln Thr His Asn Arg Arg Ala Asn Glu Arg Lys 1 5 10 15 Asn Thr Thr Met Lys Met Val Lys Ser lie Wing Wing Gly Leu Thr Wing 25 30 Ala Ala Ala lie Gly Ala Ala Ala Ala Gly Val Thr Ser lie Met Ala 35 40 45 Gly Gly Pro Val Val Tyr Gln Met Gln Pro Val Val Phe Gly Ala Pro 50 55 60 Leu Pro Leu Asp Pro Wing Wing Pro Pro Asp Val Pro Thr Wing Wing Gln 65 70 75 80 Leu Thr Ser Leu Leu Asn Ser Leu Wing Asp Pro Asn Val Ser Phe Wing 85 90 95 Asn Lys Gly Ser Leu Val Glu Gly Gly lie Gly Gly Thr Glu Ala Arg 100 105 110 lie Ala Asp His Lys Leu Lys Lys Ala Ala Glu His Gly Asp Leu Pro 115 120 125 Leu Ser Phe Ser Val Thr Asn He Gln Pro Wing Wing Wing Gly Ser Wing 130 135 140 Thr Wing Asp Val Ser Val Ser Gly Pro Lys Leu Ser Ser Pro Val Thr 145 150 '155 160 Gln Asn Val Thr Phe Val Asn Gln Gly Gly Trp Met Leu Ser Arg Wing 165 170 175 Be Wing Met Glu Leu Leu Gln Wing Ala Gly Xaa 180 185 (2) INFORMATION FOR SEC ID. N0 : 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 148 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 64: Asp Glu Val Thr Val Glu Thr Ser Ser Val Phe Arg Ala Asp Phe Leu 1 5 10 15 Ser Glu Leu Asp Ala Pro Ala Gln Ala Gly Thr Glu Ser Ala Ala Ser 20 25 30 Gly Val Glu Gly Leu Pro Pro Gly Ser Ala Leu Leu Val Val Lys Arg 40 45 Gly Pro Asn Wing Gly Being Arg Phe Leu Leu Asp Gln Wing He Thr Ser 50 55 60 Wing Gly Arg His Pro Asp Ser Asp He Phe Leu Asp Asp Val Thr Val 65 70 75 80 Being Arg Arg His Wing Glu Phe Arg Leu Glu Asn Asn Glu Phe Asn Val 85 90 95 Val Asp Val Gly Ser Leu Asn Gly Thr Tyr Val Asn Arg Glu Pro Val. 100 105 110 Asp Ser Ala Val Leu Ala Asn Gly Asp Glu Val Gln He Gly Lys Leu 115 120 125 Arg Leu Val Phe Leu Thr Gly Pro Lys Gln Gly Glu Asp Asp Gly Ser 130 135 140 Thr Gly Gly Pro 145 (2) INFORMATION FOR SEC ID. NO .: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 230 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:65: Thr Ser Asn Arg Pro Wing Arg Arg Gly Arg Arg Wing Pro Arg Asp Thr 1 5 10 15 Gly Pro Asp Arg Ser Wing Ser Leu Ser Leu Val Arg His Arg Arg Gln 20 25 30 Gln Arg Asp Ala Leu Cys Leu Be Ser Thr Gln Be Ser Arg Gln Ser 40 45 Asn Leu Pro Pro Wing Wing Gly Gly Wing Wing Asn Tyr Ser Arg Arg Asn 50 55 60 Phe Asp Val Arg He Lys He Phe Met Leu Val Thr Wing Val Val Leu 65 70 75 80 Leu Cys Cys Ser Gly Val Wing Thr Wing Wing Pro Lys Thr Tyr Cys Glu 85 90 95 Glu Leu Lys Gly Thr Asp Thr Gly Gln Wing Cys Gln lie Gln Met Ser 100 105 110 Asp Pro Ala Tyr Asn He Asn He Ser Leu Pro Ser Tyr Tyr Pro Asp 115 120 125 Gln Lys Ser Leu Glu Asn Tyr He Wing Gln Thr Arg Asp Lys Phe Leu 130 135 140 Ser Ala Ala Thr Ser Ser Thr Pro Arg Glu Ala Pro Tyr Glu Leu Asn 145 150 155 160 He Thr Ser Wing Thr Tyr Gln Ser Wing Pro Pro Arg Gly Thr Gln 165 170 175 Wing Val Val Leu Xaa Val Tyr His Asn Wing Gly Gly Thr His Pro Thr 180 185 190 Thr Thr Tyr Lys Wing Phe Asp Trp Asp Gln Wing Tyr Arg Lys Pro He 195 200 205 Thr Tyr Asp Thr Leu Trp Gln Wing Asp Thr Asp Pro Leu Pro Val Val 210 215 220 Phe Pro He Val Ala Arg 225 230 (2) INFORMATION FOR SEC ID. DO NOT. : 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 132 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 66: Thr Wing Wing Being Asp Asn Phe Gln Leu Being Gln Gly Gly Gln Gly Phe 1 5 10 15 Wing He Pro He Gly Gln Wing Met Wing He Wing Gly Gln He Arg Being 25 30 Gly Gly Gly Pro Pro Thr Val His He Gly Pro Thr Wing Phe Leu Gly 40 45 Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gln Arg Val 50 55 60 Val Gly Ser Ala Pro Ala Ala Ser Leu Gly He Ser Thr Gly Asp Val SS 70 75 80 He Thr Ala Val Asp Gly Ala Pro He Asn Be Ala Thr Ala Met Ala 85 90 95 Asp Ala Leu Asn Gly Bis Bis Pro Gly Asp Val He Ser Val Asn Trp 100 105 110 Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu Ala Glu 115 120 125 Gly Pro Pro Wing 130 (2) INFORMATION FOR SEC ID. DO NOT. : 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 100 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 67: Val Pro Leu Arg Ser Pro Ser Met Ser Pro Ser Lys Cys Leu Ala Wing 1 5 10 15 Wing Gln Arg Asn Pro Val W Arg Arg Arg W Arg Leu Ser Asn Pro Pro 20 25 30 Pro Arg Lys Tyr Arg Ser Met Pro Ser Pro Wing Thr Wing Wing Wing Gly 35 40 45 Met Wing Arg Val Arg Arg Arg Wing He Trp Arg Gly Pro Ala Thr Xaa 50 55 60 Ser Ala Gly Met Ala Arg Val Arg Arg Trp Xaa Val Met Pro Xaa Val 65 70 75 80 He Gln Ser Thr Xaa He Arg Xaa Xaa Gly Pro Phe Asp Asn Arg Gly 85 90 95 Ser Glu Arg Lys 100 (2) INFORMATION FOR SEC ID. DO NOT. : 68 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 163 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. No.: 68: Met Thr Asp Asp He Leu Leu He Asp Thr Asp Glu Arg Val Arg Thr 1 5 10 15 Leu Thr Leu Asn Arg Pro Gln Ser Arg Asn Ala Leu Ser Ala Ala Leu 25 30 Arg Asp Arg Phe Phe Ala Xaa Leu Xaa Asp Ala Glu Xaa Asp Asp Asp 40 45 He Asp Val Val He Leu Thr Gly AlaAsp Pro Val Phe Cys Ala Gly 50 55 60 Leu Asp Leu Lys Val Wing Gly Arg Wing Asp Arg Wing Wing Gly His Leu 65 70 75 80 Thr Wing Val Gly Gly His Asp Gln Wing Gly Asp Arg Arg Asp Gln Arg 85 90 95 Arg Arg Gly His Arg Arg Wing Arg Thr Gly Wing Val Leu Arg His Pro 100 105 110 Asp Arg Leu Arg Ala Arg Pro Leu Arg Arg His Pro Arg Pro Gly Gly 115 120 125 Ala Ala Ala His Leu Gly Thr Gln Cys Val Leu Ala Ala Lys Gly Arg 130 135 140 His Arg Xaa Gly Pro Val Asp Glu Pro Asp Arg Arg Leu Pro Val Arg 145 150 155 160 Asp Arg Arg (2) INFORMATION FOR SEC ID. No.:69 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 344 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. No.:69 Met Lys Phe Val Asn His He Glu Pro Val Wing Pro Arg Arg Wing Gly 1 5 10 15 Gly Ala Val Ala Glu Val Tyr Ala Glu Ala Arg Arg Glu Phe Gly Arg 25 30 Leu Pro Glu Pro Leu Wing Met Leu Ser Pro Asp Glu Gly Leu Leu Thr 35 40 45 Wing Gly Trp Wing Thr Leu Arg Glu Thr Leu Leu Val Gly Gln Val Pro 50 55 60 Arg Gly Arg Lys Glu Ala Ala Ala Ala Ala Ala Ala Ala Ala Leu Arg 65 70 75 80 Cys Pro Trp Cys Val Asp Ala His Thr Thr Met Leu Tyr Ala Ala Gly 85 90 95 Gln Thr Asp Thr Wing Wing Wing He Leu Wing Gly Thr Wing Pro Wing Wing 100 105 110 Gly Asp Pro Asn Ala Pro Tyr Val Wing Trp Wing Wing Gly Thr Gly Thr 115 120 125 Pro Wing Gly Pro Pro Wing Pro Phe Gly Pro Asp Val Wing Wing Glu Tyr 130 135 140 Leu Gly Thr Ala Val Gln Phe His Phe He Ala Arg Leu Val Leu Val 145 150 155 160 Leu Leu Asp Glu Thr Phe Leu Pro Gly Gly Pro Arg Ala Gln Gln Leu 165 170 175 Met Arg Arg Ala Gly Gly Leu Val Phe Ala Arg Lys Val Arg Ala Glu 180 185 190 His Arg Pro Gly Arg Ser Thr Arg Arg Leu Glu Pro Arg Thr Leu Pro 195 200 205 Asp Asp Leu Wing Trp Wing Thr Pro Ser Glu Pro He Wing Thr Wing Phe 210 215 220 Ala Ala Leu Ser His His Leu Asp Thr Ala Pro His Leu Pro Pro Pro 225 230 235 240 Thr Arg Gln Val Val Arg Arg Val Val Gly Ser Trp His Gly Glu Pro 245 250 255 Met Pro Met Being Ser Arg Trp Thr Asn Glu His Thr Ala Glu Leu Pro 260 265 270 Wing Asp Leu His Wing Pro Thr Arg Leu Wing Leu Leu Thr Gly Leu Wing 275 280 285 Pro His Gln Val Thr Asp Asp Asp Val Ala Ala Ala Arg Ser Leu Leu 290 295 300 Asp Thr Asp Ala Ala Leu Val Gly Ala Leu Ala Trp Ala Ala Phe Thr 305 310 315 320 Ala Ala Arg Arg He Gly Thr Trp He Gly Ala Ala Ala Glu Gly Gln 325 330 335 Val Ser Arg Gln Asn Pro Thr Gly 340 (2) INFORMATION FOR SEC ID. NO.:70 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 485 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: 1inear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:70: Asp Asp Pro Asp Met Pro Gly Thr Val Wing Lys Wing Val Wing Asp Wing 1 5 10 15 Leu Gly Arg Gly He Wing Pro Val Glu Asp He Gln Asp Cys Val Glu 25 30 Wing Arg Leu Gly Glu Wing Gly Leu Asp Asp Val Wing Arg Val Tyr He 35 40 45 He Tyr Arg Gln Arg Arg Wing Glu Leu Arg Thr Wing Lys Wing Leu Leu 50 55 60 Gly Val Arg Asp Glu Leu Lys Leu Ser Leu Ala Ala Val Thr Val Leu 65 70 75 80 Arg Glu Arg Tyr Leu Leu His Asp Glu Gln Gly Arg Pro Wing Glu Ser 85 90 95 Thr Gly Glu Leu Met Asp Arg Ser Wing Arg Cys Val Wing Ala Wing Glu 100 105 110 Asp Gln Tyr Glu Pro Gly Ser Arg Arg Trp Wing Glu Arg Phe Wing 115 120 125 Thr Leu Leu Arg Asn Leu Glu Phe Leu Pro Asn Ser Pro Thr Leu Met 130 135 140 Asn Ser Gly Thr Asp Leu Gly Leu Leu Wing Gly Cys Phe Val Leu Pro 145 150 155 160 He Glu Asp Ser Leu Gln Ser He Phe Wing Thr Leu Gly Gln Wing Wing 165 170 175 Glu Leu Gln Arg Wing Gly Gly Gly Thr Gly Tyr Wing Phe Ser His Leu 180 185 190 Arg Pro Wing Gly Asp Arg Val Wing Ser Thr Gly Gly Thr Wing Ser Gly 195 200 205 Pro Val Phe Leu Arg Leu Tyr Asp Ser Wing Wing Gly Val Val Ser 210 215 220 Met Gly Gly Arg Arg Arg Gly Wing Cys Met Wing Val Leu Asp Val Ser 225 230 235 240 His Pro Asp He Cys Asp Phe Val Thr Ala Lys Ala Glu Ser Pro Ser 245 250 255 Glu Leu Pro His Phe Asn Leu Ser Val Gly Val Thr Asp Ala Phe Leu 260 265 270 Arg Ala Val Glu Arg Asn Gly Leu His Arg Leu Val Asn Pro Arg Thr 275 280 285 Gly Lys He Val Wing Arg Met Pro Wing Wing Glu Leu Phe Asp Wing He 290 295 300 Cys Lys Ala Wing His Wing Gly Gly Asp Pro Gly Leu Val Phe Leu Asp 305 310 315 320 Thr He Asn Arg Wing Asn Pro Val Pro Gly Arg Gly Arg He Glu Wing 325 330 335 Thr Asn Pro Cys Gly Glu Val Pro Leu Leu Pro Tyr Glu Ser Cys Asn 340 345 350 Leu Gly Ser He Asn Leu Wing Arg Met Leu Wing Asp Gly Arg Val Asp 355 360 365 Trp Asp Arg Leu Glu Glu Val Wing Gly Val Wing Val Arg Phe Leu Asp. 370 375 380 Asp Val He Asp Val Ser Arg Tyr Pro Phe Pro Glu Leu Gly Glu Wing 385 390 395 400 Ala Arg Ala Thr Arg Lys He Gly Leu Gly Val Met Gly Leu Ala Glu 405 410 415 Leu Leu Ala Ala Leu Gly He Pro Tyr Asp Ser Glu Glu Ala Val Arg 420 425 430 Leu Ala Thr Arg Leu Met Arg Arg He Gln Gln Ala Ala His Thr Ala 435 440 445 Ser Arg Arg Leu Wing Glu Glu Arg Gly Wing Phe Pro Wing Phe Thr Asp 450 455 460 Ser Arg Phe Wing Arg Ser Gly Pro Arg Arg Asn Wing Gln Val Thr Ser 465 470 475 480 Val Ala Pro Thr Gly 485 (2) INFORMATION FOR SEC ID. N0.-71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 267 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:71: Gly Val He Val Leu Asp Leu Glu Pro Arg Gly Pro Leu Pro Thr Glu 1 5 10 15 He Tyr Trp Arg Arg Arg Gly Leu Wing Leu Gly He Wing Val Val Val 20 25 30 Val Gly He Wing Val Wing He Val He Wing Phe Val Asp Ser Wing 35 40 45 Gly Wing Lys Pro Val Wing Wing Asp Lys Pro Wing Ser Ala Gln Ser His 50 55 60 Pro Gly Pro Pro Wing Pro Gln Wing Pro Gln Pro Wing Gly Gln Thr Glu 65 70 75 80 Gly Asn Wing Wing Wing Pro Pro Gln Gly Gln Asn Pro Glu Thr Pro 85 90 95 Thr Pro Thr Wing Wing Val Gln Pro Pro Pro Val Leu Lys Glu Gly Asp 100 105 110 Asp Cys Pro Asp Ser Thr Leu Wing Val Lys Gly Leu Thr Asn Wing Pro 115 120 125 Gln Tyr Tyr Val Gly Asp Gln Pro Lys Phe Thr Met Val Val Thr Asn, 130 135 140 He Gly Leu Val Ser Cys Lys Arg Asp Val Gly Ala Wing Val Leu Wing 145 150 155 160 Wing Tyr Val Tyr Ser Leu Asp Asn Lys Arg Leu Trp Ser Asn Leu Asp 165 170 175 Cys Ala Pro Ser Asn Glu Thr Leu Val Lys Thr Phe Ser Pro Gly Glu 180 185 190 Gln Val Thr Thr Wing Val Thr Trp Thr Gly Met Gly Ser Wing Pro Arg 195 200 205 Cys Pro Leu Pro Arg Pro Wing He Gly Pro Gly Thr Tyr Asn Leu Val 210 215 220 Val Gln Leu Gly Asn Leu Arg Ser Leu Pro Val Pro Phe He Leu Asn 225 230 235 240 Gln Pro Pro Pro Pro Pro Gly Pro Val Pro Pro Wing Gly Pro Wing Gln 245 250 255 Wing Pro Pro Pro Glu Ser Pro Wing Gln Gly Gly 260 265 (2) INFORMATION FOR SEC ID. NO .: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 97 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 72: Leu He Ser Thr Gly Lys Ala Ser His Wing Ser Leu Gly Val Gln Val 1 5 10 15 Thr Asn Asp Lys Asp Thr Pro Gly Wing Lys He Val Glu Val Val Wing 25 30 Gly Gly Wing Wing Wing Asn Wing Gly Val Pro Lys Gly Val Val Val Thr 35 40 45 Lys Val Asp Asp Arg Pro He Asn Ser Wing Asp Wing Leu Val Wing Wing 50 55 60 Val Arg Ser Lys Wing Pro Gly Wing Thr Val Wing Leu Thr Phe Gln Asp 65 70 75 80 Pro Ser Gly Gly Ser Arg Thr Val Gln Val Thr Leu Gly Lys Ala Glu 85 90 95 Gln (2) INFORMATION FOR SEC ID. DO NOT. : 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 73: Gly Ala Ala Val Ser Leu Leu Ala Ala Gly Thr Leu Val Leu Thr Ala 1 5 10 15 Cys Gly Gly Gly Thr Asn Being Being Ser Gly Gly Wing Gly Thr Ser 25 30 Gly Ser Val His Cys Gly Gly Lys Lys Glu Leu His Ser Gly Ser 40 45 Thr Ala Gln Glu Asn Wing Met Glu Gln Phe Val Tyr Wing Tyr Val Arg 50 55 60 Ser Cys Pro Gly Tyr Thr Leu Asp Tyr Asn Wing Asn Gly Ser Gly Wing 65 70 75 80 Gly Val Thr Gln Phe Leu Asn Asn Glu Thr Asp Phe Wing Gly Ser Asp 85 90 95 Val Pro Leu Asn Pro Ser Thr Gly Gln Pro Asp Arg Ser Wing Glu Arg 100 105 110 Cys Gly Ser Pro Wing Trp Asp Leu Pro Thr Val Phe Gly Pro He Wing 115 120 125 He Thr Tyr Asn He Lys Gly Val Ser Thr Leu Asn Leu Asp Gly Pro 130 135 140 Thr Thr Wing Lys He Phe Asn Gly Thr He Thr Val Trp Asn Asp Pro 145 150 155 160 Gln He Gln Ala Leu Asn Ser Gly Thr Asp Leu Pro Pro Thr Pro He 165 170 175 Ser Val He Phe Arg Ser Asp Lys Ser Gly Thr Ser Asp Asn Phe Gln 180 185 190 Lys Tyr Leu Asp Gly Val Ser Asn Gly Wing Trp Gly Lys Gly Wing Ser 195 200 205 Glu Thr Phe Ser Gly Gly Val Gly Val Gly Wing Ser Gly Asn Asn Gly 210 215 220 Thr Ser Wing Leu Leu Gln Thr Thr Asp Gly Ser He Thr Tyr Asn Glu 225 230 235 240 Trp Ser Phe Wing Val Gly Lys Gln Leu Asn Met Wing Gln He He Thr 245 250 255 Ser Wing Gly Pro Asp Pro Val Wing He Thr Thr Glu Ser Val Gly Lys 260 265 270 Thr He Wing Gly Wing Lys He Met Gly Gln Gly Asn Asp Leu Val Leu 275 280 285 Asp Thr Ser Ser Phe Tyr Arg Pro Thr Gln Pro Gly Ser Tyr Pro He 290 295 300 Val Leu Wing Thr Tyr Glu He Val Cys Ser Lys Tyr Pro Asp Wing Thr 305 310 315 320 Thr Gly Thr Wing Val Arg Wing Phe Met Gln Wing Wing He Gly Pro Gly 325 330 335 Gln Glu Gly Leu Asp Gln Tyr Gly Ser He Pro Leu Pro Lys Ser Phe 340 345 350 Gln Ala Lys Leu Ala Ala Ala Ala Asn Ala He Ser 355 360 (2) INFORMATION FOR SEC ID. NO .: 74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 74: Gln Ala Ala Ala Gly Arg Ala Val Arg Arg Thr Gly His Ala Glu Asp 1 5 10 15 Gln Thr His Gln Asp Arg Leu His His Gly Cys Arg Arg Ala Ala Val 25 30 Val Val Arg Gln Asp Arg Ala Ser Val Ser Ala Thr Ser Ala Arg Pro 35 40 45 Pro Arg Arg His Pro Wing Gln Gly His Arg Arg Arg Val Wing Pro Ser 50 55 60 Gly Gly Arg Arg Arg Pro His Pro His His Val Gln Pro Asp Asp Arg 65 70 75 80 Arg Asp Arg Pro Wing Leu Leu Asp Arg Thr Gln Pro Wing Glu His Pro 85 90 95 Asp Pro His Arg Arg Gly Pro Wing Asp Pro Gly Arg Val Arg Gly Arg 100 105 110 Gly Arg Leu Arg Arg Val Asp Asp Gly Arg Leu Gln Pro Asp Arg Asp 115 120 125 Wing Asp His Gly Wing Pro Val Arg Gly Arg Gly Pro His Arg Gly Val 130 135 140 Gln His Arg Gly Gly Pro Val Phe Val Arg Arg Val Pro Gly Val Arg 145 150 155 160 Cys Ala His Arg Arg Gly His Arg Arg Val Ala Wing Pro Gly Gln Gly 165 170 175 Asp Val Leu Arg Wing Gly Leu Arg Val Glu Arg Leu Arg Pro Val Wing 180 185 190 Wing Val Glu Asn Leu His Arg Gly Ser Gln Arg Wing Asp Gly Arg Val 195 200 205 Phe Arg Pro He Arg Arg Gly Wing Arg Leu Pro Wing Arg Arg Ser Arg 210 215 220 Wing Gly Pro Gln Gly Arg Leu His Leu Asp Gly Ala Gly Pro Ser Pro 225 230 235 240 Leu Pro Wing Arg Wing Gln Gln Gln Gln Pro Ser Wing Wing Gly Gly Arg 245 250 255 Arg Ala Gly Gly Ala Glu Arg Ala Asp Pro Gly Gln. Arg Gly Arg His 260 265 270 His Gln Gly Gly His Asp Pro Gly Arg Gln Gly Wing Gln Arg Gly Thr 275 280 285 Ala Gly Val Ala Ala Ala Ala Ala Ala Gly Pro Arg Arg Ala Ala Ala Arg 290 295 300 Asn Arg Pro Arg Arg 305 (2) INFORMATION FOR SEC ID. NO.:75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 580 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 75 Be Wing Val Trp Cys Leu Asn Gly Phe Thr Gly Arg His Arg His Gly 1 5 10 15 Arg Cys Arg Val Arg Wing Ser Gly Trp Arg Ser Ser Asn Arg Trp Cys 25 30 Ser Thr Thr Wing Asp Cys Cys Wing Ser Lys Thr Pro Thr Gln Wing Wing 35 40 45 Ser Pro Leu Glu Arg Arg Phe Thr Cys Cys Ser Pro Wing Val Gly Cys 50 55 60 Arg Phe Arg Ser Phe Pro Val Arg Arg Leu Ala Leu Gly Ala Arg Thr 65 70 75 80 Ser Arg Thr Leu Gly Val Arg Arg Thr Leu Ser Gln Trp Asn Leu Ser 85 90 95 Pro Arg Ala Gln Pro Ser Cys Ala Val Thr Val Glu Ser His Thr His 100 105 110 Wing Pro Pro Arg Met Wing Lys Leu Wing Arg Val Val Gly Leu Val Gln 115 120 125 Glu Glu Gln Pro Ser Asp Met Thr Asn His Pro Arg Tyr Ser Pro Pro 130 135 140 Pro Gln Gln Pro Gly Thr Pro Gly Tyr Wing Gln Gly Gln Gln Gln Thr 145 150 155 160 Tyr Ser Gln Gln Phe Asp Trp Arg Tyr Pro Pro Ser Pro Pro Pro Gln 165 170 175 Pro Thr Gln Tyr Arg Gln Pro Tyr Glu Wing Leu Gly Gly Thr Arg Pro 180 185 190 Gly Leu He Pro Gly Val He Pro Thr Met Thr Pro Pro Pro Gly Met 195 200 205 Val Arg Gln Arg Pro Arg Ala Gly Met Leu Ala He Gly Ala Val Thr 210 215 220 He Ala Val Val Ser Ala Gly He Gly Gly Ala Ala Ala Ser Leu Val 225 230 235 240 Gly Phe Asn Arg Ala Pro Ala Gly Pro Ser Gly Gly Pro Val Ala Ala 245 250 255 Be Ala Ala Pro Be Pro Pro Ala Ala Asn Met Pro Pro Gly Ser Val 260 265 270 Glu Gln Val Ala Ala Lys Val Val Pro Ser Val Val Met Leu Glu Thr 275 280 285 Asp Leu Gly Arg Gln Ser Glu Glu Gly Ser Gly He He Leu Ser Ala 290 295 300 Glu Gly Leu He Leu Thr Asn Asn His Val He Ala Wing Wing Wing Lys 305 310 315 320 Pro Pro Leu Gly Pro Pro Pro Lys Thr Thr Val Thr Phe Ser Asp 325 330 335 Gly Arg Thr Ala Pro Phe Thr Val Val Gly Ala Asp Pro Thr Ser Asp 340 345 350 He Wing Val Val Arg Val Gln Gly Val Ser Gly Leu Thr Pro He Ser 355 360 365 Leu Gly Being Ser Asp Leu Arg Val Gly Gln Pro Val Leu Ala He 370 375 380 Gly Ser Pro Leu Gly Leu Glu Gly Thr Val Thr Thr Gly He Val Ser 385 390 395 400 Wing Leu Asn Arg Pro Val Ser Thr Thr Gly Glu Wing Gly Asn Gln Asn 405 410 415 Thr Val Leu Asp Ala He Gln Thr Asp Ala Ala He Asn Pro Gly Asn 420 425 430 Ser Gly Gly Wing Leu Val Asn Met Asn Wing Gln Leu Val Gly Val Asn 435 440 445 Wing Wing Wing Thr Leu Gly Wing Asp Being Wing Asp Wing Gln Being Gly 450 455 460 Ser He Gly Leu Gly Phe Wing He Pro Val Asp Gln Wing Lys Arg He 465 470 475 480 Wing Asp Glu Leu He Ser Thr Gly Lys Wing Ser His Wing Ser Leu Gly 485 490 495 Val Gln Val Thr Asn Asp Lys Asp Thr Pro Gly Ala Lys He Val Glu 500 505 510 Val Val Wing Gly Gly Wing Wing Wing Asn Wing Gly Val Pro Lys Gly Val 515 520 525 Val Val Thr Lys Val Asp Asp Arg Pro He Asn Ser Wing Asp Ala Leu 530 535 540 Val Ala Ala Val Arg Ser Lys Ala Pro Gly Ala Thr Val Ala Ala Thu 545 550 555 560 Phe Gln Asp Pro Ser Gly Gly Ser Arg Thr Val Gln Val Thr Leu Gly 565 570 575 Lys Ala Glu Gln 580 (2) INFORMATION FOR SEC ID. NO.:76 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 233 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 76: Met Asn Asp Gly Lys Arg Ala Val Thr Ser Ala Val Leu Val Val Leu 1 5 10 15 Gly Ala Cys Leu Ala Leu Trp Leu Ser Gly Cys Ser Ser Pro Lys Pro 25 30 Asp Wing Glu Glu Gln Gly Val Pro Val Ser Pro Thr Wing Ser Asp Pro 40 45 Wing Leu Leu Wing Glu He Arg Gln Ser Leu Asp Wing Thr Lys Gly Leu 50 55 60 Thr Ser Val His Val Wing Val Arg Thr Thr Gly Lys Val Asp Ser Leu 65 70 75 80 Leu Gly He Thr Ser Wing Asp Val Asp Val Arg Wing Asn Pro Leu Wing 85 90 95 Wing Lys Gly Val Cys Thr Tyr Asn Asp Glu Gln Gly Val Pro Phe Arg 100 105 110 Val Gln Gly Asp Asn He Ser Val Val Lys Leu Phe Asp Asp Trp Ser Asn 115 120 125 Leu Gly Ser He Ser Glu Leu Ser Thr Ser Arg Val Leu Asp Pro Wing 130 135 140 Wing Gly Val Thr Gln Leu Leu Ser Gly Val Thr Asn Leu Gln Ala Gln 145 150 155 160 Gly Thr Glu Val He Asp Gly He Ser Thr Thr Lys He Thr Gly Thr 165 170 175 He Pro Ala Ser Ser Val Lys Met Leu Asp Pro Gly Ala Lys Ser Ala 180 185 190 Arg Pro Wing Thr Val Trp He Wing Gln Asp Gly Ser His His Leu Val 195 200 205 Arg Ala Ser He Asp Leu Gly Ser Gly Ser He Gln Leu Thr Gln Ser 210 215 220 Lys Trp Asn Glu Pro Val Asn Val Asp 225 230 (2) INFORMATION FOR SEC. DO NOT. : 77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 66 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 77: Val He Asp He He Gly Thr Ser Pro Thr Ser Trp Glu Gln Ala Ala 1 5 10 15 Wing Glu Wing Val Gln Arg Wing Arg Asp Ser Val Asp Asp He Arg Val 20 25 30 Wing Arg Val He Glu Gln Asp Met Wing Val Asp Ser Wing Gly Lys He 40 45 Thr Tyr Arg He Lys Leu Glu Val Ser Phe Lys Met Arg Pro Ala Gln 50 55 60 Pro Arg 65 (2) INFORMATION FOR SEC ID. NO .: 78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 69 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 78: Val Pro Pro Pro Pro Pro Pro Leu Pro Pro Pro Pro Ser Pro Pro 1 5 10 15 Cys Ala Ser Pro Pro Ser Pro Pro Pro Pro Leu Pro Pro Pro 25 30 Pro Gly Pro Pro Met Pro Pro Leu Asp Pro Pro Pro Pro Pro Wing Pro 40 45 Leu Pro Tyr Ser Thr Pro Pro Gly Pro Pro Leu Pro Pro Ser Pro Pro 50 55 60 Ser Pro Pro Leu Pro 65 (2) INFORMATION FOR SEC ID. DO NOT. : 79 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 355 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 79: Met Ser Asn Ser Arg Arg Arg Ser Leu Arg Trp Ser Trp Leu Leu Ser 1 5 10 15 Val Leu Ala Ala Val Gly Leu Gly Leu Ala Thr Ala Pro Ala Gln Ala 25 30 Wing Pro Pro Wing Leu Ser Gln Asp Arg Phe Wing Asp Phe Pro Wing Leu 40 45 Pro Leu Asp Pro Be Wing Met Val Wing Gln Val Wing Pro Gln Val Val 55 55 60 Asn He Asn Thr Lys Leu Gly Tyr Asn Asn Wing Val Gly Wing Gly Thr 65 70 75 80 Gly He Val He Asp Pro Asn Gly Val Val Leu Thr Asn Asn His Val 85 90 95 He Wing Gly Wing Thr Asp He Asn Wing Phe Ser Val Gly Ser Gly Gln 100 105 110 Thr Tyr Gly Val Asp Val Gly Tyr Asp Arg Thr Gln Asp Val Ala 115 120 125 Val Leu Gln Leu Arg Gly Wing Gly Gly Leu Pro Wing Wing He Gly 130 135 140 Gly Gly Val Wing Val Gly Glu Pro Val Val Wing Met Gly Asn Ser Gly 145 150 155 160 Gly Gln Gly Gly Thr Pro Arg Wing Val Pro Gly Arg Val Val Wing Leu 165 170 175 Gly Gln Thr Val Gln Wing Being Asp Being Leu Thr Gly Wing Glu Glu Thr 180 185 190 Leu Asn Gly Leu He Gln Phe Asp Wing Wing He Gln Pro Gly Asp Ser 195 200 205 Gly Gly Pro Val Val Asn Gly Leu Gly Gln Val Val Gly Met Asn Thr 210 215 220 Wing Wing Being Asp Asn Phe Gln Leu Being Gln Gly Gly Gln Gly Phe Wing 225 230 235 240 He Pro He Gly Gln Ala Met Ala He Ala Gly Gln He Arg Ser Gly 245 250 255 Gly Gly Ser Pro Thr Val His He Gly Pro Thr Wing Phe Leu Gly Leu 260 265 270 Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gln Arg Val Val 275 280 285 Gly Ser Wing Pro Wing Wing Being Leu Gly He Being Thr Gly Asp Val He 290 295 300 Thr Wing Val Asp Gly Wing Pro He Asn Being Wing Thr Wing Met Wing Asp 305 310 315 320 Ala Leu Asn Gly His His Pro Gly Asp Val He Ser Val Asn Trp Gln 325 330 335 Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu Wing Glu Gly 340 345 350 Pro Pro Ala 355 (2) INFORMATION FOR SEC ID. DO NOT. : 80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 205 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 80: Pro Pro Lys Pro Asp Wing Glu Glu Gln Gly Val Pro Val Ser -Pro Thr 1 5 10 15 Wing Being Asp Pro Wing Leu Leu Wing Glu He Arg Gln Ser Leu Asp Wing 25 30 Thr Lys Gly Leu Thr Ser Val His Val Wing Val Arg Thr Thr Gly Lys 40 45 Val Asp Ser Leu Leu Gly He Thr Ser Wing Asp Val Asp Val Arg Wing 50 55 60 Asn Pro Leu Wing Wing Lys Gly Val Cys Thr Tyr Asn Asp Glu Gln Gly 65 70 75 80 Val Pro Phe Arg Val Gln Gly Asp Asn He Ser Val Val Lys Leu Phe Asp 85 90 95 Asp Trp Ser Asn Leu Gly Be Ser Glu Leu Ser Thr Ser Arg Val 100 105 110 Leu Asp Pro Wing Wing Gly Val Thr Gln Leu Leu Ser Gly Val Thr Asn 115 120 125 Leu Gln Wing Gln Gly Thr Glu Val He Asp Gly He Ser Thr Thr Lys 130 135 140 He Thr Gly Thr He Pro Wing Being Ser Val Lys Met Leu Asp Pro Gly 145 150 155 160 Ala Lys Ser Ala Arg Pro Ala Thr Val Trp He Ala Gln Asp Gly Ser 165 170 175 His His Leu Val Arg Ala Ser He Asp Leu Gly Ser Gly Ser He Gln 180 185 190 Leu Thr Gln Ser Lys Trp Asn Glu Pro Val Asn Val Asp 195 200 205 (2) INFORMATION FOR SEC ID. NO .: 81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 286 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . - 81: Gly Asp Ser Phe Trp Wing Wing Wing Asp Gln Met Wing Arg Gly Phe Val 1 5 10 15 Leu Gly Wing Thr Wing Gly Arg Thr Thr Leu Thr Gly Glu Gly Leu Gln 25 30 His Wing Asp Gly His Ser Leu Leu Leu Asp Wing Thr Asn Pro Wing Val 40 45 Val Ala Tyr Asp Pro Ala Phe Ala Tyr Glu He Gly Tyr He Xaa Glu 50 55 60 Ser Gly Leu Ala Arg Met Cys Gly Glu Asn Pro Glu Asn He Phe Phe 65 70 75 80 Tyr He Thr Val Tyr Asn Glu Pro Tyr Val Gln Pro Pro Glu Pro Glu 85 90 95 Asn Phe Asp Pro Glu Gly Val Leu Gly Gly He Tyr Arg Tyr His Wing 100 105 110 Wing Thr Glu Gln Arg Thr Asn Lys Xaa Gln He Leu Wing Ser Gly Val 115 120 125 Wing Met Pro Wing Wing Leu Arg Wing Wing Gln Met Leu Wing Wing Glu Trp 130 135 140 Asp Val Wing Wing Asp Val Trp Ser Val Thr Ser Trp Gly Glu Leu Asn 145 150 155 160 Arg Asp Gly Val Val He Glu Thr Glu Lys Leu Arg His Pro Asp Arg 165 170 175 Pro Wing Gly Val Pro Tyr Val Thr Arg Ala Leu Glu Asn Wing Arg Gly 180 185 190 Pro Val He Wing Val Ser Asp Trp Met Arg Wing Val Pro Glu Gln He 195 200 205 Arg Pro Trp Val Pro Gly Thr Tyr Leu Thr Leu Gly Thr Asp Gly Phe 210 215 220 Gly Phe Ser Asp Thr Arg Pro Wing Gly Arg Arg Tyr Phe Asn Thr Asp 225 230 235 240 Wing Glu Be Gln Val Gly Arg Gly Phe Gly Arg Gly Trp Pro Gly Arg 245 250 255 Arg Val Asn He Asp Pro Phe Gly Wing Gly Arg Gly Pro Pro Wing Gln 260 265 270 Leu Pro Gly Phe Asp Glu Gly Gly Glu Leu Arg Pro Xaa Lys 275 280 285 (2) INFORMATION FOR SEC ID. DO NOT. : 82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 173 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 82: Thr Lys Phe His Wing Leu Met Gln Glu Gln He His Asn Glu Phe Thr 1 5 10 15 Ala Ala Gln Gln Tyr Val Ala Ala Ala Ala Tyr Phe Asp Ser Glu Asp, 20 25 30 Leu Pro Gln Leu Ala Lys His Phe Tyr Ser Gln Ala Val Glu Glu Arg 40 45 Asn His Wing Met Met Leu Val Gln His Leu Leu Asp Arg Asp Leu Arg 50 55 60 Val Glu He Pro Gly Val Asp Thr Val Arg Asn Gln Phe Asp Arg Pro 65 70 75 80 Arg Glu Ala Leu Ala Leu Ala Leu Asp Gln Glu Arg Thr Val Thr Asp 85 90 95 Gln Val Gly Arg Leu Thr Ala Val Ala Arg Asp Glu Gly Asp Phe Leu 100 105 110 Gly Glu Gln Phe Met Gln Trp Phe Leu Gln Glu Gln He Glu Glu Val 115 120 125 Ala Leu Met Ala Thr Leu Val Arg Val Ala Asp Arg Ala Gly Ala Asn 130 135 140 Leu Phe Glu Leu Glu Asn Phe Val Wing Arg Glu Val Asp Val Wing Pro 145 150 155 160 Ala Ala Ser Gly Ala Pro His Ala Ala Ala Gly Gly Arg Leu 165 170 (2) INFORMATION FOR SEC ID. NO .: 83 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 107 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 83: Arg Ala Asp Glu Arg Lys Asn Thr Thr Met Lys Met Val Lys Ser He 1 5 10 15 Ala Ala Gly Leu Thr Ala Ala Ala Ala Ala Gly Ala Ala Ala Ala Gly 25 30 Val Thr Ser He Met Ala Gly Gly Pro Val Val Tyr Gln Met Gln Pro 35 40 45 Val Val Phe Gly Ala Pro Leu Pro Leu Asp Pro Xaa Ser Ala Pro Xaa 50 55 60 Val Pro Thr Wing Wing Gln Trp Thr Xaa Leu Leu Asn Xaa Leu Xaa Asp 65 70 75 80 Pro Asn Val Ser Phe Xaa Asn Lys Gly Ser Leu Val Glu Gly Gly He 85 90 95 Gly Gly Xaa Glu Gly Xaa Xaa Arg Arg Xaa Gln 100 105 (2) INFORMATION FOR SEC ID. DO NOT. : 84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 125 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 84: Val Leu Ser Val Pro Val Gly Asp Gly Phe Trp Xaa Arg Val Val Asn 1 5 10 15 Pro Leu Gly Gln Pro He Asp Gly Arg Gly Asp Val Asp Ser Asp Thr 25 30 Arg Arg Ala Leu Glu Leu Gln Ala Pro Ser Val Val Xaa Arg Gln Gly 40 45 Val Lys Glu Pro Leu Xaa Thr Gly He Lys Wing He Asp Wing Met Thr 50 55 60 Pro He Gly Arg Gly Gln Arg Gln Leu He He Gly Asp Arg Lys Thr 65 70 75 80 Gly Lys Asn Arg Arg Leu Cys Arg Thr Pro Ser Ser Asn Gln Arg Glu 85 90 95 Glu Leu Gly Val Arg Trp He Pro Arg Ser Arg Cys Ala Cys Val Tyr 100 105 110 Val Gly His Arg Ala Arg Arg Gly Thr Tyr His Arg Arg 115 120 125 (2) INFORMATION FOR SEC ID. NO .: 85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 117 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 85: Cys Asp Ala Val Met Gly Phe Leu Gly Gly Ala Gly Pro Leu Ala Val 1 5 10 15 Val Asp Gln Gln Leu Val Thr Arg Val Pro Gln Gly Trp Ser Phe Wing 20 25 30 Gln Wing Wing Wing Val Pro Val Val Phe Leu Thr Wing Trp Tyr Gly Leu 40 45 Wing Asp Leu Wing Glu He Lys Wing Gly Glu Ser Val Leu He His Wing 50 55 60 Gly Thr Gly Gly Val Gly Met Ala Wing Val Gln Leu Ala Arg Gln Trp 65 70 75 80 Gly Val Glu Val Phe Val Thr Ala Ser Arg Gl.y Lys Trp Asp Thr Leu 85 90 95 Arg Ala Xaa Xaa Phe Asp Asp Xaa Pro Tyr Arg Xaa Phe Pro His Xaa 100 105 110 Arg Ser Ser Xaa Gly 115 (2) INFORMATION FOR SEC ID. DO NOT. : 86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 103 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 86: Met Tyr Arg Phe Wing Cys Arg Thr Leu Met Leu Wing Wing Cys He Leu 1 5 10 15 Ala Thr Gly Val Ala Gly Leu Gly Val Gly Ala Gln Ser Ala Ala Gln 20 25 30 Thr Ala Pro Val Pro Asp Tyr Tyr Trp Cys Pro Gly Gln Pro Phe Asp 40 45 Pro Wing Trp Gly Pro Asn Trp Asp Pro Tyr Thr Cys His Asp Asp Phe 50 55 60 His Arg Asp Ser Asp Gly Pro Asp His Ser Arg Asp Tyr Pro Gly Pro 65 70 75 80 He Leu Glu Gly Pro Val Leu Asp Asp Pro Gly Ala Wing Pro Pro Pro 85 90 95 Pro Ala Ala Gly Gly Ala 100 Wing (2) INFORMATION FOR SEC ID. NO .: 87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 88 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 87: Val Gln Cys Arg Val Trp Leu Glu He Gln Trp Arg Gly Met Leu Gly 1 5 10 15 Wing Asp Gln Wing Arg Wing Gly Gly Pro Wing Arg He Trp Arg Glu His 20 25 30 Being Met Wing Wing Met Lys Pro Arg Thr Gly Asp Gly Pro Leu Glu Wing 40 45 Thr Lys Glu Gly Arg Gly He Val Met Arg Val Pro Leu Glu Gly Gly 50 55 60 Gly Arg Leu Val Val Glu Leu Thr Pro Asp Glu Ala Ala Ala Leu Gly 65 70 75 80 Asp Glu Leu Lys Gly Val Thr Ser 85 (2) INFORMATION FOR SEC ID. NO .: 88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 95 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 88: Thr Asp Ala Ala Thr Leu Ala Gln Glu Ala Gly Asn Phe Glu Arg He 1 5 10 15 Ser Gly Asp Leu Lys Thr Gln He Asp Gln Val Glu Ser Thr Ala Gly 25 30 Ser Leu Gln Gly Gln Trp Arg Gly Wing Wing Gly Thr Wing Wing Gln Wing 40 45 Ala Val Val Arg Phe Gln Glu Ala Ala Asn Lys Gln Lys Gln Glu Leu 50 55 60 Asp Glu He Ser Thr Asn He Arg Gln Wing Gly Val Gln Tyr Ser Arg 65 70 75 80 Wing Asp Glu Glu Gln Gln Gln Wing Leu Being Ser Gln Met Gly Phe 85 90 95 (2) INFORMATION FOR SEC ID. DO NOT . : 89 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 166 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 89: Met Thr Gln Ser Gln Thr Val Thr Val Asp Gln Gln Glu He Leu Asn 1 5 10 15 Arg Ala Asn Glu Val Glu Ala Pro Met Ala Asp Pro Pro Thr Asp Val 25 30 Pro He Thr Pro Cys Glu Leu Thr Xaa Xaa Lys Asn Ala Wing Gln Gln 35 40 45 Xaa Val Leu Ser Wing Asp Asn Met Arg Glu Tyr Leu Wing Wing Gly Ala 50 55 60 Lys Glu Arg Gln Arg Leu Wing Thr Ser Leu Arg Asn Wing Wing Lys Xaa 65 70 75 80 Tyr Gly Glu Val Asp Glu Glu Wing Wing Thr Wing Leu Asp Asn Asp Gly 85 90 95 Glu Gly Thr Val Gln Ala Glu Be Ala Gly Ala Val Gly Gly Asp Ser 100 105 110 Be Ala Glu Leu Thr Asp Thr Pro Arg Val Ala Thr Ala Gly Glu Pro 115 120 125 Asn Phe Met Asp Leu Lys Glu Ala Ala Arg Lys Leu Glu Thr Gly Asp 130 135 140 Gln Gly Ala Ser Leu Ala His Xaa Gly Asp Gly Trp Asn Thr Xaa Thr 145 150 155 160 Leu Thr Leu Gln Gly Asp 165 (2) INFORMATION FOR SEC ID. NO.:90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 90: Arg Ala Glu Arg Met 1 5 (2) INFORMATION FOR SEC ID. DO NOT. : 91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 263 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 91: Val Ala Trp Met Ser Val Thr Ala Gly Gln Ala Glu Leu Thr Ala Ala 1 5 10 15 Gln Val Arg Val Ala Ala Ala Ala Tyr Glu Thr Ala Tyr Gly Leu Thr 25 30 Val Pro Pro Pro Val He Wing Glu Asn Arg Wing Glu Leu Met He Leu 40 45 He Ala Thr Asn Leu Leu Gly Gln Asn Thr Pro Wing He Wing Val Asn 50 55 60 Glu Wing Glu Tyr Gly Glu Met Trp Wing Gln Asp Wing Wing Met Phe 65 70 75 80 Gly Tyr Ala Ala Ala Thr Ala Thr Ala Thr Ala Thr Leu Leu Pro Phe 85 90 95 Glu Glu Ala Pro Glu Met Thr Ser Ala Gly Gly Leu Leu Glu Gln Ala 100 105 110 Ala Ala Val Glu Glu Ala Be Asp Thr Ala Ala Ala Asn Gln Leu Met 115 120 125 Asn Asn Val Pro Gln Ala Leu Lys Gln Leu Ala Gln Pro Thr Gln Gly 130 135 140 Thr Thr Pro Ser Ser Lys Leu Gly Gly Leu Trp Lys Thr Val Ser Pro 145 150 155 160 His Arg Ser Pro Be Ser Asn Met Val Ser Met Wing Asn Asn His Met 165 170 175 Ser Met Thr Asn Ser Gly Val Ser Met Thr Asn Thr Leu Ser Ser Met 180 185 190 Leu Lys Gly Phe Wing Pro Wing Wing Wing Wing Gln Wing Val Gln Thr Wing 195 200 205 Wing Gln Asn Gly Val Arg Wing Met Being Ser Leu Gly Being Ser Leu Gly 210 215 220 Being Ser Gly Leu Gly Gly Gly Val Wing Wing Asn Leu Gly Arg Wing Ala 225 230 235 240 Ser Val Arg Tyr Gly His Arg Asp Gly Gly Lys Tyr Ala Xaa Ser Gly 245 250 255 Arg Arg Asn Gly Gly Pro Ala 260 (2) INFORMATION FOR SEC ID. DO NOT. : 92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 303 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 92: Met Thr Tyr Pro Pro Gly Asn Pro Gly Tyr Pro Gln Wing Gln Pro Wing 1 5 10 15 Gly Ser Tyr Gly Gly Val Thr Pro Ser Phe Ala His Wing Asp Glu Gly 25 30 Wing Ser Lys Leu Pro Met Tyr Leu Asn He Wing Val Wing Val Leu Gly 40 45 Leu Ala Ala Tyr Phe Ala Ser Phe Gly Pro Met Phe Thr Leu Ser Thr 50 55 60 Glu Leu Gly Gly Gly Asp Gly Wing Val Ser Gly Asp Thr Gly Leu Pro 65 70 75 80 Val Gly Val Ala Leu Leu Ala Ala Leu Leu Ala Gly Val Val Leu Val 85 90 95 Pro Lys Wing Lys Ser Val Val Val Val Wing Val Leu Gly Val Leu 100 105 110 Val Val Phe Leu Met Val Ser Wing Thr Phe Asn Lys Pro Ser Wing Tyr 115 120 125 Ser Thr Gly Trp Wing Leu Trp Val Val Leu Wing Phe He Val Phe Gln 130 135 140 Wing Val Wing Wing Val Leu Wing Leu Leu Val Glu Thr Gly Wing He Thr145 150 155 160 Wing Pro Wing Pro Arg Pro Lys Phe Asp Pro Tyr Gly Gln Tyr Gly Arg 165 170 175 Tyr Gly Gln Tyr Gly Gln Tyr Gly Val Gln Pro Gly Gly Tyr Tyr Gly 180 185 190 Gln Gln Gly Wing Gln Gln Wing Wing Gly Leu Gln Ser Pro Gly Pro Gln 195 200 205 Gln Ser Pro Gln Pro Pro Gly Tyr Gly Ser Gln Tyr Gly Gly Tyr Ser 210 215 220 Ser Ser Pro Gln Ser Gly Ser Gly Tyr Thr Wing Gln Pro Pro Wing 225 230 235 240 Gln Pro Pro Wing Gln Ser Gly Ser Gln Gln Ser His Gln Gly Pro Ser 245 250 255 Thr Pro Pro Thr Gly Phe Pro Ser Phe Ser Pro Pro Pro Pro Val Ser 260 265 270 Wing Gly Thr Gly Ser Gln Wing Gly Ser Wing Pro Val Asn Tyr Ser Asn 275 280 285 Pro Ser Gly Gly Glu Gln Ser Ser Ser Pro Gly Gly Ala Pro Val 290 295 300 (2) INFORMATION FOR SEC ID. NO .: 93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 93: Gly Cys Gly Glu Thr Asp Ala Ala Thr Leu Ala Gln Glu Ala Gly Asn 1 5 10 15 Phe Glu Arg He Ser Gly Asp Leu Lys Thr Gln He 20 25 (2) INFORMATION FOR SEC ID. NO .: 94 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:94 sp Gln Val Glu Ser Thr Wing Gly Ser Leu Gln Gly Gln Trp Arg Gly 1 5 10 15 (2) INFORMATION FOR SEC ID. DO NOT. : 95: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 95: Gly Cys Gly Ser Thr Ala Gly Ser Leu Gln Gly Gln Trp Arg Gly Ala 1 5 10 15 Ala Gly Thr Ala Ala Gln Ala Ala Val Val Arg 20 25 (2) INFORMATION FOR SEC ID. DO NOT. : 96: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 96: Gly Cys Gly Gly Thr Ala Ala Gln Ala Ala Val Val Arg Phe Gln Glu 1 5 10 15 Ala Wing Asn Lys Gln Lys Gln Glu Leu Asp Glu 20 25 (2) INFORMATION FOR SEC ID. DO NOT. : 97: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 97: Gly Cys Gly Wing Asn Lys Gln Lys Gln Glu Leu Asp Glu He Ser Thr 1 5 10 15 Asn He Arg Gln Wing Gly Val Gln Tyr Ser Arg 20 25 (2) INFORMATION FOR SEC ID. DO NOT. : 98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 98: Gly Cys Gly He Arg Gln Wing Gly Val Gln Tyr Ser Arg Wing Asp Glu 1 5 10 15 Glu Gln Gln Gln Wing Leu Being Ser Gln Met Gly Phe 20 25 (2) INFORMATION FOR SEC ID. NO .: 99: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 507 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 99: ATGAAGATGG TGAAATCGAT CGCCGCAGGT CTGACCGCCG CGGCTGCAAT CGGCGCCGCT 60 GCGGCCGGTG TGACTTCGAT CATGGCTGGC GGCCCGGTCG TATACCAGAT GCAGCCGGTC 120 GTCTTCGGCG CGCCACTGCC GTTGGACCCG GCATCCGCCC CTGACGTCCC GACCGCCGCC 180 CAGTTGACCA GCCTGCTCAA CAGCCTCGCC GATCCCAACG TGTCGTTTGC GAACAAGGGC 240 AGTCTGGTCG AGGGCGGCAT CGGGGGCACC GAGGCGCGCA TCGCCGACCA CAAGCTGAAG 300 AAGGCCGCCG AGCACGGGGA TCTGCCGCTG TCGTTCAGCG TGACGAACAT CCAGCCGGCG 360 GCCGCCGGTT CGGCCACCGC CGACGTTTCC GTCTCGGGTC CGAAGCTCTC GTCGCCGGTC 420 ACGCAGAACG TCACGTTCGT GAATCAAGGC GGCTGGATGC TGTCACGCGC ATCGGCGATG 480 GAGTTGCTGC AGGCCGCAGG GAACTGA 507 (2) INFORMATION FOR SEC ID. NO.:100: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 168 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 100: Met Lys Met Val Lys Ser Wing Wing Wing Gly Leu Thr Wing Wing Wing Wing 1 5 10 15 He Gly Wing Wing Wing Wing Gly Val Thr Ser He Met Wing Wing Gly Pro 20 25 30 Val Val Tyr Gln Met Gln Pro Val Val Phe Gly Wing Pro Pro Leu Pro Leu 35 40 45 Asp Pro Wing Ser Wing Pro Asp Val Pro Thr Ala Ala Gln Leu Thr Ser 50 55 60 Leu Leu Asn Ser Leu Ala Asp Pro Asn Val Ser Phe Ala Asn Lys Gly 65 70 75 80 Ser Leu Val Glu Gly Gly He Gly Gly Thr Glu Wing Arg He Wing Asp 85 90 95 His Lys Leu Lys Lys Wing Wing Glu His Gly Asp Leu Pro Leu Ser Phe 100 105 110 Ser Val Thr Asn He Gln Pro Wing Wing Wing Gly Ser Ala Thr Ala Asp 115 120 125 Val Ser Val Ser Gly Pro Lys Leu Ser Ser Pro Val Thr Gln Asn Val 130 135 140 Thr Phe Val Asn Gln Gly Gly Trp Met Leu Ser Arg Wing Being Wing Met 145 150 155 160 Glu Leu Leu Gln Ala Wing Gly Asn 165 (2) INFORMATION FOR SEC ID. NO.:101: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 500 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:101: CGTGGCAATG TCGTTGACCG TCGGGGCCGG GGTCGCCTCC GCAGATCCCG TGGACGCGGT 60 CATTAACACC ACCTGCAATT ACGGGCAGGT AGTAGCTGCG CTCAACGCGA GGATCCGGG 120 GGCTGCCGCA CAGTTCAACG CCTCACCGGT GGCGCAGTCC TATTTGCGCA ATTTCCTCGC 180 CGCACCGCCA CCTCAGCGCG CTGCCATGGC CGCGCAATTG CGGGGGCGGC CAAGCTGTGC 240 ACAGTACATC GGCCTTGTCG AGTCGGTTGC CGGCTCCTGC AACAACTATT AAGCCCATGC 300 GGGCCCCATC CCGCGACCCG GCATCGTCGC CGGGGCTAGG CCAGATTGCC CCGCTCCTCA 360 ACGGGCCGCA TCCCGCGACC CGGCATCGTC GCCGGGGCTA GGCCAGATTG CCCCGCTCCT 420 CAACGGGCCG CATCTCGTGC CGAATTCCTG CAGCCCGGGG GATCCACTAG TTCTAGAGCG 480 GCCGCCACCG CGGTGGAGCT 500 (2) INFORMATION FOR SEC ID. NO.:102: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 96 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 102: Val Ala Met Ser Leu Thr Val Gly Wing Gly Val Wing Ser Wing Asp Pro 1 5 10 15 Val Asp Wing Val He Asn Thr Thr Cys Asn Tyr Gly Gln Val Val Wing 25 30 Ala Leu Asn Ala Thr Asp Pro Gly Ala Ala Ala Gln Phe Asn Ala Ser 40 45 Pro Val Wing Gln Ser Tyr Leu Arg Asn Phe Leu Wing Wing Pro Pro Pro 50 55 60 Gln Arg Wing Wing Met Wing Wing Gln Leu Gln Wing Val Pro Gly Wing Wing 65 70 75 80 Gln Tyr He Gly Leu Val Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr 85 90 95 (2) INFORMATION FOR SEC ID. DO NOT. : 103: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 154 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 103: ATGACAGAGC AGCAGTGGAA TTTCGCGGGT ATCGAGGCCG CGGCAAGCGC AATCCAGGGA 60 AATGTCACGT CCATTCATTC CCTCCTTGAC GAGGGGAAGC AGTCCCTGAC CAAGCTCGCA 120 GCGGCCTGGG GCGGTAGCGG TTCGGAAGCG TACC-154 (2) INFORMATION FOR SEC ID. DO NOT. : 104: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 104: Met Thr Glu Gln Gln Trn Asn Phe Wing Gly He Glu Wing Wing Wing 1 5 10 15 Wing He Gln Gly Asn Val Thr Ser He His Ser Leu Leu Asp Glu Gly 20 25 30 Lys Gln Ser Leu Thr Lys Leu Ala Wing Wing Trp Gly Gly Ser Gly Ser 35 40 45 Glu Wing Tyr 50 (2) INFORMATION FOR SEC ID. DO NOT. : 105: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 282 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 105: CGGTCGCGCA CTTCCAGGTG ACTATGAAAG TCGGCTTCCG NCTGGAGGAT TCCTGAACCT 60 TCAAGCGCGG CCGATAACTG AGGTGCATCA TTAAGCGACT TTTCCAGAAC ATCCTGACGC 120 GCTCGAAACG CGGCACAGCC GACGGTGGCT CCGNCGAGGC GCTGNCTCCA AAATCCCTGA 180 GACAATTCGN CGGGGGCGCC TACAAGGAAG TCGGTGCTGA ATTCGNCGNG TATCTGGTCG 240 ACCTGTGTGG TCTGNAGCCG GACGAAGCGG TGCTCGACGT CG 282 (2) INFORMATION FOR SEC ID. DO NOT . : 106: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3058 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 106: GATCGTACCC GTGCGAGTGC TCGGGCCGTT TGAGGATGGA GTGCACGTGT CTTTCGTGAT 60 GGCATACCCA GAGATGTTGG CGGCGGCGGC TGACACCCTG CAGAGCATCG GTGCTACCAC 120 TGTGGCTAGC AATGCCGCTG CGGCGGCCCC GACGACTGGG GTGGTGCCCC CCGCTGCCGA 180 TGAGGTGTCG GCGCTGACTG CGGCGCACTT CGCCGCACAT GCGGCGATGT ATCAGTCCGT 240 GAGCGCTCGG GCTGCTGCGA TTCATGACCA GTTCGTGGCC ACCCTTGCCA GCAGCGCCAG 300 CTCGTATGCG GCCACTGAAG TCGCCAATGC GGCGGCGGCC AGCTAAGCCA GGAACAGTCG 360 GCACGAGAAA CCACGAGAAA TAGGGACACG TAATGGTGGA TTTCGGGGCG TTACCACCGG 420 AGATCAACTC CGCGAGGATG TACGCCGGCC CGGGTTCGGC CTCGCTGGTG GCCGCGGCTC 480 AGATGTGGGA CAGCGTGGCG AGTGACCTGT TTTCGGCCGC GTCGGCGTTT CAGTCGGTGG 540 TCTGGGGTCT GACGGTGGGG TCGTGGATAG GTTCGTCGGC GGGTCTGATG GTGGCGGCGG 600 CCTCGCCGTA TGTGGCGTGG ATGAGCGTCA CCGCGGGGCA GGCCGAGCTG ACCGCCGCCC 660 AGGTCCGGGT TGCTGCGGCG GCCTACGAGA CGGCGTATGG GCTGACGGTG CCCCCGCCGG 720 TGATCGCCGA GAACCGTGCT GAACTGATGA TTCTGATAGC GACCAACCTC TTGGGGCAAA 780 ACACCCCGGC GATCGCGGTC AACGAGGCCG AATACGGCGA GATGTGGGCC CAAGACGCCG 840 CCGCGATGTT TGGCTACGCC GCGGCGACGG CGACGGCGAC GGCGACGTTG CTGCCGTTCG 900 AGGAGGCGCC GGAGATGACC AGCGCGGGTG GGCTCCTCGA GCAGGCCGCC GCGGTCGAGG 960 AGGCCTCCGA CACCGCCGCG GCGAACCAGT TGATGAACAA TGTGCCCCAG GCGCTGCAAC 1020 AGCTGGCCCA GCCCACGCAG GGCACCACGC CTTCTTCCAA GCTGGGTGGC CTGTGGAAGA 1080 CGGTCTCGCC GCATCGGTCG CCGATCAGCA ACATGGTGTC GATGGCCAAC AACCACATGT 1140 CGATGACCAA CTCGGGTGTG TCGATGACCA ACACCTTGAG CTCGATGTTG AAGGGCTTTG 1200 CTCCGGCGGC GGCCGCCCAG GCCGTGCAAA CCGCGGCGCA AAACGGGGTC CGGGCGATGA 1260 GCTCGCTGGG CAGCTCGCTG GGTTCTTCGG GTCTGGGCGG TGGGGTGGCC GCCAACTTGG 1320 GTCGGGCGGC CTCGGTCGGT TCGTTGTCGG TGCCGCAGGC CTGGGCCGCG GCCAACCAGG 1380 CAGTCACCCC GGCGGCGCGG GCGCTGCCGC TGACCAGCCT GACCAGCGCC GCGGAAAGAG 1440 GGCCCGGGCA G ATGCTGGGC GGGCTGCCGG TGGGGCAGAT GGGCGCCAGG GCCGGTGGTG 1500 GGCTCAGTGG TGTGCTGCGT GTTCCGCCGC GACCCTATGT GATGCCGCAT TCTCCGGCGG 1560 CCGGCTAGGA GAGGGGGCGC AGACTGTCGT TATTTGACCA GTGATCGGCG GTCTCGGTGT 1620 TTCCGCGGCC GGCTATGACA ACAGTCAATG TGCATGACAA GTTACAGGTA TTAGGTCCAG 1680 GTTCAACAAG GAGACAGGCA ACATGGCCTC ACGTTTTATG ACGGATCCGC ACGCGATGCG 1740 GGACATGGCG GGCCGTTTTG AGGTGCACGC CCAGACGGTG GAGGACGAGG CTCGCCGGAT 1800 GTGGGCGTCC GCGCAAAACA TTTCCGGTGC GGGCTGGAGT GGCATGGCCG AGGCGACCTC 1860 GCTAGACACC ATGGCCCAGA TGAATCAGGC GTTTCGCAAC ATCGTGAACA TGCTGCACGG 1920 GGTGCGTGAC GGGCTGGTTC GCGACGCCAA CAACTACGAG CAGCAAGAGC AGGCCTCCCA 1980 GCAGATCCTC AGCAGCTAAC GTCAGCCGCT GCAGCACAAT ACTTTTACAA GCGAAGGAGA 2040 ACAGGTTCGA TGACCATCAA CTATCAATTC GGGGATGTCG ACGCTCACGG CGCCATGATC 2100 CGCGCTCAGG CCGGGTTGCT GGAGGCCGAG CATCAGGCCA TCATTCGTGA TGTGTTGACC 2160 GCGAGTGACT TTTGGGGCGG CGCCGGTTCG GCGGCCTGCC AGGGGTTCAT TACCCAGTTG 2220 GGCCGTAACT TCCAGGTGAT CTACGAGCAG GCCAACGCCC ACGGGCAGAA GGTGCAGGCT 2280 GCCGGCAACA ACATGGC GCA AACCGACAGC GCCGTCGGCT CCAGCTGGGC CTGACACCAG 2340 GCCAAGGCCA GGGACGTGGT GTACGAGTGA AGTTCCTCGC GTGATCCTTC GGGTGGCAGT 2400 CTAAGTGGTC AGTGCTGGGG TGTTGGTGGT TTGCTGCTTG GCGGGTTCTT CGGTGCTGGT 2460 CAGTGCTGCT CGGGCTCGGG TGAGGACCTC. GAGGCCCAGG TAGCGCCGTC CTTCGATCCA 2520 TTCGTCGTGT TGTTCGGCGA GGACGGCTCC GACGAGGCGG ATGATCGAGG CGCGGTCGGG 2580 GAAGATGCCC ACGACGTCGG TTCGGCGTCG TACCTCTCGG TTGAGGCGTT CCTGGGGGTT 2640 GTTGGACCAG ATTTGGCGCC AGATCTGCTT GGGGAAGGCG GTGAACGCCA GCAGGTCGGT 2700 GCGGGCGGTG TCGAGGTGCT CGGCCACCGC GGGGAGTTTG TCGGTCAGAG CGTCGAGTAC 2760 CCGATCATAT TGGGCAACAA CTGATTCGGC GTCGGGCTGG TCGTAGATGG AGTGCAGCAG 2820 GGTGCGCACC CACGGCCAGG AGGGCTTCGG GGTGGCTGCC ATCAGATTGG CTGCGTAGTG 2880 GGTTCTGCAG CGCTGCCAGG CCGCTGCGGG CAGGGTGGCG CCGATCGCGG CCACCAGGCC 2940 GGCGTGGGCG TCGCTGGTGA CCAGCGCGAC CCCGGACAGG CCGCGGGCGA CCAGGTCGCG 3000 GAAGAACGCC AGCCAGCCGG CCCCGTCCTC GGCGGAGGTG ACCTGGATGC CCAGGATC 3058 (2) INFORMATION FOR SEC ID. NO.:107: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 391 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 107: Met Val Asp Phe Gly Ala Leu Pro Pro Glu He Asn Be Ala Arg Met 1 5 10 15 Tyr Ala Gly Pro Gly Ser Ala Be Leu Val Ala Ala Ala Gln Met Trp 20 25 30 Asp Ser Val Ala Ser Asp Leu Phe Ser Ala Ala Ser Ala Phe Gln Ser 40, 45 Val Val Trp Gly Leu Thr Val Gly Ser Trp He Gly Ser Wing Gly 50 55 60 Leu Met Val Wing Wing Wing Pro Pro Tyr Val Wing Trp Met Ser Val Thr 65 70 75 80 Ala Gly Gln Ala Glu Leu Thr Ala Ala Gln Val Arg Val Ala Ala Ala 85 90 95 Ala Tyr Glu Thr Ala Tyr Gly Leu Thr Val Pro Pro Pro Val He Ala 100 105 110 Glu Asn Arg Ala Glu Leu Met He Leu He Ala Thr Asn Leu Leu Gly 115 120 125 Gln Asn Thr Pro Wing Wing Wing Val Asn Glu Wing Glu Tyr Gly Glu Met 130 135 140 Trp Wing Gln Asp Wing Wing Wing Met Phe Gly Tyr Wing Wing Wing Thr Wing 145 150 155 160 Thr Ala Thr Ala Thr Leu Leu Pro Phe Glu Glu Ala Pro Glu Met Thr 165 170 175 Be Wing Gly Gly Leu Glu Gln Ala Wing Wing Val Glu Glu Ala Wing 180 185 190 Asp Thr Wing Wing Wing Asn Gln Leu Met Asn Asn Val Pro Gln Wing Leu 195 200 205 Gln Gln Leu Wing Gln Pro Thr Gln Gly Thr Thr Pro Ser Ser Lys Leu 210 215 220 Gly Gly Leu Trp Lys Thr Val Ser Pro His Arg Ser Pro He Ser Asn 225 230 235 240 Met Val Ser Met Ala Asn Asn His Met Ser Met Thr Asn Ser Gly Val 245 250 255 Being Met Thr Asn Thr Leu Ser Being Met Leu Lys Gly Phe Wing Pro Wing 260 265 270 Wing Wing Wing Gln Wing Val Gln Thr Wing Wing Gln Asn Gly Val Arg Wing 275 280 285 Met Being Ser Leu Gly Being Ser Leu Gly Being Ser Gly Leu Gly Gly Gly 290 295 300 Val Ala Ala Asn Leu Gly Arg Ala Ala Ser Val Gly Ser Leu Ser Val 305 310 315 320 Pro Gln Ala Trp Ala Ala Ala Asn Gln Ala Val Thr Pro Ala Ala Arg 325 330 335 Wing Leu Pro Leu Thr Be Leu Thr Ser Wing Wing Glu Arg Gly Pro Gly 340 345 350 Gln Met Leu Gly Le Glu Leu Pro Val Gly Gln Met Gly Ala Arg Wing Gly 355 360 365 Gly Gly Leu Ser Gly Val Leu Arg Val Pro Pro Arg Pro Tyr Val Met 370 375 380 Pro His Ser Pro Wing Ala Gly 385 390 (2) INFORMATION FOR SEC ID. DO NOT . : 108: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1725 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:108: GACGTCAGCA CCCGCCGTGC AGGGCTGGAG CGTGGTCGGT TTTGATCTGC GGTCAAGGTG 60 ACGTCCCTCG GCGTGTCGCC GGCGTGGATG CAGACTCGAT GCCGCTCTTT AGTGCAACTA 120 ATTTCGTTGA AGTGCCTGCG AGGTATAGGA CTTCACGATT GGTTAATGTA GCGTTCACCC 180 CGTGTTGGGG TCGATTTGGC CGGACCAGTC GTCACCAACG CTTGGCGTGC GCGCCAGGCG 240 GGCGATCAGA TCGCTTGACT ACCAATCAAT CTTGAGCTCC CGGGCCGATG CTCGGGCTAA 300 ATGAGGAGGA GCACGCGTGT CTTTCACTGC GCAACCGGAG ATGTTGGCGG CCGCGGCTGG 360 CGAACTTCGT TCCCTGGGGG CAACGCTGAA GGCTAGCAAT GCCGCCGCAG CCGTGCCGAC 420 GACTGGGGTG GTGCCCCCGG CTGCCGACGA GGTGTCGCTG CTGCTTGCCA CACAATTCCG 480 TACGCATGCG GCGACGTATC AGACGGCCAG CGCCAAGGCC GCGGTGATCC ATGAGCAGTT 540 TGTGACCACG CTGGCCACCA GCGCTAGTTC ATATGCGGAC ACCGAGGCCG CCAACGCTGT 600 GGTCACCGGC TAGCTGACCT GACGGTATTC GAGCGGAAGG ATTATCGAAG TGGTGGATTT 660 CGGGGCGTTA CCACCGGAGA TCAACTCCGC GAGGATGTAC GCCGGCCCGG GTTCGGCCTC 720 GCTGGTGGCC GCCGCGAAGA TGTGGGACAG CGTGGCGAGT GACCTGTTTT CGGCCGCGTC 780 GGCGTTTCAG TCGGTGGTCT GGGGTCTGAC GGTGGGGTCG TGGATAGGTT CGTCGGCGGG 840 TCTGATGGCG G CGGCGGCCT CGCCGTATGT GGCGTGGATG AGCGTCACCG CGGGGCAGGC 900 CCAGCTGACC GCCGCCCAGG TCCGGGTTGC TGCGGCGGCC TACGAGACAG CGTATAGGCT 960 GACGGTGCCC CCGCCGGTGA TCGCCGAGAA CCGTACCGAA CTGATGACGC TGACCGCGAC 1020 CAACCTCTTG GGGCAAAACA CGCCGGCGAT CGAGGCCAAT CAGGCCGCAT ACAGCCAGAT 1080 GTGGGGCCAA GACGCGGAGG CGATGTATGG CTACGCCGCC ACGGCGGCGA CGGCGACCGA 1140 GGCGTTGCTG CCGTTCGAGG ACGCCCCACT GATCACCAAC CCCGGCGGGC TCCTTGAGCA 1200 GGCCGTCGCG GTCGAGGAGG CCATCGACAC CGCCGCGGCG AACCAGTTGA TGAACAATGT 1260 GCCCCAAGCG CTGCAACAGC TGGCCCAGCC AGCGCAGGGC GTCGTACCTT CTTCCAAGCT 1320 GGGTGGGCTG TGGACGGCGG TCTCGCCGCA TCTGTCGCCG CTCAGCAACG TCAGTTCGAT 1380 AGCCAACAAC CACATGTCGA TGATGGGCAC GGGTGTGTCG ATGACCAACA CCTTGCACTC 1440 GATGTTGAAG GGCTTAGCTC CGGCGGCGGC TCAGGCCGTG GAAACCGCGG CGGAAAACGG 1500 GGTCTGGGCG ATGAGCTCGC TGGGCAGCCA GCTGGGTTCG TCGCTGGGTT CTTCGGGTCT 1560 GGGCGCTGGG GTGGCCGCCA ACTTGGGTCG GGCGGCCTCG GTCGGTTCGT TGTCGGTGCC 1620 GCCAGCATGG GCCGCGGCCA ACCAGGCGGT CACCCCGGCG GCGCGGGCGC TGCCGCTGAC 1680 CAGCCTGACC AGCGCCGCC C AAACCGCCCC CGGACACATG CTGGG 1725 (2) INFORMATION FOR SEC ID. NO.:109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 109: Val Val Asp Phe Gly Ala Leu Pro Pro Glu He Asn Be Ala Arg Met 1 5 10 15 Tyr Ala Gly Pro Gly Ser Ala Ser Leu Val Ala Ala Ala Lys Met Trp 20 25 30 Asp Ser Val Ala Ser Asp Leu Phe Ser Ala Ala Ser Ala Phe Gln Ser 35 40 45 Val Val Trp Gly Leu Thr Val Gly Ser Trp He Gly Ser Ser Ala Gly 50 55 60 Leu Met Ala Ala Ala Ala Ser Ser Tyr Val Ala Trp Met Ser Val Thr 65 70 75 80 Ala Gly Gln Ala Gln Leu Thr Ala Ala Gln Val Arg Val Ala Ala Ala 85 90 95 Ala Tyr Glu Thr Ala Tyr Arg Leu Thr Val Pro Pro Pro Val He Ala 100 105 110 Glu Asn Arg Thr Glu Leu Met Thr Leu Thr Wing Thr Asn Leu Leu Gly 115 120 125 Gln Asn Thr Pro Wing He Glu Wing Asn Gln Wing Wing Tyr Being Gln Met 130 135 140 Trp Gly Gln Asp Ala Glu Ala Met Tyr Gly Tyr Ala Ala Thr Ala Ala 145 150 155 160 Thr Ala Thr Glu Ala Leu Leu Pro Phe Glu Asp Ala Pro Leu He Thr 165 170 175 Asn Pro Gly Gly Leu Leu Glu Gln Wing Val Wing Val Glu Glu Wing He 180 185 190 Asp Thr Ala Ala Ala Asn Gln Leu Met Asn Asn Val Pro Gln Ala Leu 195 200 205 Gln Gln Leu Ala Gln Pro Ala Gln Gly Val Val Pro Ser Ser Lys Leu 210 215 220 Gly Gly Leu Trp Thr Wing Val Pro Pro His Leu Ser Pro Leu Ser Asn 225 230 235 240 Val Ser Ser Wing Asn Asn His Met Met Met Met Met Gly Thr Gly Val 245 250 255 Being Met Thr Asn Thr Leu His Being Met Leu Lys Gly Leu Pro Ala Wing 260 265 270 Ala Ala Gln Ala Val Glu Thr Ala Ala Glu Asn Gly Val Trp Ala Met 275 280 285 Ser Ser Leu Gly Ser Gln Leu Gly Ser Ser Leu Gly Ser Ser Gly Leu. 290 295 300 Gly Ala Gly Val Ala Ala Asn Leu Gly Arg Ala Ala Ser Val Gly Ser 305 310 315 320 Leu Ser Val Pro Pro Ala Trp Ala Ala Ala Asn Gln Ala Val Thr Pro 325 330 335 Ala Ala Arg Ala Leu Pro Leu Thr Ser Leu Thr Ser Wing Wing Gln Thr 340 345 350 Wing Pro Gly His Met Leu Gly 355 (2) INFORMATION FOR SEC ID. DO NOT . : 110: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3027 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 110: AGTTCAGTCG AGAATGATAC TGACGGGCTG TATCCACGAT GGCTGAGACA ACCGAACCAC 60 CGTCGGACGC GGGGACATCG CAAGCCGACG CGATGGCGTT GGCCGCCGAA GCCGAAGCCG 120 CCGAAGCCGA AGCGCTGGCC GCCGCGGCGC GGGCCCGTGC CCGTGCCGCC CGGTTGAAGC 180 GTGAGGCGCT GGCGATGGCC CCAGCCGAGG ACGAGAACGT CCCCGAGGAT ATGCAGACTG 240 GGAAGACGCC GAAGACTATG ACGACTATGA CGACTATGAG GCCGCAGACC AGGAGGCCGC 300 ACGGTCGGCA TCCTGGCGAC GGCGGTTGCG GGTGCGGTTA CCAAGACTGT CCACGATTGC 360 CATGGCGGCC GCAGTCGTCA TCATCTGCGG CTTCACCGGG CTCAGCGGAT ACATTGTGTG 420 GCAACACCAT GAGGCCACCG AACGCCAGCA GCGCGCCGCG GCGTTCGCCG CCGGAGCCAA 480 GCAAGGTGTC ATCAACATGA CCTCGCTGGA CTTCAACAAG GCCAAAGAAG ACGTCGCGCG 540,133 TGTGATCGAC AGCTCCACCG GCGAATTCAG GGATGACTTC CAGCAGCGGG CAGCCGATTT 600 CACCAAGGTT GTCGAACAGT CCAAAGTGGT CACCGAAGGC ACGGTGAACG CGACAGCCGT 660 CGAATCCATG AACGAGCATT CCGCCGTGGT GCTCGTCGCG GCGACTTCAC GGGTCACCAA 720 TTCCGCTGGG GCGAAAGACG AACCACGTGC GTGGCGGCTC AAAGTGACCG TGACCGAAGA 780 GGGGGGACAG TACAAGATGT CGAAAGTTGA GTTCGTACCG TGACCGATGA CGTACGCGAC 840 GTCAAC ACCG AAACCACTGA CGCCACCGAA GTCGCTGAGA TCGACTCAGC CGCAGGCGAA 900 GCCGGTGATT CGGCGACCGA GGCATTTGAC ACCGACTCTG CAACGGAATC TACCGCGCAG 960 AAGGGTCAGC GGCACCGTGA CCTGTGGCGA ATGCAGGTTA CCTTGAAACC CGTTCCGGTG 1020 ATTCTCATCC TGCTCATGTT GATCTCTGGG GGCGCGACGG GATGGCTATA CCTTGAGCAA 1080 TACGACCCGA TCAGCAGACG GACTCCGGCG CCGCCCGTGC TGCCGTCGCC GCGGCGTCTG 1140 ACGGGACAAT CGCGCTGTTG TGTATTCACC CGACACGTCG ACCAAGACTT CGCTACCGCC 1200 AGGTCGCACC TCGCCGGCGA TTTCCTGTCC TATACGACCA GTTCACGCAG CAGATCGTGG 1260 CTCCGGCGGC CAAACAGAAG TCACTGAAAA CCACCGCCAA GGTGGTGCGC GCGGCCGTGT 1320 CGGAGCTACA TCCGGATTCG GCCGTCGTTC TGGTTTTTGT CGACCAGAGC ACTACCAGTA 1380 AGGACAGCCC CAATCCGTCG ATGGCGGCCA GCAGCGTGAT GGTGACCCTA GCCAAGGTCG 1440 ACGGCAATTG GCTGATCACC AAGTTCACCC CGGTTTAGGT TGCCGTAGGC GGTCGCCAAG 1500 TCTGACGGGG GCGCGGGTGG CTGCTCGTGC GAGATACCGG CCGTTCTCCG GACAATCACG 1560 GCCCGACCTC AAACAGATCT CGGCCGCTGT CTAATCGGCC GGGTTATTTA AGATTAGTTG 1620 CCACTGTATT TACCTGATGT TCAGATTGTT CAGCTGGATT TAGCTTCGCG GCAGGGCGGC 1680 TGGTGCACTT TGC ATCTGGG GTTGTGACTA CTTGAGAGAA TTTGACCTGT TGCCGACGTT 1740 GTTTGCTGTC CATCATTGGT GCTAGTTATG GCCGAGCGGA AGGATTATCG AAGTGGTGGA 1800 CTTCGGGGCG TTACCACCGG AGATCAACTC CGCGAGGATG TACGCCGGCC CGGGTTCGGC 1860 CTCGCTGGTG GCCGCCGCGA AGATGTGGGA CAGCGTGGCG AGTGACCTGT TTTCGGCCGC 1920 GTCGGCGTTT CAGTCGGTGG TCTGGGGTCT GACGACGGGA TCGTGGATAG GTTCGTCGGC 1980 GGGTCTGATG GTGGCGGCGG CCTCGCCGTA TGTGGCGTGG ATGAGCGTCA CCGCGGGGCA 2040 GGCCGAGCTG ACCGCCGCCC AGGTCCGGGT TGCTGCGGCG GCCTACGAGA CGGCGTATGG 2100 GCTGACGGTG CCCCCGCCGG TGATCGCCGA GAACCGTGCT GAACTGATGA TTCTGATAGC 2160 GACCAACCTC TTGGGGCAAA ACACCCCGGC GATCGCGGTC AACGAGGCCG AATACGGGGA 2220 GATGTGGGCC CAAGACGCCG CCGCGATGTT TGGCTACGCC GCCACGGCGG CGACGGCGAC 2280 CGAGGCGTTG CTGCCGTTCG AGGACGCCCC ACTGATCACC AACCCCGGCG GGCTCCTTGA 2340 GCAGGCCGTC GCGGTCGAGG AGGCCATCGA CACCGCCGCG GCGAACCAGT TGATGAACAA 2400 TGTGCCCCAA GCGCTGCAAC AACTGGCCCA GCCCACGAAA AGCATCTGGC CGTTCGACCA 2460 ACTGAGTGAA CTCTGGAAAG CCATCTCGCC GCATCTGTCG CCGCTCAGCA ACATCGTGTC 2520 GATGCTCAAC AACCACGTGT CGATGACCAA CTCGGGTGTG TCGATGGCCA GCACCTTGCA 2580 CTCAATGTTG AAGGGCTTTG CTCCGGCGGC GGCTCAGGCC GTGGAAACCG CGGCGCAAAA 2640 CGGGGTCCAG GCGATGAGCT CGCTGGGCAG CCAGCTGGGT TCGTCGCTGG GTTCTTCGGG 2700 TCTGGGCGCT GGGGTGGCCG CCAACTTGGG TCGGGCGGCC TCGGTCGGTT CGTTGTCGGT 2760 GCCGCAGGCC TGGGCCGCGG CCAACCAGGC GGTCACCCCG GCGGCGCGGG CGCTGCCGCT 2820 GACCAGCCTG ACCAGCGCCG CCCAAACCGC CCCCGGACAC ATGCTGGGCG GGCTAC CGCT 2880 GGGGCAACTG ACCAATAGCG GCGGCGGGTT CGGCGGGGTT AGCAATGCGT TGCGGATGCC 2940 GCCGCGGGCG TACGTAATGC CCCGTGTGCC CGCCGCCGGG TAACGCCGAT CCGCACGCAA 3000 TGCGGGCCCT CTATGCGGGC AGCGATC 3027 (2) INFORMATION FOR SEC ID. NO .: 111: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 396 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. NO.rlll: Val Val Asp Phe Gly Ala Leu Pro Pro Glu He Asn Ser Ala Arg Met 1 5 10 15 Tyr Ala Gly Pro Gly Ser Ala Ser Leu Val Ala Ala Ala Ala Lys Met Trp 20 25 30 125Asp Ser Val Ala Ser Asp Leu Phe Ser Ala Ala Ser Ala Phe Gln Ser 40 45 Val Val Trp Gly Leu Thr Thr Gly Ser Trp He Gly Ser Wing Gly 50 55 60 Leu Met Val Wing Wing Wing Pro Pro Tyr Val Wing Trp Met Ser Val Thr 65 '70 75 80 Ala Gly Gln Ala Glu Leu Thr Ala Ala Gln Val Arg Val Ala Ala Ala 85 90 95 Ala Tyr Glu Thr Ala Tyr Gly Leu Thr Val Pro Pro Pro Val lie Ala 100 105 110 Glu Asn Arg Ala Glu Leu Met He Leu He Ala Thr Asn Leu Leu Gly 115 120 125 Gln Asn Thr Pro Wing He Wing Val Asn Glu Wing Glu Tyr Gly Glu Met 130 135 140 Trp Wing Gln Asp Wing Wing Wing Met Phe Gly Tyr Wing Wing Thr Wing Wing 145 150 155 160 Thr Ala Thr Glu Ala Leu Leu Pro Phe Glu Asp Ala Pro Leu He Thr 165 170 175 Asn Pro Gly Glu Leu Leu Glu Gln Wing Val Wing Val Glu Glu Wing He 180 185 190 Asp Thr Wing Wing Wing Asn Gln Leu Met Asn Asn Val Pro Gln, Wing Leu 195 200 205 Gln Gln Leu Wing Gln Pro Thr Lys Ser He Trp Pro Phe Asp Gln Leu 210 215 220 Ser Glu Leu Trp Lys Wing He Pro Pro His Leu Ser Pro Leu Ser Asn 225 230 235 240 He Val Ser Met Leu Asn Asn His Val Ser Met Thr Asn Ser Gly Val 245 250 255 Ser Met Wing Ser Thr Leu His Ser Met Leu Lys Gly Phe Wing Pro Wing 260 265 270 Wing Wing Gln Wing Val Glu Thr Wing Wing Gln Asn Gly Val Gln Wing Met 275 280 285 Ser Ser Leu Gly Ser Gln Leu Gly Ser Ser Leu Gly Ser Ser Gly Leu 290 295 '300 Gly Ala Gly Val Ala Ala Asn Leu Gly Arg Ala Ala Ser Val Gly Ser 305 310 315 320 Leu Ser Val Pro Gln Wing Trp Wing Wing Wing Asn Gln Wing Val Thr Pro 325 330 335 Ala Ala Arg Ala Leu Pro Leu Thr Ser Leu Thr Ser Ala Ala Gln Thr 340 345 350 Wing Pro Gly His Met Leu Gly Gly Leu Pro Leu Gly Gln Leu Thr Asn 355 360 365 Ser Gly Gly Gly Phe Gly Gly Val Ser Asn Ala Leu Arg Met Pro Pro 370 375 380 Arg Wing Tyr Val Met Pro Pro Arg Val Pro Wing Ala Gly 385 390 395 (2) INFORMATION FOR SEC ID. N0 : 112: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1616 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (i) SEQUENCE DESCRIPTION: SEC ID. NO.:112: CATCGGAGGG AGTGATCACC ATGCTGTGGC ACGCAATGCC ACCGGAGTAA ATACCGCACG 60 GCTGATGGCC GGCGCGGGTC CGGCTCCAAT GCTTGCGGCG GCCGCGGGAT GGCAGACGCT 120 TTCGGCGGCT CTGGACGCTC AGGCCGTCGA GTTGACCGCG CGCCTGAACT CTCTGGGAGA 180 GGAGGTGGCA AGCCTGGACT GCGACAAGGC GCTTGCGGCT GCAACGCCGA TGGTGGTCTG 240 GCTACAAACC GCGTCAACAC AGGCCAAGAC CCGTGCGATG CAGGCGACGG CGCAAGCCGC 300 GGCATACACC CAGGCCATGG CCACGACGCC GTCGCTGCCG GAGATCGCCG CCAACCACAT 360 CACCCAGGCC GTCCTTACGG CCACCAACTT CTTCGGTATC AACACGATCC CGATCGCGTT 420 GACCGAGATG GATTATTTCA TCCGTATGTG GAACCAGGCA GCCCTGGCAA TGGAGGTCTA 480 CCAGGCCGAG ACCGCGGTTA ACACGCTTTT CGAGAAGCTC GAGCCGATGG CGTCGATCCT 540 TGATCCCGGC GCGAGCCAGA GCACGACGAA CCCGATCTTC GGAATGCCCT CCCCTGGCAG 600 CTCAACACCG GTTGGCCAGT TGCCGCCGGC GGCTACCCAG ACCCTCGGCC AACTGGGTGA 660 GATGAGCGGC CCGATGCAGC AGCTGACCCA GCCGCTGCAG CAGGTGACGT CGTTGTTCAG 720 CCAGGTGGGC GGCACCGGCG GCGGCAACCC AGCCGACGAG GAAGCCGCGC AGATGGGCCT 780 GCTCGGCACC AGTCCGCTGT CGAACCATCC GCTGGCTGGT GGATCAGGCC CCAGCGCGGG 840 CGCGGGCCTG C TGCGCGCGG AGTCGCTACC TGGCGCAGGT GGGTCGTTGA CCCGCACGCC 900 GCTGATGTCT CAGCTGATCG AAAAGCCGGT TGCCCCCTCG GTGATGCCGG CGGCTGCTGC 960 CGGATCGTCG GCGACGGGTG GCGCCGCTCC GGTGGGTGCG GGAGCGATGG GCCAGGGTGC 1020 GCAATCCGGC GGCTCCACCA GGCCGGGTCT GGTCGCGCCG GCACCGCTCG CGCAGGAGCG 1080 TGAAGAAGAC GACGAGGACG ACTGGGACGA AGAGGACGAC TGGTGAGCTC CCGTAATGAC 1140 AACAGACTTC CCGGCCACCC GGGCCGGAAG ACTTGCCAAC ATTTTGGCGA GGAAGGTAAA 1200 GAGAGAAAGT AGTCCAGCAT GGCAGAGATG AAGACCGATG CCGCTACCCT CGCGCAGGAG 1260 GCAGGTAATT TCGAGCGGAT CTCCGGCGAC CTGAAAACCC AGATCGACCA GGTGGAGTCG 1320 ACGGCAGGTT CGTTGCAGGG CCAGTGGCGC GGCGCGGCGG GGACGGCCGC CCAGGCCGCG 1380 GTGGTGCGCT TCCAAGAAGC AGCCAATAAG CAGAAGCAGG AACTCGACGA GATCTCGACG 1440 AATATTCGTC AGGCCGGCGT CCAATACTCG AGGGCCGACG AGGAGCAGCA GCAGGCGCTG 1500 TCCTCGCAAA TGGGCTTCTG ACCCGCTAAT ACGAAAAGAA ACGGAGCAAA AACATGACAG 1560 AGCAGCAGTG GAATTTCGCG GGTATCGAGG CCGCGGCAAG CGCAATCCAG GGAAAT 1616 (2) INFORMATION FOR SEQ ID. NO .: 113: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 432 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:113: CTAGTGGATG GGACCATGGC CATTTTCTGC AGTCTCACTG CCTTCTGTGT TGACATTTTG 60 GCACGCCGGC GGAAACGAAG CACTGGGGTC GAAGAACGGC TGCGCTGCCA TATCGTCCGG 120 AGCTTCCATA CCTTCGTGCG GCCGGAAGAG CTTGTCGTAG TCGGCCGCCA TGACAACCTC 180 TCAGAGTGCG CTCAAACGTA TAAACACGAG AAAGGGCGAG ACCGACGGAA GGTCGAACTC 240 GCCCGATCCC GTGTTTCGCT ATTCTACGCG AACTCGGCGT TGCCCTATGC GAACATCCCA 300 GTGACGTTGC CTTCGGTCGA AGCCATTGCC TGACCGGCTT CGCTGATCGT CCGCGCCAGG 360 TTCTGCAGCG CGTTGTTCAG CTCGGTAGCC GTGGCGTCCC ATTTTTTGCTG GACACCCTGG 420 TACGCCTCCG AA 432 (2) INFORMATION FOR SEC ID. NO .: 114: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 368 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. N0.:11_: Met Leu Trp His Wing Met Pro Pro Glu Xaa Asn Thr Wing Arg Leu Met 1 5 10 15 Wing Gly Wing Gly Pro Wing Pro Met Leu Wing Wing Wing Wing Gly Trp Gln 20 25 30 Thr Leu Ser Wing Wing Leu Asp Ala Gln Ala Val Glu Leu Thr Ala Arg 35 40 45 Leu Asn Ser Leu Gly Glu Wing Trp Thr Gly Gly Gly Ser Asp Lys Wing 50 55 60 Leu Wing Wing Wing Thr Pro Met Val Val Trp Leu Gln Thr Wing Ser Thr 65 70 75 80 Gln Ala Lys Thr Arg Wing Met Gln Wing Thr Wing Gln Wing Wing Wing Tyr 85 90 95 Thr Gln Wing Wing Wing Thr Thr Pro Ser Leu Pro Glu Wing Wing Wing Asn 100 105 110 His He Thr Gln Wing Val Leu Thr Wing Thr Asn Phe Phe Gly He Asn 115 120 125 Thr He Pro He Wing Leu Thr Glu Met Asp Tyr Phe He Arg Met Trp 130 135 140 Asn Gln Wing Wing Leu Wing Met Glu Val Tyr Gln Wing Glu Thr Wing Val 145 150 155 160 Asn Thr Leu Phe Glu Lys Leu Glu Pro Met Wing Ser He Leu Asp Pro 165 170 175 Gly Wing Being Gln Being Thr Thr Asn Pro He Phe Gly Met Pro Being Pro 180 185 190 Gly Ser Ser Thr Pro Val Gly Gln Leu Pro Pro Ala Wing Thr Gln Thr 195 200 205 Leu Gly Gln Leu Gly Glu Met Ser Gly Pro Met Gln Gln Leu Thr Gln 210 215 220 Pro Leu Gln Gln Val Thr Ser Leu Phe Ser Gln Val Gly Gly Thr Gly 225 230 235 240 Gly Gly Asn Pro Wing Asp Glu Glu Wing Wing Gln Met Gly Leu Leu Gly 245 250 255 Thr Ser Pro Leu Ser Asn His Pro Leu Wing Gly Gly Ser Gly Pro Ser 260 265 270 Ala Gly Ala Gly Leu Leu Arg Ala Glu Ser Leu Pro Gly Ala Gly Gly 275 280 285 Ser Leu Thr Arg Thr Pro Leu Met Ser Gln Leu He Glu Lys Pro Val 290 295 300 Pro Wing Ser Val Met Pro Wing Ala Wing Ala Gly Ser Ser Ala Thr Gly 305 310 315 320 Gly Ala Ala Pro Val Gly Ala Gly Ala Met Gly Gln Glly Ala Gln Ser 325 330 335 Gly Gly Ser Thr Arg Pro Gly Leu Val Ala Pro Ala Pro Leu Ala Gln 340 345 350 Glu Arg Glu Glu Asp Asp Glu Asp Asp Trp Asp Glu Glu Asp Asp Trp 355 360 365 (2) INFORMATION FOR SEC ID. NO .. -115: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 100 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 115: Met Wing Glu Met Lys Thr Asp Wing Wing Thr Leu Wing Gln Glu Wing Gly 1 5 10 15 Asn Phe Glu Arg He Ser Gly Asp Leu Lys Thr Gln He Asp Gln Val 20 25 30 Glu Ser Thr Wing Gly Ser Leu Gln Gly Gln Trp Arg Gly Wing Wing Gly 40 45 Thr Ala Ala Gln Ala Ala Val Val Arg Phe Gln Glu Ala Ala Asn Lys 50 55 60 Gln Lys Gln Glu Leu Asp Glu He Ser Thr Asn lie Arg Gln Ala Gly 65 70 75 80 Val Gln Tyr Ser Arg Wing Asp Glu Gln Gln Gln Gln Wing Leu Ser Ser 85 90 95 Gln Met Gly Phe 100 (2) INFORMATION FOR SEC ID. No .: 116: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 396 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xí) SEQUENCE DESCRIPTION: SEC ID. No .: 116: GATCTCCGGC GACCTGAAAA CCCAGATCGA CCAGGTGGAG TCGACGGCAG GTTCGTTGCA 60 GGGCCAGTGG CGCGGCGCGG CGGGGACGGC CGCCCAGGCC GCGGTGGTGC GCTTCCAAGA 120 AGCAGCCAAT AAGCAGAAGC AGGAACTCGA CGAGATCTCG ACGAATATTC GTCAGGCCGG 180 CGTCCAATAC TCGAGGGCCG ACGAGGAGCA GCAGCAGGCG CTGTCCTCGC AAATGGGCTT 240 CTGACCCGCT AATACGAAAA GAAACGGAGC AAAAACATGA CAGAGCAGCA GTGGAATTTC 300 GCGGGTATCG AGGCCGCGGC AAGCGCAATC CAGGGAAATG TCACGTCCAT TCATTCCCTC 360 CTTGACGAGG GGAAGCAGTC CCTGACCAAG CTCGCA 396 (2) INFORMATION FOR SEC ID. No.:117: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 80 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. N? . : 117: He Be Gly Asp Leu Lys Thr Gln He Asp Gln Val Glu Ser Thr Wing 1 5 10 15 Gly Ser Leu Gln Gly Gln Trp Arg Gly Wing Wing Gly Thr Wing Wing Gln 20 25 30 Wing Wing Val Arg Phe Gln Glu Ala Ala Asn Lys Gln Lys Gln Glu 35 40 45 Leu Asp Glu Be Ser Thr Asn He Arg Gln Wing Gly Val Gln Tyr Ser 50 55 60 Arg Wing Asp Glu Gllu Gln Gln Gln Ala Leu Ser Ser Gln Met Gly Phe 65 70 75 80 (2) INFORMATION FOR SEC ID. DO NOT . : 118: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 387 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:118: GTGGATCCCG ATCCCGTGTT TCGCTATTCT ACGCGAACTC GGCGTTGCCC TATGCGAACA 60 TCCCAGTGAC GTTGCCTTCG GTCGAAGCCA TTGCCTGACC GGCTTCGCTG ATCGTCCGCG 120 CCAGGTTCTG CAGCGCGTTG TTCAGCTCGG TAGCCGTGGC GTCCCATTTT TGCTGGACAC 180 CCTGGTACGC CTCCGAACCG CTACCGCCCC AGGCCGCTGC GAGCTTGGTC AGGGACTGCT 240 TCCCCTCGTC AAGGAGGGAA TGAATGGACG TGACATTTCC CTGGATTGCG CTTGCCGCGG 300 CCTCGATACC CGCGAAATTC CACTGCTGCT CTGTCATGTT TTTGCTCCGT TTCTTTTCGT 360 ATTAGCGGGT CAGAAGCCCA TTTGCGA 387 (2) INFORMATION FOR SEC ID. NO .: 119: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 272 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:119: CGGCACGAGG ATCTCGGTTG GCCCAACGGC GCTGGCGAGG GCTCCGTTCC GGGGGCGAGC 60 TGCGCGCCGG ATGCTTCCTC TGCCCGCAGC CGCGCCTGGA TGGATGGACC AGTTGCTACC 120 TTCCCGACGT TTCGTTCGGT GTCTGTGCGA TAGCGGTGAC CCCGGCGCGC ACGTCGGGAG 180 TGTTGGGGGG CAGGCCGGGT CGGTGGTTCG GCCGGGGACG CAGACGGTCT GGACGGAACG 240 GGCGGGGGTT CGCCGATTGG CATCTTTGCC CA 272 (2) INFORMATION FOR SEQ ID. NO.:120: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 120: Asp Pro Val Asp Ala Val He Asn Thr Thr Cys Asn Tyr Gly Gln Val 1 5 10 15 Val Ala Ala Leu 20 (2) INFORMATION FOR SEC ID. DO NOT . : 121: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. NO.:121: Wing Val Glu Ser Gly Met Leu Wing Leu Gly Thr Pro Wing Pro Ser 1 5 10 15 (2) INFORMATION FOR SEC ID. NO.:122: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 122: Ala Wing Met Lys Pro Arg Thr Gly Asp Gly Pro Leu Glu Ala Wing Lys 1 5 10 15 Glu Gly Arg (2) INFORMATION FOR SEC ID. NO.:123: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. NO.:123: Tyr Tyr Trp Cys Pro Gly Gln Pro Phe Asp Pro Wing Trp Gly Pro 1 5 10 15 (2) INFORMATION FOR SEC ID. NO.:124: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. NO .: 124: Asp lie Gly Ser Glu Ser Thr Glu Asp Gln Gln Xaa Ala Val 1 5 10 (2) INFORMATION FOR SEC ID. NO.:125: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. NO.:125: Wing Glu Glu Ser lie Thr Xaa Glu Xaa lie Val Pro 1 5 10 (2) INFORMATION FOR SEC ID. NO.:126: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. NO.:126: Asp Pro Glu Pro Wing Pro Pro Val Pro Thr Thr Wing Wing Pro Pro Pro 1 5 10 15 Ser (2) INFORMATION FOR SEC ID. NO .: 127: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. NO .: 127: Ala Pro Lys Thr Tyr Xaa Glu Glu Leu Lys Gly Thr Asp Thr Gly 1 5 10 15 (2) INFORMATION FOR SEC ID. NO.:128: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 128: Asp Pro Wing Wing Pro Asp Val Pro Thr Ala Wing Gln Leu Thr Ser 1 5 10 15 Leu Leu Asn Ser Leu Wing Asp Pro Asn Val Ser Phe Wing Asn 20 25 30 (2) INFORMATION FOR SEC ID. DO NOT. : 129: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 129: Psp Pro Pro Asp Pro His Gln Xaa Asp Met Thr Lys Gly Tyr Tyr Pro 1 5 10 15 Gly Gly Arg Arg Xaa Phe 20 (2) INFORMATION FOR SEC ID. DO NOT. : 130: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 130: Asp Pro Gly Tyr Thr Pro Gly 1 5 (2) INFORMATION FOR SEC ID. DO NOT. : 131: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (ix) CHARACTERISTICS: (D) OTHER INFORMATION: / note = "The Second Residue can be either Pro or Thr" (xi) SEQUENCE DESCRIPTION: SEC ID. NO .: 131: Xaa Xaa Gly Phe Thr Gly Pro Gln Phe Tyr 1 5 10 (2) INFORMATION FOR SEC ID. NO.:132: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (ix) CHARACTERISTICS: (D) OTHER INFORMATION: / note = "The Third Residue can be either Gln or Leu" (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:132: Xaa Pro Xaa Val Thr Ala Tyr Ala Gly 1 5 (2) INFORMATION FOR SEQ. ID NO: 133: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) HEBRA: D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. NO.:133: Xaa Xaa Xaa Glu Lys Pro Phe Leu Arg 1 5 (2) INFORMATION FOR SEC ID. NO.:134: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. N0.:134: Xaa Asp Ser Glu Lys Ser Wing Thr lie Lys Val Thr Asp Wing Ser 1 5 10 15 (2) INFORMATION FOR SEC ID. NO .: 135: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. NO.:135: Wing Gly Asp Thr Xaa lie Tyr lie Val Gly Asn Leu Thr Wing Asp 1 5 10 15 (2) INFORMATION FOR SEC ID. NO.:136: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:136: Pro Glu Wing Ser Gly Wing Gly Leu Gly Gly Thr Val Gln Wing Gly 1 5 10 15 (2) INFORMATION FOR SEC ID. DO NOT. : 137: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 137: Xaa Tyr He Ala Tyr Xaa Thr Thr Ala Gly He Val Pro Gly Lys He 1 5 10 15 Asn Val His Leu Val 20 (2) INFORMATION FOR SEC ID. NO .: 138: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 882 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear MOLECULE TYPE: DNA (genomic) (xi) DESCRIPTION OF SEQUENCE: SEC ID. NO.:138: GCAACGCTGT CGTGGCCTTT GCGGTGATCG GTTTCGCCTC GCTGGCGGTG GCGGTGGCGG 60 TCACCATCCG ACCGACCGCG GCCTCAAAAC CGGTAGAGGG ACACCAAAAC GCCCAGCCAG 120 GGAAGTTCAT GCCGTTGTTG CCGACGCAAC AGCAGGCGCC GGTCCCGCCG CCTCCGCCCG 180 ATGATCCCAC CGCTGGATTC CAGGGCGGCA CCATTCCGGC TGTACAGAAC GTGGTGCCGC 240 GGCCGGGTAC CTCACCCGGG GTGGGTGGGA CGCCGGCTTC GCCTGCGCCG GAAGCGCCGG 300 CCGTGCCCGG TGTTGTGCCT GCCCCGGTGC CAATCCCGGT CCCGATCATC ATTCCCCCGT 360 TCCCGGGTTG GCAGCCTGGA ATGCCGACCA TCCCCACCGC ACCGCCGACG ACGCCGGTGA 420 CCACGTCGGC GACGACGCCG CCGACCACGC CGCCGACCAC GCCGGTGACC ACGCCGCCAA 480 CGACGCCGCC GACCACGCCG GTGACCACGC CGCCAACGAC GCCGCCGACC ACGCCGGTGA 540 CCACGCCACC AACGACCGTC GCCCCGACGA CCGTCGCCCC GACGACGGTC GCTCCGACCA 600 CCGTCGCCCC GACCACGGTC GCTCCAGCCA CCGCCACGCC GACGACCGTC GCTCCGCAGC 660 CGACGCAGCA GCCCACGCAA CAACCAACCC AACAGATGCC AACCCAGCAG CAGACCGTGG 720 CCCCGCAGAC GGTGGCGCCG GCTCCGCAGC CGCCGTCCGG TGGCCGCAAC GGCAGCGGCG 780 GGGGCGACTT ATTCGGCGGG TTCTGATCAC GGTCGCGGCT TCACTACGGT CGGAGGACAT 840 GGCCGGTGAT G CGGTGACGG TGGTGCTGCC CTGTCTCAAC GA 882 (2) INFORMATION FOR SEC ID. NO.:139: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 815 base pairs (B) TYPE: nucleic acid (C) HEBRA: Simple (D) TOPOLOGY: linear MOLECULE TYPE: DNA (genomic) (xi) DESCRIPTION OF SEQUENCE: SEC ID. NO.:139: CCATCAACCA ACCGCTCGCG CCGCCCGCGC CGCCGGATCC GCCGTCGCCG CCACGCCCGC 60 CGGTGCCTCC GGTGCCCCCG TTGCCGCCGT CGCCGCCGTC GCCGCCGACC GGCTGGGTGC 120 CTAGGGCGCT GTTACCGCCC TGGTTGGCGG GGACGCCGCC GGCACCACCG GTACCGCCGA 180 TGGCGCCGTT GCCGCCGGCG GCACCGTTGC CACCGTTGCC ACCGTTGCCA CCGTTGCCGA 240 CCAGCCACCC GCCGCGACCA CCGGCACCGC CGGCGCCGCC CGCACCGCCG GCGTGCCCGT 300 TCGTGCCCGT ACCGCCGGCA CCGCCGTTGC CGCCGTCACC GCCGACGGAA CTACCGGCGG 360 ACGCGGCCTG CCCGCCGGCG CCGCCCGCAC CGCCATTGGC ACCGCCGTCA CCGCCGGCTG 420 GGAGTGCCGC GATTAGGGCA CTGACCGGCG CAACCAGCGC AAGTACTCTC GGTCACCGAG 480 CACTTCCAGA CGACACCACA GCACGGGGTT GTCGGCGGAC TGGGTGAAAT GGCAGCCGAT 540 AGCGGCTAGC TGTCGGCTGC GGTCAACCTC GATCATGATG TCGAGGTGAC CGTGACCGCG 600 CCCCCCGAAG GAGGCGCTGA ACTCGGCGTT GAGCCGATCG GCGATCGGTT GGGGCAGTGC 660 CCAGGCCAAT ACGGGGATAC CGGGTGTCNA AGCCGCCGCG AGCGCAGCTT CGGTTGCGCG 720 ACNGTGGTCG GGGTGGCCTG TTACGCCGTT GTCNTCGAAC ACGAGTAGCA GGTCTGCTCC 780 GGCGAGGGCA TCCACCACGC GTTGCGTCAG CTCGT 815 (2) INFORMATION FOR SEC ID. NO .: 140: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1152 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear MOLECULE TYPE: DNA (genomic) (xi) DESCRIPTION OF SEQUENCE: SEC ID. NO.:140: ACCAGCCGCC GGCTGAGGTC TCAGATCAGA GAGTCTCCGG ACTCACCGGG GCGGTTCAGC 60 CTTCTCCCAG AACAACTGCT GAAGATCCTC GCCCGCGAAA CAGGCGCTGA TTTGACGCTC 120 TATGACCGGT TGAACGACGA GATCATCCGG CAGATTGATA TGGCACCGCT GGGCTAACAG 180 GTGCGCAAGA TGGTGCAGCT GTATGTCTCG GACTCCGTGT CGCGGATCAG CTTTGCCGAC 240 GGCCGGGTGA TCGTGTGGAG CGAGGAGCTC GGCGAGAGCC AGTATCCGAT CGAGACGCTG 300 GACGGCATCA CGCTGTTTGG GCGGCCGACG ATGACAACGC CCTTCATCGT TGAGATGCTC 360 AAGCGTGAGC GCGACATCCA GCTCTTCACG ACCGACGGCC ACTACCAGGG CCGGATCTCA 420 ACACCCGACG TGTCATACGC GCCGCGGCTC CGTCAGCAAG TTCACCGCAC CGACGATCCT 480 GCGTTCTGCC TGTCGTTAAG CAAGCGGATC GTGTCGAGGA AGATCCTGAA TCAGCAGGCC 540 TTGATTCGGG CACACACGTC GGGGCAAGAC GTTGCTGAGA GCATCCGCAC GATGAAGCAC 600 TCGCTGGCCT GGGTCGATCG ATCGGGCTCC CTGGCGGAGT TGAACGGGTT CGAGGGAAAT 660 GCCGCAAAGG CATACTTCAC CGCGCTGGGG CATCTCGTCC CGCAGGAGTT CGCATTCCAG 720 GGCCGCTCGA CTCGGCCGCC GTTGGACGCC TTCAACTCGA TGGTCAGCCT CGGCTATTCG 780 CTGCTGTACA AGAACATCAT AGGGGCGATC GAGCGTCACA GCCTGAACGC GTATATCGGT 840 TTCCTACACC AGGATTCACG AGGGCACGCA ACGTCTCGTG CCGAATTCGG CACGAGCTCC 900 GCTGAAACCG CTGGCCGGCT GCTCAGTGCC CGTACGTAAT CCGCTGCGCC CAGGCCGGCC 960 CGCCGGCCGA ATACCAGCAG ATCGGACAGC GAATTGCCGC CCAGCCGGTT GGAGCCGTGC 1020 ATACCGCCGG CACACTCACC GGCAGCGAAC AGGCCTGGCA CCGTGGCGGC GCCGGTGTCC 1080 GCGTCTACTT CGACACCGCC CATCACGTAG TGACACGTCG GCCCGACTTC CATTGCCTGC 1140 GTTCGGCACG AG 1152 (2) INFORMATION FOR SEC ID. NO .: 141: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 655 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( xi) SEQUENCE DESCRIPTION: SEC ID. No.-141: CTCGTGCCGA TTCGGCAGGG TGTACTTGCC GGTGGTGTAN GCCGCATGAG TGCCGACGAC 60 CAGCAATGCG GCAACAGCAC GGATCCCGGT CAACGACGCC ACCCGGTCCA CGTGGGCGAT 120 CCGCTCGAGT CCGCCCTGGG CGGCTCTTTC CTTGGGCAGG GTCATCCGAC GTGTTTCCGC 180 CGTGGTTTGC CGCCATTATG CCGGCGCGCC GCGTCGGGCG GCCGGTATGG CCGAANGTCG 240 ATCAGCACAC CCGAGATACG GGTCTGTGCA AGCTTTTTGA GCGTCGCGCG GGGCAGCTTC 300 GCCGGCAATT CTACTAGCGA GAAGTCTGGC CCGATACGGA TCTGACCGAA GTCGCTGCGG 360 TGCAGCCCAC CCTCATTGGC GATGGCGCCG ACGATGGCGC CTGGACCGAT CTTGTGCCGC 420 TTGCCGACGG CGACGCGGTA GGTGGTCAAG TCCGGTCTAC GCTTGGGCCT TTGCGGACGG 480 TCCCGACGCT GGTCGCGGTT GCGCCGCGAA AGCGGCGGGT CGGGTGCCAT CAGGAATGCC 540 TCACCGCCGC GGCACTGCAC GGCCAGTGCC GCGGCGATGT CAGCCATCGG GACATCATGC 600 TCGCGTTCAT ACTCCTCGAC CAGTCGGCGG AACAGCTCGA TTCCCGGACC GCCCA 655 (2) INFORMATION FOR SEC ID. NO .: 142: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 267 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) MOLECULA TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 142: Asn Ala Val Val Ala Phe Ala Val He Gly Phe Ala Ser Leu Ala Val 1 5 10 15 Wing Val Wing Val Thr He Arg Pro Thr Wing Wing Ser Lys Pro Val Glu 20 25 30 Gly His Gln Asn Wing Gln Pro Gly Lys Phe Met Pro Leu Leu Pro Thr 35 40 45 Gln Gln Gin Wing Pro Val Pro Pro Pro Pro Asp Asp Pro Thr Ala 50 55 60 Gly Phe Gln Gly Gly Thr He Pro Wing Val Gln Asn Val Val Pro Arg 65 70 75 80 Pro Gly Thr Ser Pro Gly Val Gly Gly Thr Pro Wing Ser Pro Wing Pro 85 90 95 Glu Ala Pro Wing Val Pro Gly Val Val Pro Wing Pro Val Pro Pro 100 105 110 Val Pro He He Pro Pro Pro Ghe Pro Gly Pro Gln Pro Met Pro 115 120 125 Thr Pro Pro Pro Wing Pro Thr Thr Pro Val Thr Thr Ser Ala Thr 130 135 140 Thr Pro Pro Thr Thr Pro Pro Thr Thr Pro Val Thr Thr Pro Pro Thr 145 150 155 160 Thr Pro Pro Thr Thr Pro Thr Pro Pro Thr Thr Thr Pro Pro Thr 165 170 175 Thr Pro Val Thr Thr Thr Pro Pro Thr Thr Val Pro Thr Thr Thr Val Wing 180 185 190 Pro Thr Thr Val Wing Pro Thr Thr Val Wing Pro Thr Thr Val Wing Pro 195 200 205 Wing Thr Wing Thr Pro Thr Thr Val Wing Pro Pro Gln Pro Thr Gln Gln Pro 210 215 220 Thr Gln Gln Pro Thr Gln Gln Met Pro Thr Gln Gln Gln Thr Val Wing 225 230 235 240Pro Gln Thr Val Wing Pro Wing Pro Gln Pro Pro Ser Gly Gly Arg Asn 245 250 255 Gly Ser Gly Gly Gly Asp Leu Phe Gly Gly Phe 260 265 (2) INFORMATION FOR SEC ID. DO NOT. : 143: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 174 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 143: He Asn Gln Pro Leu Ala Pro Pro Pro Pro Pro Asp Pro Pro Ser Pro 1 5 10 15 Pro Pro Pro Pro Val Pro Pro Val Pro Pro Pro Pro Ser Pro Pro 20 25 30 Pro Pro Pro Pro Val Pro Arg Ala Leu Leu Pro Pro Pro Tr Tr Leu 40 45 Wing Gly Thr Pro Pro Wing Pro Pro Val Pro Pro Met Wing Pro Leu Pro 50 55 60 Pro Pro Wing Pro Leu Pro Pro Pro Pro Leu Leu Pro Pro Leu Pro Thr 65 70 75 80 Be His Pro Pro Arg Pro Pro Pro Pro Wing Pro Pro Pro 85 Pro Wing 85 95 95 Wing Cys Pro Phe Val Pro Wing Pro Pro Wing Pro Pro Pro 100 100 110 110 Pro Pro Thr Glu Leu Pro Wing Asp Ala Wing Cys Pro Pro Wing Pro Pro 115 120 125 Wing Pro Pro Leu Wing Pro Pro Pro Pro Wing Gly Be Ala Ala He 130 135 140 Arg Ala Leu Thr Gly Ala Thr Ser Ala Ser Thr Leu Gly His Arg Ala 145 150 155 160 Leu Pro Asp Asp Thr Thr Wing Arg Gly Cys Arg Arg Thr Gly 165 170 (2) INFORMATION FOR SEC ID. NO.:144: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (i i) MOLECULE TYPE: peptide gone (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 144: Gln Pro Pro Wing Glu Val Ser Asp Gln Arg Val Ser Gly Leu Thr Gly 1 5 10 15 Wing Val Gln Pro Ser Pro Arg Thr Thr Wing Glu Asp Pro Arg Pro Arg 25 30 Asn Arg Arg 35 (2) INFORMATION FOR SEC ID. NO.:145: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 104 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) TYPE MOLECULE: peptide 10 (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 145: Arg Ala Asp Ser Wing Gly Cys Thr Cys Arg Trp Cys Xaa Pro His Glu 1 5 10 15 Cys Arg Arg Pro Wing Met Arg Gln Gln Hxs Gly Ser Arg Ser Thr Thr 20 25 30 Pro Pro Gly Pro Arg Gly Arg Be Wing Arg Val Arg Pro Gly Arg Leu 35 40 45 Phe Pro Trp Wing Gly Ser Ser Asp Val Phe Pro Pro Trp Phe Wing Ala 50 55 60 20 lie Met Pro Ala Arg Arg Val Gly Arg Pro Val Trp Pro Xaa Val Asp 65 70 75 80 Gln His Thr Arg Asp Thr Gly Leu Cys Lys Leu Phe Glu Arg Arg Wing 85 90 95 Gly Gln Leu Arg Arg Gln Phe Tyr 25 100 (2) INFORMATION FOR SEC ID. NO.:146 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 53 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) MOLECULA TYPE: other nucleic acid (A) DESCRIPTION: / desc = "PCR primer" (vi) ORIGINAL SOURCE: (A) ORGANISM: Mycobacterium tuberculosis (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:146: GGATCCATAT GGGCCATCAT CATCATCATC ACGTGATCGA CATCATCGGG ACC 53 (2) INFORMATION FOR SEC ID. NO.:147: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) TYPE MOLECULES: other nucleic acids (A) ) DESCRIPTION: / desc = "PCR primer" (vi) ORIGINAL SOURCE: (A) ORGANISM: Mycobacterium tuberculosis (xí) SEQUENCE DESCRIPTION: SEC ID. NO.:147: CCTGAATTCA GGCCTCGGTT GCGCCGGCCT CATCTTGAAC GA 42 (2) INFORMATION FOR SEC ID. NO .: 148 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) MOLECULA TYPE: other nucleic acid (A) DESCRIPTION: / desc = "PCR primer" (vi) ORIGINAL SOURCE: (A) ORGANISM: Mycobacterium tuberculosis (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:148 GGATCCTGCA GGCTCGAAAC CACCGAGCGG T 31 (2) INFORMATION FOR SEC ID. NO.:149 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) MOLECULA TYPE: other nucleic acid (A) DESCRIPTION: / desc = "PCR primer" (vi) ORIGINAL SOURCE: (A) ORGANISM: Mycobacterium tuberculosis (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:149 CTCTGAATTC AGCGCTGGAA ATCGTCGCGA T 31 (2) INFORMATION FOR SEC ID. NO.:150 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: / desc = "PCR primer" (vi) ORIGINAL SOURCE: (A) ORGANISM: Mycobacterium tuberculosis (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:150 GGATCCAGCG CTGAGATGAA GACCGATGCC GCT 33 (2) INFORMATION FOR SEC ID. NO .: 151 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) MOLECULA TYPE: other nucleic acid (A) DESCRIPTION: / desc = "PCR primer" (vi) ORIGINAL SOURCE: (A) ORGANISM: Mycobacterium tuberculosis (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:151 GAGAGAATTC TCAGAAGCCC ATTTGCGAGG ACA 33 (2) INFORMATION FOR SEC ID. NO.:152: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1993 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (ii) MOLECULA TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Mycobacterium tuberculosis (ix) FEATURE: (A) NAME / KEY: CDS (B) LOCATION: 152..1273 (xi) SEQUENCE DESCRITION: SEC ID. DO NOT . 152: TGTTCTTCGA CGGCAGGCTG GTGGAGGAAG GGCCCACCGA ACAGCTGTTC TCCTCGCCGA 60 AGCATGCGGA AACCGCCCGA TACGTCGCCG GACTGTCGGG GGACGTCAAG GACGCCAAGC 120 GCGGAAATTG AAGAGCACAG AAAGGTATGG C GTG AAA ATT CGT TTG CAT ACG 172 Val Lys He Arg Leu His Thr 1 May CTG TTG GCC GTG TTG ACC GCT GCG GCC CTG CTG CTA GCA GCG GCG GGC 220 Leu Leu Ala Val Leu Thr Ala Ala Pro Leu Leu Leu Ala Ala Ala Gly 10 15 20 TGT GGC TCG AAA CCA CCG AGC GGT TCG CCT GAA ACG GGC GCC GGC GCC 268 Cys Gly Ser Lys Pro Pro Ser Gly Ser Pro Glu Thr Gly Wing Gly Wing 25 30 35 GGT ACT GTC GCG ACT ACC CCC GCG TCG TCG CCG GTG ACG TTG GCG GAG 316 Gly Thr Val Wing Thr Thr Pro Wing Ser Ser Pro Val Thr Leu Wing Glu 40 45 50 55 ACC GGT AGC ACG CTG CTC TAC CCG CTG TTC AAC CTG TGG GGT CCG GCC 364 Thr Gly Ser Thr Leu Leu Tyr Pro Leu Phe Asn Leu Trp Gly Pro Wing 60 65 70 TTT CAC GAG AGG TAT CCG AAC GTC ACG ATC ACC GCT CAG GGC ACC GGT 412 Phe His Glu Arg Tyr Pro Asn Val Thr He Thr Wing Gln Gly Thr Gly 75 80 85 TCT GGT GCC GGG ATC GCG CAG GCC GCC G CC GGG ACG GTC AAC ATT GGG 460 Ser Gly Wing Gly Wing Wing Gln Wing Wing Wing Gly Thr Val Asn He Gly 90 95 100 GCC TCC GAC TCC CTG CTG GAA GGT GAT ATG GCC GCG CAC AAG GGG 508 Wing Ser Asp Wing Tyr Leu Ser Glu Gly Asp Met Ala Ala His Lys Gly 105 110 115 CTG ATG AAC ATC GCG CTA GCC ATC TCC GCT CAG CAG GTC AAC TAC AAC 556 Leu Met Asn He Ala Leu Ala Wing Gln Gln Val Asn Tyr Asn 120 125 130 135 CTG CCC GGA GTG AGC GAG CAC CTC AAG CTG AAC GGA AAA GTC CTG GCG 604 Leu Pro Gly Val Ser Glu His Leu Lys Leu Asn Gly Lys Val Leu Wing 140 145 150 GCC ATG TAC CAG GGC ACC ATC AAA ACC TGG GAC GAC CCG CAG ATC GCT 652 Wing Met Tyr Gln Gly Thr He Lys Thr Trp Asp Asp Pro Gln He Wing 155 160 165 GCG CTC AAC CCC GGC GTG AAC CTG CCC GGC ACC GCG GTA GTT CCG CTG 700 Wing Leu Asn Pro Gly Val Asn Leu Pro Gly Thr Wing Val Val Pro Leu 170 175 180 CAC CGC TCC GAC GGG TCC GGT GAC ACC TTC TTG TTC ACC CAG TAC CTG 748 His Arg Ser Asp Gly Ser Gly Asp Thr Phe Leu Phe Thr Gln Tyr Leu 185 190 195 TCC AAG CAA GAT CCC GAG GGC TGG GGC AAG TCG CCC GGC TTC GGC ACC 796 Ser Lys Gln Asp Pro Glu Gly Trp Gly Lys Ser Pro Gly Phe Gly Thr 200 205 210 215 ACC GTC GAC TTC CCG GCG GTG CCG GGT GCG CTG GGT GAG AAC GGC AAC 844 Thr Val Asp Phe Pro Wing Val Pro Gly Wing Leu Gly Glu Asn Gly Asn 220 225 230 GGC GGC ATG GTG ACC GGT TGC GCC GAG ACA CCG GGC TGC GTG GCC TAT 892 Gly Gly Met Val Thr Gly Cys Wing Glu Thr Pro Gly Cys Val Wing Tyr 235 240 245 ATC GGC ATC AGC TTC CTC GAC CAG GCC AGT CAA CGG GGA CTC GGC GAG 940 He Gly He Ser Phe Leu Asp Gln Wing Gln Arg Gly Leu Gly Glu 250 255 260 GCC CAA CTA GGC AAT AGC TCT GGC AAT TTC TTG TTG CCC GAC GCG CAA 988 Wing Gln Leu Gly Asn Ser Ser Gly Asn Phe Leu Leu Pro Asp Wing Gln 265 270 275 AGC ATT CAG GCC GCG GCT GGC TTC GCA TCG AAA ACC CCG GCG AAC 1036 Ser He Gln Wing Wing Wing Wing Gly Phe Wing Ser Lys Thr Pro Wing Asn 280 285 290 295 CAG GCG ATT TCG ATG ATC GAC GGG CCC GCC CCG GAC GGC TAC CCG ATC 1084 Gln Wing He Ser Met He Asp Gly Pro Wing Pro Asp Gly Tyr Pro He 300 305 310 ATC AAC TAC GAG TAC GCC ATC GTC AAC AAC CGAC CAA AAG GAC GCC GCC 1132 He Asn Tyr Glu Tyr Wing Hen Val Asn Asn Arg Gln Lys Asp Wing Wing 315 320 325 ACC GCG CAG ACC TTG CAG GCA TTT CTG CAC TGG GCG ATC ACC GAC GGC 1180 Thr Wing Gln Thr Leu Gln Wing Phe Leu His Trp Wing He Thr Asp Gly 330 335 340 AAC AAG GCC TCG TTC CTC GAC CAG GTT CAT TTC CAG CCG CTG CCG CCC 1228 Asn Lys Ala Ser Phe Leu Asp Gln Val His Phe Gln Pro Leu Pro Pro 345 350 355 GCG GTG GTG AAG TTG TCT GAC GCG TTG ATC GCG ACG ATT TCC AGC 1273 Wing Val Val Lys Leu Ser Asp Wing Leu He Wing Thr He Ser Ser 360 365 370 TAGCCTCGTT GACCACCACG CGACAGCAAC CTCCGTCGGG CCATCGGGCT GCTTTGCGGA 1333 GCATGCTGGC CCGTGCCG GT GAAGTCGGCC GCGCTGGCCC GGCCATCCGG TGGTTGGGTG 1393 GGATAGGTGC GGTGATCCCG CTGCTTGCGC TGGTCTTGGT GCTGGTGGTG CTGGTCATCG 1453 AGGCGATGGG TGCGATCAGG CTCAACGGGT TGCATTTCTT CACCGCCACC GAATGGAATC 1513 CAGGCAACAC CTACGGCGAA ACCGTTGTCA CCGACGCGTC GCCCATCCGG TCGGCGCCTA 1573 CTACGGGGCG TTGCCGCTGA TCGTCGGGAC GCTGGCGACC TCGGCAATCG CCCTGATCAT 1633 CGCGIGTGCCG GTCTCTGTAG GAGCGGCGCT GGTGATCGTG GAACGGCTGC CGAAACGGTT 1693 GGCCGAGGCT GTGGGAATAG TCCTGGAATT GCTCGCCGGA ATCCCCAGCG TGGTCGTCGG 1753 TTTGTGGGGG GCAATGACGT TCGGGCCGTT CATCGCTCAT CACATCGCTC CGGTGATCGC 1813 TCACAACGCT CCCGATGTGC CGGTGCTGAA CTACTTGCGC GGCGACCCGG GCAACGGGGA 1873 GGGCATGTTG GTGTCCGGTC TGGTGTTGGC GGTGATGGTC GTTCCCATTA TCGCCACCAC 1933 CACTCATGAC CTGTTCCGGC AGGTGCCGGT GTTGCCCCGG GAGGGCGCGA TCGGGAATTC 1993 (2) INFORMATION FOR SEC ID. NO.:153: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 374 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULA TYPE: protein (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 153: Val Lys He Arg Leu His Thr Leu Leu Wing Val Leu Thr Ala Wing Pro 1 5 10 15 Leu Leu Leu Wing Wing Wing Gly Cys Gly Ser Lys Pro Pro Ser Gly Ser 20 25 30 Pro Glu Thr Gly Wing Gly Wing Gly Thr Val Wing Thr Thr Pro Wing Ser 35 40 45 Ser Pro Val Thr Leu Wing Glu Thr Gly Ser Thr Leu Leu Tyr Pro Leu 50 55 60 Phe Asn Leu Trp Gly Pro Wing Phe His Glu Arg Tyr Pro Asn Val Thr 65 70 75 80 He Thr Wing Gln Gly Thr Gly Ser Gly Wing Gly He Wing Gln Wing Wing 85 90 95 Wing Gly Thr Val Asn He Gly Wing Ser Asp Wing Tyr Leu Ser Glu Gly 100 105 110 Asp Met Ala Ala His Lys Gly Leu Met Asn He Ala Ala Leu Ala He Ser 115 120 125 Ala Gln Gln Val Asn Tyr Asn Leu Pro Gly Val Ser Glu His Leu Lys 130 135 140 Leu Asn Gly Lys Val Leu Wing Ala Met Tyr Gln Gly Thr He Lys Thr 145 150 155 160 Trp Asp Asp Pro Gln He Ala Wing Leu Asn Pro Gly Val Asn Leu Pro 165 170 175 Gly Thr Ala Val Val Pro Leu His Arg Ser Asp Gly Ser Gly Asp Thr 180 185 190 Phe Leu Phe Thr Gln Tyr Leu Ser Lys Gln Asp Pro Glu Gly Trp Gly 195 200 205 Lys Ser Pro Gly Phe Gly Thr Thr Val Asp Phe Pro Wing Val Pro Gly 210 215 220 Wing Leu Gly Glu Asn Gly Asn Gly Gly Met Val Thr Gly Cys Ala Glu 225 230 235 240 Thr Pro Gly Cys Val Wing Tyr He Gly He Being Phe Leu Asp Gln Wing 245 250 255 Being Gln Arg Gly Leu Gly Glu Wing Gln Leu Gly Asn Being Ser Gly Asn 260 265 270 Phe Leu Leu Pro Asp Wing Gln Ser He Gln Wing Wing Wing Wing Gly Phe 275 280 285 Wing Ser Lys Thr Pro Wing Asn Gln Wing He Ser Met He Asp Gly Pro 290 295 300 Wing Pro Asp Gly Tyr Pro He He Asn Tyr Glu Tyr Wing He Val Asn 305 310 315 320 Asn Arg Gln Lys Asp Ala Ala Thr Ala Gln Thr Leu Gln Ala Phe Leu 325 330 335 His Trp Wing He Thr Asp Gly Asn Lys Wing Being Phe Leu Asp Gln Val 340 345 350 His Phe Gln Pro Leu Pro Pro Wing Val Val Lys Leu Ser Asp Ala Leu 355 360 365 He Ala Thr He Ser Ser 370 (2) INFORMATION FOR SEC ID. NO.:154 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1993 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. N0.:154: TGTTCTTCGA CGGCAGGCTG GTGGAGGAAG GGCCCACCGA ACAGCTGTTC TCCTCGCCGA 60 AGCATGCGGA AACCGCCCGA TACGTCGCCG GACTGTCGGG GGACGTCAAG GACGCCAAGC 120 GCGGAAATTG AAGAGCACAG AAAGGTATGG CGTGAAAATT CGTTTGCATA CGCTGTTGGC 180 CGTGTTGACC GCTGCGCCGC TGCTGCTAGC AGCGGCGGGC TGTGGCTCGA AACCACCGAG 240 CGGTTCGCCT GAAACGGGCG CCGGCGCCGG TACTGTCGCG ACTACCCCCG CGTCGTCGCC 300 GGTGACGTTG GCGGAGACCG GTAGCACGCT GCTCTACCCG CTGTTCAACC TGTGGGGTCC 360 GGCCTTTCAC GAGAGGTATC CGAACGTCAC GATCACCGCT CAGGGCACCG GTTCTGGTGC 420 CGGGATCGCG CAGGCCGCCG CCGGGACGGT CAACATTGGG GCCTCCGACG CCTATCTGTC 480 GGAAGGTGAT ATGGCCGCGC ACAAGGGGCT GATGAACATC GCGCTAGCCA TCTCCGCTCA 540 GCAGGTCAAC TACAACCTGC CCGGAGTGAG CGAGCACCTC AAGCTGAACG GAAAAGTCCT 600 GGCGGCCATG TACCAGGGCA CCATCAAAAC CTGGGACGAC CCGCAGATCG CTGCGCTCAA 660 CCCCGGCGTG AACCTGCCCG GCACCGCGGT AGTTCCGCTG CACCGCTCCG ACGGGTCCGG 720 TGACACCTTC TTGTTCACCC AGTACCTGTC CAAGCAAGAT CCCGAGGGCT GGGGCAAGTC 780 GCCCGGCTTC GGCACCACCG TCGACTTCCC GGCGGTGCCG GGTGCGCTGG GTGAGAACGG 840 CAACGGCGGC ATGGTGACCG GTTGCGCCGA GACACCGGGC TGCGTGGCCT ATATCGGCAT 900 CAGCTTCCTC GACCAGGCC A GTCAACGGGG ACTCGGCGAG GCCCAACTAG GCAATAGCTC 960 TGGCAATTTC TTGTTGCCCG ACGCGCAAAG CATTCAGGCC GCGGCGGCTG GCTTCGCATC 1020 GAAAACCCCG GCGAACCAGG CGATTTCGAT GATCGACGGG CCCGCCCCGG ACGGCTACCC 1080 GATCATCAAC TACGAGTACG CCATCGTCAA CAACCGGCAA AAGGACGCCG CCACCGCGCA 1140 GACCTTGCAG GCATTTCTGC ACTGGGCGAT CACCGACGGC AACAAGGCCT CGTTCCTCGA 1200 CCAGGTTCAT TTCCAGCCGC TGCCGCCCGC GGTGGTGAAG TTGTCTGACG CGTTGATCGC 1260 GACGATTTCC AGCTAGCCTC GTTGACCACC ACGCGACAGC AACCTCCGTC GGGCCATCGG 1320 GCTGCTTTGC GGAGCATGCT GGCCCGTGCC GGTGAAGTCG GCCGCGCTGG CCCGGCCATC 1380 CGGTGGTTGG GTGGGATAGG TGCGGTGATC CCGCTGCTTG CGCTGGTCTT GGTGCTGGTG 1440 GTGCTGGTCA TCGAGGCGAT GGGTGCGATC AGGCTCAACG GGTTGCATTT CTTCACCGCC 1500 ACCGAATGGA ATCCAGGCAA CACCTACGGC GAAACCGTTG TCACCGACGC GTCGCCCATC 1560 CGGTCGGCGC CTACTACGGG GCGTTGCCGC TGATCGTCGG GACGCTGGCG ACCTCGGCAA 1620 TCGCCCTGAT CATCGCGGTG CCGGTCTCTG TAGGAGCGGC GCTGGTGATC GTGGAACGGC 1680 TGCCGAAACG GTTGGCCGAG GCTGTGGGAA TAGTCCTGGA ATTGCTCGCC GGAATCCCCA 1740 GCGTGGTCGT CGGTTTGTGG GGGGCAATGA CGTTCGGGCC GTTCATCGCT CATCACATCG 1800 CTCCGGTGAT CGCTCACAAC GCTCCCGATG TGCCGGTGCT GAACTACTTG CGCGGCGACC 1860 CGGGCAACGG GGAGGGCATG TTGGTGTCCG GTCTGGTGTT GGCGGTGATG GTCGTTCCCA 1920 TTATCGCCAC CACCACTCAT GACCTGTTCC GGCAGGTGCC GGTGTTGCCC CGGGAGGGCG 1980 CGATCGGGAA TTC 1993 (2) INFORMATION FOR SEC ID. NO .: 155: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 374 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 155: Met Lys He Arg Leu His Thr Leu Leu Ala Val Leu Thr Wing Ala Pro 1 5 10 15 Leu Leu Leu Wing Wing Wing Gly Cys Gly Ser Lys Pro Pro Ser Gly Ser 20 25 30 Pro Glu Thr Gly Wing Gly Wing Gly Thr Val Ala Thr Thr Pro Ala Ser 40 45 Ser Pro Val Thr Leu Ala Glu Thr Gly Ser Thr Leu Leu Tyr Pro Leu 50 55 60 Phe Asn Leu Trp Gly Pro Wing Phe His Glu Arg Tyr Pro Asn Val Thr 65 70 75 80 He Thr Wing Gln Gly Thr Gly Ser Gly Wing Gly He Wing Gln Wing Wing 85 90 95 Wing Gly Thr Val Asn He Gly Wing Being Asp Wing Tyr Leu Being Glu Gly 100 105 110 Asp Met Wing Wing His Lys Gly Leu Met Asn He Wing Wing Leu Wing Being 115 120 125 Wing Gln Gln Val Asn Tyr Asn Leu Pro Gly Val Ser Glu His Leu Lys 130 135 140 Leu Asn Gly Lys Val Leu Wing Wing Met Tyr Gln Gly Thr He Lys Thr 145 150 155 160 Trp Asp Asp Pro Gln He Ala Wing Leu Asn Pro Gly Val Asn Leu Pro 165 170 175 Gly Thr Wing Val Val Pro Leu His Arg Ser Asp Gly Ser Gly Asp Thr 180 185 190 Phe Leu Phe Thr Gln Tyr Leu Ser Lys Gln Asp Pro Glu Gly Trp Gly 195 200 205 Lys Ser Pro Gly Phe Gly Thr Thr Val Asp Phe Pro Wing Val Pro Gly 210 215 220 Wing Leu Gly Glu Asn Gly Asn Gly Gly Met Val Thr Gly Cys Ala Glu 225 230 235 240 Thr Pro Gly Cys Val Wing Tyr He Gly He Ser Phe Leu Asp Gln Wing 245 250 255 Being Gln Arg Gly Leu Gly Glu Wing Gln Leu Gly Asn Being Ser Gly Asn 260 265 270 Phe Leu Leu Pro Asp Wing Gln Ser He Gln Wing Wing Wing Wing Gly Phe 275 280 285 Wing Ser Lys Thr Pro Wing Asn Gln Wing He Ser Met He Asp Gly Pro 290 295 300 Wing Pro Asp Gly Tyr Pro He He Asn Tyr Glu Tyr Wing He Val Asn 305 310 315 320 Asn Arg Gln Lys Asp Ala Ala Thr Ala Gln Thr Leu Gln Ala Phe Leu 325 330 335 His Trp Wing He Thr Asp Gly Asn Lys Wing Being Phe Leu Asp Gln Val 340 345 350 His Phe Gln Pro Leu Pro Pro Wing Val Val Lys Leu Ser Asp Ala Leu 355 360 365 He Ala Thr He Ser Ser 370 (2) INFORMATION FOR SEC ID. NO.:156: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1777 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:156: GGTCTTGACC ACCACCTGGG TGTCGAAGTC GGTGCCCGGA TTGAAGTCCA GGTACTCGTG 60 GGTGGGGCGG GCGAAACAAT AGCGACAAGC ATGCGAGCAG CCGCGGTAGC CGTTGACGGT 120 GTAGCGAAAC GGCAACGCGG CCGCGTTGGG CACCTTGTTC AGCGCTGATT TGCACAACAC 180 CTCGTGGAAG GTGATGCCGT CGAATTGTGG CGCGCGAACG CTGCGGACCA GGCCGATCCG 240 CTGCAACCCG GCAGCGCCCG TCGTCAACGG GCATCCCGTT CACCGCGACG GCTTGCCGGG 300 CCCAACGCAT ACCATTATTC GAACAACCGT TCTATACTTT GTCAACGCTG GCCGCTACCG 360 AGCGCCGCAC AGGATGTGAT ATGCCATCTC TGCCCGCACA GACAGGAGCC AGGCCTTATG 420 ACAGCATTCG GCGTCGAGCC CTACGGGCAG CCGAAGTACC TAGAAATCGC CGGGAAGCGC 480 ATGGCGTATA TCGACGAAGG CAAGGGTGAC GCCATCGTCT TTCAGCACGG CAACCCCACG 540 TCGTCTTACT TGTGGCGCAA CATCATGCCG CACTTGGAAG GGCTGGGCCG GCTGGTGGCC 600 TGCGATCTGA TCGGGATGGG CGCGTCGGAC AAGCTCAGCC CATCGGGACC CGACCGCTAT 660 AGCTATGGCG AGCAACGAGA CTTTTTGTTC GCGCTCTGGG ATGCGCTCGA CCTCGGCGAC 720 CACGTGGTAC TGGTGCTGCA CGACTGGGGC TCGGCGCTCG GCTTCGACTG GGCTAACCAG 780 CATCGCGACC GAGTGCAGGG GATCGCGTTC ATGGAAGCGA TCGTCACCCC GATGACGTGG 840 GCGGACTGGC C GCCGGCCGT GCGGGGTGTG TTCCAGGGTT TCCGATCGCC TCAAGGCGAG 900 CCAATGGCGT TGGAGCACAA CATCTTTGTC GAACGGGTGC TGCCCGGGGC GATCCTGCGA 960 CAGCTCAGCG ACGAGGAAAT GAACCACTAT CGGCGGCCAT TCGTGAACGG CGGCGAGGAC 1020 CGTCGCCCCA CGTTGTCGTG GCCACGAAAC CTTCCAATCG ACGGTGAGCC CGCCGAGGTC 1080 GTCGCGTTGG TCAACGAGTA CCGGAGCTGG CTCGAGGAAA CCGACATGCC GAAACTGTTC 1140 ATCAACGCCG AGCCCGGCGC GATCATCACC GGCCGCATCC GTGACTATGT CAGGAGCTGG 1200 CCCAACCAGA CCGAAATCAC AGTGCCCGGC GTGCATTTCG TTCAGGAGGA CAGCGATGGC 1260 GTCGTATCGT GGGCGGGCGC TCGGCAGCAT CGGCGACCTG GGAGCGCTCT CATTTCACGA 1320 GACCAAGAAT GTGATTTCCG GCGAAGGCGG CGCCCTGCTT GTCAACTCAT AAGACTTCCT 1380 GCTCCGGGCA GAGATTCTCA GGGAAAAGGG CACCAATCGC AGCCGCTTCC TTCGCAACGA 1440 GGTCGACAAA TATACGTGGC AGGACAAAGG TCTTCCTATT TGCCCAGCGA ATTAGTCGCT 1500 GCCTTTCTAT GGGCTCAGTT CGAGGAAGCC GAGCGGATCA CGCGTATCCG ATTGGACCTA 1560 TGGAACCGGT ATCATGAAAG CTTCGAATCA TTGGAACAGC GGGGGCTCCT GCGCCGTCCG 1620 ATCATCCCAC AGGGCTGCTC TCACAACGCC CACATGTACT ACGTGTTACT AGCGCCCAGC 1680 GCCGATCGGG AGGAGGTGC T GGCGCGTCTG ACGAGCGAAG GTATAGGCGC GGTCTTTCAT 1740 TACGTGCCGC TTCACGATTC GCCGGCCGGG CGTCGCT 1777 (2) INFORMATION FOR SEC ID. DO NOT. : 157: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 324 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:157: GAGATTGAAT CGTACCGGTC TCCTTAGCGG CTCCGTCCCG TGAATGCCCA TATCACGCAC 60 GGCCATGTTC TGGCTGTCGA CCTTCGCCCC ATGCCCGGAC GTTGGTAAAC CCAGGGTTTG 120 ATCAGTAATT CCGGGGGACG GTTGCGGGAA GGCGGCCAGG ATGTGCGTGA GCCGCGGCGC 180 CGCCGTCGCC CAGGCGACCG CTGGATGCTC AGCCCCGGTG CGGCGACGTA GCCAGCGTTT 240 GGCGCGTGTC GTCCACAGTG GTACTCCGGT GACGACGCGG CGCGGTGCCT GGGTGAAGAC 300 CGTGACCGAC GCCGCCGATT CAGA 324 (2) INFORMATION FOR SEC ID. NO.:158: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1338 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 158: GCGGTACCGC CGCGTTGCGC TGGCACGGGA CCTGTACGAC CTGAACCACT TCGCCTCGCG 60 AACGATTGAC GAACCGCTCG TGCGGCGGCT GTGGGTGCTC AAGGTGTGGG GTGATGTCGT 120 CGATGACCGG CGCGGCACCC GGCCACTACG CGTCGAAGAC GTCCTCGCCG CCCGCAGCGA 180 GCACGACTTC CAGCCCGACT CGATCGGCGT GCTGACCCGT CCTGTCGCTA TGGCTGCCTG 240 GGAAGCTCGC GTTCGGAAGC GATTTGCGTT CCTCACTGAC CTCGACGCCG ACGAGCAGCG 300 GTGGGCCGCC TGCGACGAAC GGCACCGCCG CGAAGTGGAG AACGCGCTGG CGGTGCTGCG 360 GTCCTGATCA ACCTGCCGGC GATCGTGCCG TTCCGCTGGC ACGGTTGCGG CTGGACGCGG 420 CTGAATCGAC TAGATGAGAG CAGTTGGGCA CGAATCCGGC TGTGGTGGTG AGCAAGACAC 480 GAGTACTGTC ATCACTATTG GATGCACTGG ATGACCGGCC TGATTCAGCA GGACCAATGG 540 AACTGCCCGG GGCAAAACGT CTCGGAGATG ATCGGCGTCC CCTCGGAACC CTGCGGTGCT 600 GGCGTCATTC GGACATCGGT CCGGCTCGCG GGATCGTGGT GACGCCAGCG CTGAAGGAGT 660 GGAGCGCGGC GGTGCACGCG CTGCTGGACG GCCGGCAGAC GGTGCTGCTG CGTAAGGGCG 720 GGATCGGCGA GAAGCGCTTC GAGGTGGCGG CCCACGAGTT CTTGTTGTTC CCGACGGTCG 780 CGCACAGCCA CGCCGAGCGG GTTCGCCCCG AGCACCGCGA CCTGCTGGGC CCGGCGGCCG 840 CCGACAGCAC CGA CGAGTGT GTGCTACTGC GGGCCGCAGC GAAAGTTGTT GCCGCACTGC 900 CGGTTAACCG GCCAGAGGGT CTGGACGCCA TCGAGGATCT GCACATCTGG ACCGCCGAGT 960 CGGTGCGCGC CGACCGGCTC GACTTTCGGC CCAAGCACAA ACTGGCCGTC TTGGTGGTCT 1020 CGGCGATCCC GCTGGCCGAG CCGGTCCGGC TGGCGCGTAG GCCCGAGTAC GGCGGTTGCA 1080 CCAGCTGGGT GCAGCTGCCG GTGACGCCGA CGTTGGCGGC GCCGGTGCAC GACGAGGCCG 1140 CGCTGGCCGA GGTCGCCGCC CGGGTCCGCG AGGCCGTGGG TTGACTGGGC GGCATCGCTT 1200 GGGTCTGAGC TGTACGCCCA GTCGGCGCTG CGAGTGATCT GCTGTCGGTT CGGTCCCTGC 1260 TGGCGTCAAT TGACGGCGCG GGCAACAGCA GCATTGGCGG CGCCATCCTC CGCGCGGCCG 1320 GCGCCCACCG CTACAACC 1338 (2) INFORMATION FOR SEC ID. NO .: 159 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 321 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:159: CCGGCGGCAC CGGCGGCACC GGCGGTACCG GCGGCAACGG CGCTGACGCC GCTGCTGTGG 60 TGGGCTTCGG CGCGAACGGC GACCCTGGCT TCGCTGGCGG CAAAGGCGGT AACGGCGGAA 120 TAGGTGGGGC CGCGGTGACA GGCGGGGTCG CCGGCGACGG CGGCACCGGC GGCAAAGGTG 180 GCACCGGCGG TGCCGGCGGC GCCGGCAACG ACGCCGGCAG CACCGGCAAT CCCGGCGGTA 240 AGGGCGGCGA CGGCGGGATC GGCGGTGCCG GCGGGGCCGG CGGCGCGGCC GGCACCGGCA 300 ACGGCGGCCA TGCCGGCAAC C 321 (2) INFORMATION FOR SEC ID. NO.:160 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 492 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:160: GAAGACCCGG CCCCGCCATA TCGATCGGCT CGCCGACTAC TTTCGCCGAA CGTGCACGCG 60 GCGGCGTCGG GCTGATCATC ACCGGTGGCT ACGCGCCCAA CCGCACCGGA TGGCTGCTGC 120 CGTTCGCCTC CGAACTCGTC ACTTCGGCGC AAGCCCGACG GCACCGCCGA ATCACCAGGG 180 CGGTCCACGA TTCGGGTGCA AAGATCCTGC TGCAAATCCT GCACGCCGGA CGCTACGCCT 240 ACCACCCACT TGCGGTCAGC GCCTCGCCGA TCAAGGCGCC GATCACCCCG TTTCGTCCGC 300 GAGCACTATC GGCTCGCGGG GTCGAAGCGA CCATCGCGGA TTTCGCCCGC TGCGCGCAGT 360 TGGCCCGCGA TGCCGGCTAC GACGGCGTCG AAATCATGGG CAGCGAAGGG TATCTGCTCA 420 ATCAGTTCCT GGCGCCGCGC ACCAACAAGC GCACCGACTC GTGGGGCGGC ACACCGGCCA 480 ACCGTCGCCG GT 492 (2) INFORMATION FOR SEC ID. NO .: 162: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 536 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:161: Phe Ala Gln His Leu Val Glu Gly Asp Ala Val Glu Leu Trp Arg Ala 1 5 10 15 Asn Ala Ala Asp Gln Ala Asp Pro Leu Gln Pro Gly Be Ala Arg Arg 20 25 30 Gln Arg Ala Ser Arg Ser Pro Arg Arg Leu Ala Gly Pro Asn Ala Tyr 40 45 His Tyr Ser Asn Asn Arg Ser He Leu Cys Gln Arg Trp Pro Leu Pro 50 55 60 Wing Wing Gln Asp Val He Cys His Leu Cys Pro His Arg Gln Glu 65 70 75 80 Pro Gly Leu Met Thr Wing Phe Gly Val Glu Pro Tyr Gly Gln Pro Lys 85 90 95 Tyr Leu Glu He Wing Gly Lys Arg Met Wing Tyr lie Asp Glu Gly Lys 100 105 110 Gly Asp Wing He Val Phe Gln His Gly Asn Pro Thr Ser Ser Tyr Leu 115 120 125 Trp Arg Asn He Met Pro His Leu Glu Gly Leu Gly Arg Leu Val Wing 130 135 140 Cys Asp Leu He Gly Met Gly Wing Ser Asp Lys Leu Ser Pro Ser Gly 145 150 155 160 Pro Asp Arg Tyr Ser Tyr Gly Glu Gln Arg Asp Phe Leu Phe Ala Leu 165 170 175 Trp Asp Ala Leu Asp Leu Gly Asp His Val Val Leu Val Leu His Asp 180 185 190 Trp Gly Ser Ala Leu Gly Phe Asp Trp Wing Asn Gln His Arg Asp Arg 195 200 205 Val Gln Gly He Wing Phe Met Glu Wing He Val Thr Pro Met Thr Trp 210 215 220 Wing Asp Trp Pro Pro Wing Val Arg Gly Val Phe Gln Gly Phe Arg Ser 225 230 235 240 Pro Gln Gly Glu Pro Met Wing Leu Glu His Asn He Phe Val Glu Arg 245 250 255 Val Leu Pro Gly Ala He Leu Arg Gln Leu Ser Asp Glu Glu Met Asn 260 265 270 His Tyr Arg Arg Pro Phe Val Asn Gly Gly Glu Asp Arg Arg Pro Thr 275 280 285 Leu Ser Trp Pro Arg Asn Leu Pro He Asp Gly Glu Pro Wing Glu Val 290 295 300 Val Ala Leu Val Asn Glu Tyr Arg Ser Trp Leu Glu Glu Thr Asp Met 305 310 315 320 Pro Lys Leu Phe He Asn Wing Glu Pro Gly Wing He He Thr Gly Arg 325 330 335 He Arg Asp Tyr Val Arg Ser Trp Pro Asn Gln Thr Glu He Thr Val 340 345 350 Pro Gly Val His Phe Val Gln Glu Asp Ser Asp Gly Val Val Ser Trp 355 360 365 Wing Gly Wing Arg Gln His Arg Arg Pro Gly Wing Leu He Ser Arg 370 375 380 Asp Gln Glu Cys Asp Phe Arg Arg Arg Arg Arg Pro Wing Cys Gln Leu 385 390 395 400 He Arg Leu Pro Wing Pro Gly Arg Asp Ser Gln Gly Lys Gly His Gin 405 410 415 Ser Gln Pro Leu Pro Ser Gln Arg Gly Arg Gln He Tyr Val Wing Ala 420 425 430 Gln Arg Ser Ser Tyr Leu Pro Ser Glu Leu Val Wing Ala Phe Leu Trp 435 440 445 Wing Gln Phe Glu Glu Wing Glu Arg He Thr Arg He Arg Leu Asp Leu 450 455 460 Trp Asn Arg Tyr His Glu Ser Phe Glu Ser Leu Glu Gln Arg Gly Leu 465 470 475 480 Leu Arg Arg Pro He He Pro Gln Gly Cys Ser His Asn Wing His Met 485 490 495 Tyr Tyr Val Leu Leu Wing Pro Ser Wing Asp Arg Glu Glu Val Leu Wing 500 505 510 Arg Leu Thr Ser Glu Gly He Gly Wing Val Phe His Tyr Val Pro Leu 515 520 525 His Asp Ser Pro Ala Gly Arg Arg 530 535 (2) INFORMATION FOR SEC ID. NO.:162: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 284 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:162: Asn Glu Be Wing Pro Arg Ser Pro Met Leu Pro Be Wing Arg Pro Arg 1 5 10 15 Tyr Asp Ala He Ala Val Leu Leu Asn Glu Met His Wing Gly His Cys 25 30 Asp Phe Gly Leu Val Gly Pro Pro Wing Asp He Val Thr Asp Ala Wing 35 40 45 Gly Asp Asp Arg Wing Gly Leu Gly Val Asp Glu Gln Phe Arg Hxs Val 50 55 60 Gly Phe Leu Glu Pro Pro Wing Val Leu Val Asp Gln Arg Asp Asp Leu 65 70 75 80 Gly Gly Leu Thr Val Asp Trp Lys Val Ser Trp Pro Arg Gln Arg Gly 85 90 95 Ala Thr Val Leu Ala Ala Val His Glu Trp Pro Pro He Val Val His 100 105 110 Phe Leu Val Wing Glu Leu Ser Gln Asp Arg Pro Gly Gln His Pro Phe 115 120 125 Asp Lys Asp Val Val Leu Gln Arg His Trp Leu Ala Leu Arg Arg Ser 130 135 140 Glu Thr Leu Glu His Thr Pro His Gly Arg Arg Pro Val Arg Pro Arg 145 150 155 160 His Arg Gly Asp Asp Arg Phe His Glu Arg Asp Pro Leu His Ser Val 165 170 175 Ala Met Leu Val Ser Pro Val Glu Ala Glu Arg Arg Ala Pro Val Val 180 185 190 Gln His Gln Tyr His Val Val Ala Glu Val Glu Arg He Pro Glu Arg 195 200 205 Glu Gln Lys Val Ser Leu Leu Wing He Wing He Wing Val Gly Ser Arg 210 215 220 Trp Wing Glu Leu Val Arg Arg Wing Hxs Pro Asp Gln He Wing Gly His 225 230 235 240 Gln Pro Wing Gln Pro Phe Gln Val Arg His Asp Val Wing Pro Gln Val 245 250 255 Arg Arg Arg Gly Val Wing Val Leu Lys Asp Asp Gly Val Thr Leu Wing 260 265 270 Phe Val Asp He Arg His Ala Leu Pro Gly Asp Phe 275 280 (2) INFORMATION FOR SEC ID. NO ..- 163 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 264 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:163 ATGAACATGT CGTCGGTGGT GGGTCGCAAG GCCTTTGCGC GATTCGCCGG CTACTCCTCC 60 GCCATGCACG CGATCGCCGG TTTCTCCGAT GCGTTGCGCC AAGAGCTGCG GGGTAGCGGA 120 ATCGCCGTCT CGGTGATCCA CCCGGCGCTG ACCCAGACAC CGCTGTTGGC CAACGTCGAC 180 CCCGCCGACA TGCCGCCGCC GTTTCGCAGC CTCACGCCCA TTCCCGTTCA CTGGGTCGCG 240 GCAGCGGTGC TTGACGGTGT GGCG 264 (2) INFORMATION FOR SEC ID. NO.:164: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1171 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear. (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 164: TAGTCGGCGA CGATGACGTC GCGGTCCAGG CCGACCGCTT CAAGCACCAG CGCGACCACG 60 AAGCCGGTGC GATCCTTACC CGCGAAGCAG TGGGTGAGCA CCGGGCGTCC GGCGGCAAGC 120 AGTGTGACGA CACGATGTAG CGCGCGCTGT GCTCCATTGC GCGTTGGGAA TTGGCGATAC 180 TCGTCGGTCA TGTAGCGGGT GGCCGCGTCA TTTATCGACT GGCTGGATTC GCCGGACTCG 240 CCGTTGGACC CGTCATTGGT TAGCAGCCTC TTGAATGCGG TTTCGTGCGG CGCTGAGTCG 300 TCGGCGTCAT CATCGGCGAG GTCGGGGAAC GGCAGCAGGT GGACGTCGAT GCCGTCCGGA 360 ACCCGTCCTG GACCGCGGCG GGCAACCTCC CGGGACGACC GCAGGTCGGC AACGTCGGTG 420 ATCCCCAGCC GGCGCAGCGT TGCCCCTCGT GCCGAATTCG GCACGAGGCT GGCGAGCCAC 480 CGGGCATCAC CAAGCAACGC TTGCCCAGTA CGGATCGTCA CTTCCGCATC CGGCAGACCA 540 ATCTCCTCGC CGCCCATCGT CAGATCCCGC TCGTGCGTTG ACAAGAACGG CCGCAGATGT 600 GCCAGCGGGT ATCGGAGATT GAACCGCGCA CGCAGTTCTT CAATCGCTGC GCGCTGCCGC 660 ACTATTGGCA CTTTCCGGCG GTCGCGGTAT TCAGCAAGCA TGCGAGTCTC GACGAACTCG 720 CCCCACGTAA CCCACGGCGT AGCTCCCGGC GTGACGCGGA GGATCGGCGG GTGATCTTTG 780 CCGCCACGCT CGTAGCCGTT GATCCACCGC TTCGCGGTGC CGGCGGGGAG GCCGATCAGC 840 TTATCGACCT CGGC GTATGC CGACGGCAAG CTGGGCGCGT TCGTCGAGGT CAAGAACTCC 900 ACCATCGGCA CCGGCACCAA GGTGCCGCAC CTGACCTACG TCGGCGACGC CGACATCGGC 960 GAGTACAGCA ACATCGGCGC CTCCAGCGTG TTCGTCAACT ACGACGGTAC GTCCAAACGG 1020 CGCACCACCG TCGGTTCGCA CGTACGGACC GGGTCCGACA CCATGTTCGT GGCCCCAGTA 1080 ACCATCGGCG ACGGCGCGTA TACCGGGGCC GGCACAGTGG TGCGGGAGGA TGTCCCGCCG 1140 C 1171 GGGGCGCTGG CAGTGTCGGC GGGTCCGCAA (2) INFORMATION FOR SEC ID. NO.:165 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 227 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . 165: GCAAAGGCGG CACCGGCGGG GCCGGCATGA ACAGCCTCGA CCCGCTGCTA GCCGCCCAAG 60 ACGGCGGCCA AGGCGGCACC GGCGGCACCG GCGGCAACGC CGGCGCCGGC GGCACCAGCT 120 TCACCCAAGG CGCCGACGGC AACGCCGGCA ACGGCGGTGA CGGCGGGGTC GGCGGCAACG 180 GCGGAAACGG CGGAAACGGC GCAGACAACA CCACCACCGC CGCCGCC 227 (2) INFORMATION FOR SEQ ID. NO.:166: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 304 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:166: CCTCGCCACC ATGGGCGGGC AGGGCGGTAG CGGTGGCGCC GGCTCTACCC CAGGCGCCAA 60 GGGCGCCCAC GGCTTCACTC CAACCAGCGG CGGCGACGGC GGCGACGGCG GCAACGGCGG 120 CAACTCCCAA GTGGTCGGCG GCAACGGCGG CGACGGCGGC AATGGCGGCA ACGGCGGCAG CGCCGGCACG 180 GGCGGCAACG 240 GCGGCCGCGG CGGCGACGGC GCGTTTGGTG GCATGAGTGC CAACGCCACC AACCCTGGTG AAAACGGGCC AAACGGTAAC CCCGGCGGCA ACGGTGGCGC 300 CGGC 304 (2) INFORMATION FOR SEC ID. NO.:167: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1439 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:167 GTGGGACGCT GCCGAGGCTG TATAACAAGG ACAACATCGA CCAGCGCCGG CTCGGTGAGC 60 TGATCGACCT ATTTAACAGT GCGCGCTTCA GCCGGCAGGG CGAGCACCGC GCCCGGGATC 120 TGATGGGTGA GGTCTACGAA TACTTCCTCG GCAATTTCGC TCGCGCGGAA GGGAAGCGGG 180 GTGGCGAGTT CTTTACCCCG CCCAGCGTGG TCAAGGTGAT CGTGGAGGTG CTGGAGCCGT 240 CGAGTGGGCG GGTGTATGAC CCGTGCTGCG GTTCCGGAGG CATGTTTGTG CAGACCGAGA 300 AGTTCATCTA CGAACACGAC GGCGATCCGA AGGATGTCTC GATCTATGGC CAGGAAAGCA 360 TTGAGGAGAC CTGGCGGATG GCGAAGATGA ACCTCGCCAT CCACGGCATC GACAACAAGG 420 GGCTCGGCGC CCGATGGAGT GATACCTTCG CCCGCGACCA GCACCCGGAC GTGCAGATGG 480 ACTACGTGAT GGCCAATCCG CCGTTCAACA TCAAAGACTG GGCCCGCAAC GAGGAAGACC 540 CACGCTGGCG CTTCGGTGTT CCGCCCGCCA ATAACGCCAA CTACGCATGG ATTCAGCACA 600 TCCTGTACAA CTTGGCGCCG GGAGGTCGGG CGGGCGTGGT GATGGCCAAC GGGTCGATGT 660 CGTCGAACTC CAACGGCAAG GGGGATATTC GCGCGCAAAT CGTGGAGGCG GATTTGGTTT 720 CCTGCATGGT CGCGTTACCC ACCCAGCTGT TCCGCAGCAC CGGAATCCCG GTGTGCCTGT 780 GGTTTTTCGC CAAAAACAAG GCGGCAGGTA AGCAAGGGTC TATCAACCGG TGCGGGCAGG 840 TGCTGTTCAT CGACGCTCGT GAACTGGGCG ACCTAGTGGA CCGGGCCGAG CGGGCGCTGA 900 CCAACGAGGA GATCGTCCGC ATCGGGGATA CCTTCCACGC GAGCACGACC ACCGGCAACG 960 CCGGCTCCGG TGGTGCCGGC GGTAATGGGG GCACTGGCCT CAACGGCGCG GGCGGTGCTG 1020 GCGGGGCCGG CGGCAACGCG GGTGTCGCCG GCGTGTCCTT CGGCAACGCT GTGGGCGGCG 1080 ACGGCGGCAA CGGCGGCAAC GGCGGCCACG GCGGCGACGG CACGACGGGC GGCGCCGGCG 1140 GCAAGGGCGG CAACGGCAGC AGCGGTGCCG CCAGCGGCTC AGGCGTCGTC AACGTCACCG 1200 CCGGCCACGG CGGCAACGGC GGCAATGGCG GCAACGGCGG CAACG GCTCC GCGGGCGCCG 1260 GCGGCCAGGG CGGTGCCGGC GGCAGCGCCG GCAACGGCGG CCACGGCGGC GGTGCCACCG 1320 GCGGCGCCAG CGGCAAGGGC GGCAACGGCA CCAGCGGTGC CGCCAGCGGC TCAGGCGTCA 1380 TCAACGTCAC CGCCGGCCAC GGCGGCAACG GCGGCAATGG CCGCAACGGC GGCAACGGC 1439 (2) INFORMATION FOR SEQ ID. NO.:168: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 329 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:168: GGGCCGGCGG GGCCGGATTT TCTCGTGCCT TGATTGTCGC TGGGGATAAC GGCGGTGATG 60 GTGGTAACGG CGGGATGGGC GGGGCTGGCG GGGCTGGCGG CCCCGGCGGG GCCGGCGGCC 120 TGATCAGCCT GCTGGGCGGC CAAGGCGCCG GCGGGGCCGG CGGGACCGGC GGGGCCGGCG 180 GTGTTGGCGG TGACGGCGGG GCCGGCGGCC CCGGCAACCA GGCCTTCAAC GCAGGTGCCG 240 GCGGGGCCGG CGGCCTGATC AGCCTGCTGG GCGGCCAAGG CGCCGGCGGG GCCGGCGGGA 300 CCGGCGGGGC CGGCGGTGTT GGCGGTGAC 329 (2) INFORMATION FOR SEC ID. NO.:169: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:169 GCAACGGTGG CAACGGCGGC ACCAGCACGA CCGTGGGGAT GGCCGGAGGT AACTGTGGTG 60 CCGCCGGGCT GATCGGCAAC 80 (2) INFORMATION FOR SEC ID. NO.:170: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 392 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 170: GGGCTGTGTC GCACTCACAC CGCCGCATTC GGCGACGTTG GCCGCCCAAT ATCCAGCTCA 60 AGGCCTACTA CTTACCGTCG GAGGACCGCC GCATCAAGGT GCGGGTCAGC GCCCAAGGAA 120 TCAAGGTCAT CGACCGCGAC GGGCATCGAG GCCGTCGTCG CGCGGCTCGG GCAGGATCCG 180 CCCCGGCGCA CTTCGCGCGC CAAGCGGGCT CATCGCTCCG AACGGCGGCG ATCCTGTGAG 240 CACAACTGAT GGCGCGCAAC GAGATTCGTC CAATTGTCAA GCCGTGTTCG ACCGCAGGGA 300 CCGGTTATAC GTATGTCAAC CTATGTCACT CGCAAGAACC GGCATAACGA TCCCGTGATC 360 CGCCGACAGC CCACGAGTGC AAGACCGTTA CA 392 (2) INFORMATION FOR SEC ID. NO.:171: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 535 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 171: ACCGGCGCCA CCGGCGGCAC CGGGTTCGCC GGTGGCGCCG GCGGGGCCGG CGGGCAGGGC 60 GGTATCAGCG GTGCCGGCGG CACCAACGGC TCTGGTGGCG CTGGCGGCAC CGGCGGACAA 120 GGCGGCGCCG GGGGCGCTGG CGGGGCCGGC GCCGATAACC CCACCGGCAT CGGCGGCGCC 180 GGCGGCACCG GCGGCACCGG CGGAGCGGCC GGAGCCGGCG GGGCCGGTGG CGCCATCGGT 240 ACCGGCGGCA CCGGCGGCGC GGTGGGCAGC GTCGGTAACG CCGGGATCGG CGGTACCGGC 300 GGTACGGGTG GTGTCGGTGG TGCTGGTGGT GCAGGTGCGG CTGCGGCCGC TGGCAGCAGC 360 GCTACCGGTG GCGCCGGGTT CGCCGGCGGC GCCGGCGGAG AAGGCGGACC GGGCGGCAAC 420 AGCGGTGTGG GCGGCACCAA CGGCTCCGGC GGCGCCGGCG GTGCAGGCGG CAAGGGCGGC 480 ACCGGAGGTG CCGGCGGGTC CGGCGCGGAC AACCCCACCG GTGCTGGTTT CGCCG 535 (2) INFORMATION FOR SEC ID. DO NOT. : 172: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 690 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 172: CCGACGTCGC CGGGGCGATA CGGGGGTCAC CGACTACTAC ATCATCCGCA CCGAGAATCG 60 GCCGCTGCTG CAACCGCTGC GGGCGGTGCC GGTCATCGGA GATCCGCTGG CCGACCTGAT 120 CCAGCCGAAC CTGAAGGTGA TCGTCAACCT GGGCTACGGC GACCCGAACT ACGGCTACTC 180 GACGAGCTAC GCCGATGTGC GAACGCCGTT CGGGCTGTGG CCGAACGTGC CGCCTCAGGT 240 CATCGCCGAT GCCCTGGCCG CCGGAACACA AGAAGGCATC CTTGACTTCA CGGCCGACCT 300 GCAGGCGCTG TCCGCGCAAC CGCTCACGCT CCCGCAGATC CAGCTGCCGC AACCCGCCGA 360 TCTGGTGGCC GCGGTGGCCG CCGCACCGAC GCCGGCCGAG GTGGTGAACA CGCTCGCCAG 420 GATCATCTCA ACCAACTACG CCGTCCTGCT GCCCACCGTG GACATCGCCC TCGCCTGGTC 480 ACCACCCTGC CGCTGTACAC CACCCAACTG TTCGTCAGGC AACTCGCTGC GGGCAATCTG 540 ATCAACGCGA TCGGCTATCC CCTGGCGGCC ACCGTAGGTT TAGGCACGAT CGATAGCGGG 600 CGGCDTGGAA TTGCTCACCC TCCTCGCGGC GGCCTCGGAC ACCGTTCGAA ACATCGAGGG 660 CCTCGTCACC TAACGGATTC CCGACGGCAT 690 (2) INFORMATION FOR SEC ID. DO NOT . : 173 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 407 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 173: ACGGTGACGG CGGTACTGGC GGCGGCCACG GCGGCAACGG CGGGAATCCC GGGTGGCTCT 60 TGGGCACAGC CGGGGGTGGC GGCAACGGTG GCGCCGGCAG CACCGGTACT GCAGGTGGCG 120 GCTCTGGGGG CACCGGCGGC GACGGCGGGA CCGGCGGGCG TGGCGGCCTG TTAATGGGCG 180 CCGGCGCCGG CGGGCACGGT GGCACTGGCG GCGCGGGCGG TGCCGGTGTC GACGGTGGCG 240 GCGCCGGCGG GGCCGGCGGG GCCGGCGGCA ACGGCGGCGC CGGGGGTCAA GCCGCCCTGC 300 TGTTCGGGCG CGGCGGCACC GGCGGAGCCG GCGGCTACGG CGGCGATGGC GGTGGCGGCG 360 GTGACGGCTT CGACGGCACG ATGGCCGGCC TGGGTGGTAC CGGTGGC 407 (2) INFORMATION FOR SEC ID. NO.:174: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 468 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:174: GATCGGTCAG CGCATCGCCC TCGGCGGCAA GCGATTCCGC GGTCTCACCG AAGAACATCG 60 TGCACGCGGC GGCGCGGACC AGCCCGCTGC GCTGCGGCGC GTCGAACGCC TCCAGCAGGC 120 AcAGCCAGTC CTTGGCGGCC TGCGAGGCGA ACACGTCGGT GTCACCGGTG TAGATCGCCG 180 GGATGCCCGC CTCCGCCAAC GCATTCCGGC ACGCCCGCGC GTCTTTGTGA TGCTCGACGA 240 TCACCGCGAT GTCTGCGGCC ACCACGGGCC GCCCGGCGAA GGTGGCCCCG CTGGCCAGTA 300 GCGCCGCGAC GTCGGCGGCC AGGTCGTCGG GGATGTGCCG CCGGCGCGAC GCGCAGCGCT 360 GCCCGAAAAA CGACCCCTCA CCCAGCTGGG TCCCGCTGGC ATATCCCTTG CCGTCCTGGG 420 CGATATTGGA CGCGCATGCC CCGACCGCGT ACAGGCCGGC CACCACCG 468 (2) INFORMATION FOR SEC ID. NO.:175 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 219 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:175: GGTGGTAACG GCGGCCAGGG TGGCATCGGC GGCGCCGGCG AGAGAGGCGC CGACGGCGCC 60 GGCCCCAATG CTAACGGCGC AAACGGCGAG AACGGCGGTA GCGGTGGTAA CGGTGGCGAC 120 GGCGGCGCCG GCGGCAATGG CGGCGCGGGC GGCAACGCGC AGGCGGCCGG GTACACCGAC 180 GGCGCCACGG GCACCGGCGG CGACGGCGGC AACGGCGGC 219 (2) INFORMATION FOR SEC ID. NO.:176 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 494 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:176: TAGCTCCGGC GAGGGCGGCA AGGGCGGCGA CGGTGGCCAC GGCGGTGACG GCGTCGGCGG 60 CAACAGTTCC GTCACCCAAG GCGGCAGCGG CGGTGGCGGC GGCGCCGGCG GCGCCGGCGG 120 CAGCGGCTTT TTCGGCGGCA AGGGCGGCTT CGGCGGCGAC GGCGGTCAGG GCGGCCCCAA 180 CGGCGGCGGT ACCGTCGGCA CCGTGGCCGG TGGCGGCGGC AACGGCGGTG TCGGCGGCCG 240 GGGCGGCGAC GGCGTCTTTG CCGGTGCCGG CGGCCAGGGC GGCCTCGGTG GGCAGGGCGG 300 CAATGGCGGC GGCTCCACCG GCGGCAACGG CGGCCTTGGC GGCGCGGGCG GTGGCGGAGG 360 CAACGCCCCG GCTCGTGCCG AATCCGGGCT GACCATGGAC AGCGCGGCCA AGTTCGCTGC 420 CATCGCATCA GGCGCGTACT GCCCCGAACA CCTGGAACAT CACCCGAGTT AGCGGGGCGC 480 ATTTCCTGAT CACC 494 (2) INFORMATION FOR SEC ID. NO.:177: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 220 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:177: GGGCCGGTGG TGCCGCGGGC CAGCTCTTCA GCGCCGGAGG CGCGGCGGGT GCCGTTGGGG 60 TTGGCGGCAC CGGCGGCCAG GGTGGGGCTG GCGGTGCCGG AGCGGCCGGC GCCGACGCCC 120 CCGCCAGCAC AGGTCTAACC GGTGGTACCG GGTTCGCTGG CGGGGCCGGC GGCGTCGGCG 180 GCCAGAGCGG CAACGCCATT GCCGGCGGCA TCAACGGCTC 220 (2) INFORMATION FOR SEC ID. NO.:178: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 388 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 178: ATGGCGGCAA CGGGGGCCCC GGCGGTGCTG GCGGGGCCGG CGACTACAAT TTCCAACGGC 60 GGGCAGGGTG GTGCCGGCGG CCAAGGCGGC CAAGGCGGCC TGGGCGGGGC AAGCACCACC 120 TGATCGGCCT AGCCGCACCC GGGAAAGCCG ATCCAACAGG CGACGATGCC GCCTTCCTTG 180 CCGCGTTGGA CCAGGCCGGC ATCACCTACG CTGACCCAGG CCACGCCATA ACGGCCGCCA 240 AGGCGATGTG TGGGCTGTGT GCTAACGGCG TAACAGGTCT ACAGCTGGTC GCGGACCTGC 300 GGGACTACAA TCCCGGGCTG ACCATGGACA GCGCGGCCAA GTTCGCTGCC ATCGCATCAG 360 GCGCGTACTG CCCCGAACAC CTGGAACA 388 (2) INFORMATION FOR SEC ID. NO.:179 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 400 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:179: GCAAAGGCGG CACCGGCGGG GCCGGCATGA ACAGCCTCGA CCCGCTGCTA GCCGCCCAAG 60 ACGGCGGCCA AGGCGGCACC GGCGGCACCG GCGGCAACGC CGGCGCCGGC GGCACCAGCT 120 TCACCCAAGG CGCCGACGGC AACGCCGGCA ACGGCGGTGA CGGCGGGGTC GGCGGCAACG 180 GCGDAAACGG CGGAAACGGC GCAGACAACA CCACCACCGC CGCCGCCGGC ACCACAGGCG 240 GCGACGGCGG GGCCGGCGGG GCCGGCGGAA CCGGCGGAAC CGGCGGAGCC GCCGGCACCG 300 GCACCGGCGG CCAACAAGGC AACGGCGGCA ACGGCGGCAC CGGCGGCAAA GGCGGCACCG 360 GCGGCGACGG TGCACTCTCA GGCAGCACCG GTGGTGCCGG 400 (2) INFORMATION FOR SEC ID. NO.:180: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 538 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:180: GGCAACGGCG GCAACGGCGG CATCGCCGGC ATTGGGCGGC AACGGCGTTC CGGGACGGGC 60 AGCGGCAACG GCGGCCAACG GCGGCAGCGG CGGCAACGGC 120 GGCAACGCCG GCATGGGCGG CAACAGCGGC ACCGGCAGCG GCGACGGCGG TGCCGGCGGG AACGGCGGCG CGGCGGGCAC 180 GGGCGGCACC GGCGGCGACG GCGGCCTCAC CGGTACTGGC GGCACCGGCG GCAGCGGTGG 240 CACCGGCGGT GACGGCGGTA ACGGCGGCAA CGGAGCAGAT AACACCGCAA ACATGACTGC 300 GCAGGCGGGC GGTGACGGTG GCAACGGCGG CGACGGTGGC TTCGGCGGCG GGGCCGGGGC 360 CGGCGGCGGT GGCTTGACCG CTGGCGCCAA CGGCACCGGC GGGCAAGGCG GCGCCGGCGG 420 CGATGGCGGC AACGGGGCCA TCGGCGGCCA CGGCCCACTC ACTGACGACC CCGGCGGCAA 480 CGGGGGCACC GGCGGCAACG GCGGCACCGG CGGCACCGGC GGCGCGGGCA TCGGCAGC 538 (2) INFORMATION FOR SEC ID. NO.:181: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 239 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:181: GGGCCGGTGG TGCCGCGGGC CAGCTCTTCA GCGCCGGAGG CGCGGCGGGT GCCGTTGGGG 60 TTGGCGGCAC CGGCGGCCAG GGTGGGGCTG GCGGTGCCGG AGCGGCCGGC GCCGACGCCC 120 CCGCCAGCAC AGGTCTAACC GGTGGTACCG GGTTCGCTGG CGGGGCCGGC GGCGTCGGCG 180 GCCACGGCGG CAACGCCATT GCCGGCGGCA TCAACGGCTC CGGTGGTGCC GGCGGCACC 239 (2) INFORMATION FOR SEC ID. NO.:182: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 985 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 182: AGCAGCGCTA CCGGTGGCGC CGGGTTCGCC GGCGGCGCCG GCGGAGAAGG CGGAGCGGGC 60 GGCAACAGCG GTGTGGGCGG CACCAACGGC TCCGGCGGCG CCGGCGGTGC AGGCGGCAAG 120 GGCGGCACCG GAGGTGCCGG CGGGTCCGGC GCGGACAACC CCACCGGTGC TGGTTTCGCC 180 GGTGGCGCCG GCGGCACAGG TGGCGCGGCC GGCGCCGGCG GGGCCGGCGG GGCGACCGGT 240 ACCGGCGGCA CCGGCGGCGT TGTCGGCGCC ACCGGTAGTG CAGGCATCGG CGGGGCCGGC 300 GGCCGCGGCG GTGACGGCGG CGATGGGGCC AGCGGTCTCG GCCTGGGCCT CTCCGGCTTT 360 GACGGCGGCC AAGGCGGCCA AGGCGGGGCC GGCGGCAGCG CCGGCGCCGG CGGCATCAAC 420 GGGGCCGGCG GGGCCGGCGG CAACGGCGGC GACGGCGGGG ACGGCGCAAC CGGTGCCGCA 480 GTCTCGGCG ACAACGGCGG GGTCGGCGGT GACGGTGGGG CCGGTGGCGC CGCCGGCAAC 540 GGCGGCAACG CGGGCGTCGG CCTGACAGCC AAGGCCGGCG ACGGCGGCGC CGCGGGCAAT 600 GGCGGCAACG GGGGCGCCGG CGGTGCTGGC GGGGCCGGCG ACAACAATTT CAACGGCGGC 660 CAGGGTGGTG CCGGCGGCCA AGGCGGCCAA GGCGGCTTGG GCGGGGCAAG CACCACCTGA 720 TCGGCCTAGC CGCACCCGGG AAAGCCGATC CAACAGGCGA CGATGCCGCC TTCCTTGCCG 780 CGTTGGACCA GGCCGGCATC ACCTACGCTG ACCCAGGCCA CGCCATAACG GCCGCCAAGG 840 CGATGTGTGG GCTGTGTGCT AACGGCGTAA CAGGTCTACA GCTGGTCGCG GACCTGCGGG 900 AATACAATCC CGGGCTGACC ATGGACAGCG CGGCCAAGTT CGCTGCCATC GCATCAGGCG 960 CGTACTGCCC CGAACACCTG GAACA 985 (2) INFORMATION FOR SEC ID. NO.:183: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2138 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:183: CGGCACGAGG ATCGGTACCC CGCGGCATCG GCAGCTGCCG ATTCGCCGGG TTTCCCCACC 60 CGAGGAAAGC CGCTACCAGA TGGCGCTGCC GAAGTAGGGC GATCCGTTCG CGATGCCGGC 120 ATGAACGGGC GGCATCAAAT TAGTGCAGGA ACCTTTCAGT TTAGCGACGA TAATGGCTAT 0.180 AGCACTAAGG AGGATGATCC GATATGACGC AGTCGCAGAC CGTGACGGTG GATCAGCAAG 240 AGATTTTGAA CAGGGCCAAC GAGGTGGAGG CCCCGATGGC GGACCCACCG ACTGATGTCC 300 CCATCACACC GTGCGAACTC ACGGCGGCTA AAAACGCCGC CCAACAGCTG GTATTGTCCG 360 CCGACAACAT GCGGGAATAC CTGGCGGCCG GTGCCAAAGA GCGGCAGCGT CTGGCGACCT 420 CGCTGCGCAA CGCGGCCAAG GCGTATGGCG AGGTTGATGA GGAGGCTGCG ACCGCGCTGG 480 ACAACGACGG CGAAGGAACT GTGCAGGCAG AATCGGCCGG GGCCGTCGGA GGGGACAGTT 540 CGGCCGAACT AACCGATACG CCGAGGGTGG CCACGGCCGG TGAACCCAAC TTCATGGATC 600 TCAAAGAAGC GGCAAGGAAG CTCGAAACGG GCGACCAAGG CGCATCGCTC GCGCACTTTG 660 CGGATGGGTG GAACACTTTC AACCTGACGC TGCAAGGCGA CGTCAAGCGG TTCCGGGGGT 720 TTGACAACTG GGAAGGCGAT GCGGCTACCG CTTGCGAGGC TTCGCTCGAT CAACAACGGC 780 AATGGATACT CCACATGGCC AAATTGAGCG CTGCGATGGC CAAGCAGGCT CAATATGTCG 840 CGCAGCTGCA CGTGTGGGCT AGGCGGGAAC ATCCGACTTA TGAAGACATA GTCGGGCTCG 900 AACGGCTTTA CGCGGAAAAC CCTTCGGCCC GCGACCAAAT TCTCCCGGTG TACGCGGAGT 960 ATCAGCAGAG GTCGGAGA AG GTGCTGACCG AATACAACAA CAAGGCAGCC CTGGAACCGG 1020 TAAACCCGCC GAAGCCTCCC CCCGCCATCA AGATCGACCC GCCCCCGCCT CCGCAAGAGC 1080 AGGGATTGAT CCCTGGCTTC CTGATGCCGC CGTCTGACGG CTCCGGTGTG ACTCCCGGTA 1140 CCGGGATGCC AGCCGCACCG ATGGTTCCGC CTACCGGATC GCCGGGTGGT GGCCTCCCGG 1200 CTGACACGGC GGCGCAGCTG ACGTCGGCTG GGCGGGAAGC CGCAGCGCTG TCGGGCGACG 1260 TGGCGGTCAA AGCGGCATCG CTCGGTGGCG GTGGAGGCGG CGGGGTGCCG TCGGCGCCGT 1320 TGGGATCCGC GATCGGGGGC GCCGAATCGG TGCGGCCCGC TGGCGCTGGT GACATTGCCG 1380 GCTTAGGCCA GGGAAGGGCC GGCGGCGGCG CCGCGCTGGG CGGCGGTGGC ATGGGAATGC 1440 CGATGGGTGC CGCGCATCAG GGACAAGGGG GCGCCAAGTC CAAGGGTTCT CAGCAGGAAG 1500 ACGAGGCGCT CTACACCGAG GATCGGGCAT GGACCGAGGC CGTCATTGGT AACCGTCGGC 1560 GCCAGGACAG TAAGGAGTCG AAGTGAGCAT GGACGAATTG GACCCGCATG TCGCCCGGGC 1620 GTTGACGCTG GCGGCGCGGT TTCAGTCGGC CCTAGACGGG ACGCTCAATC AGATGAACAA 1680 CGGATCCTTC CGCGCCACCG ACGAAGCCGA GACCGTCGAA GTGACGATCA ATGGGCACCA 1740 GTGGCTCACC GGCCTGCGCA TCGAAGATGG TTTGCTGAAG AAGCTGGGTG CCGAGGCGGT 1800 GGCTCAGCGG GTCAACGAGG CGCTGCACAA TGCGCAGGCC GCGGCGTCCG CGTATAACGA 1860 C GCGGCGGGC GAGCAGCTGA CCGCTGCGTT ATCGGCCATG TCCCGCGCGA TGAACGAAGG 1920 AATGGCCTAA GCCCATTGTT GCGGTGGTAG CGACTACGCA CCGAATGAGC GCCGCAATGC 1980 GGTCATTCAG CGCGCCCGAC ACGGCGTGAG TACGCATTGT CAATGTTTTG ACATGGATCG 2040 GCCGGGTTCG GAGGGCGCCA TAGTCCTGGT CGCCAATATT GCCGCAGCTA GCTGGTCTTA 2100 GGTTCGGTTA CGCTGGTTAA TTATGACGTC CGTTACCA 2138 (2) INFORMATION FOR SEC ID. NO.:184: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 460 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: l inear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 184: Met Thr Gln Ser Gln Thr Val Thr Val Asp Gln Gln Glu He Leu Asn 1 5 10 15 Arg Wing Asn Glu Val Glu Wing Pro Met Wing Asp Pro Pro Thr Asp Val 20 25 30 Pro He Thr Pro Cys Glu Leu Thr Ala Ala Lys Asn Ala Ala Gln Gln 35 40 45 Leu Val Leu Ser Ala Asp Asn Met Arg Glu Tyr Leu Ala Ala Gly Ala 50 55 60 Lys Glu Arg Gln Arg Leu Ala Thr Ser Leu Arg Asn Ala Ala Lys Ala 65 70 75 80 Tyr Gly Glu Val Asp Glu Glu Ala Ala Thr Ala Leu Asp Asn Asp Gly 85 90 95 Glu Gly Thr Val Gln Ala Glu Be Ala Gly Ala Val Gly Gly Asp Ser 100 105 110 Ser Ala Glu Leu Thr Asp Thr Pro Arg Val Ala Thr Ala Gly Glu Pro 115 120 125 Asn Phe Met Asp Leu Lys Glu Ala Ala Arg Lys Leu Glu Thr Gly Asp 130 135 140 Gln Gly Wing Ser Leu Wing His Phe Wing Asp Gly Trp Asn Thr Phe Asn 145 150 155 160 Leu Thr Leu Gln Gly Asp Val Lys Arg Phe Arg Gly Phe Asp Asn Trp 165 170 175 Glu Gly Asp Ala Ala Thr Ala Cys Glu Ala Ser Leu Asp Gln Gln Arg 180 185 190 Gln Trp He Leu His Met Wing Lys Leu Ser Wing Wing Met Wing Lys Gln 195 200 205 Wing Gln Tyr Val Wing Gln Leu His Val Trp Wing Arg Arg Glu His Pro 210 215 220 Thr Tyr Glu Asp He Val Gly Leu Glu Arg Leu Tyr Ala Glu Asn Pro 225 230 235 240 Be Wing Arg Asp Gln He Leu Pro Val Tyr Wing Glu Tyr Gln Gln Arg 245 250 255 Ser Glu Lys Val Leu Thr Glu Tyr Asn Asn Lys Ala Wing Leu Glu Pro 260 265 270 Val Asn Pro Pro Lys Pro Pro Pro Wing He Lys He Asp Pro Pro Pro 275 280 285 Pro Pro Gln Glu Gln Gly Leu He Pro Gly Phe Leu Met Pro Pro Ser 290 295 300 Asp Gly Ser Gly Val Thr Pro Gly Thr Gly Met Pro Ala Ala Pro Met 305 310 315 320 Val Pro Pro Thr Gly Ser Pro Gly Gly Gly Leu Pro Wing Asp Thr Ala 325 330 335 Ala Gln Leu Thr Ser Ala Gly Arg Glu Ala Ala Ala Leu Ser Gly Asp 340 345 350 Val Wing Val Lys Wing Wing Ser Leu Gly Gly Gly Gly Gly Gly Gly Val 355 360 365 Pro Wing Pro Pro Leu Gly Ser Wing Gly Wing Gly Wing Ser Val Arg 370 375 380 Pro Wing Gly Wing Gly Wing Asp Gly Wing Leu Gly Gln Gly Arg Wing Gly 385 390 395 400 Gly Gly Wing Wing Leu Gly Gly Gly Gly Met Gly Met Pro Met Gly Wing 405 410 415 Ala His Gln Gly Gln Gly Gly Ala Lys Ser Lys Gly Ser Gln Gln Glu 420 425 430 Asp Glu Wing Leu Tyr Thr Glu Asp Arg Wing Trp Thr Glu Wing Val He 435 440 445 Gly Asn Arg Arg Arg Gln Asp Ser Lys Glu Ser Lys 450 455 460 (2) INFORMATION FOR SEC ID. NO.:185: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 277 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 185: Ala Gly Asn Val Thr Ser Ala Ser Gly Pro His Arg Phe Gly Ala Pro 1 5 10 15 Asp Arg Gly Ser Gln Arg Arg Arg Arg His Pro Wing Wing Being Thr Wing 25 30 Thr Glu Arg Cys Arg Phe Asp Arg His Val Wing Arg Gln Arg Cys Gly 40 45 Phe Pro Pro Ser Arg Arg Gln Leu Arg Arg Arg Val Ser Arg Glu Ala 50 55 60 Thr Thr Arg Arg Ser Gly Arg Arg Asn His Arg Cys Gly Trp His Pro 65 70 75 80 Gly Thr Gly Ser His Thr Gly Wing Val Arg Arg Arg His Gln Glu Wing 85 90 95 Arg Asp Gln Be Leu Leu Leu Arg Arg Arg Gly Arg Val Asp Leu Asp 100 105 110 Gly Gly Gly Arg Leu Arg Arg Val Tyr Arg Phe Gln Gly Cys Leu Val 115 120 125 Val Val Phe Gly Gln His Leu Leu Arg Pro Leu Leu He Leu Arg Val 130 135 140 His Arg Glu Asn Leu Val Wing Gly Arg Arg Val Phe Arg Val Lys Pro 145 150 155 160 Phe Glu Pro Asp Tyr Val Phe He Ser Arg Met Phe Pro Pro Ser Pro 165 170 175 His Val Gln Leu Arg Asp He Leu Ser Leu Leu Gly His Arg Ser Wing 180 185 190 Gln Phe Gly His Val Glu Tyr Pro Leu Pro Leu Leu He Glu Arg Ser 195 200 205 Leu Wing Ser Gly Ser Arg He Wing Phe Pro Val Val Lys Pro Pro Glu 210 215 220 Pro Leu Asp Val Ala Leu Gln Arg Gln Val Glu Ser Val Pro Pro He 225 230 235 240 Arg Lys Val Arg Glu Arg Cys Ala Leu Val Ala Arg Phe Glu Leu Pro 245 250 255 Cys Arg Phe Phe Glu He His Glu Val Gly Phe Thr Gly Arg Gly His 260 265 270 Pro Arg Arg He Gly 275 (2) INFORMATION FOR SEC ID. NO.:186: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 192 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 186: Arg Val Ala Ala Ser Phe He Asp Trp Leu Asp Ser Pro Asp Ser Pro 1 5 10 15 Leu Asp Pro Ser Leu Val Ser Ser Leu Leu Asn Ala Val Ser Cys Gly 25 30 Wing Glu Being Wing Being Being Wing Arg Being Gly Asn Gly Being Arg 40 45 Trp Thr Ser Met Pro Ser Gly Thr Arg Pro Gly Pro Arg Arg Wing Thr 50 55 60 Ser Arg Asp Asp Arg Arg Ser Wing Thr Ser Val He Pro Ser Arg Arg 65 70 75 80 Ser Val Ala Pro Arg Ala Glu Phe Gly Thr Arg Leu Ala Ser His Arg 85 90 95 Wing Ser Pro Pro Asn Wing Cys Pro Val Arg He Val Thr Ser Ala Ser 100 105 110 Gly Arg Pro Be Ser Pro Pro Pro He Val Arg Ser Arg Ser Cys Val 115 120 125 Asp Lys Asn Gly Arg Arg Cys Wing Ser Gly Tyr Arg Arg Leu Asn Arg 130 135 140 Wing Arg Being Ser Wing Wing Wing Arg Cys Arg Thr He Gly Thr Phe 145 150 155 160 Arg Arg Ser Arg Tyr Ser Ala Ser Met Arg Val Ser Thr Asn Ser Pro 165 170 175 His Val Thr His Gly Val Wing Pro Gly Val Thr Arg Arg He Gly Gly 180 185 190 (2) INFORMATION FOR SEC ID. DO NOT. : 187: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 196 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 187: Gln Glu Arg Pro Gln Met Cys Gln Arg Val Ser Glu He Glu Pro Arg 1 5 10 15 Thr Gln Phe Phe Asn Arg Cys Ala Leu Pro His Tyr Trp His Phe Pro 20 25 30 Wing Val Wing Val Phe Ser Lys His Wing Ser Leu Asp Glu Leu Wing Pro 40 45 Arg Asn Pro Arg Arg Ser Ser Arg Arg Asp Wing Glu Asp Arg Arg Val 50 55 60 He Phe Wing Wing Thr Leu Val Wing Val Asp Pro Pro Leu Arg Gly Wing 65 70 75 80 Gly Gly Glu Wing Asp Gln Leu He Asp Leu Gly Val Cys Arg Arg Gln 85 90 95 Wing Gly Arg Val Arg Arg Gly Gln Glu Leu His His Arg His Arg Hxs 100 105 110 Gln Gly Ala Ala Pro Asp Leu Arg Arg Arg Arg Arg His Arg Arg Val 115 120 125 Gln Gln His Arg Arg Leu Gln Arg Val Arg Gln Leu Arg Arg Tyr Val 130 135 140 Gln Thr Ala His His Arg Arg Phe Ala Arg Thr Asp Arg Val Arg His 145 150 155 160 His Val Arg Gly Pro Ser Asn His Arg Arg Arg Arg Val Tyr Arg Gly 165 170 175 Arg His Ser Gly Wing Gly Gly Cys Pro Wing Gly Gly Wing Gly Ser Val 180 185 190 Gly Gly Ser Wing 195 (2) INFORMATION FOR SEC ID. NO.:188: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 311 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:188: Val Arg Cys Gly Thr Leu Val Pro Val Pro Met Val Glu Phe Leu Thr 1 5 10 15 Being Thr Asn Ala Pro Being Leu Pro Being Wing Tyr Wing Glu Val Asp Lys 20 25 30 Leu He Gly Leu Pro Wing Gly Thr Wing Lys Arg Trp He Asn Gly Tyr 40 45 Glu Arg Gly Gly Lys Asp His Pro Pro He Leu Arg Val Thr Pro Gly 50 55 60 Wing Thr Pro Trp Val Thr Trp Gly Glu Phe Val Glu Thr Arg Met Leu 65 70 75 80 Wing Glu Tyr Arg Asp Arg Arg Lys Val Pro He Val Arg Gln Arg Wing 85 90 95 Wing He Glu Glu Leu Arg Wing Arg Phe Asn Leu Arg Tyr Pro Leu Wing 100 105 110 His Leu Arg Pro Phe Leu Ser Thr His Glu Arg Asp Leu Thr Met Gly 115 120 125 Gly Glu Glu He Gly Leu Pro Asp Ala Glu Val Thr He Arg Thr Gly 130 135 140 Gln Ala Leu Leu Gly Asp Ala Arg Trp Leu Ala Ser Leu Val Pro Asn 145 150 155 160 Be Wing Arg Gly Wing Thr Leu Arg Arg Leu Gly He Thr Asp Val Wing 165 170 175 Asp Leu Arg Ser Ser Arg Glu Val Wing Arg Arg Gly Pro Gly Arg Val 180 185 190 Pro Asp Gly He Asp Val His Leu Leu Pro Phe Pro Asp Leu Ala Asp 195 200 205 Asp Asp Wing Asp Asp Ser Wing Pro His Glu Thr Wing Phe Lys Arg Leu 210 215 220 Leu Thr Asn Asp Gly Ser Asn Gly Glu Ser Gly Glu Ser Ser Gln Ser 225 230 235 240 He Asn Asp Wing Wing Thr Arg Tyr Met Thr Asp Glu Tyr Arg Gln Phe 245 250 255 Pro Thr Arg Asn Gly Wing Gln Arg Ala Leu His Arg Val Val Thr Leu 260 265 270 Leu Ala Ala Gly Arg Pro Val Leu Thr His Cys Phe Ala Gly Lys Asp 275 280 285 Arg Thr Gly Phe Val Val Ala Leu Val Leu Glu Wing Val Gly Leu Asp 290 295 300 Arg Asp Val He Val Wing Asp 305 310 (2) INFORMATION FOR SEC ID. NO.:189: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2072 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N?: 189: CTCGTGCCGA TTCGGCACGA GCTGAGCAGC CCAAGGGGCC GTTCGGCGAA GTCATCGAGG 60 CATTCGCCGA CGGGCTGGCC GGCAAGGGTA AGCAAATCAA CACCACGCTG AACAGCCTGT 120 CGCAGGCGTT GAACGCCTTG AATGAGGGCC GCGGCGACTT CTTCGCGGTG GTACGCAGCC 180 TGGCGCTATT CGTCAACGCG CTACATCAGG ACGACCAACA GTTCGTCGCG TTGAACAAGA 240 ACCTTGCGGA GTTCACCGAC AGGTTGACCC ACTCCGATGC GGACCTGTCG AACGCCATCC 300 AGCAATTCGA CAGCTTGCTC GCCGTCGCGC GCCCGTTCTT CGCCAAGAAC CGCGAGGTGC 360 TGACGCATGA CGTCAATAAT CTCGCGACCG TGACCACCAC GTTGCTGCAG CCCGATCCGT 420 TGGATGGGTT GGAGACCGTC CTGCACATCT TCCCGACGCT GGCGGCGAAC ATTAACCAGC 480 TTTACCATCC GACACACGGT GGCGTGGTGT CGCTTTCCGC GTTCACGAAT TTCGCCAACC 540 CGATGGAGTT CATCTGCAGC TCGATTCAGG CGGGTAGCCG GCTCGGTTAT CAAGAGTCGG 600 CCGAACTCTG TGCGCAGTAT CTGGCGCCAG TCCTCGATGC GATCAAGTTC AACTACTTTC 660 CGTTCGGCCT GAACGTGGCC AGCACCGCCT CGACACTGCC TAAAGAGATC GCGTACTCCG 720 AGCCCCGCTT GCAGCCGCCC AACGGGTACA AGGACACCAC GGTGCCCGGC ATCTGGGTGC 780 CGGATACGCC GTTGTCACAC CGCAACACGC AGCCCGGTTG GGTGGTGGCA CCCGGGATGC 840 AAGGGGTTCA GGTGGGACCG ATCACGCAGG GTTTGCTGAC GCCGGAGTCC CTGGCCGAAC 900 TCATGGGTGG TCCCGATATC GCCCCTCCGT CGTCAGGGCT GCAAACCCCG CCCGGACCCC 960 CGAATGCGTA CGACGAGTAC CCCGTGCTGC CGCCGATCGG TTTACAGGCC CCACAGGTGC 1020 CGATACCACC GCCGCCTCCT GGGCCCGACG TAATCCCGGG TCCGGTGCCA CCGGTCTTGG 1080 CGGCGATCGT GTTCCCAAGA GATCGCCCGG CAGCGTCGGA AAACTTCGAC TACATGGGCC 1140 TCTTGTTGCT GTCGCCGGGC CTGGCGACCT TCCTGTTCGG GGTGTCATCT AGCCCCGCCC 1200 GTGGAACGAT GGCCGATCGG CACGTGTTGA TACCGGCGAT CACCGGCCTG GCGTTGATCG 1260 CGGCATTCGT CGCACATTCG TGGTACCGCA CAGAACATCC GCTCATAGAC ATGCGCTTGT 1320 TCCAGAACCG AGCGGTCGCG CAGGCCAACA TGACGATGAC GGTGCTCTCC CTCGGGCTGT 1380 TTGGCTCCTT CTTGCTGCTC CCGAGCTACC TCCAGCAAGT GTTGCACCAA TCACCGATGC 1440 AATCGGGGGT GCATATCATC CCACAGGGCC TCGGTGCCAT GCTGGCGATG CCGATCGCCG 1500 GAGCGATGAT GGACCGACGG GGACCGGCCA AGATCGTGCT GGTTGGGATC ATGCTGATCG 1560 CTGCGGGGTT GGGCACCTTC GCCTTTGGTG TCGCGCGGCA AGCGGACTAC TTACCCATTC 1620 TGCCGACCGG GCTGGCAATC ATGGGCATGG GCATGGGCTG CTCCATGATG CCACTGTCCG 1680 GGGCGGCAGT GCAGACCCTG GCCCCACATC AGATCGCTCG CGGTTCGACG CTGATCAGCG 1740 TCAACCAGCA GGTGGGCGGT TCGATAGGGA CCGCACTGAT GTCGGTGCTG CTCACCTACC 1800 AGTTCAATCA CAGCGAAATC ATCGCTACTG CAAAGAAAGT CGCACTGACC CCAGAGAGTG 1860 GCGCCGGGCG GGGGGCGGCG GTTGACCCTT CCTCGCTACC GCGCCAAACC AACTTCGCGG 1920 CCCAACTGCT GCATGACCTT TCGCACGCCT ACGCGGTGGT ATTCGTGATA GCGACCGCGC 1980 TAGTGGTCTC GACGCTGATC CCCGCGGCAT TCCTGCCGAA ACAGCAGGCT AGTCATCGAA 2040 GAGCACCGTT GCTATCCGCA TGACGTCTGC TT 2072 (2) INFORMATION FOR SEC ID. NO .: 190: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1923 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:190: TCACCCCGGA GAAGTCGTTC GTCGACGACC TGGACATCGA CTCGCTGTCG ATGGTCGAGA 60 TCGCCGTGCA GACCGAGGAC AAGTACGGCG TCAAGATCCC CGACGAGGAC CTCGCCGGTC 120 TGCGTACCGT CGGTGACGTT GTCGCCTACA TCCAGAAGCT CGAGGAAGAA AACCCGGAGG 180 CGGCTCAGGC GTTGCGCGCG AAGATTGAGT CGGAGAACCC CGATGCGGCA CGAGCAGATC 240 GGTGCGTTTC ACCCACATCG CAAGCTCGAG ACGCCCGTCG TCCTCTTGCA CGCTCAGCCA 300 GGTTGGCGTG TCGCCGCCTT CCAGCAAGTG TTCCCACCAC ACGAAGGGAC CCTCGCGAAA 360 GGTGACTGAT CCGCGGACCA CATAGTCGAT GCCACCGTGG CTGACAATTG CGCCGGGTCC 420 GAGTTGGCGG GGGCCGAATT GCGGCATTGC GTCGAAGGCC AGCGGATCCC GGCGCCCGCC 480 CGGCGTGGCT GGTGTTTTGG GCCGCCGGAT GGCCACGACG AGAACGACGA TGGCGGCGAT 540 GAACAGCGCC ACGGCAATCA CGACCAGCAG ATTTCCCACG CATACCCTCT CGTACCGCTG 600 CGCCGCGGTT GGTCGATCGG TCGCATATCG ATGGCGCCGT TTAACGTAAC AGCTTTCGCG 660 GGACCGGGGG TCACAACGGG CGAGTTGTCC GGCCGGGAAC CCGGCAGGTC TCGGCCGCGG 720 TCACCCCAGC TCACTGGTGC ACCATCCGGG TGTCGGTGAG CGTGCAACTC AAACACACTC 780 AACGGCAACG GTTTCTCAGG TCACCAGCTC AACCTCGACC CGCAATCGCT CGTACGTTTC 840 GACCGCGCGC A GGTCGCGAG TCAGCAGCTT TGCGCCGGCA GCTTTCGCCG TGAAGCCGAC 900 CAGGGCATCG TAGGTTGCGC CACCGGTGAC ATCGTGCTCG GCGAGGTGGT CGGTCAAGCC 960 GCGATATGAG CAGGCATCCA GTGCCAGGTA GTTGCTGGAG GTGATGTCCG CCAAGTAGGC 1020ACAGGGGCAA TACGATGCGG CGGTGGTAGC CGGGTCAAGA CCGAATAGGT 1080 TTCCACAGCC GCGTGCGCGA TCAGATGGAC GCCACGGTTG AGCGCGCGCA CGGCGGCCTC 1140 GTGCCCTTCG TGCCAGGTCG CGAATCCGGC AACCAGCACG CTGGTGTCTG GTGCGATCAC 1200 CGCCGTGTGC GATCGAGCGT TTCCCGAACG ATTTCGTCGG TCAACGGGGG CAGGGGACGT 1260 TCTGGCCGTG CGACGAGAAC CGAGCCTTCC CGAACGAGTT CGACACCGGT CGGGGCCGGC 1320 TCAATCTCGA TGCGCCCATC GCGCTCGGTG ATCTCCACCT GGTCGTTCCC GCGCAAGCCA 1380 AGGCGCTCGC GAATCCGCTT GGGAATCACC AGACGTCCTG CGACATCGAT GGTTGTTCGC 1440 ATGGTAGGAA ATTTACCATC GCACGTTCCA TAGGCGTGTC CTGCGCGGGA TGTCGGGACG 1500 ATCCGCTAGC GTATCGAACG ATTGTTTCGG AAATGGCTGA GGGAGCGTGC GGTGCGGGTG 1560 ATGGGTGTCG ATCCCGGGTT GACCCGATGC GGGCTGTCGC TCATCGAGAG TGGGCGTGGT 1620 CGGCAGCTCA CCGCGCTGGA TGTCGACGTG GTGCGCACAC CGTCGGATGC GGCCTTGGCG 1680 CAGCGCCTGT TGGCCATCAG CGATGCCGTC GAGCACTGGC TGGACACCCA TCATCCGGAG 1740 GTGGTGGCTA TCGAACGGGT GTTCTCTCAG CTCAACGTGA CCACGGTGAT GGGCACCGCG 1800 CAGGCCGGCG GCGTGATCGC CCTGGCGGCG GCCAAACGTG GTGTCGACGT GCATTTCCAT 1860 ACCCCCAGCG AGGTCAAGGC GGCGGTCACT GGCAACGGTT CCGCAGACAA GGCTCAGGTC 1920 ACC 1923 (2) INFORMATION FOR SEC ID. NO .: 191: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1055 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:191: CTGGCGTGCC AGTGTCACCG GCGATATGAC GTCGGCATTC AATTTCGCGG CCCCGCCGGA 60 CCCGTCGCCA CCCAATCTGG ACCACCCGGT CCGTCAATTG CCGAAGGTCG CCAAGTGCGT 120 GCCCAATGTG GTGCTGGGTT TCTTGAACGA AGGCCTGCCG TATCGGGTGC CCTACCCCCA 180 AACAACGCCA GTCCAGGAAT CCGGTCCCGC GCGGCCGATT CCCAGCGGCA TCTGCTAGCC 240 GGGGATGGTT CAGACGTAAC GGTTGGCTAG GTCGAAACCC GCGCCAGGGC CGCTGGACGG 300 GCTCATGGCA GCGAAATTAG AAAACCCGGG ATATTGTCCG CGGATTGTCA TACGATGCTG 360 AGTGCTTGGT GGTTCGTGTT TAGCCATTGA GTGTGGATGT GTTGAGACCC TGGCCTGGAA 420 GGGGACAACG TGCTTTTGCC TCTTGGTCCG CCTTTGCCGC CCGACGCGGT GGTGGCGAAA 480 CGGGCTGAGT CGGGAATGCT CGGCGGGTTG TCGGTTCCGC TCAGCTGGGG AGTGGCTGTG 540 CCACCCGATG ATTATGACCA CTGGGCGCCT GCGCCGGAGG ACGGCGCCGA TGTCGATGTC 600 CAGGCGGCCG AAGGGGCGGA CGCAGAGGCC GCGGCCATGG ACGAGTGGGA TGAGTGGCAG 660 GCGTGGAACG AGTGGGTGGC GGAGAACGCT GAACCCCGCT TTGAGGTGCC ACGGAGTAGC 720 AGCAGCGTGA TTCCGCATTC TCCGGCGGCC GGCTAGGAGA GGGGGCGCAG ACTGTCGTTA 780 TTTGACCAGT GATCGGCGGT CTCGGTGTTC CCGCGGCCGG CTATGACAAC AGTCAATGTG 840 CATGACAAGT T ACAGGTATT AGGTCCAGGT TCAACAAGGA GACAGGCAAC ATGGCAACAC 900 GTTTTATGAC GGATCCGCAC GCGATGCGGG ACATGGCGGG CCGTTTTGAG GTGCACGCCC 960 AGACGGTGGA GGACGAGGCT CGCCGGATGT GGGCGTCCGC GCAAAACATC TCGGGNGCGG 1020 GCTGGAGTGG CATGGCCGAG GCGACCTCGC TAGAC 1055 (2) INFORMATION FOR SEC ID. NO.:192: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 192: CCGCCTCGTT GTTGGCATAC TCCGCCGCGG CCGCCTCGAC CGCACTGGCC GTGGCGTGTG 60 TCCGGGCTGA CCACCGGGAT CGCCGAACCA TCCGAGATCA CCTCGCAATG ATCCACCTCG 120 CGCAGCTGGT CACCCAGCCA CCGGGCGGTG TGCGACAGCG CCTGCATCAC CTTGGTATAG_180_CCGTCGCGCC CCAGCCGCAG GAAGTTGTAG TACTGGCCCA CCACCTGGTT ACCGGGACGG 240 GAGAAGTTCA GGGTGAAGGT CGGCATGTCG CCGCCGAGGT AGTTGACCCG GAAAACCAGA 300 TCCTCCGGCA GGTGCTCGGG CCCGCGCCAC ACGACAAACC CGACGCCGGG ATAGGTCAG 359 (2) INFORMATION FOR SEC ID NO .: 193: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 350 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:193: AACGGGCCCG TGGGCACCGC TCCTCTAAGG GCTCTCGTTG GTCGCATGAA GTGCTGGAAG 60 GATGCATCTT GGCAGATTCC CGCCAGAGCA AAACAGCCGC TAGTCCTAGT CCGAGTCGCC 120 CGCAAAGTTC CTCGAATAAC TCCGTACCCG GAGCGCCAAA CCGGGTCTCC TTCGCTAAGC 180 TGCGCGAACC ACTTGAGGTT CCGGGACTCC TTGACGTCCA GACCGATTCG TTCGAGTGGC 240 TGATCGGTTC GCCGCGCTGG CGCGAATCCG CCGCCGAGCG GGGTGATGTC AACCCAGTGG 300 GTGGCCTGGA AGAGGTGCTC TACGAGCTGT CTCCGATCGA GGACTTCTCC 350 (2) INFORMATION FOR SEC ID. NO .: 194: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 679 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 194: Glu Gln Pro Lys Gly Pro Phe Gly Glu Val He Glu Wing Phe Wing Asp 1 5 10 15 Gly Leu Wing Gly Lys Gly Lys Gln He Asn Thr Thr Leu Asn Ser Leu 25 30 Ser Gln Ala Leu Asn Ala Leu Asn Glu Gly Arg Gly Asp Phe Phe Wing 35 40 45 Val Val Arg Ser Leu Ala Leu Phe Val Asn Ala Leu His Gln Asp Asp 50 55 60 Gln Gln Phe Val Wing Leu Asn Lys Asn Leu Wing Glu Phe Thr Asp Arg 65 70 75 80 Leu Thr His Ser Asp Wing Asp Leu Ser Asn Wing Gln Gln Phe Asp 85 90 95 Ser Leu Leu Ala Val Ala Arg Pro Phe Phe Ala Lys Asn Arg Glu Val 100 105 110 Leu Thr His Asp Val Asn Asn Leu Wing Thr Val Thr Thr Thr Leu Leu 115 120 125 Gln Pro Asp Pro Leu Asp Gly Leu Glu Thr Val Leu His He Phe Pro 130 135 140 Thr Leu Ala Ala Asri He Asn Gln Leu Tyr His Pro Thr His Gly Gly 145 150 155 160 Val Val Ser Leu Ser Wing Phe Thr Asn Phe Wing Asn Pro Met Glu Phe 165 170 175 He Cys Ser Ser He Gln Ala Gly Ser Arg Leu Gly Tyr Gln Glu Ser 180 185 190 Wing Glu Leu Cys Wing Gln Tyr Leu Wing Pro Val Leu Asp Wing He Lys 195 200 205 Phe Asn Tyr Phe Pro Phe Gly Leu Asn Val Wing Ser Thr Wing Ser Thr 210 215 220 Leu Pro Lys Glu He Ala Tyr Ser Glu Pro Arg Leu Gln Pro Pro Asn 225 230 235 240 Gly Tyr Lys Asp Thr Thr Val Pro Gly He Trp Val Pro Asp Thr Pro 245 250 255 Leu Ser His Arg Asn Thr Gln Pro Gly Trp Val Val Wing Pro Gly Met 260 265 270 Gln Gly Val Gln Val Gly Pro He Thr Gln Gly Leu Leu Thr Pro Glu 275 280 285 Ser Leu Wing Glu Leu Met Gly Gly Pro Asp He Wing Pro Pro Being 290 295 300 Gly Leu Gln Thr Pro Pro Gly Pro Pro Asn Ala Tyr Asp Glu Tyr Pro 305 310 315 320 Val Leu Pro Pro He Gly Leu Gln Ala Pro Gln Val Pro Pro Pro 325 330 335 Pro Pro Pro Gly Pro Asp Val He Pro Gly Pro Val Pro Pro Val Leu 340 345 350 Wing Wing Val Phe Pro Arg Asp Arg Pro Wing Wing Ser Glu Asn Phe 355 360 365 Asp Tyr Met Gly Leu Leu Leu Leu Ser Pro Gly Leu Wing Thr Phé Leu 370 375 380 Phe Gly Val Ser Ser Pro Pro Wing Arg Gly Thr Met Wing Asp Arg His 385 390 395 400 Val Leu He Pro Wing He Thr Gly Leu Wing Leu He Wing Wing Phe Val 405 410 415 Ala His Ser Trp Tyr Arg Thr Glu His Pro Leu He Asp Met Arg Leu 420 425 430 Phe Gln Asn Arg Ala Val Ala Gln Ala Asn Met Thr Met Thr Val Leu 435 440 445 Ser Leu Gly Leu Phe Gly Ser Phe Leu Leu Leu Pro Ser Tyr Leu Gln 450 455 460 Gln Val Leu His Gln Ser Pro Met Gln Ser Gly Val His He He Pro 465 470 475 480 Gln Gly Leu Gly Wing Met Leu Wing Met Pro He Wing Gly Wing Met Met 485 490 495 Asp Arg Arg Gly Pro Wing Lys He Val Val Leu Val Gly He Met Leu He 500 505 510 Wing Wing Gly Leu Gly Thr Phe Wing Phe Gly Val Wing Arg Grh Wing Asp 515 520 525 Tyr Leu Pro He Leu Pro Thr Gly Leu Wing He Met Gly Met Gly Met 530 535 540 Gly Cys Ser Met Met Pro Leu Ser Gly Wing Wing Val Gln Thr Leu Wing 545 550 555 560 Pro His Gln He Wing Arg Gly Ser Thr Leu He Ser Val Asn Gln Gln 565 570 575 Val Gly Gly Be He Gly Thr Ala Leu Met Be Val Leu Leu Thr Tyr 580 585 590 Gln Phe Asn His Ser Glu He He Wing Thr Wing Lys Lys Val Wing Leu 595 600 605 Thr Pro Glu Ser Gly Wing Gly Arg Gly Wing Wing Val Asp Pro Ser Ser 610 615 620 Leu Pro Arg Gln Thr Asn Phe Wing Wing Gln Leu Leu His Asp Leu Ser 625 630 635 640 His Ala Tyr Ala Val Val Phe Val He Ala Thr Ala Leu Val Val Ser 645 645 655 Thr Leu He Pro Wing Wing Phe Leu Pro Lys Gln Gln Wing Ser His Arg 660 665 670 Arg Ala Pro Leu Leu Ser Ala 675 (2) INFORMATION FOR SEC ID. NO.:195 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 195: Thr Pro Glu Lys Ser Phe Val Asp Asp Leu Asp He Asp Ser Leu Ser 1 5 10 15 Met Val Glu He Wing Val Gln Thr Glu Asp Lys Tyr Gly Val Lys He 20 25 30 Pro Asp Glu Asp Leu Wing Gly Leu Arg Thr Val Gly Asp Val Val Wing 35 40 45 Tyr He Gln Lys Leu Glu Glu Glu Asn Pro Glu Wing Ala Gln Ala Leu 50 55 60 Arg Ala Lys He Glu Ser Glu Asn Pro Asp Ala Ala Arg Ala Asp Arg 65 70 75 80 Cys Val Ser Pro Thr Ser Gln Wing Arg Asp Wing Arg Arg Pro Leu Wing 85 90 95 Arg Ser Ala Arg Leu Ala Cys Arg Arg Leu Pro Ala Ser Val Pro Thr 100 105 110 Thr Arg Arg Asp Pro Arg Glu Arg 115 120 (2) INFORMATION FOR SEC ID. DO NOT. : 196: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 89 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 196: Leu Ala Cys Gln Cys His Arg Arg Tyr Asp Val Gly He Gln Phe Arg 1 5 10 15 Gly Pro Wing Gly Pro Val Wing Thr Gln Ser Gly Pro Pro Gly Pro Ser 20 25 30 He Wing Glu Gly Arg Gln Val Arg Wing Gln Cys Gly Wing Gly Phe Leu 40 45 Glu Arg Arg Pro Wing Val Ser Gly Wing Leu Pro Pro Asn Asn Wing Ser 50 55 60 Pro Gly He Arg Ser Arg Wing Wing Asp Ser Gln Arg His Leu Leu Wing 65 70 75 80 Gly Asp Gly Ser Asp Val Thr Val Gly 85 (2) INFORMATION FOR SEC ID. NO.:197: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 119 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 197: Ala Ser Leu Leu Ala Tyr Be Ala Ala Ala Ala Be Thr Ala Ala Ala 1 5 10 15 Val Ala Cys Val Arg Ala Asp His Arg Asp Arg Arg Thr He Arg Asp 25 30 His Leu Wing Met He His Leu Wing Gln Leu Val Thr Gln Pro Pro Gly 35 40 45 Gly Val Arg Gln Arg Leu His His Leu Gly He Wing Val Wing Pro Gln 50 55 60 Pro Gln Glu Val Val Val Leu Wing His His Leu Val Thr Gly Thr Gly 65 70 75 80 Glu Val Gln Gly Glu Gly Arg His Val Ala Glu Wing Val Val Asp Pro 85 90 95 Glu Asn Gln He Leu Arg Gln Val Leu Gly Pro Wing Pro His Asp Lys 100 105 110 Pro Asp Wing Gly He Gly Gln 115 (2) INFORMATION FOR SEC ID. NO.:198:; i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 116 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 198: Arg Ala Arg Gly His Arg Ser Ser Lys Gly Ser Arg Trp Ser His Glu 1 5 10 15 Val Leu Glu Gly Cys He Leu Wing Asp Ser Arg Gln Ser Lys Thr Ala 25 30 Wing Pro Pro Ser Pro Arg Pro Gln Ser Ser As Asn Asn Ser Val 35 40 45 Pro Gly Ala Pro Asn Arg Val Ser Phe Ala Lys Leu Arg Glu Pro Leu 50 55 60 Glu Val Pro Gly Leu Leu Asp Val Gln Thr Asp Ser Phe Glu Trp Leu 65 70 75 80 He Gly Ser Pro Arg Trp Arg Glu Ser Ala Ala Glu Arg Gly Asp Val 85 90 95 Asn Pro Val Gly Glu Leu Glu Glu Val Leu Tyr Glu Leu Ser Pro He 100 105 110 Glu Asp Phe Ser 115 (2) INFORMATION FOR SEC ID. NO.:199 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 811 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:199: TGCTACGCAG CAATCGCTTT GGTGACAGAT GTGGATGCCG GCGTCGCTGC TGGCGATGGC 60 GTGAAAGCCG CCGACGTGTT CGCCGCATTC GGGGAGAACA TCGAACTGCT CAAAAGGCTG 120 GTGCGGGCCG CCATCGATCG GGTCGCCGAC GAGCGCACGT GCACGCACTG TCAACACCAC 180 GCCGGTGTTC CGTTGCCGTT CGAGCTGCCA TGAGGGTGCT GCTGACCGGC GCGGCCGGCT 240 TCATCGGGTC GCGCGTGGAT GCGGCGTTAC GGGCTGCGGG TCACGACGTG GTGGGCGTCG 300 ACGCGCTGCT GCCCGCCGCG CACGGGCCAA ACCCGGTGCT GCCACCGGGC TGCCAGCGGG 360 TCGACGTGCG CGACGCCAGC GCGCTGGCCC CGTTGTTGGC CGGTGTCGAT CTGGTGTGTC 420 ACCAGGCCGC CATGGTGGGT GCCGGCGTCA ACGCCGCCGA CGCACCCGCC TATGGCGGCC 480 ACAACGATTT CGCCACCACG GTGCTGCTGG CGCAGATGTT CGCCGCCGGG GTCCGCCGTT 540 TGGTGCTGGC GTCGTCGATG GTGGTTTACG GGCAGGGGCG CTATGACTGT CCCCAGCATG 600 GACCGGTCGA CCCGCTGCCG CGGCGGCGAG CCGACCTGGA CAATGGGGTC TTCGAGCACC 660 GTTGCCCGGG GTGCGGCGAG CCAGTCATCT GGCAATTGGT CGACGAAGAT GCCCCGTTGC 720 GCCCGCGCAG CCTGTACGCG GCAGCAAGAC CGCGCAGGAG CACTACGCGC TGGCGTGGTC 780 GGAAACGAAT GGCGGTTCCG TGGTGGCGTT G 811 (2) INFORMATION FOR SEC ID. NO .: 200: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 966 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 200: GTCCCGCGAT GTGGCCGAGC ATGACTTTCG GCAACACCGG CGTAGTAGTC GAAGATATCG 60 GACTTTGTGG TCCCGGTGGC GGGATAGAGC ACCTGTCGGC GTTGGTCAGC GTCACCCGTT 120 GCTCGGACGC CGAACCCATG CTTTCAACGT AGCCTGTCGG TCACACAAGT CGCGAGCGTA 180 ACGTCACGGT CAAATATCGC GTGGAATTTC GCCGTGACGT TCCGCTCGCG GACAATCAAG 240 GCATACTCAC TTACATGCGA GCCATTTGGA CGGGTTCGAT CGCCTTCGGG CTGGTGAACG 300 TGCCGGTCAA GGTGTACAGC GCTACCGCAG ACCACGACAT CAGGTTCCAC CAGGTGCACG 360 CCAAGGACAA CGGACGCATC CGGTACAAGC GCGTCTGCGA GGCGTGTGGC GAGGTGGTCG 420 ACTACCGCGA TCTTGCCCGG GCCTACGAGT CCGGCGACGG CCAAATGGTG GCGATCACCG 480 ACGACGACAT CGCCAGCTTG CCTGAAGAAC GCAGCCGGGA GATCGAGGTG TTGGAGTTCG 540 TCCCCGCCGC CGACGTGGAC CCGATGATGT TCGACCGCAG CTACTTTTTG GAGCCTGATT 600 CGAAGTCGTC GAAATCGTAT GTGCTGCTGG CTAAGACACT CGCCGAGACC GACCGGATGG 660 CGATCGTGGA TCGCCCCACC GGCCGTGAAT GCAGGAAAAA TAAGAGCCGC TATCCACAAT 720 TCGGBGTCGA GCTCGGCTAC CACAAACGGT AGAACGATCG AGACATTCCC GAGCTGAAGT 780 GCGGCGCTAT AGAAGCCGCT CTGCGCGATT ATCAAACGCA AAATACGCTT ACTCATGCCA 840 TCGGCGCTGC TCACCCGATG CGACGTTTTT GCCACGCTCC ACCGCCTGCC GCGCGACCTC 900 AAGTGGGCAT GCATCCCACC CGTTCCCGGA AACCGGTTCC GGCGGGTCGG CTCATCGCTT CATCCT 960 966 (2) INFORMATION FOR SEC ID. DO NOT. : 201: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2367 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 201: CCGCACCGCC GGCAATACCG CCAGCGCCAC CGTTACCGCC GTTTGCGCCG TTGCCCCCGT 60 TGCCGCCCGT CCCGCCGGCC CCGCCGATGG AGTTCTCATC GCCAAAAGTA CTGGCGTTGC 120 CACCGGAGCC GCCGTTGCCG CCGTCACCGC CAGCCCCGCC GACTCCACCG GCCCCACCGA 180 CTCCGCCGCT GCCACCGTTG CCGCCGTTGC CGATCAACAT GCCGCTGGCG CCACCCTTGC 240 CACCCACGCC ACCGGCTCCG CCCACCCCGC CGACACCAAG CGAGCTGCCG CCGGAGCCAC 300 CATCACCACC TACGCCACCG ACCGCCCAGA CACCAGCGAC CGGGTCTTCG TGAAACGTCG 360 CGGTGCCACC ACCGCCGCCG TTACCGCCAA CCCCACCGGC AACGCCGGCG CCGCCATCCC 420 CGCCGGCCCC GGCGTTGCCG CCGTTGCCGC CGTTGCCGAA CAACAACCCG CCGGCGCCGC 480 CGTTGCCGCC CGCGCCGCCG GTCCCGCCGG CGCCGCCGAC GCCAAGGCCG CTGCCGCCCT 540 TGCCGCCATC ACCACCCTTG CCGCCGACCA CATCGGGTTC TGCCTCGGGG TCTGGGCTGT 600 CAAACCTCGC GATGCCAGCG TTGCCGCCGC TTCCCCCGGG CCCCCCCGTG GCGCCGTCAC 660 CACCGATACC ACCCGCGCCA CCGGCGCCAC CGTTGCCGCC ATCACCGAAT AGCAACCCGC 720 CGGCGCCACC ATTGCCGCCA GCTCCCCCTG CGCCACCGTC GGCGCCGGAG GCGGCACTGG 780 CAGCCCCGTT ACCACCGAAA CCGCCGCTAC CACCGGTAGA GGTGGCAGTG GCGATGTGTA 840 CGAAAGCGCC GCCT CCGGCG CCGCCGCTAC CACCCCCACT GCCGGCGGCT ACACCGTCGG 900 ACCCGTTGCC ACCATCACCG CCAAAGGCGC TCGCAATGTC GCCCTGCGCG ACTCCGCCGT 960 CGCCGCCGTT GCCGCCGCCG CCACCGGCAG CGGCGGTACC GCCGTCACCA CCGGCACCGC 1020 CGGTGGCCTT GCCCGAGCCT GCCGTCGCGG TGGCACCGTC GCCGCCGGTG CCACCGGTCG 1080 GCGTGCCGGC AGTGCCATGG CCGCCCGTGC CGCCGTCGCC GCCGGTTTGA TCACCGATGC 1140 CGGACACATC TGCCGGGCTG TCCCCGGTGC TGGCCGCGGG GCCGGGCGTG GGATTGACCC 1200 CGTTTGCCCC GGCGAGGCCG GCGCCGCCGG TACCACCGGC GCCGCCATGG CCGAACAGCC 1260 CGGCGTTGCC GCCGTTACCG CCCGCACCCC CGATGCCTGC GGCCACGCTG GTGCCGCCGA 1320 CACCGCCGTT GCCGCCGTTG CCCCACAACC ACCCCCCGTT CCCACCGGCA CCGCCGGCCG 1380 CGCCGGTACC ACCGGCCCCG CCGTTGCCGC CGTTGCCGAT CAACCCGGCC GCGCCTCCGC 1440 TGCCGCCGGT TTGACCGAAC CCGCCAGCCG CGCCGTTGCC ACCGTTGCCA AACAGCAACC 1500 CGCCGGCCGC GCCAGGCTGC CCGGGTGCCG TCCCGTCGGC GCCGTTTCCG ATCAACGGGC 1560 GCCCCAAAAG CGCCTCGGTG GGCGCATTCA CCGCACCCAG CAGACTCCGC TCAACAGCGG 1620 CTTCAGTGCT GGCATACCGA CCCGCGGCCG CAGTCAACGC CTGCACAAAC TGCTCGTGAA 1680 ACGCTGCCAC CTGTACGCTG A GCGCCTGAT ACTGCCGAGC ATGGGCCCCG AACAACCCCG 1740 CAATCGCCGC CGACACTTCA TCGGCAGCCG CAGCCACCAC TTCCGTCGTC 'GGGATCGCCG 1800 CGGCCGCATT AGCCGCGCTC ACCTGCGAAC CAATAGTCGA TAAATCCAAA GCCGCAGTTG 1860 CCAGCAGCTG CGGCGTCGCG ATCACCAAGG ACACCTCGCA CCTCCGGATA CCCCATATCG 1920 CCGCACCGTG TCCCCAGCGG CCACGTGACC TTTGGTCGCT GGCTGGCGGC CCTGACTATG 1980 GCCGCGACGG CCCTCGTTCT GATTCGCCCC GGCGCGCAGC TTGTTGCGCG AGTTGAAGAC 2040 GGGAGGACAG GCCGAGCTTG GTGTAGACGT GGGTCAAGTG GGAATGCACG GTCCGCGGCG 2100 AGATGAATAG GCGGACGCCG ATCTCCTTGT TGCTGAGTCC CTCACCGACC AGTAGAGCCA 2160 CCTCAAGCTC TGTCGGTGTC AACGCGCCCC AGCCACTTGT CGGGCGTTTC CGTGCACCGC 2220 GGCCTCGTTG CGCGTACGCG ATCGCCTCAT CGATCGATAA CGCAGTTCCT TBGGCCCAGG 2280 CATCGTCGAA CTCGCTGTCA CCCATGGATT TTCGAAGGGT GGCTAGCGAC GAGTTACAGC 2340 CCGCCTGGTA GATCCCGAAG CGGACCG 2367 (2) INFORMATION FOR SEC ID. NO.:202 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 202: Gln Pro Wing Gly Wing Thr Wing Wing Being Ser Pro Cys Wing Thr Val 1 5 10 15 Gly Wing Gly Gly Gly Thr Gly Ser Pro Val Thr Thr Glu Thr Wing Wing 20 25 30 Thr Thr Gly Arg Gly Gly Ser Gly Asp Val Tyr Glu Ser Ala Ala Ser 40 45 Gly Wing Wing Wing Thr Thr Pro Thr Wing Gly Gly Tyr Thr Val Gly Pro 50 55 60 Val Wing Thr He Thr Wing Lys Gly Wing Arg Asn Val Wing Leu Arg Asp 65 70 75 80 Be Ala Ala Ala Ala Ala Ala Ala Ala Ala Thr Gly Ser Gly Gly Thr 85 90 95 Wing Val Thr Thr Gly Thr Wing Gly Gly Leu Wing Arg Wing Cys Arg Arg 100 105 110 Gly Gly Thr Val Wing Wing Gly Wing Thr Gly Arg Arg Wing Gly Wing 115 120 125 Met Ala Ala Arg Ala Ala Ala Ala Ala Ala Gly Leu He Thr Asp Ala Gly. 130 135 140 His He Cys Arg Wing Val Pro Gly Wing Gly Arg Gly Wing Gly Arg Gly 145 150 155 160 He Asp Pro Val Cys Pro Gly Glu Wing Gly Wing Wing Gly Thr Thr Gly 165 170 175 Ala Ala Met Ala Gllu Gln Pro Gly Val Ala Ala Val Thr Ala Arg Thr 180 185 190 Pro Asp Ala Cys Gly His Ala Gly Ala Ala Ala Asp Thr Ala Val Ala Ala 195 200 205 Val Wing Pro Gln Pro Pro Val Pro Thr Gly Thr Wing Gly Arg Wing 210 215 220 Gly Thr Thr Gly Pro Wing Wing Wing Wing Val Wing Asp Gln Pro Gly Arg 225 230 235 240 Wing Wing Wing Wing Wing Gly Leu Thr Glu Pro Wing Wing Arg Ala Wing Wing 245 250 255 Thr Val Wing Lys Gln Gln Pro Wing Gly Arg Wing Arg Leu Pro Gly Cys 260 265 270 Arg Pro Val Gly Ala Val Ser Asp Gln Arg Ala Pro Gln Lys Arg Leu 275 280 285 Gly Gly Arg He His Arg Thr Gln Gln Thr Pro Leu Asn Ser Gly Phe 290 295 300 Be Ala Gly He Pro Thr Arg Gly Arg Ser Gln Arg Leu his Lys Leu 305 310 315 320 Leu Val Lys Arg Cys His Leu Tyr Ala Glu Arg Leu He Leu Pro Ser 325 330 335 Met Gly Pro Glu Gln Pro Arg Asn Arg Arg Arg His Phe He Gly Ser 340 345 350 Arg Ser Hxs His Phe Arg Arg Arg Asp Arg Arg Gly Arg lie Ser Arg 355 360 365 Ala His Leu Arg Thr Asn Ser Arg 370 375 (2) INFORMATION FOR SEC ID. NO.:203 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2852 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. 203: GGCCAAAACG CCCCGGCGAT CGCGGCCACC GAGGCCGCCT ACGACCAGAT GTGGGCCCAG 60 GACGTGGCGG CGATGTTTGG CTACCATGCC GGGGCTTCGG CGGCCGTCTC GGCGTTGACA 120 CCGTTCGGCC AGGCGCTGCC GACCGTGGCG GGCGGCGGTG CGCTGGTCAG CGCGGCCGCG 180 GCTCAGGTGA CCACGCGGGT CTTCCGCAAC CTGGGCTTGG CGAACGTCCG CGAGGGCAAC 240 GTCCGCAACG GTAATGTCCG GAACTTCAAT CTCGGCTCGG CCAACATCGG CAACGGCAAC 300 ATCGGCAGCG GCAACATCGG CAGCTCCAAC ATCGGGTTTG GCAACGTGGG TCCTGGGTTG 360 ACCGCAGCGC TGAACAACAT CGGTTTCGGC AACACCGGCA GCAACAACAT CGGGTTTGGC 420 AACACCGGCA GCAACAACAT CGGGTTCGGC AATACCGGAG ACGGCAACCG AGGTATCGGG 480 CTCACGGGTA GCGGTTTGTT GGGGTTCGGC GGCCTGAACT CGGGCACCGG CAACATCGGT 540 CTGTTCAACT CGGGCACCGG AAACGTCGGC ATCGGCAACT CGGGTACCGG GAACTGGGGC 600 ATTGGCAACT CGGGCAACAG CTACAACACC GGTTTTGGCA ACTCCGGCGA CGCCAACACG 660 GGCTTCTTCA ACTCCGGAAT AGCCAACACC GGCGTCGGCA ACGCCGGCAA CTACAACACC 720 GGTAGCTACA ACCCGGGCAA CAGCAATACC GGCGGCTTCA ACATGGGCCA GTACAACACG 780 GGCTACCTGA ACAGCGGCAA CTACAACACC GGCTTGGCAA ACTCCGGCAA TGTCAACACC 840 GGCGCCTTCA TT ACTGGCAA CTTCAACAAC GGCTTCTTGT GGCGCGGCGA CCACCAAGGC 900 CTGATTTTCG GGAGCCCCGG CTTCTTCAAC TCGACCAGTG CGCCGTCGTC GGGATTCTTC 960 AACAGCGGTG CCGGTAGCGC GTCCGGCTTC CTGAACTCCG GTGCCAACAA TTCTGGCTTC 1020 TTCAACTCTT CGTCGGGGGC CATCGGTAAC TCCGGCCTGG CAAACGCGGG CGTGCTGGTA 1080 TCGGGCGTGA TCAACTCGGG CAACACCGTA TCGGGTTTGT TCAACATGAG CCTGGTGGCC 1140 ATCACAACGC CGGCCTTGAT CTCGGGCTTC TTCAACACCG GAAGCAACAT GTCGGGATTT 1200 TTCGGTGGCC CACCGGTCTT CAATCTCGGC CTGGCAAACC GGGGCGTCGT GAACATTCTC 1260 GGCAACGCCA ACATCGGCAA TTACAACATT CTCGGCAGCG GAAACGTCGG TGACTTCAAC 1320 ATCCTTGGCA GCGGCAACCT CGGCAGCCAA AACATCTTGG GCAGCGGCAA CGTCGGCAGC 1380 TTCAATATCG GCAGTGGAAA CATCGGAGTA TTCAATGTCG GTTCCGGAAG CCTGGGAAAC 1440 TACAACATCG GATCCGGAAA CCTCGGGATC TACAACATCG GTTTTGGAAA CGTCGGCGAC 1500 TACAACGTCG GCTTCGGGAA CGCGGGCGAC TTCAACCAAG GCTTTGCCAA CACCGGCAAC 1560 AACAACATCG GGTTCGCCAA CACCGGCAAC AACAACATCG GCATCGGGCT GTCCGGCGAC 1620 AACCAGCAGG GCTTCAATAT TGCTAGCGGC TGGAACTCGG GCACCGGCAA CAGCGGCCTG 1680 TTCAATTCGG GCACCAATAA CGTTGGCATC TTCAACGCGG GCACCGGAAA CGTCGGCATC 1740 GCAAACTCGG GCACCGGGAA CTGGGGTATC GGGAACCCGG GTACCGACAA TACCGGCATC 1800 CTCAATGCTG GCAGCTACAA CACGGGCATC CTCAACGCCG GCGACTTCAA CACGGGCTTC 1860 TACAAC ACGG GCAGCTACAA CACCGGCGGC TTCAACGTCG GTAACACCAA CACCGGCAAC 1920 TTCAACGTGG GTGACACCAA TACCGGCAGC TATAACCCGG GTGACACCAA CACCGGCTTC 1980 TTCAATCCCG GCAACGTCAA TACCGGCGCT TTCGACACGG GCGACTTCAA CAATGGCTTC 2040 TTGGTGGCGG GCGATAACCA GGGCCAGATT GCCATCGATC TCTCGGTCAC CACTCCATTC 2100 ATCCCCATAA ACGAGCAGAT GGTCATTGAC GTACACAACG TAATGACCTT CGGCGGCAAC 2160 ATGATCACGG TCACCGAGGC CTCGACCGTT TTCCCCCAAA CCTTCTATCT GAGCGGTTTG 2220 TTCTTCTTCG GCCCGGTCAA TCTCAGCGCA TCCACGCTGA CCGTTCCGAC GATCACCCTC 2280 ACCATCGGCG GACCGACGGT GACCGTCCCC ATCAGCATTG TCGGTGCTCT GGAGAGCCGC 2340 ACGATTACCT TCCTCAAGAT CGATCCGGCG CCGGGCATCG GAAATTCGAC CACCAACCCC 2400 TCGTCCGGCT TCTTCAACTC GGGCACCGGT GGCACATCTG GCTTCCAAAA CGTCGGCGGC 2460 GGCAGTTCAG GCGTCTGGAA CAGTGGTTTG AGCAGCGCGA TAGGGAATTC GGGTTTCCAG 2520 AACCTCGGCT CGCTGCAGTC AGGCTGGGCG AACCTGGGCA ACTCCGTATC GGGCTTTTTC 2580 AACACCAGTA CGGTGAACCT CTCCACGCCG GCCAATGTCT CGGGCCTGAA CAACATCGGC 2640 ACCAACCTGT CCGGCGTGTT CCGCGGTCCG ACCGGGACGA TTTTCAACGC GGGCCTTGCC 2700 AACCTGGGCC AGTTGAACAT CGGCAGCGCC TCGTGCCGAA TTCGGCACGA GTTAGATACG 2760 GTTTCAACAA TCATATCCGC GTTTTGCGGC AGTGCATCAG ACGAATCGAA CCCGGGAAGC 2820 GTAAGCGAAT AAACCGAATG GCGGCCTGTC AT 2852 (2) INFORMATION FOR SEC ID. NO .: 204: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 943 amino acids (B) TYPE: amino acid (C) HEBRA: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 204: Gly Gln Asn Wing Pro Wing He Wing Wing Thr Glu Wing Wing Tyr Asp Gln. 1 5 10 15 Met Trp Wing Gln Asp Val Wing Wing Met Phe Gly Tyr His Wing Gly Wing 20 25 30 Wing Wing Val Wing Wing Leu Thr Pro Phe Gly Gln Wing Leu Pro Thr 35 40 45 Val Wing Gly Gly Wing Wing Leu Val Be Ala Ala Ala Ala Gln Val Thr 50 55 60 Thr Arg Val Phe Arg Asn Leu Gly Leu Wing Asn Val Arg Glu Gly Asn 65 70 75 80 Val Arg Asn Gly Asn Val Arg Asn Phe Asn Leu Gly Be Ala Asn He 85 90 95 Gly Asn Gly Asn He Gly Be Gly Asn He Gly Be Ser Asn He Gly 100 105 110 Phe Gly Asn Val Gly Pro Gly Leu Thr Ala Ala Leu Asn Asn He Gly 115 120 125 Phe Gly Asn Thr Gly Ser Asn Asn He Gly Phe Gly Asn Thr Gly Ser 130 135 140 Asn Asn He Gly Phe Gly Asn Thr Gly Asp Gly Asn Arg Gly He Gly 145 150 155. 160 Leu Thr Gly Ser Gly Leu Leu Gly Phe Gly Gly Leu Asn Ser Gly Thr 165 170 175 Gly Asn He Gly Leu Phe Asn Ser Gly Thr Gly Asn Val Gly He Gly 180 185 190 Asn Ser Gly Thr Gly Asn Trp Gly lie Gly Asn Ser Gly Asn Ser Tyr 195 200 205 Asn Thr Gly Phe Gly Asn Ser Gly Asp Wing Asn Thr Gly Phe Phe Asn 210 215 220 Ser Gly He Wing Asn Thr Gly Val Gly Asn Wing Gly Asn Tyr Asn Thr 225 230 235 240 Gly Ser Tyr Asn Pro Gly Asn Ser Asn Thr Gly Gly Phe Asn Met Gly 245 250 255 Gln Tyr Asn Thr Gly Tyr Leu Asn Ser Gly Asn Tyr Asn Thr Gly Leu 260 265 270 Wing Asn Ser Gly Asn Val Asn Thr Gly Wing Phe He Thr Gly Asn Phe 275 280 285 Asn Asn Gly Phe Leu Trp Arg Gly Asp His Gln Gly Leu He Phe Gly 290 295 300 Ser Pro Gly Phe Phe Asn Ser Thr Ser Wing Pro Ser Ser Gly Phe Phe 305 310 315 320 Asn Ser Gly Wing Gly Ser Wing Ser Gly Phe Leu Asn Ser Gly Wing Asn 325 330 335 Asn Ser Gly Phe Phe Asn Being Ser Gly Wing He Gly Asn Ser Gly 340 345 350 Leu Wing Asn Wing Gly Val Leu Val Ser Gly Val He Asn Ser Gly Asn 355 360 365 Thr Val Ser Gly Leu Phe Asn Met Ser Leu Val Wing He Thr Thr Pro 370 375 380 Wing Leu He Ser Gly Phe Phe Asn Thr Gly Ser Asn Met Ser Gly Phe 385 390 395 400 Phe Gly Pro Pro Val Phe Asn Leu Gly Leu Ala Asn Arg Gly Val 405 410 415 Val Asn He Leu Gly Asn Wing Asn He Gly Asn Tyr Asn He Leu Gly 420 425 430 Ser Gly Asn Val Gly Asp Phe Asn He Leu Gly Ser Gly Asn Leu Gly 435 440 445 Ser Gln Asn He Leu Gly Ser Gly Asn Val Gly Ser Phe Asn He Gly 450 455 460 Ser Gly Asn He Gly Val Phe Asn Val Gly Ser Gly Ser Leu Gly Asn 465 470 475 480 Tyr Asn He Gly Ser Gly Asn Leu Gly He Tyr Asn He Gly Phe Gly 485 490 495 Asn Val Gly Asp Tyr Asn Val Gly Phe Gly Asn Wing Gly Asp Phe Asn 500 505 510 Gln Gly Phe Wing Asn Thr Gly Asn Asn Asn He Gly Phe Wing Asn Thr 515 520 525 Gly Asn Asn Asn He Gly He Gly Leu Ser Gly Asp Asn Gln Gln Gly 530 535 540 Phe Asn He Wing Ser Gly Trp Asn Ser Gly Thr Gly Asn Ser Gly Leu 545 550 555 560 Phe Asn Ser Gly Thr Asn Asn Val Gly He Phe Asn Wing Gly Thr Gly 565 570 575 Asn Val Gly He Wing Asn Being Gly Thr Gly Asn Trp Gly He Gly Asn 580 585 590 Pro Gly Thr Asp Asn Thr Gly lie Leu Asn Wing Gly Ser Tyr Asn Thr 595 600 605 Gly He Leu Asn Wing Gly Asp Phe Asn Thr Gly Phe Tyr Asn Thr Gly 610 615 620 Ser Tyr Asn Thr Gly Gly Phe Asn Val Gly Asn Thr Asn Thr Gly Asn 625 630 635 640 Phe Asn Val Gly Asp Thr Asn Thr Gly Ser Tyr ASn Pro Gly Asp Thr 645 650 655 Asn Thr Gly Phe Phe Asn Pro Gly Asn Val Asn Thr Gly Wing Phe Asp 660 665 670 Thr Gly Asp Phe Asn Asn Gly Phe Leu Val Wing Gly Asp Asn Gln Gly 675 680 685 Gln He Wing He Asp Leu Ser Val Thr Thr Pro Phe He Pro He Asn 690 695 700 Glu Gln Met Val He Asp Val His Asn Val Met Thr Phe Gly Gly Asn 705 710 715 720 Met He Thr Val Thr Glu Ala Ser Thr Val Phe Pro Gln Thr Phe Tyr 725 730 735 Leu Be Gly Leu Phe Phe Phe Gly Pro Val Asn Leu Be Ala Be Thr 740 745 750 Leu Thr Val Pro Thr He Thr Leu Thr He Gly Gly Pro Thr Val Thr 755 760 765 Val Pro He Ser He Val Gly Ala Leu Glu Ser Arg Thr He Thr Phe 770 775 780 Leu Lys He Asp Pro Pro Wing Gly He Gly Asn Ser Thr Thr Asn Pro 785 790 795 800 Ser Ser Gly Phe Phe Asn Ser Gly Thr Gly Gly Thr Ser Gly Phe Gln 805 810 815 Asn Val Gly Gly Gly Ser Gly Val Trp Asn Ser Gly Leu Ser Ser 820 825 830 Wing He Gly Asn Ser Gly Phe Gln Asn Leu Gly Ser Leu Gln Ser Gly 835 840 845 Trp Wing Asn Leu Gly Asn Ser Val Ser Gly Phe Phe Asn Thr Ser Thr 850 855 860 Val Asn Leu Ser Thr Pro Wing Asn Val Ser Gly Leu Asn Asn He Gly 865 870 875 880 Thr Asn Leu Ser Gly Val Phe Arg Gly Pro Thr Gly Thr He Phe Asn 885 890 895 Wing Gly Leu Wing Asn Leu Gly Gln Leu Asn He Gly Being Wing Being Cys 900 905 910 Arg He Arg His Glu Leu Asp Thr Val Ser Thr He He Ser Ala Phe 915 920 925 Cys Gly Ser Wing Ser Asp Glu Ser Asn Pro Gly Ser Val Ser Glu 930 935 940 (2) INFORMATION FOR SEC ID. NO.:205 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 53 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:205: GGATCCATAT GGGCCATCAT CATCATCATC ACGTGATCGA CATCATCGGG ACC 53 (2) INFORMATION FOR SEC ID. NO .: 206 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 206: CCTGAATTCA GGCCTCGGTT GCGCCGGCCT CATCTTGAAC GA 42 (2) INFORMATION FOR SEC ID. DO NOT. : 207: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 207 GGATCCTGCA GGCTCGAAAC CACCGAGCGG T 31 (2) INFORMATION FOR SEC ID. NO.:208 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:208 CTCTGAATTC AGCGCTGGAA ATCGTCGCGA T 31 (2) INFORMATION FOR SEC ID. NO .: 209 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT. : 209: GGATCCAGCG CTGAGATGAA GACCGATGCC GCT 33 (2) INFORMATION FOR SEC ID. DO NOT. : 210 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:210 GGATATCTGC AGAATTCAGG TTTAAAGCCC ATTTGCGA 38 (2) INFORMATION FOR SEC ID. NO .: 211: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:211: CCGCATGCGA GCCACGTGCC CACAACGGCC 30 (2) INFORMATION FOR SEC ID. NO.:212: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:212: CTTCATGGAA TTCTCAGGCC GGTAAGGTCC GCTGCGG 37 (2) INFORMATION FOR SEC ID. DO NOT. : 213 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7676 base pairs (B) TYPE: nucleic acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. NO.:213: TGGCGAATGG GACGCGCCCT GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG TGGTTACGCG 60 CAGCGTGACC GCTACACTTG CCAGCGCCCT AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC 120 CTTTCTCGCC ACGTTCGCCG GCTTTCCCCG TCAAGCTCTA AATCGGGGGC TCCCTTTAGG 180 GTTCCGATTT AGTGCTTTAC GGCACCTCGA CCCCAAAAAA CTTGATTAGG GTGATGGTTC 240 ACGTAGTGGG CCATCGCCCT GATAGACGGT TTTTCGCCCT TTGACGTTGG AGTCCACGTT 300 CTTTAATAGT GGACTCTTGT TCCAAACTGG AHCAACACTC AACCCTATCT CGGTCTATTC 360 TTTTGATTTA TAAGGGATTT TGCCGATTTC GGCCTATTGG TTAAAAAATG AGCTGATTTA 420 ACAAAAATTT AACGCGAATT TTAACAAAAT ATTAACGTTT ACAATTTCAG GTGGCACTTT 480 TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC TAAATACATT CAAATATGTA 540 TCCGCTCATG AATTAATTCT TAGAAAAACT CATCGAGCAT CAAATGAAAC TGCAATTTAT 600 TCATATCAGG AT ATCAATA CCATATTTTT GAAAAAGCCG TTTCTGTAAT GAAGGAGAAA 660 ACTCACCGAG GCAGTTCCAT AGGATGGCAA GATCCTGGTA TCGGTCTGCG ATTCCGACTC 720 GTCCAACATC AATACAACCT ATTAATTTCC CCTCGTCAAA AATAAGGTTA TCAAGTGAGA 780 AATCACCATG AGTGACGACT GAATCCGGTG AGAATGGCAA AAGTTTATGC ATTTCTTTCC 840 AGACTTGTTC AACAGGCCAG CCATTACGCT CGTCATCAAA ATCACTCGCA TCAACCAAAC 900 CGTTATTCAT TCGTGATTGC GCCTGAGCGA GACGAAATAC GCGATCGCTG TTAAAAGGAC 960 AATTACAAAC AGGAATCGAA TGCAACCGGC GCAGGAACAC TGCCAGCGCA TCAACAATAT 1020 TTTCACCTGA ATCAGGATAT TCTTCTAATA CCTGGAATGC TGTTTTCCCG GGGATCGCAG 1080 TGGTGAGTAA CCATGCATCA TCAGGAGTAC GGATAAAATG CTTGATGGTC GGAAGAGGCA 1140 TAAATTCCGT CAGCCAGTTT AGTCTGACCA TCTCATCTGT AACATCATTG GCAACGCTAC 1200 CTTTGCCATG TTTCAGAAAC AACTCTGGCG CATCGGGCTT CCCATACAAT CGATAGATTG 1260 TCGCACCTGA TTGCCCGACA TTATCGCGAG CCCATTTATA CCCATATAAA TCAGCATCCA 1320 TGTTGGAATT TAATCGCGGC CTAGAGCAAG ACGTTTCCCG TTGAATATGG CTCATAACAC 1380 CCCTTGTATT ACTGTTTATG TAAGCAGACA GTTTTATTGT TCATGACCAA AATCCCTTAA 1440 CGTGAGTTTT CGTTCCACTG AGCGTCAGAC CCCGTAGAAA AGATCAAAGG ATCTTCTTGA 1500 GATCCTTTTT TTCTGCGCGT AATCTGCTGC TTGCAAACAA AAAAACCACC GCTACCAGCG 1560 GTGGTTTGTT TGCCGGATCA AGAGCTACCA ACTCTTTTTC CGAAGGTAAC TGGCTTCAGC 1620 AGAGCGCAGA TACCAAATAC TGTCCTTCTA GTGTAGCCGT AGTTAGGCCA CCACTTCAAG 1680 AACTCTGTAG CACCGCCTAC ATACCTCGCT CTGCTAATCC TGTTACCAGT GGCTGCTGCC 1740 AGTGGCGATA AGTCGTGTCT TACCGGGTTG GACTCAAGAC GATAGTTACC GGATAAGGCG 1800 CAGCGGTCGG GCTGAACGGG GGGTTCGTGC ACACAGCCCA GCTTGGAGCG AACGACCTAC 1860 ACCGAACTGA GATACCTACA GCGTGAGCTA TGAGAAAGCG CCACGCTTCC CGAAGGGAGA 1920 AAGGCGGACA GGTATCCGGT AAGCGGCAGG GTCGGAACAG GAGAGCGCAC GAGGGAGCTT 1980 CCAGGGGGAA ACGCCTGGTA TCTTTATAGT CCTGTCGGGT TTCGCCACCT CTGACTTGAG 2040 CGTCGATTTT TGTGATGCTC GTCAGGGGGG CGGAGCCTAT GGAAAAACGC CAGCAACGCG 2100 GCCTTTTTAC GGTTCCTGGC CTTTTGCTGG CCTTTTGCTC ACATGTTCTT TCCTGCGTTA 2160 TCCCCTGATT CTGTGGATAA CCGTATTACC GCCTTTGAGT GAGCTGATAC CGCTCGCCGC 2220 AGCCGAACGA CCGAGCGCAG CGAGTCAGTG AGCGAGGAAG CGGAAGAGCG CCTGATGCGG 2280 TATTTTCTCC TTACGCATCT GTGCGGTATT TCACACCGCA TATATGGTGC ACTCTCAGTA 2340 CAATCTGCTC TGATGCCGCA TAGTTAAGCC AGTATA CACT CCGCTATCGC TACGTGACTG 2400 GGTCATGGCT GCGCCCCGAC ACCCGCCAAC ACCCGCTGAC GCGCCCTGAC GGGCTTGTCT 2460 GCTCCCGGCA TCCGCTTACA GACAAGCTGT GACCGTCTCC GGGAGCTGCA TGTGTCAGAG 2520 GTTTTCACCG TCATCACCGA AACGCGCGAG GCAGCTGCGG TAAAGCTCAT CAGCGTGGTC 2580 GTGAAGCGAT TCACAGATGT CTGCCTGTTC ATCCGCGTCC AGCTCGTTGA GTTTCTCCAG 2640 AAGCGTTAAT GTCTGGCTTC TGATAAAGCG GGCCATGTTA AGGGCGGTTT TTTCCTGTTT 2700 GGTCACTGAT GCCTCCGTGT AAGGGGGATT TCTGTTCATG GGGGTAATGA TACCGATGAA 2760 ACGAGAGAGG ATGCTCACGA TACGGGTTAC TGATGATGAA CATGCCCGGT TACTGGAACG 2820 TTGTGAGGGT AAACAACTGG CGGTATGGAT GCGGCGGGAC CAGAGAAAAA TCACTCAGGG 2880 TCAATGCCAG CGCTTCGTTA ATACAGATGT AGGTGTTCCA CAGGGTAGCC AGCAGCATCC 2940 TGCGATGCAG ATCCGGAACA TAATGGTGCA GGGCGCTGAC TTCCGCGTTT CCAGACTTTA 3000 CGAAACACGG AAACCGAAGA CCATTCATGT TGTTGCTCAG GTCGCAGACG TTTTGCAGCA 3060 GCAGTCGCTT CACGTTCGCT CGCGTATCGG TGATTCATTC TGCTAACCAG TAAGGCAACC 3120 CCGCCAGCCT AGCCGGGTCC TCAACGACAG GAGCACGATC ATGCGCACCC GTGGGGCCGC 3180 CATGCCGGCG ATAATGGCCT GCTTCTCGCC GAAACGTTTG GTGGCGGGAC CAGTGACGAA 3240 GGCTTGAGCG AGGGCGTGCA AGATTCCGAA TACCGCAAGC GACAGGCCGA TCATCGTCGC 3300 GCTCCAGCGA AAGCGGTCCT CGCCGAAAAT GACCCAGAGC GCTGCCGGCA CCTGTCCTAC 3360 GAGTTGCATG ATAAAGAAGA CAGTCATAAG TGCGGCGACG ATAGTCATGC CCCGCGCCCA.3420 CCGGAAGGAG CTGACTGGGT TGAAGGCTCT CAAGGGCATC GGTCGAGATC CCGGTGCCTA 3480 ATGAGTGAGC TAACTTACAT TAATTGCGTT GCGCTCACTG CCCGCTTTCC AGTCGGGAAA 3540 CCTGTCGTGC CAGCTGCATT AATGAATCGG CCAACGCGCG GGGAGAGGCG GTTTGCGTAT 3600 TGGGCGCCAG GGTGGTTTTT CTTTTCACCA GTGAGACGGG CAACAGCTGA TTGCCCTTCA 3660 CCGCCTGGCC CTGAGAGAGT TGCAGCAAGC GGTCCACGCT GGTTTGCCCC AGCAGGCGAA 3720 AATCCTGTTT GATGGTGGTT AACGGCGGGA TATAACATGA GCTGTCTTCG GTATCGTCGT 3780 ATCCCACTAC CGAGATATCC GCACCAACGC GCAGCCCGGA CTCGGTAATG GCGCGCATTG 3840 CGCCCAGCGC CATCTGATCG TTGGCAACCA GCATCGCAGT GGGAACGATG CCCTCATTCA 3900 GCATTTGCAT GGTTTGTTGA AAACCGGACA TGGCACTCCA GTCGCCTTCC CGTTCCGCTA 3960 TCGGCTGAAT TTGATTGCGA GTGAGATATT TATGCCAGCC AGCCAGACGC AGACGCGCCG 4020 AGACAGAACT TAATGGGCCC GCTAACAGCG CGATTTGCTG GTGAC CCAAT GCGACCAGAT 4080 GCTCCACGCC CAGTCGCGTA CCGTCTTCAT GGGAGAAAAT AATACTGTTG ATGGGTGTCT 4140 GGTCAGAGAC ATCAAGAAAT AACGCCGGAA CATTAGTGCA GGCAGCTTCC ACAGCAATGG 4200 CATCCTGGTC ATCCAGCGGA TAGTTAATGA TCAGCCCACT GACGCGTTGC GCGAGAAGAT 4260 TGTGCACCGC CGCTTTACAG GCTTCGACGC CGCTTCGTTC TACCATCGAC ACCACCACGC 4320 TGGCACCCAG TTGATCGGCG CGAGATTTAA TCGCCGCGAC AATTTGCGAC GGCGCGTGCA 4380 GGGCCAGACT GGAGGTGGCA ACGCCAATCA GCAACGACTG TTTGCCCGCC AGTTGTTGTG 4440 CCACGCGGTT GGGAATGTAA TTCAGCTCCG CCATCGCCGC TTCCACTTTT TCCCGCGTTT 4500 TCGCAGAAAC GTGGCTGGCC TGGTTCACCA CGCGGGAAAC GGTCTGATAA GAGACACCGG 4560 CATACTCTGC GACATCGTAT AACGTTACTG GTTTCACATT CACCACCCTG AATTGACTCT 4620 CTTCCGGGCG CTATCATGCC ATACCGCGAA AGGTTTOGCG CCATTCGATG GTGTCCGGGA 4680 TCTCGACGCT CTCCCTTATG CGACTCCTGC ATTAGGAAGC AGCCCAGTAG TAGGTTGAGG 4740 CCGTTGAGCA CCGCCGCCGC AAGGAATGGT GCATGCAAGG AGATGGCGCC CAACAGTCCC 4800 CCGGCCACGG GGCCTGCCAC CATACCCACG CCGAAACAAG CGCTCATGAG CCCGAAGTGG 4860 CGAGCCCGAT CTTCCICATC GGTGATGTCG GCGATATAGG CGCCAGCAAC CGCACCTGTG 4920 GCGCCGGTGA TGCCGGCCAC GATGCGTCCG GCGTAGAGGA TCGAGATCTC GATCCCGCGA 4980 AATTAATACG ACTCACTATA GGGGAATTGT GAGCGGATAA CAATTCCCCT CTAGAAATAA 5040 TTTTGTTTAA CTTTAAGAAG GAGATATACA TATGGGCCAT CATCATCATC ATCACGTGAT 5100 CGACATCATC GGGACCAGCC CCACATCCTG GGAACAGGCG GCGGCGGAGG CGGTCCAGCG 5160 GGCGCGGGAT AGCGTCGATG ACATCCGCGT CGCTCGGGTC ATTGAGCAGG ACATGGCCGT 5220 GGACAGCGCC GGCAAGATCA CCTACCGCAT CAAGCTCGAA GTGTCGTTCA AGATGAGGCC 5280 GGCGCAACCG AGGGGCTCGA AACCACCGAG CGGTTCGCCT GAAACGGGCG CCGGCGCCGG 5340 TACTGTCGCG ACTACCCCCG CGTCGTCGCC GGTGACGTTG GCGGAGACCG GTAGCACGCT 5400 GCTCTACCCG CTGTTCAACC TGTGGGGTCC GGCCTTTCAC GAGAGGTATC CGAACGTCAC 5460 GATCACCGCT CAGGGCACCG GTTCTGGTGC CGGGATCGCG CAGGCCGCCG CCGGGACGGT 5520 CAACATTGGG GCCTCCGACG CCTATCTGTC GGAAGGTGAT ATGGCCGCGC ACAAGGGGCT 5580 GATGAACATC GCGCTAGCCA TCTCCGCTCA GCAGGTCAAC TACAACCTGC CCGGAGTGAG 5640 CGAGCACCTC AAGCTGAACG GAAAAGTCCT GGCGGCCATG TACCAGGGCA CCATCAAAAC 5700 CTGGGA CGAC CCGCAGATCG CTGCGCTCAA CCCCGGCGTG AACCTGCCCG GCACCGCGGT 5760 AGTTCCGCTG CACCGCTCCG ACGGGTCCGG TGACACCTTC TTGTTCACCC AGTACCTGTC 5820 CAAGCAAGAT CCCGAGGGCT GGGGCAAGTC GCCCGGCTTC GGCACCACCG TCGACTTCCC 5880 GGCGGTGCCG GGTGCGCTGG GTGAGAACGG CAACGGCGGC ATGGTGACCG GTTGCGCCGA 5940 GACACCGGGC TGCGTGGCCT ATATCGGCAT CAGCTTCCTC GACCAGGCCA GTCAACGGGG 6000 ACTCGGCGAG GCCCAACTAG GCAATAGCTC TGGCAATTTC TTGTTGCCCG ACGCGCAAAG 6060 CATTCAGGCC GCGGCGGCTG GCTTCGCATC GAAAACCCCG GCGAACCAGG CGATTTCGAT 6120 GATCGACGGG CCCGCCCCGG ACGGCTACCC GATCATCAAC TACGAGTACG CCATCGTCAA 6180 CAACCGGCAA AAGGACGCCG CCACCGCGCA GACCTTGCAG GCATTTCTGC ACTGGGCGAT 6240 CACCGACGGC AACAAGGCCT CGTTCCTCGA CCAGGTTCAT TTCCAGCCGC TGCCGCCCGC 6300 GGTGGTGAAG TTGTCTGACG CGTTGATCGC GACGATTTCC AGCGCTGAGA TGAAGACCGA 6360 TGCCGCTACC CTCGCGCAGG AGGCAGGTAA TTTCGAGCGG ATCTCCGGCG ACCTGAAAAC 6420 CCAGATCGAC CAGGTGGAGT CGACGGCAGG TTCGTTGCAG GGCCAGTGGC GCGGCGCGGC 6480 GGGGACGGCC GCCCAGGCCG CGGTGGTGCG CTTCCAAGAA GCAGCCAATA AGCAGAAGCA 6540 GGAACTCGAC G AGATCTCGA CGAATATTCG TCAGGCCGGC GTCCAATACT CGAGGGCCGA 6600 CGAGGAGCAG CAGCAGGCGC TGTCCTCGCA AATGGGCTTT GTGCCCACAA CGGCCGCCTC 6660 GCCGCCGTCG ACCGCTGCAG CGCCACCCGC ACCGGCGACA CCTGTTGCCC CCCCACCACC 6720 GGCCGCCGCC AACACGCCGA ATGCCCAGCC GGGCGATCCC AACGCAGCAC CTCCGCCGGC 6780 CGACCCGAAC GCACCGCCGC CACCTGTCAT TGCCCCAAAC GCACCCCAAC CTGTCCGGAT 6840 CGACAACCCG GTTGGAGGAT TCAGCTTCGC GCTGCCTGCT GGCTGGGTGG AGTCTGACGC 6900 CGCCCACTTC GACTACGGTT CAGCACTCCT CAGCAAAACC ACCGGGGACC CGCCATTTCC 6960 CGGACAGCCG CCGCCGGTGG CCAATGACAC CCGTATCGTG CTCGGCCGGC TAGACCAAAA 7020 GCTTTACGCC AGCGCCGAAG CCACCGACTC CAAGGCCGCG GCCCGGTTGG GCTCGGACAT 7080 GGGTGAGTTC TATATGCCCT ACCCGGGCAC CCGGATCAAC CAGGAAACCG TCTCGCTTGA 7140 CGCCAACGGG GTGTCTGGAA GCGCGTCGTA TTACGAAGTC AAGTTCAGCG ATCCGAGTAA 7200 GCCGAACGGC CAGATCTGGA CGGGCGTAAT CGGCTCGCCC GCGGCGAACG CACCGGACGC 7260 CGGGCCCCCT CAGCGCTGGT TTGTGGTATG GCTCGGGACC GCCAACAACC CGGTGGACAA 7320 GGGCGCGGCC AAGGCGCTGG CCGAATCGAT CCGGCCTTTG GTCGCCCCGC CGCCGGCGCC 7380 GGCACCGGCT CCTGCAG AGC CCGCTCCGGC GCCGGCGCCG GCCGGGGAAG TCGCTCCTAC 7440 CCCGACGACA CCGACACCGC AGCGGACCTT ACCGGCCTGA GAATTCTGCA GATATCCATC 7500 ACACTGGCGG CCGCTCGAGC ACCACCACCA CCACCACTGA GATCCGGCTG CTAACAAAGC 7560 CCGAAAGGAA GCTGAGTTGG CTGCTGCCAC CGCTGAGCAA TAACTAGCAT AACCCCTTGG 7620 GGCCTCTAAA CGGGTCTTGA GGGGTTTTTT GCTGAAAGGA GGAACTATAT CCGGAT 7676 (2) INFORMATION FOR SEC ID. DO NOT. : 214: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 802 amino acids (B) TYPE: amino acid (C) HEBRA: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID. DO NOT . : 214: Met Gly His His His His His His Val He Asp He He Gly Thr Ser i 5 10 15 Pro Thr Ser Trp Glu Gln Ala Wing Wing Glu Wing Val Gln Arg Wing Arg 20 25 30 Asp Ser Val Asp Asp He Arg Val Wing Arg Val He Glu Gln Asp Met 35 40 45 Wing Val Asp Ser Wing Gly Lys He Thr Tyr Arg He Lys Leu Glu Val 50 55 60 Ser Phe Lys Met Arg Pro Wing Gln Pro Arg Gly Ser Lys Pro Pro Ser 65 70 75 80 Gly Ser Pro Glu Thr Gly Wing Gly Wing Gly Thr Val Wing Thr Thr Pro 85 90 95 Wing Being Ser Pro Val Thr Leu Wing Glu Thr Gly Ser Thr Leu Leu Tyr 100 105 110 Pro Leu Phe Asn Leu Trp Gly Pro Wing Phe His Glu Arg Tyr Pro Asn 115 120 125 Val Thr He Thr Wing Gln Gly Thr Gly Ser Gly Wing Gly He Wing Gln 130 135 140 Wing Wing Wing Gly Thr Val Asn He Gly Wing Wing Asp Wing Tyr Leu Ser 145 150 155 160 Glu Gly Asp Met Wing Wing His Lys Gly Leu Met Asn Wing Wing Leu Wing 165 170 175 I Have To Be Wing Gln Gln Val Asn Tyr Asn Leu Pro Gly Val Ser Glu His 180 185 190 Leu Lys Leu Asn Gly Lys Val Leu Wing Wing Met Tyr Gln Gly Thr He 195 200 205 Lys Thr Trp Asp Asp Pro Gln He Ala Wing Leu Asn Pro Gly Val Asn 210 215 220 Leu Pro Gly Thr Ala Val Val Pro Leu His Arg Ser Asp Gly Ser Gly 225 230 235 240 Asp Thr Phe Leu Phe Thr Gln Tyr Leu Ser Lys Gln Asp Pro Glu Gly 245 250 255 Trp Gly Lvs Ser Pro Gly Phe Gly Thr Thr Val Asp Phe Pro Wing Val 260 265 270 Pro Gly Ala Leu Gly Glu Asn Gly Asn Gly Gly Met Val Thr Gly Cys 275 280 285 Wing Glu Thr Pro Gly Cys Val Wing Tyr He Gly He Ser Phe Leu Asp 290 295 300 Gln Ala Ser Gln Arg Gly Leu Gly Glu Wing Gln Leu Gly Asn Ser Ser 305 310 315 320 Gly Asn Phe Leu Leu Pro Asp Wing Gln Ser He Gln Wing Wing Wing 325 325 335 Gly Phe Wing Ser Lys Thr Pro Wing Asn Gln Wing He Ser Met He Asp 340 345 350 Gly Pro Wing Pro Asp Gly Tyr Pro He lie Asn Tyr Glu Tyr Wing He 355 360 365 Val Asn Asn Arg Gln Lys Asp Wing Wing Thr Wing Gln Thr Leu Gln Wing 370 375 380 Phe Leu His Trp Wing He Thr Asp Gly Asn Lys Wing Being Phe Leu Asp 385 390 395 400 Gln Val His Phe Gln Pro Leu Pro Pro Wing Val Val Lys Leu Ser Asp 405 410 415 Wing Leu He Wing Thr He Ser Being Wing Glu Met Lys Thr Asp Wing Wing 420 425 430 Thr Leu Wing Gln Glu Wing Gly Asn Phe Glu Arg He Ser Gly Asp Leu 435 440 445 Lys Thr Gln He Asp Gln Val Glu Ser Thr Wing Gly Ser Leu Gln Gly 450 455 460 Gln Trp Arg Gly Wing Wing Gly Thr Wing Wing Gln Wing Wing Val Val Arg 465 470 475 480 Phe Gln Glu Ala Ala Asn Lys Gln Lys Gln Glu Leu Asp Glu He Ser 485 490 495 Thr Asn He Arg Gln Wing Gly Val Gln Tyr Ser Arg Wing Asp Glu Glu 500 505 510 Gln Gln Gln Wing Leu Being Ser Gln Met Gly Phe Val Pro Thr Thr Wing 515 520 525 Ala Ser Pro Pro Ser Thr Ala Ala Ala Pro Pro Ala Ala Ala Thr Pro 530 535 540 Val Ala Pro Pro Pro Pro Ala Ala Ala Asn Thr Pro Asn Ala Gln Pro 545 550 555 560 Gly Asp Pro Asn Ala Ala Pro Pro Pro Ala Asp Pro Asn Ala Pro Pro 565 570 575 Pro Pro Val He Wing Pro Asn Wing Pro Gln Pro Val Arg He Asp Asn 580 585 590 Pro Val Gly Gly Phe Ser Phe Ala Leu Pro Wing Gly Trp Val Glu Ser 595 600 605 Asp Wing Wing His Phe Asp Tyr Gly Be Wing Leu Leu Ser Lys Thr Thr 610 615 620 Gly Asp Pro Pro Phe Pro Gly Gln Pro Pro Pro Val Wing Asn Asp Thr 625 630 635 640 Arg He Val Leu Gly Arg Leu Asp Gln Lys Leu Tyr Ala Ser Wing Glu 645 650 655 Wing Thr Asp Ser Lys Wing Wing Wing Arg Leu Gly Ser Asp Met Gly Glu 660 665 670 Phe Tyr Met Pro Tyr Pro Gly Thr Arg He Asn Gln Glu Thr Val Ser 675 680 685 Leu Asp Wing Asn Gly Val Ser Gly Ser Wing Tyr Tyr Glu Val Lys 690 695 700 Phe Ser Asp Pro Ser Lys Pro Asn Gly Gln He Trp Thr Gly Val He 705 710 715 720 Gly Ser Pro Wing Wing Asn Wing Pro Asp Wing Gly Pro Pro Gln Arg Trp 725 730 735 Phe Val Val Trp Leu Gly Thr Ala Asn Asn Pro Val Asp Lys Gly Ala 740 745 750 Ala Lys Ala Leu Ala Glu Ser He Arg Pro Leu Val Ala Pro Pro Pro 755 760 765 Wing Pro Wing Pro Wing Pro Wing Glu Pro Pro Wing Pro Wing Pro Wing 770 775 780 Gly Wing Val Wing Pro Thr Pro Thr Thr Pro Thr Pro Gln Arg Thr Leu 785 790 795 800 Pro Ala

Claims (37)

CLAIMS 1. A polypeptide comprising an immunogenic portion of a soluble M. tuberculosis antigen, or a variant of the antigen that differs only in substitutions and / or conservative modifications, wherein the antigen has an N-terminal sequence selected from the group consisting of from: (a) Asp-Pro-Val-Asp-Ala-Val-Ile-Asn-Thr-Thr-Cys-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala-Leu; (SEQ ID No. 120), (b) Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro-Ala-Pro-Ser; (SEQ ID No. 121), (c) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg; (SEQ ID No. 122), (d) Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala-Trp-Gly-Pro; (SEQ ID No. 123), (e) Asp-Ile-Gly-Ser-Glu-Ser-Thr-Glu-Asp-Gln-Gln-Xaa-Ala-Val; (SEQ ID No. 124), (f) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val-Pro; (SEQ ID No. 125), (g) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Thr-Ala-Ala-Ser-Pro-Pro-Ser;
1. (SEQ ID No. 126), (h) Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly; (SEC ID No. 127), (i) Asp-Pro-Ala-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Leu-Thr-Ser-Leu-Leu-Asn- Ser-Leu-Ala-Asp-Pro-Asn-Val-Ser-Phe-Ala-Asn; (SEQ ID No. 128), and (j) Ala-Pro-Glu-Ser-Gly-Ala-Gly-Leu-Gly-Gly-Thr-Val-Gln-AlaGly; (SEQ ID No. 136), wherein Xaa can be any amino acid.
2. 2. A polypeptide comprising an immunogenic portion of an M. tuberculosis antigen or a variant of the antigen that differs only in substitutions and / or conservative modifications, wherein the antigen has an N-terminal sequence selected from the group consisting of: (a) Asp-Pro-Pro-Asp-Pro-His-Gln-Xaa-Asp-Met-Thr-Lys-Gly-Tyr-Tyr-Pro-Gly-Gly-Arg-Arg-Xaa-Phe; (SEQ ID No. 129) and (b) Xaa-Tyr-Ile-Ala-Tyr-Xaa-Thr-Thr-Ala-Gly-Ile-Val-Pro-Gly-Lys-Ile-Asn-Val-His -Leu-Val; (SEQ ID No. 137), wherein Xaa can be any amino acid.
3. 3. A polypeptide comprising an immunogenic portion of a soluble M. tuberculosis antigen, or a variant of the antigen that differs only in substitutions and / or conservative modifications, wherein the antigen comprises the amino acid sequence encoded by a selected DNA sequence of the group consisting of the sequences described in SEQ ID Nos. 1, 2, 4-10, 13-25, 52, 99 and 101, the complements of the sequences and DNA sequences that hybridize to a sequence described in Sec ID Nos. 1, 2, 4-10, 13-25, 52, 99 and 101 or a complement thereof under moderately strict conditions.
4. 4. A polypeptide comprising an immunogenic portion of a M. tuberculosis antigen or a variant of the antigen that differs only in substitutions and / or conservative modifications, wherein the antigen comprises an amino acid sequence encoded by a DNA sequence selected from the group consists of the sequences described in Seq. ID Nos. 26-51, 138, 139, 163-183 and 201, the complements of the sequences and DNA sequences that hybridize to a sequence described in Sec. ID Nos .: 26 -51, 138, 139, 163-183 and 201 or a complement thereof, under moderately strict conditions.
5. 5. A DNA molecule comprising a nucleotide sequence is encoded a polypeptide according to any of claims 1-4.
6. 6. An expression vector comprising a DNA molecule according to claim 5.
7. 7. A host cell transformed with an expansion vector according to claim 6.
8. 8. The host cell according to claim 7, characterized because the host cell is selected from the group consisting of E. coli, yeast and mammalian cells.
9. 9. A pharmaceutical composition comprising one or more polypeptides according to any of claims 1-4 and a physiologically acceptable carrier.
10. 10. A pharmaceutical composition comprising one or more DNA molecules according to claim 5 and a physiologically acceptable carrier.
11. 11. A pharmaceutical composition comprising one or more DNA sequences described in Sec. Nos. Nos. 3, 11, 12, 140 and 141; and a physiologically acceptable carrier.
12. 12. A vaccine comprising one or more polypeptides according to any of claims 1-4 and a non-specific immune response enhancer.
13. 13. A vaccine comprising: a polypeptide having an N-terminal sequence selected from the group consisting of sequences described in SEQ ID NOS: 134 and 135; and a non-specific immune response enhancer.
14. 14. A vaccine comprising: one or more polypeptides encoded by a DNA sequence selected from the group consisting of Seq ID No: 3, 11, 12, 140 and 141, the complements of the sequences and DNA sequences that hybridize to a sequence described in SEQ ID Nos. 3, 11, 12, 140 and 141; and a non-specific immune response enhancer.
15. 15. The vaccine of claims 12-14, characterized in that the non-specific immune response enhancer is an adjuvant.
16. 16. A vaccine comprising one or more DNA molecules according to claim 5 and a non-specific immune response enhancer.
17. 17. A vaccine comprising one or more DNA sequences described in SEQ ID Nos. 3, 11, 12, 140 and 141; and a non-specific immune response enhancer.
18. 18. The vaccine of claims 16 or 17, characterized in that the non-specific immune response enhancer is an adjuvant.
19. 19. A pharmaceutical composition according to any of claims 9-11, for use in the manufacture of a medicament for inducing protective immunity in a patient.
20. 20. A vaccine according to any of claims 12-18, for use in the manufacture of a medicament for inducing protective immunity in a patient.
21. 21. A fusion protein comprising two or more polypeptides according to any of claims 1-4.
22. 22. A fusion protein comprising one or more polypeptides according to any of claims 1-4 and ESAT-6. 23. A fusion protein comprising one or more polypeptides according to any of claims 1-4 and the M. tuberculosis 38 kD antigen
23. (ID of Sec. No.: 155).
24. 24. A pharmaceutical composition comprising a fusion protein according to any of claims 21-23 and a physiologically acceptable carrier.
25. 25. A vaccine comprising a fusion protein according to any of claims 21-23 and a non-specific immune response enhancer.
26. 26. The vaccine according to claim 25, characterized in that the non-specific immune response enhancer is an adjuvant.
27. 27. A pharmaceutical composition according to claim 24, for using a manufacture of a medicament for inducing protective immunity of a patient.
28. 28. A vaccine according to claim 25 or 26, for use in the manufacture of a medicament for inducing protective immunity in a patient.
29. 29. A method for detecting tuberculosis in a patient, characterized in that it comprises: (a) contacting dermal cells of a patient with one or more polypeptides according to any of claims 1-4; and (b) detecting an immune response in the patient's skin and hence detecting tuberculosis in the patient.
30. 30. A method for detecting tuberculosis in a patient, characterized in that it comprises: (a) contacting dermal cells of a patient with a polypeptide having an N-terminal sequence selected from the group consisting of sequences described in Sec. ID Nos.: 134 and 135; and (b) detecting an immune response in the patient's skin and hence detecting tuberculosis in the patient.
31. 31. A method for detecting tuberculosis in a patient, characterized in that it comprises: (a) contacting dermal cells of a patient with one or more polypeptides encoded by a DNA sequence selected from the group consisting of Sec. ID Nos. 3; 11, 12, 140, 141, 156-160, 189-193, 199, 200 and 203, the complements of the sequences and DNA sequences that hybridize to a sequence described in Seq. ID Nos. 3, 11, 12, 140, 141, 156-160, 189-193, 199, 200 and 203; and (b) detecting an immune response in the patient's skin and hence detecting tuberculosis in the patient.
32. 32. The method according to any of claims 29-31, characterized in that the immune response is induration.
33. 33. A diagnostic kit characterized in that it comprises: (a) a polypeptide according to any of claims 1-4; and (b) apparatus sufficient to contact the polypeptide with skin cells of a patient.
34. 34. A diagnostic kit, characterized in that it comprises: (a) a polypeptide having an N-terminal sequence selected from the group consisting of sequences described in Seq. ID Nos. 134 and 135; and (b) apparatus sufficient to contact the polypeptide with skin cells of a patient.
35. 35. A diagnostic kit, characterized in that it comprises: (a) a polypeptide encoded by a DNA sequence selected from the group consisting of Sec. ID Nos. 3, 11, 12, 140, 141, 156-160, 189 -193, 199, 200 and 203, the complements of the sequences and DNA sequences that hybridize to a sequence described in SEQ ID Nos. 3, 11, 12, 140, 141, 156-160, 189-193, 199, 200 and 203; and (b) apparatuses sufficient to contact the polypeptide with the dermal cells of a patient.
36. 36. A diagnostic kit, characterized in that it comprises: (a) a fusion protein according to any of claims 21-23; and (b) apparatus sufficient to contact the fusion protein with the skin cells of a patient.
37. 37. A fusion protein according to claim 23, characterized in that it comprises an amino acid sequence selected from the group consisting of sequences described in SEQ ID Nos .: 153 and 209.